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The research presented in this thesis concerns the improvement of the particle morphology of 
pharmaceutically relevant materials, focussing largely on the use of additives in crystallisations. The 
work fits into the wider context of the research carried out at the Future Manufacturing Hub in 
Continuous Manufacturing and Advanced Crystallisation (CMAC), funded by the EPSRC.  
Opening chapters provide an introduction to the general research area, including the background 
of the project. A general overview of the analysis techniques used and methodology employed are 
also detailed in chapters 2-3. 
Chapter 4-5 pertain to the experiments carried out to improve the morphology of the primary Active 
Pharmaceutical Ingredient (API) being investigated, isoniazid (IZN). Chapter 4 focuses on the use of 
different solvents and intentionally added impurities (additives). Additives chosen include both size-
matched molecules and polymers. The effect of the additives is related to the crystallisation method 
and dependent on the concentration added. This chapter also reports the successful transfer of 
solvent effects into a continuous crystallisation platform, the Kinetically Regulated Automated Input 
Crystalliser (KRAIC). Face indexing and analysis of the crystal structure were used to rationalise the 
effects of the additives. In chapter 5, additives are used as co-formers with the aim of producing 
new multi-component crystals with favourable morphologies. The properties of each new co-crystal 
were determined and the improvements to morphology discussed with respect to experimental face 
indexing.  
 Chapter 6 applies the methodology used in the IZN research to a second API, pyridoxine (PYR). The 
effects of solvent, additives and formation of multi-component materials are discussed in terms of 
their influence on the crystal morphology achieved. Face indexing analysis was carried out to aid the 
comparison of crystal shapes produced.  
Chapter 7 details the benchmarking of a workflow, produced by Dr. Lauren Hatcher, using CMAC 
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Chapter 1 Introduction 
 
1.1 Research context 
Crystallisation is an integral step in the processing of pharmaceutical products, with more than 80% 
of market drugs being formulated in crystalline form.1 Comprehensive screening is necessary to fully 
characterise the solid forms of each drug and their related physical properties in order to improve 
the safety and effectiveness of a treatment. Poor understanding of the solid state behaviour of 
crystals produced can result in unwanted phase transitions and, therefore, a change in the 
properties, such as stability and solubility. As a consequence of such changes, the final product will 
not perform in the expected way, for example affecting bioavailability of formulated products. 
Crystallisation conditions can also be invaluable in the control of particle attributes of the crystalline 
material, such as particle size distribution and crystal morphology.  
The research carried out here focuses particularly on controlling the shape (morphology) of the 
crystals produced, a physical property often considered important later in processing. The 
morphology of a crystal largely affects the downstream processing steps required to produce the 
final drug product, often leading to extra steps being required. The downside of such extra steps is 
the added time required and the associated extra costs. As a result, research into controlling the 
morphology of a crystal during the initial crystallisation stage of the process is of distinct interest to 
the pharmaceutical industry.  
This project is carried out in the broader context of the CMAC Future Manufacturing Hub, an 
academic-industrial collaboration with a specific research focus on the development of crystalline 
materials and particles (single or multi-component) and the transfer of their manufacture in 
continuous flow environments. Small molecule systems with challenging physical properties or 
performance limitations are chosen for development to help inform new approaches for advanced 
predictive design and integrated manufacturing.2 Collaborations within CMAC across multiple 
disciplines allows for research to occur into the processing of materials from initial discovery 
through to formulated end products. Research at the University of Bath spoke of the CMAC Hub 
programme is strongly related to multi-component crystallisations and the use of additives to 
control solid form at the molecular and primary particle level. Multi-component crystallisations can 
be very beneficial for tuning the solid-state properties of small pharmaceutically active molecules. 
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The key areas of interest at Bath are targeting the formation of co-crystals and other multi-
component crystalline systems, primary particle control and the alteration of morphology and habit. 
All of these areas can be controlled by changing crystallisation conditions (including choice of co-
former molecules) and using appropriate additives in the crystallisation process. A second focus of 
the Bath strand of the CMAC Hub is the development of transfer from lab scale batch to small scale 
continuous crystallisations and the operation of the continuous crystallisation platforms. 
Implementing lab scale batch crystallisations in continuous platforms often poses many problems 
and work is carried out to minimise this disruption in transferring from lab scale tests to continuous 
systems available at Bath. 
1.2 Crystallisation theory 
Crystallisation is an important technique utilised in industry for the separation and purification of 
chemical mixtures, and for producing solid form materials for further processing and application. 
Crystals are favoured in the production of pharmaceuticals due to the ease of processing and 
characterisation coupled with the possibility to control their specific properties.3 
The crystallisation method chosen is key to achieving desired properties, through controlling the 
crystalline structure and the macroscopic characteristics of crystalline particles, such as shape. 
There are several methods for forming crystals, including crystallising from solution and 
solidification of melts.4 In the pharmaceutical industry the main focus is on growing crystals from 
solution, and this forms the major focus of the work discussed here. The crystallisation process, 
whilst complex, can be described in general terms by considering three distinct stages: 
supersaturation, nucleation and crystal growth. 
1.2.1 Supersaturation 
Figure 1.1 shows the relationship between temperature and the saturation solubility of a solution. 
A typical solubility curve shows an increase in solubility as temperature rises. The solution is 
saturated at a given temperature along the solubility curve. A solution whose concentration lies 
below the solubility line is undersaturated, where the solute is more stable in solution, and solutions 
that lie above the curve are supersaturated. A supersaturated solution contains a greater 
concentration than can ordinarily be dissolved at that given temperature.5  This supersaturation of 




Figure 1.1. Solubility curve, metastable zone and metastable boundary 4 
It is not possible to maintain supersaturation over an infinite concentration range, as new phases 
will ultimately be induced. However, spontaneous nucleation does not tend to occur within the 
metastable zone (MSZ) indicated in figure 1.1; only existing crystals will grow in this region.6 The 
temperature at which spontaneous nucleation can occur can be determined for a specific saturation 
concentration and marks the limit of the metastable region (metastable boundary marked with 
black dotted line). The width of the MSZ is dependent on the nature of the system being studied 
and can vary depending on conditions used such as scale, cooling rate or impurities present.7 Once 
a solution lies beyond the metastable boundary it is termed labile, and spontaneous, uncontrolled 
nucleation can occur.4 
Supersaturation is the driving force for the crystallisation process, a fundamental parameter. There 
are different ways of defining supersaturation. Calculating the difference between the 
concentration of the solution (c) and the concentration at equilibrium (c*) at the same temperature 
gives a value for the concentration driving force of the crystallisation (equation 1.1). The 
supersaturation can also be calculated by a ratio of the two concentrations (equation 1.2) or take 
into account the relative supersaturation (equation 1.3).8 
∆𝑐 = 𝑐 − 𝑐∗              Equation 1.1 
𝑆 =  
𝑐
𝑐∗




              Equation 1.3 
∆𝜇 = 𝜇 − 𝜇∗ = 𝑘𝑇 𝑙𝑛
𝑐
𝑐∗
             Equation 1.4 
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It is also possible to define supersaturation thermodynamically. The driving force is therefore 
defined as the dimensionless difference between chemical potential between the molecule in its 
equilibrium state (μ) and its supersaturated state (μ*) (equation 1.4) where k is the Boltzmann 
constant and T is the absolute temperature.4, 8 
In industry processes it is possible to achieve supersaturation via evaporating the solvent, cooling 
the solution, adding an anti-solvent to decrease solubility or performing a chemical reaction (where 
a reaction results in a less soluble product which is supersaturated upon formation). 
 1.2.2 Nucleation 
The process by which new solid phases are created from supersaturated solution or super-cooled 
liquids, i.e. melt crystallisation, is known as nucleation.4 Nucleation plays a decisive role in defining 
the initial population of crystals and can influence the initial state of succeeding processes, such as 
crystal growth.9 Therefore, nucleation plays a significant role in determining the final crystal product 
quality. There are two types of nucleation: primary and secondary (figure 1.2). 
 
Figure 1.2. Differences in primary and secondary nucleation processes.6 
1.2.2.1  Primary nucleation 
Primary nucleation can occur homogeneously or heterogeneously, distinguishable by the absence 
or presence of a solid interface. Homogeneous nucleation is spontaneous formation of solid phases 
as a result of supersaturation with no solid interface required. In practice heterogeneous nucleation, 
where there is a solid interface present, is observed more often; homogeneous nucleation is 
generally not observed in larger volumes.10  
The mechanism behind nucleation is not fully known, however, there are two widely accepted 
theories used to describe the events occurring. These are known as classical nucleation theory (CNT) 
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and the two-step mechanism. Both theories start with a supersaturated solution and both consider 
that clusters are forming/disintegrating through the attachment/detachment of building units.11  
 
Figure 1.3. Two alternative pathways for nucleation. Top: classical nucleation theory (CNT) Bottom: two-step nucleation 
theory. 
CNT assumes the addition of single growth units to the cluster until a critical size is reached (figure 
1.3, top).12 Further molecular additions to a cluster after the critical cluster size has been reached 
result in nucleation and subsequent growth of crystals.13 Clusters that reach a critical size are known 
as critical nuclei and their likelihood of forming depends on the free energy barrier that must be 
overcome (figure 1.4). The maximum of the curve, zc, corresponds to the size required to achieve a 
decrease in free energy with further growth of the cluster. If the cluster is smaller than this critical 
size the only way to reduce free energy is dissolution. Increasing supersaturation serves to reduce 
not only the height of the free energy barrier but also the critical size of the clusters required. 





Figure 1.4. Free energy change as a function of cluster size. (a) at low supersaturation, (b) at high supersaturation 
In the alternative two-step mechanism, a dense, disordered liquid phase precedes the crystal 
formation (figure 1.3, bottom). The ordered crystalline clusters observed in CNT are formed from 
these liquid phase droplets in the second step of this mechanism. When the critical cluster size – 
creating critical nuclei – is reached, further attachment of building units is energetically favoured, 
thus leading to the formation of macroscopic crystals.11, 14 
Primary nucleation more often occurs through heterogeneous routes, with homogeneous 
nucleation being uncommon in practice.15 Heterogeneous nucleation is also spontaneous nucleation 
but requires a foreign particle, such as dust from the wall of the crystallisation vessel or inherent 
impurities in the crystallisation solution, to induce the process.16 The presence of these foreign 
particles allows heterogeneous nucleation to occur at lower supersaturation than homogeneous 
nucleation by reducing the free energy barrier of the system.4 
1.2.2.2  Secondary nucleation 
Secondary nucleation can only occur via heterogeneous nucleation and requires the presence of 
undissolved solute particles or crystals of the solute to act as nucleation sites.12 The presence of 
solute particles can occur through a number of different mechanisms. Attrition of crystals is 
considered the most likely cause of secondary nucleation in industrial processes. Mechanical force 
applied to most solution mediated crystallisations can induce a number of different collisions; 
between crystal and crystalliser wall, crystal-crystal collisions and crystal-impellor attrition. These 
collisions result in crystal breakage and the formation of new nucleation sites.14 There is also 
evidence to suggest the shear forces imposed on a crystal by the solution flowing past are sufficient 
to produce secondary nucleation: this effect is known as shear nucleation. Generally, nucleation via 




In crystallisation it is necessary to strike a balance between nucleation and growth in order to control 
particle size and other structural properties of the crystal. 
 1.2.3 Growth 
The growth of a crystal occurs when a nucleus reaches a critical size and is exposed to a 
supersaturated environment. There are a number of different theoretical pathways by which a 
solute molecule can adsorb to the face of a crystal from a supersaturated solution. The ability of a 
crystal face to integrate growth units into the lattice is dependent on the number and strength of 
interactions available between the incoming solute and the surface.4 Three types of crystal faces 
can be defined depending upon the interactions they can form with an incoming growth unit;4, 6, 12 
a surface only site has one attachment, a step surface has two attachments and a kink site has three 
attachments (figure 1.5). Energetically kink sites are the most favoured as solute molecules joining 
here are able to form three interactions. This is followed by a step surface attachment with two 
interactions and then the surface site with only one point of contact.12  
 
Figure 1.5. Crystal growth surface showing potential growth sites: a surface only site, a step surface site and a kink site.  
Crystal growth is often thought of as occurring in layers. It was suggested by Volmer (1939) that 
growth was a discontinuous process, taking place layer by layer via adsorption to the crystal 
surface.17 First, growth units need to be transferred from a solution to a solid state. This can be 
described by a schematic of free energy barriers that need to be overcome during the crystallisation 




Figure 1.6. Crystal growth free energy barriers to be overcome 
This requires an initially solvated solute molecule to shed the solvent layer before it can adsorb to a 
growth surface (ΔGdesolv). After this desolvation has occurred, the growth unit will enter the 
adsorption layer (position 1) and then diffuse across the surface (ΔGSdiff) to a step position (position 
2). At this point further desolvation is necessary in order for the molecule to further diffuse across 
the surface to a final kink site at position 3 (ΔGK).4, 12 
Crystalline materials with high surface roughness grow via continuous growth mechanisms. There 
are enough kink and step sites for all approaching growth units to be incorporated efficiently, as 
every approaching growth unit will find a vacant growth site. This mechanism follows a linear growth 
rate with respect to supersaturation. Many materials do not have sufficiently rough surfaces to 
achieve continuous growth mechanisms. As a result, steps on the surface need to be created to 
facilitate incoming growth units.4, 12 One mechanism for step creation is known as two-dimensional 
nucleation. Clusters of growth units form on the surface of the crystal, forming nuclei on the surface. 
The clusters must reach a critical size in order for further growth to be favoured.18 Several models 
have been developed to describe the continued growth.   
The simplest model for layer completion is known as the mononuclear model. This model assumes 
the surface nuclei spread across the surface at an infinite velocity. The growth rate of each face is 
therefore proportional to its area. This growth velocity indicates larger faces grow faster than small 
faces, contradicting the observation that the fastest growing faces on a crystal have the smallest 
areas. This model can therefore be eliminated from serious consideration. The contrasting 
polynuclear method assumes the spreading velocity of the surface nuclei is zero. In this second 
model, layer completion is achieved by the formation of enough critical size surface nuclei to cover 
the layer. Nucleation is the rate determining step of this model, with the growth rate increasing with 
the increased nucleation rate. However, the growth rate will decrease with decreasing critical nuclei 
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size. As a result, the model indicates that crystal growth rate does not increase continuously with 
supersaturation. The final model is known as the birth and spread model. This model suggests nuclei 
spread at a finite, constant rate that is assumed to be independent of size. Nuclei can form at any 
location on the surface, including as incomplete layers, and no intergrowth between the nuclei 
occurs. This model predicts the growth rate increases with increasing supersaturation and 
temperature, making it more suitable than the other two models. The rate determining step in all 
three models discussed above is the formation of the two-dimensional crystal nucleus, making these 
models for discontinuous growth. 12, 18  
The above models all fail to account for growth rates at low supersaturation; addressing this resulted 
in the development of the Burton-Cabrera-Frank (BCF) model. This model proposes growth is self-
perpetuating as a result of screw-dislocations. A dislocation results from stresses occurring during 
crystal growth: one part of the lattice becomes misaligned with the rest of the crystal. Screw 
dislocations create steps at the point of emergence on which growth occur. Molecules adsorb on 
the surface and diffuse to the top step creating a ‘spiral staircase’ feature (figure 1.7). Once a layer 
is complete, the dislocation is still present on the higher layer. In this model surface nucleation is 
not required, allowing growth to occur at a finite rate at low supersaturation. Surface diffusion is 
now assumed to be the rate determining step.4, 18  
 
Figure 1.7. Spiral growth model as a result of screw dislocations19 
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1.3  Crystal morphology 
Crystal morphology is used to describe the overall shape of a crystal, governed by the external faces 
present. It can be defined as either growth or equilibrium morphology. Equilibrium morphology is 
observed when the surface free energies associated with each crystal face are minimised and 
equilibrium is achieved between the crystal and its surroundings. Growth morphologies arise as a 
direct result of crystal growth kinetics in the system; this type of morphology is much more 
commonly observed.4, 20  
The morphology of a crystal largely affects the downstream processing steps required to produce 
the final drug product, such as filtration, drying and compaction.18, 21, 22 A poor morphology can often 
lead to extra processing steps being required, resulting in a more expensive process for 
pharmaceutical companies. For most manufacturing procedures, crystals with a needle shape are 
considered a hindrance. Needles often filter poorly due to their ability to align with the mother 
liquor as it flows and block the pores of the filter (figure 1.8). Suspensions containing needle crystals 
tend to have an increased viscosity making it difficult to pump the solution from the initial vessel to 
the filter.18 Needles are also prone to agglomeration, resulting in poor drying efficiency and the 
potential for solvent and impurities to become trapped.23 Needle-shaped crystals can also result in 
issues for tableting processes due to their poor flowability, creating the potential for unpredictable 
dosage quantities.24-26 In an attempt to reduce the impact of needle crystals on the manufacturing 
procedure, extra milling steps are often introduced to break the crystals, creating more equant 
aspect ratios. The downside of this extra step is the added time required and the associated extra 
costs. Plate-shaped crystals are also a less desirable morphology due to inefficient filtration and 
washing steps. This arises as a result of their tendency to pack into impermeable layers on filter beds 
(figure 1.8).4, 18 As a result, block-shaped crystals are much more favourable for the large scale 





Figure 1.8. Effect of crystal morphology on filtration: block-like crystals filter well (left), plate-shape crystals are less 
efficient, creating an impermeable layer (centre) and needles block pores in filter medium (right). 4 
Methods attempting to alter morphology during crystallisation generally focus on influencing the 
crystal growth. Crystal morphology is mainly governed by the relative growth rates of the crystal 
faces; those with faster growth rates will have a smaller area than those faces that grow more 
slowly. Growth rates are influenced not only by the internal structure of the material but also by 
external factors, such as solvent choice, mixing conditions, degree of supersaturation, seeding and 
the presence of impurities.27 The presence of impurities in crystallisations often has a significant 
effect on the nucleation and growth kinetics of the system. This can be of substantial benefit for 
modifying the morphology (shape) of crystals produced. The mechanism by which impurities 
influence growth is still debated, but the majority of researchers in the area agree that selective 
reduction of growth rates caused by impurities is responsible for the changes in morphology 
observed.17, 18 
1.3.1  Effects of impurities on crystal morphology 
Impurities are inherently present in pharmaceutical crystallisations. They are often generated 
during process chemistry and retained through to crystallisation processes. The FDA names 
organics, inorganics and residual solvents as likely impurities in a pharmaceutical product. Possible 
impurities resulting from storage and manufacture include: those present in starting materials; by-
products and intermediates of the process; degradation products and other reagents, solvents, 
ligands, catalysts and stereoisomers present in the manufacturing process. Any impurities, actual or 
potential, that could arise during synthesis, purification and storage must be noted in any new drug 
specifications.28 Whilst impurities need to be tightly controlled in the pharmaceutical industry to 
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maintain the safety of products, additives are often intentionally added to improve certain 
properties of the final drug product.  
There are a number of different ways in which impurities can affect the structure of an API. They 
can influence the primary structure of a molecule and induce a specific polymorph to form. Research 
suggests that using impurities with a similar conformation, within their crystal structure, to the 
desired polymorph can influence nucleation kinetics and growth to achieve a desired metastable 
polymorph or avoid an undesirable form of the crystal structure.29, 30 This change in polymorphism 
often results in a change in morphology, as the primary crystal structure and shape of a crystal are 
inherently linked. Impurities are often structurally similar to the target molecule for the 
crystallisation. As a result, if present in large enough quantities, these impurities can sometimes 
become incorporated into the primary crystal structure, producing a co-crystal.31, 32 Co-crystals often 
possess altered morphologies, again due to their inherently different crystal structure. However, 
this incorporation can cause problems with pharmaceutical regulation; if the impurity is not 
Generally Regarded as Safe (GRAS) for use in food and medicine its combination into the crystal 
structure would pose a health risk. Impurities also have to potential to affect the microstructure of 
a crystal, causing point defects to occur, by blocking potential growth sites and altering growth 
mechanisms. Most point defects arise due to the potential for molecules to be missing or orientated 
irregularly in the structure. Impurity defects are also possible, with foreign molecules either 
replacing some of the API molecules making up the solid or locating into interstices. This is 
particularly likely when the impurity is structurally similar to the crystallising molecule.33, 34 In some 
crystallisations, impurities are deliberately added in order to produce a crystal with a desired 
morphology; these are known as additives. 
Additives are notably used in drug formulation, in their role as excipients, to produce the final tablet 
form and improve the related properties.35 The use of additives is also considered in early 
crystallisation steps to exert control over specific physical properties, including solid form and 
crystal size and shape.30 Whilst there are different categories of additive, defined by how they are 
used, chemically they are the same; one molecule can be an impurity, an additive or a co-former 
depending on the application.  
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1.3.2 Choosing effective additives 
Additives can have major effects on crystal morphology by disrupting growth mechanisms and 
inhibiting growth rates on particular faces.36 Additives are often chosen based on the likelihood of 
their binding preferentially to desired faces to inhibit growth in a chosen direction. By designing an 
additive to block the fast growing faces in crystals with a needle morphology, for example, a more 
equant shape can be achieved.4, 37 The presence of additives even at low concentrations can have 
significant effects on crystal morphology.4  
Several factors must be considered when choosing additives as growth inhibitors in multi-
component crystallisations, such as size and structural similarity to target. It is particularly important 
to consider functional groups on the target and choose additives which will form complementary 
interactions. However, designing additives to inhibit growth is often not fully reliable at present and 
the process relies on empirical approaches and a degree of trial and error.38 
Generally, additives fall into one of three categories: size-matched, structurally similar or polymeric. 
1.3.2.1  Structurally similar and size-matched additives 
There are many examples of structurally similar additives being used in crystallisations to control 
primary particle attributes. Structurally similar additives are inherently size-matched, therefore 
these types of additives fall into very similar categories. A series of experiments were carried out by 
Berkovitch-Yellin et al. in the early 1980s to study systematically the effect of additives on the crystal 
growth and resulting shape.27, 39-43 Using the relationship between the structure of the target crystal, 
the additives used and the affected surfaces, a mechanism was derived to explain the changes 
observed in the shape. It is suggested that the additive selectively adsorbs to the target crystal on 
the faces where the structurally similar part emerges from the crystal surface. The additive is bound 
in a very similar way to a substrate molecule as a result of the interactions possible due to the related 
structure. This adsorption disturbs the regular deposition of oncoming crystal layers, interrupting 
normal growth to these faces and resulting in an overall retardation of the growth. This generally 
leads to a relative increase in the surface area of the affected face, and therefore a change in 
morphology.43  
Extensive research has been carried out on the effect of additives on paracetamol morphology.44, 45 
One example uses the structurally related molecule metacetamol as an additive in the 
crystallisation. Progressive morphology changes were observed, from tabular crystals to columnar 
habits, with increasing concentrations of metacetamol in the crystallisation. A significant effect from 
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the solvent system used is also noted in this experiment.46 Previous research suggests the 
metacetamol affects the nucleation of paracetamol, therefore, altering the resulting growth 
mechanism and final crystal shape.45  
Another industrially important example involves the reduction of needle growth of urea in the 
presence of biuret. Urea strongly hydrogen bonds at the (001) face, causing the elongation of the 
morphology. The biuret (100) face is indistinguishable from that of urea and so can easily become 
attached at growth sites on this face. The NH2 groups needed by urea to maintain growth through 
hydrogen bonding on this face are no longer accessible, resulting in reduced growth and a shorter 
crystal morphology. This example further illustrates the usefulness of structurally similar additives 
in modifying growth mechanisms and the resulting morphology. This example also suggests the 
most useful additives are those that are able to bind effectively to a growth surface and then 
successfully prevent any further growth from occurring.17, 38, 47 
Another class of structurally similar additives are known as ‘tailor-made’ additives. Tailor-made 
additives are ‘designed’ to resemble the target system but with differences that will allow the 
growth mechanism to be affected in a desired way. Additives are usually modified versions of the 
target molecule, designed by analysis of the crystal structure and growth faces. Parts of the molecule 
that interact with chosen faces are maintained with the function of the opposite end of the molecule 
being changed. As a result, the additive can bind at specific surface sites but blocks any further 
growth from occurring as it is no longer compatible with the target crystal growth.46 Best results 
have been reported when the modifications are minor, for example, methyl or chlorine substituents 
instead of hydrogen atoms. A specific example, investigated by a number of researchers, is the effect 
of benzoic acid on benzamide crystals.41, 46 The additive, benzoic acid, is related to benzamide by 
replacing an NH2 with a hydroxyl group. The usual plate morphology becomes rod-like in the 
presence of benzoic acid due to retardation of growth along the crystallographic b axis.41 This small 
change in structure in the additive thus influences a large change in the crystal growth and resulting 
morphology.  
A large number of examples of using structurally similar additives to control polymorphism can 
also be found in the literature.29, 32, 48-53 
1.3.2.2  Polymeric additives 
Crystal morphology can also be controlled using non-size-matched additives. A major benefit of 
using non-size-matched additives is the reduction in potential for them to become incorporated into 
the crystal structure. Generally, polymers are used due to their common occurrence in processing 
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steps, such as their use as excipients in drug formulation, and their extreme dissimilarity in structure 
and size to target molecules. Polymer additives are particularly successful in reducing crystal growth 
rates when added to the medium, often referred to as poisoning crystals.54-56 The success of 
polymers in reducing crystal growth largely depends on their ability to adsorb to the target molecule 
and the level of surface coverage achieved.57, 58 An example of this is seen in experiments carried 
out on ibuprofen by Vetter et al. A reduction in crystal growth rate in the presence of co-block 
polymer Pluronic F127 was observed with binding of the polymer indiscriminately to all crystal faces, 
hindering the diffusion of solute molecules.59 A series of experiments were also carried out on 
ritonavir by Ilevbare et al. to determine the effect of polymers on the crystallisation.56, 60 The 
effective polymer in these experiments is hydroxypropyl methyl cellulose, which behaves as a 
growth inhibitor and binds non-preferentially to the crystal faces. Although these polymers appear 
to be influencing nucleation and crystal growth, no major changes in macroscopic properties are 
observed. It is possible for a polymer to impede the growth of specific faces, allowing growth to 
continue on certain crystallographic planes, resulting in an altered morphology.54, 61 An early 
example of this effect was reported in 1965 by Holder and Winkler, who observed a change in the 
morphology of paraffin wax from lozenge shaped plates to dendrites with increasing amounts of 
block co-polymer impurities.61 Experiments carried out on salbutamol sulphate display a change in 
morphology from needles to plates in the presence of polyvinylpyrrolidone (PVP). In this 
investigation, it was hypothesized that the polymer preferentially binds to a specific surface based 
on the hydrogen bonding available between the polymer and the crystal structure.62 A more recent 
success in changing crystal morphology using polymers involved an investigation on succinic acid. 
Pluronic P123 (PP123), a triblock co-polymer, in small quantities successfully modified the 
morphology of crystals obtained from water, from plates to blocks. The investigation also 
determines the effect of the polymer to be dependent on both the concentration of succinic acid 
and the concentration of PP123 in solution.63, 64 In the majority of published studies on polymeric 
additives, nucleation and growth are not discussed as separate phenomena. As a result, it is difficult 
to deduce a specific mechanism of interference for the additives chosen.59  
Polymeric additives can also be used to control the polymorph produced in a crystallisation.65, 66 In 
experiments with tolfenamic acid, a screening mechanism known as polymer induced 
heteronucleation was used to show that at least five polymorphic forms exist where before it was 
believed there were only two. This technique, unlike those in the examples previously discussed, 
utilizes insoluble polymers as heterogeneous growth sites.67-69  
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1.3.3 Effect of additive concentration 
The concentrations of additives in the system can have a major impact on the outcomes of the 
crystallisation. Additives in crystallisations in larger concentrations are likely to have an effect on 
the solubility profile of the system. It has been reported that high concentrations of additives can 
reduce the supersaturation and metastable zone width of a system, and therefore the nucleation 
temperature of the solution.70, 71 There is little discussion in the literature discussing the optimal 
amount of additive to use, however, all reports agree they can have significant effects in small 
concentrations. Lower concentrations of additives are not only favoured due to their limited effects 
on solubility profiles, but also to prevent incorporation into the crystal structure, especially in the 
case of size-matched additives. 
Size-matched additives have been reported to have an influence on the crystallisation in small 
percentages, below 10 mol%. Structurally similar and size-matched additives are successful in 
altering morphology at concentrations between 1-4 mol%.44, 45, 72 Similarly, structurally related 
additives at a concentration of up to 6 mol% have successfully altered the growth morphology of 
biuret.47 However, there are examples of much higher percentages of additives. In templating 
experiments used to control the polymorph of paracetamol, in an attempt to stabilise the 
metastable polymorph, a concentration of 25 wt% metacetamol is required to achieve the desired 
outcome.52 However, despite examples of much higher percentages used, it is generally found that 
morphology modifications can often be achieved with low concentrations of size-matched and 
structurally similar additives. 
Polymeric additive concentrations used in crystallisations also tend to be low. This is important, 
since as concentrations of polymers in crystallisations increase they can have effects on the solution 
viscosity and on the equilibrium solubility of the system37. Polymer adsorption onto the growing 
surface is thought to follow the Langmuir adsorption isotherm. However, at low polymeric 
concentrations it is believed deviations occur due to significant size differences between the 
polymer and solvent.55, 56, 73 In the case of succinic acid noted above, additive concentrations used 
were seen to have an effect on the morphology achieved. Weight percentages of 0.17%, 0.25% and 
0.5% were used, with lower percentages giving a better modification. Polymer concentrations used 
are often chosen in regions where micellar formation is favoured, however, it is unclear how this 
might influence the possible interaction with the growing crystal faces.63, 64 Low concentrations of 
polymeric additives are also often favoured in an attempt to reduce their impact on the solution 
kinetics. Due to the large difference in sizes between polymers and target molecules, incorporation 
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into the crystal structure is unlikely and is not a consideration that needs to be made for polymeric 
additives. 
1.3.4 Surface interactions and solution interventions 
Impurities are thought to inhibit growth by adsorbing to crystal faces and preventing further growth 
from occurring. This adsorption changes the relative surface energies of the faces and can block 
sites essential to the incorporation of solute into the lattice. These effects often result in changes to 
growth kinetics and therefore can be useful for changing crystal morphology.74 Many different 
mechanisms of interaction have been theorized, with the first most widely regarded mechanism 
suggested in 1958. Cabrera and Vermilyea published their ‘pinning mechanism’, suggesting the 
progress of growth layers on a surface is blocked by impurities adsorbing. It was proposed that 
growth would completely stop when the adsorbed impurities were less than twice the critical radius 
from one another. Larger distances than this would allow growth layers to continue through the 
gaps, thus only slowing the growth and, significantly, not stopping it all together.17 In 1974, Davey 
and Mullin summarized the potential sites of additive and impurity adsorption to effect growth 
kinetics: these possible sites include surface steps, kinks and ledges (figure 1.9).  
 
Figure 1.9. Sites of impurity adsorption on a growing crystal: (a) kink site, (b) surface steps and (c) ledge 
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Adsorption of the impurity at a kink site would effectively reduce the number of kinks present on a 
growing crystal surface. These sites are considered one of the most important for solute 
incorporation into the lattice and, as a result, their reduction would reduce the velocity of the 
growth. This reduction of growth causes ‘dead zones’ to occur on crystal surfaces where solute 
molecules are sufficiently blocked, preventing further propagation. Similar arguments can be used 
for adsorption to steps. Again, this would reduce the number available for solute molecules and 
reduce the velocity of growth. However, in this example it is believed that if adsorption falls below 
that of monostep coverage growth could squeeze between blocking impurities with relative ease, 
reducing their effectiveness. A critical concentration of additive or impurity is, therefore, implied in 
this example, with the layer velocity being relatively unaffected below this concentration.74, 75 The 
relationship between the concentration of impurity and the blockage of surface sites can be 
described by a simple Langmuir isotherm.17 The final point of adsorption, the ledge, will only have a 
strong effect on the crystal growth when the growth mechanism is strongly contributed to by 
surface processes, particularly diffusion. Adsorption at this location would decrease the surface area 
of the ledge causing a decrease in surface flux of growth units and, therefore, a reduction in step 
velocity.74, 75 These concepts were revised in 1995 by Kubota and Mullin to incorporate the impurity 
effectiveness into calculations, offering the opportunity to explain anomalous patterns of 
behavior.17, 76 The adsorption discussed is believed to occur via a modified version of the original 
pinning mechanism.77  
Whilst the original pinning mechanism model is widely accepted, it does not accurately describe 
results observed in many investigations. Many commonly investigated systems do not exhibit the 
predicted behaviour.78-80 This suggested a new model was required to describe the anomalous 
results being observed.  
A new model emerged in 2006 known as the competitive adsorption model (CAM). This model 
differs considerably from the pinning mechanism previously discussed. This method gave new 
perspectives on the impurity adsorption mechanism and also gave an alternative description of the 
impurity effect on the crystal growth rate. The CAM considers the kinetic effect of impurities in the 
system, not the modifications their presence may induce on solution properties. Crystal growth in 
the presence of impurities is viewed as a competition between crystallising solute and the foreign 
additive for the adsorption sites.81 Three of the stages involved in crystal growth can be affected by 
the kinetic effect of the impurity in solution: surface adsorption of molecules diffusing from solution, 
migration of molecules across the surface and step/kink adsorption of migrating molecules.82 The 
CAM mechanism is assumed when the crystallising solute and the impurity dispute the coverage of 
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the crystal surface and the occupation of energetically favourable places at surface steps. This model 
introduces a new variable, impurity concentration, which plays an important role in crystal growth 
from impure solutions and, arguably, improves the accuracy above those based on the original 
pinning mechanism.81 A further adaptation of this model was developed for unsteady-state 
conditions (CAMUS). The CAM model assumes adsorption equilibrium is achieved instantaneously, 
which is not an accurate assumption for all systems. The CAMUS model describes experimental 
observations arising as a result of dynamic equilibrium between impurity and solute molecules. The 
impurity is adsorbed first at the crystal surface and then is gradually replaced by the solute target 
molecules until a steady-state is reached.  These small changes made to the model for systems which 
take a period of time to reach equilibrium can successfully explain previously reported unusual 
growth rate trends.83 
A further model was developed in 2016 to describe the effects of multiple impurities in the 
crystallisation on the final product. The multi-impurity adsorption model (MIAM) extends the CAM 
and pinning mechanism models to allow for simultaneous modelling of multiple impurities in a 
crystallisation that have the potential for different adsorption mechanisms to be present. The MIAM 
model is able to describe the different effects of multiple impurities on certain characteristic 
properties, such as crystal purity and shape and size distribution, using a mechanism of multi-
component and multi-site adsorption.84 
Computational models were developed as early as 1973, devoted to understanding and predicting 
the external crystal shape in terms of the internal solid state structure.27, 85, 86 There are now a 
number of computational models that exist to determine the effect of external factors on the crystal 
morphology predicted from the internal structure. These models combine early calculations to 
predict the morphology with calculations of attachment and lattice energy to help determine the 
effects of solvent and additives on the growth morphology of target molecules.87, 88 Despite the 
number of computational models developed, there is no complete agreement between them. In 
addition, the models are often not available to researchers outside the groups in which they were 
developed.  
1.3.5 Effects of solvent on crystal morphology 
Choice of solvent is often considered the most crucial design decision for solution based 
crystallisations.89 Solvent can play an important role in the structure and morphology of a crystalline 
material. The choice of solvent can often allow the manipulation of crystal morphologies without 
changing the intrinsic packing of the crystal growth units, maintaining the crystal structure of the 
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compound.90-92 However, in some crystallisations the solvent can have significant effects on the 
crystal structure by changing the molecular packing. This change in packing could result in a new 
polymorphic form or the solvent could enter the crystal lattice creating a solvated form, often 
inaccurately termed a pseudopolymorph. Changing the form also influences the final morphology 
of the crystalline material.93-96 
Different morphologies can often be accessed in different solvents for similar reasons to those seen 
with additives. Solvent molecules have the potential to form favourable interactions with functional 
groups exposed on crystal faces, resulting in inhibited growth and slowed growth rates on selected 
faces. Since crystal shape is largely determined by the relative growth rates of the various faces, 
determined primarily by the binding strength of the particles arriving at the surface, any factor 
which may alter the rate of deposition, such as solvent, will influence the crystal morphology. Due 
to differences in the functional groups present on specific faces preferential adsorption of solvent 
molecules can occur. The solvation layer needs to be removed from the surface of a crystal in order 
for growth units to bind. If solvent-surface interactions are stable enough to compete with the 
incoming solute molecules they can exert a significant influence over the final crystal morphology.27 
Due to these surface specific interactions it is possible for crystallisation from different solvents to 
result in different growth mechanisms, therefore causing a morphology change of the crystal. 
However, other factors also need to be considered, such as the physical properties of the solvent, 
crystal surface properties and supersaturation.89, 97  
Most common crystal morphology prediction methods use the bulk crystal properties, such as 
interplanar distance or attachment energy (discussed further in section 1.3.6). These methods do 
not take into account the effect of a solvent on the crystal morphology. As a result, other parameters 
must be introduced to the models in order to accurately predict the effects of solvent on the 
system.98 Many models have been created in order to simulate the effects of solvent on crystal 
morphology. Critical to the models developed are the interaction energetics. The presence of 
solvent alters surface interactions due to the solvation of a crystal surface. In order to predict the 
effects of the solvents correctly, the modification of the interactions must be determined.89 
Molecular dynamics simulations can focus on different parameters to achieve the prediction of 
solvent effect on morphology. These include modelling a solvent layer against the crystal surfaces98, 
calculating lattice energies99 and using chemical potential calculations100 to deduce which faces will 
be most affected by the solvent system chosen. Molecular simulations are the most accurate 
method to obtain the relevant free energies, however, the often complex modelling involved limits 
the advantages of this modelling over experimental screening.89 Other theoretical calculations often 
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use attachment energy as a basis for the models and assume the attachment energy is proportional 
to the growth rate of the crystal surface. The development of activation energy models simulates 
the interactions of solvent with growing crystal faces to predict the resulting crystal morphologies. 
This method seems to achieves good agreement between calculations and experimental results and 
is argued to be the most effective model for quick solvent screening.90, 92, 96 
Computational modelling and investigative experiments have suggested solvent polarity is an 
important consideration when choosing a solvent to affect the growth morphology achieved. 
Experimental research and computational simulations suggest the aspect ratios of resulting crystals 
can be directly altered by changing the polarity of the solvent system used. Studies carried out with 
benzoic acid found the aspect ratio decreased with increasing solvent polarity: a linear relationship 
was determined.90 Experiments carried out on ibuprofen agree with the hypothesis determined 
from the findings for benzoic acid. Ibuprofen crystals grown from polar protic solvents, such as 
ethanol, produced less needle-like crystals than those prepared in less polar and aprotic solvents.99 
However, investigation into the influence of solvent polarity on isoniazid suggests the opposite 
relationship. Crystallisation experiments show a more needle-like crystal is achieved from water, 
compared to more rod-shaped crystals from alcohols. This suggests a decrease in aspect ratio 
resulting from a decrease in solvent polarity.100 These differences are likely the result of different 
growth mechanisms in the crystal systems. Polarity affects the interactions between solvent and 
solute molecules at the different crystal faces leading to specific faces having different growth 
rates.92 Polar solvents are thought to interact preferentially with polar faces, with non-polar solvents 
interacting more favourably with non-polar faces.27 As a result, the effect of solvent polarity on the 
aspect ratio of the final modified crystal morphologies will depend on the specific interactions on 
the faces of the system being investigated.  
The solubility of the solute in a particular solvent is also thought to affect significantly the ability to 
create more equant morphologies from needle-like crystals, by directly impacting the time it takes 
to reach the steady-state crystal shape. Although the solvent system will not alter the steady-state 
shape classification of the crystal system, a solvent system that slows down the creation of steady-
state morphologies could result in a less needle-like crystal.21  
Crystalline systems that form needles can be categorised into two different groups: ‘absolute’ 
needles are formed irrespective of the solvent whereas ‘conditional’ needles only form in specific 
solvents. For absolute needles, the solvent choice will not be driven by morphologies achieved. 
Attempts to reduce the impact of absolute needles will lie in additional processing steps, e.g. 
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mechanical milling or chemical temperature cycling. For conditional needles, attempt to improve 
crystal morphology via solvent selection merits consideration.21   
1.3.6 Morphology prediction methods 
Prediction of theoretical growth morphology is possible as a relationship exists between 
morphology and the crystal packing. The first methods developed for predicting growth rates of 
crystal faces relied exclusively on the crystal structure, interactions within it and their relation to the 
energies of the crystal faces.20  
In this work the Bravais-Friedel-Donnay-Harker (BFDH) prediction method is the simplest model 
used. Bravais and Friedel initially established the relationship between the internal crystal structure 
and the external shape achieved. This work was expanded by Donnay and Harker by adding the 
influence of screw axes and glide planes to establish the BFDH rule.101-103 The method assumes the 
binding energy of faces is inversely proportional to the interplanar spacing, where closer molecules 
will have larger interaction energies. As a result, the growth rate of the (hkl) face is proportional to 
the inverse of the distance between the (hkl) planes within the structure. Therefore, relative growth 
rates can be determined purely using the knowledge of the crystal structure.4 The BFDH prediction 
approach does not take into account detail of intermolecular interactions nor the effects of external 
influences that may be present during growth steps, relying solely on the crystal structure data.  
A model relating the interaction energies between building units and the external shape was 
developed by Hartman and Perdok.104 Their model identified periodic repeated chains of strong, 
non-bonding interactions within the crystal structure, named periodic bond chains (PBC). These 
chains were hypothesised to determine the external shape of a crystal. Hartman and Perdok also 
classified crystal faces in a similar way to those discussed in section 1.2.3. The number of PBCs found 
in the plane parallel to a face determine the type of face and speed at which it grows: flat (F) faces 
are the slow-growing, followed by the step (S) faces, with kink (K) faces growing most rapidly.104 
Hartman and Bennema extended the model by introducing a proportionality relationship between 
attachment energy and growth rate. The hypothesis suggests faces with smallest attachment 
energies grow slowest, therefore, having the most morphological importance.102, 103  
Both models discussed can provide good predictions for crystals grown from vapour, however, 
neither can account for any external interactions from the growth medium.27, 86 Most 
crystallisations, especially those carried out in an industrial setting, involve solvent media, where 
interactions between the solvent and solute are inevitable. The presence of impurities in the system 
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will also have an effect on the interactions present in the crystallisation. These external interactions 
significantly decrease the accuracy of the models discussed.   
1.4 Crystallisation methods 
In order for crystallisation to occur from solution, supersaturation must be achieved. There are a 
number of techniques able to generate supersaturation including evaporation, cooling and the use 
of an anti-solvent. Mechanochemical methods, such as grinding, can facilitate the formation of 
multi-component crystal systems without the need to generate supersaturation.  
1.4.1 Evaporative crystallisations 
Evaporative crystallisations involve supersaturation being generated by allowing solvent to 
evaporate at a constant temperature. This evaporation causes the concentration of the solution to 
increase and pass through the MSZ becoming supersaturated. At higher supersaturations, the 
system moves beyond the metastable limit (dotted line in figure 1.10) into the so-called labile 
region. In this region spontaneous nucleation can occur and this results in the concentration of 
solute decreasing in the solution. Constant evaporation allows the solution concentration to 
increase and again reach increased supersaturation. Further nucleation and growth occurs, reducing 
the concentration again. The cycle (figure 1.10) continues to repeat until complete evaporation 
occurs or the crystallisation is halted and crystals isolated from solution. Evaporative crystallisations 
are a good screening mechanism to use in materials discovery experiments. They are easy to set up 
and do not require any further intervention. Variables, such as temperature and solvent medium, 




Figure 1.10. Generation of supersaturation in evaporative crystallisation methods (orange arrow). Variation of solute 
concentration throughout the evaporative process is depicted by the double headed arrow between supersaturated and 
metastable zone regions (purple arrow) 
1.4.2 Cooling crystallisations 
In cooling crystallisation methods, supersaturation is achieved by slowly cooling an undersaturated 
solution from an elevated temperature. This cooling decreases the solubility of the solute in the 
solvent system and drives the process to supersaturation. The temperature decrease moves 
saturation across the metastable zone and towards spontaneous nucleation in the labile region, and 
subsequently crystal growth (figure 1.11). Initially the solution is cooled to exceed the metastable 
zone and promote spontaneous primary nucleation, this generates a drop in concentration. After 
initial spontaneous nucleation further cooling repeats the same process until a final temperature is 
reached and the crystals are isolated. Controlled cooling is favoured in industrial processes to 
prevent uncontrolled primary nucleation. When the MSZW is known, the process can be controlled 
to maintain the concentration within this determined zone where following initial nucleation, only 
growth of existing crystals is possible, as shown in figure 1.11. By limiting the primary nucleation in 




Figure 1.11. Ideal profile for a cooling crystallisation, including initial spontaneous nucleation, shown on a solubility 
diagram.7 
1.4.3 Anti-solvent crystallisations 
Another method to achieve supersaturation involves the addition of an anti-solvent. The solubility 
of the desired product decreases with the addition of a second solvent in which it is sparingly soluble 
or insoluble (the anti-solvent). This crystallisation method is often used for solutes whose solubility 
shows little change with temperature or to further decrease solubility towards the end of a cooling 
crystallisation to improve the yield achieved.105 
1.4.4 Mechanochemical grinding 
Mechanical methods for the creation of co-crystals is becoming a popular line of research; the most 
notable technique being used is grinding.106 It differs from other crystallisation techniques as it does 
not require supersaturation to be achieved, as nucleation and growth do not occur. There are two 
methods by which this can be done, by grinding two components in a pestle and mortar either with 
the addition of solvent (liquid assisted grinding – LAG) or without. By grinding together components 
in this way, with the input of mechanical energy, it is hoped that a new co-crystal phase will form. 
Addition of a small amount of solvent is believed to play a catalytic role in the co-crystal formation 
before evaporating during the process.106 The energy put in by the mechanochemical process allows 
for the breaking of intermolecular interactions, allowing rearrangement to form new interactions 
between multiple components. This mechanochemical based alternative is advantageous over 
solution based methods for screening multi-component crystal systems due to its rapidity, 
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avoidance of solubility effects and solvent competition as well as being an inherently green process, 
with little to no waste being created.106, 107  
1.4.5 Slurry crystallisation 
Slurry crystallisation is a solvent-mediated method that does not require in-depth knowledge of 
solubility profiles of the solute. This method is useful for the formation of new crystalline phases 
and encouraging the transformation to the most stable forms.95, 108 In slurrying, a suspension of 
starting materials is set up in a solvent with each dissolving until it reaches its solubility limit in the 
solvent system chosen. The suspension is stirred continuously to aid the establishment of an 
equilibrium of the solid materials and those dissolved in solution: the solutes continually move in 
and out of solution, continually making and breaking interactions. If favourable interactions 
between the two materials in the system exist a new co-crystalline form could be formed, reducing 
the concentration of individual components in the system. Once the individual components 
concentration is reduced, the equilibrium is disrupted and further dissolution occurs. After enough 
time has elapsed, full conversion of all starting materials will have occurred. A similar principle can 
be applied to metastable polymorphs, with full conversion to the more stable form being achieved 
after equilibrium is reached and enough time has elapsed. Varying conditions such as the solvent 
medium or the temperature can alter whether the transformation is favoured or not. 
1.5 Industrial crystallisation 
Crystallisation is widely applied in a number of different fine chemical industries and is essential for 
the production of many pharmaceuticals.  The equipment and methods used vary from multi-
purpose batch crystallisers to highly specialised equipment specific to particular processes and 
products.109  
1.5.1 Batch crystallisation 
Batch crystallisation methods are the most widely utilised processes within a number of different 
industries to produce crystalline products. The platform largely employed in production and 
purification of pharmaceuticals is the stirred tank reactor (STR). An STR consists of a jacketed batch 
vessel with a motor-controlled impeller to allow mixing to occur. Although widely used in the 
pharmaceutical industry, STRs present a range of difficulties with regards to control of crystallisation 
conditions at larger scales. With an STR it is harder to maintain consistent heat transfer throughout 
the whole volume as the scale increases, often resulting in longer reaction times. Mixing is a critical 
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success factor during the crystallisation process and, as a result, when reactions are scaled up the 
optimisation of mixing conditions becomes paramount.110 Due to the difficulties maintaining 
consistent conditions throughout the whole STR the control of product specifications, such as size 
distribution, polymorphic form and morphology, can be difficult, resulting in inconsistency and 
causing problems for downstream processes.7, 111 STRs require a large amount of solvent and take 
up a substantial amount of space due to their large volumes and pose difficulties when it comes to 
cleaning vessels between batches, causing an increase in downtimes of processing plants. 
1.5.2 Continuous crystallisation 
Whilst batch techniques are well-established in the pharmaceutical industry, there is significant 
interest in continuous methods of crystallisation. This involves feed solution being continuously 
pumped into a crystalliser whilst product is continually being removed at the same rate. Continuous 
techniques are often more difficult to develop but they offer the potential for enhanced 
reproducibility and control of crystal physical properties.112 In addition, continuous methods can 
allow for better efficiency with respect to reagents, solvents, energy and space as well as minimising 
waste production and reactor downtime, for cleaning and maintenance.7 By allowing better control 
of physical properties, such as particle size and shape, it is possible to eliminate some downstream 
corrective processes, for example milling to produce a more homogeneous particle size.112 In 
comparison to STRs, scale up of an existing crystallisation method is simpler as the process simply 
requires running for longer, therefore having no effect on variables such as solution concentration 
or mixing. Continuous crystallisers have the potential for the establishment of fully integrated 
processes involving flow chemistry, purification and final formulation. 
There are various platforms with which to carry out continuous crystallisation. An STR can be 
adapted to allow for continuous feed of solution into the vessel and product removal at the same 
rate, a mixed-suspension, mixed-product removal (MSMPR) crystalliser. Additional vessels can be 
added to create a series of STRs (as an STR cascade (cSTR) or multi-stage MSMPR) to allow for an 
increase in the length of time a solution spends within the crystalliser cascade (residence time), 
although this will increase the running costs of the process.7  
Tubular flow platforms can also be used to achieve continuous crystallisation. This is the method 
utilised in continuous oscillatory baffled crystallisers (COBCs). The use of COBCs can help overcome 
a number of problems faced when using batch processing techniques.7 The COBC set up at the 
University of Bath is shown in figure 1.12. The tube has a number of ‘restrictions’ (baffles) equally 
spaced along its length to ensure equal volumes in each.113 Between each restriction mixing is 
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provided by oscillatory motion as an additional flow mechanism superimposed on the net flow of 
the feed solution.7 The combination of restrictions in the tube and oscillatory pressure generates 
whirlpools in each section of the tube, optimising mixing.113 
 
Figure 1.12. Set up of COBC at the University of Bath. (a) input of feed solution via peristaltic pump, (b) output of solvent 
and crystalline product, (c) motor driven bellows to set up oscillation and (d) direction of flow along temperature gradient 
represented by colour change (red to blue shows hot to cold) 
A solution is fed into the crystalliser via a peristaltic pump, the continuous feed drives the flow of 
the solution through the length of the crystalliser. Motor driven bellows also help pump the feed 
solution through the baffled tubing, providing the oscillatory flow and aiding mixing. Controlled 
cooling is possible using jacketed tubing attached to temperature-control circulators: 
supersaturation is achieved due to the establishment of this temperature gradient. The jacketed 
tubing allows for improved heat transfer when compared to the MSMPR set up. Once cooling 
crystallisation is complete, with the feed solution having travelled through the length of the 
crystalliser, the crystalline product is filtered from the solution and isolated.   
The nature of the flow through continuous crystalliser systems is important as it can affect vital 
parameters throughout the system. Ideally, they would operate under plug flow (figure 1.13) to 
provide ideal mixing profiles as well as consistent heat transfer, though this is often hard to achieve.7 
Carrying out continuous crystallisations as close to plug flow as possible is vital for production of 
crystals with uniform properties. Near plug flow conditions can be obtained by using very high flow 
rates in a tubular reactor to create a turbulent flow environment (figure 1.13).7 Laminar flow, on the 
other hand, provides unfavourable conditions for consistent heat transfer and ideal mixing profiles, 




Figure 1.13. Illustrations of different flow mechanisms; (a) laminar flow, (b) turbulent flow and (c) plug flow 
A further example of a tubular crystalliser is the KRAIC (Kinetically Regulated Automated Input 
Crystalliser), developed at the University of Bath. This is a mesoscale flow reactor that works on the 
basis of segmented flow, in which individual segments (slugs) of feed solution are separated by air 
and carrier fluid. The creation of discrete solution slugs allows each slug to act as its own micro-
batch reactor; importantly, no back mixing can occur. A carrier fluid is chosen with favourable 
wetting properties to coat the inside of the tube and prevent the solution segment from touching 
the walls, thus removing this as a nucleation site and preventing encrustation.  The carrier fluid and 
solvent used must be immiscible to allow for segmentation and to create a non-slip boundary 
between the two, generating bolus flow to provide mixing within each slug throughout the length 
of the crystalliser.114 More in depth discussion about the KRAIC set up is provided in chapter 3.  
Microscale continuous reactors are also available. Microfluidic continuous platforms have the 
benefits of well-defined laminar flow characteristics and enhanced heat and mass transfer. They are 
closed systems so also protect from undesired nucleation resulting from the presence of foreign 
particles.115 Due to their size they have a low consumption of reagents, an attribute that is 
particularly attractive in research on expensive pharmaceutical materials. However, due to the small 
internal diameter there is an increased risk of sedimentation and blockages occurring in the reactor. 
So far microfluidics has not been widely used for the continuous crystallisation of APIs. 
Despite the potential benefits of using continuous crystallisation, its uptake in the pharmaceutical 
industry has been slow. The majority of industrial scale production is still carried out using batch 
crystallisation methods, such as cooling and anti-solvent crystallisations.112 The slow uptake of 
continuous processes in industrial production is largely due to the significant research already 
available for batch crystallisation. Batch methods have been implemented for many years with 
substantial capability for mass production already available to pharmaceutical companies. The well-
established processes allow rapid development of new pharmaceutical products and efficient 
production. There is considerably less understanding of continuous crystallisation processing which 
could result in long development times, presenting a significantly increased risk to the companies.   
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Another hurdle the industry must overcome to see increased implementation of continuous 
crystallisation is the strict regulatory framework imposed on the pharmaceutical industry. Quality 
control can be simplified in batch processes. The introduction of powerful process analytical 
techniques (PAT) that can be used in-situ during a continuous crystallisation is key to overcoming 
the regulatory barriers and allowing wider scale use of continuous crystallisation.116 
Research within the CMAC Future Manufacturing Research Hub is aimed at developing continuous 
manufacturing processes and exploring the extent to which these platforms can improve control of 
production, looking to establish these as a competitor to batch approaches for pharmaceutical 
manufacturing. It is important to understand that the crystallisation method chosen is based on the 
specific requirements for the particular product being developed. Continuous crystallisation is not 
always the most suitable method to choose and a number of different factors need to be considered 
when making the decision.    
1.6 Crystal engineering 
Multi-component systems are an interesting area of research, particularly for pharmaceuticals, as 
they allow for the possibility of property manipulation of crystalline solids. The difficulty is predicting 
the interactions components may have with each other and, therefore, the resulting multi-
component crystals they may form. Crystal engineering is a means by which to attempt to combat 
these unknowns. Crystal engineering was first coined in literature in 1955 but has been largely 
associated with a paper published by G. M. J. Schmidt in 1964. The paper correlated the solid-state 
reactivity of trans-cinnamic acid with their crystal structures.117-119  
The primary focus of crystal engineering is to establish reliable intermolecular interactions between 
molecular structures.73 Interactions between molecules are broken down into supramolecular 
synthons, kinetically defined units that contain the essential features of the crystal structure. 
Supramolecular synthons are developed to closely resemble the functional groups within the 
molecules. Designing synthons requires a strong understanding of the intermolecular interactions 
within a structure.120 Crystal engineering focuses on interactions between molecules and, therefore, 
mainly focusses on the manipulation of the intermolecular forces. Due to their collective strength, 
reliability and, importantly, directionality, the most widely utilised intermolecular force in crystal 
engineering is hydrogen bonding.119, 121 Other molecular interactions can be utilised, such as van der 
Waals or π-interactions, but hydrogen bonds are considered the strongest, non-ionic intermolecular 
interactions that can exist within a structure.122 
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1.6.1 Intermolecular interactions 
Crystalline solids are held together by a variety of different bonds and interactions. They can be 
strongly ionically or covalently bonded (for example the bonding within molecules) and involve a 
range of intermolecular interactions. In order to apply crystal engineering principles to design new 
crystalline forms an in-depth understanding of hydrogen bonding and other intermolecular 
interactions is required.11, 118, 120 There are many possible intermolecular interactions to consider, 
including hydrogen bonds, halogen bonds, π-π interactions and van der Waals interactions. Once 
those present are recognised they can be categorised and applied to crystal design. 
 1.6.1.1  Hydrogen bonds 
Hydrogen bonds can be described as “an attractive interaction between a hydrogen atom from a 
molecule or a molecular fragment, D-H, in which D is more electronegative than H, and an atom or 
a group of atoms in the same or a different molecule, in which there is evidence of bond 
formation”.123 For the design of extended crystal structures, considerations of hydrogen bonds 
between two different molecules are more important than those within a molecule.  The relative 
strength of hydrogen bonds often depends on the electronegativity of the hydrogen bond donor (D 
atom), but also the acceptor atom with which the hydrogen bond is being formed. These 
interactions are often considered to be electrostatic between a covalently bonded hydrogen (with 
a partially positive charge) and a lone pair on the hydrogen bond acceptor. However, it is not always 
possible to rationalise the interactions this way as stronger interactions often point towards more 
covalent contributions.124 Typically hydrogen bonds are considered the strongest, non-ionic 
intermolecular interactions that can exist within a structure.122  
 
Figure 1.14. Typical hydrogen bond motifs (synthons); in the definition of hydrogen bond donors given above, the DH 
donor fragment here has D = O or N.  (a) carboxylic acid dimer homo-synthon, (b) amide∙∙∙acid hetero-synthon 
The components forming the hydrogen bonds often form in identifiable and repeatedly occurring 
patterns known as supramolecular synthons; the directionality of hydrogen bonds is key in allowing 
potential rationalisation of these. These synthons represent an intermolecular building block 
involving more than one molecule (hence supramolecular), held together by interactions that are 
not covalent. These can then be considered as a supramolecular building block that helps define the 
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interactions within the crystal packing. Hydrogen bonds can form between homo-synthons, two or 
more of the same molecules, or hetero-synthons, two or more chemically distinct organic molecules 
(figure 1.14).125 In order to define the interactions forming such synthons, hydrogen bond graph set 
notation was established by Etter et al.; the symbolic representation of this is shown in equation 
1.5.126 There are four types of hydrogen bonding interactions in this classification: a ring (R), a chain 
(C), a non-cyclic dimer (D) and an intramolecular interaction (S). A hydrogen bond acceptor (A) is 
the molecule that accepts the proton whereas the hydrogen bond donor (D) donates it (in this 
nomenclature, DH is the equivalent of XH in the definition given above). In the equation describing 
Etter rules for naming hydrogen bond interactions, X denotes the type of hydrogen bond, A 
represents the number of hydrogen bond acceptors and D represents the number of hydrogen bond 
donors. (n) designates the total number of atoms involved in the interaction pattern being described 
𝑋𝐴𝐷(𝑛)                      Equation 1.5  
Hydrogen bonds can vary in strength depending on the atoms present in the hydrogen bonds (table 
1.1). The strength is characterised by the distances between the donor and acceptor involved. 
Table 1.1. Properties of different strength hydrogen bonds 127 
 Strong Moderate Weak 
A-H∙∙D interaction Mostly covalent Mostly electrostatic Electrostatic 
Bond lengths A-H ≈ H∙∙D A-H < H∙∙D A-H << H∙∙D 
H∙∙D (Å) ~ 1.2 – 2.5 ~ 1.5 – 2.2 2.2 – 3.2 
A∙∙D (Å) 2.2 – 2.5 2.5 – 3.2 3.2 – 4.0 
Bond angles (ᵒ) 175 - 180 130 – 180 90 – 150 
Bond energy (kcal mol-1) 14 - 40 4 – 15 < 4 
As well as more commonly observed intermolecular hydrogen bonds, it is also possible to form 
intramolecular hydrogen bonds between donors and acceptors within the same molecule. These 
hydrogen bonding interactions can fix a molecular conformation and therefore influence the crystal 
structure and packing. Hydrogen bonds primarily occur between one donor and acceptor group, 
known as two-centred interactions. However, multiple interactions are also possible between 
donors and acceptors, forming bifurcated or three-centred hydrogen bonds. These generally involve 





Figure 1.15. Different hydrogen bonding interactions where D is the donor and A is the acceptor. (a) a two-centred 
hydrogen bond, (b) a bifurcated hydrogen bond between one donor and two acceptors and (c) a bifurcated hydrogen 
bond between two donors and one acceptor.  
 1.6.1.2  π-stacking 
When two or more aromatic rings are within close proximity to each other they can form 
interactions known as π-π interactions or π-stacking. These interactions occur when the attraction 
of the π-electrons and the σ-framework outweighs any unfavourable interactions, such as π-
repulsions.129 Different arrangements of neighbouring aromatic rings are possible, with each 
potentially leading to significant π-stacking interactions (figure 1.16). The geometry of the 
interaction between the rings is influenced by their substituents, whose presence alters the electron 
cloud polarisation. For example, the use of an electron-withdrawing substituent will decrease the 
π-electron density in the ring, reducing repulsions and allowing a stacked geometry to occur.129 
 
Figure 1.16.  Face-centred stacking, (b) off-centre parallel stacking, (c) edge-to-face interactions.130 
 1.6.1.3  Weak interactions 
Further weak interactions are also present in crystal structures but are often not considered in 
crystal engineering as they are less easy to predict. These weak interactions can be both attractive 
and repulsive and are often known as van der Waals interactions. This umbrella term includes 
dipole-dipole, dipole-induced dipole and London dispersion (instantaneous dipole) forces.131  
Dispersion forces arise between non-polar species, where neither possesses a permanent dipole. 
Fluctuations of electron density result in the formation transient dipoles and an interaction is 
possible between the molecules. If a polar molecule is present, dipole-induced dipole interactions 
can occur. The presence of a molecule with a permanent dipole can influence the electron cloud of 
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a nearby non-polar molecule and induce a dipole. If both molecules have a permanent dipole, 
dipole-dipole interactions can occur between molecules. These interactions are dependent on the 
orientation of the molecules present and the distance between them in the structure.132   
1.6.2 Multi-component crystallisations 
The materials of interest in crystallisation studies have increasingly broadened their scope from 
single-component systems to an enhanced focus on the use of multi-component crystallisations to 
manipulate the properties of the desired products, without affecting the biological activity of the 
API itself. Multi-component crystallisations require the active ingredient to be crystallised in the 
presence of one or more other components to change the conditions of the crystallisation and, 
hopefully, the final product. The effect of the secondary component on the system depends on its 
properties and the interactions it can achieve with the API. When crystallising from a solution 
containing two separate molecular solutes the most common outcome, when no chemical reaction 
occurs, is the recrystallisation of the two separate molecular crystals. In such cases, the presence of 
the secondary molecule can sometimes act as a ‘template’, causing changes in properties such as 
crystal morphology and the polymorphic form of the target component.51, 133. The second outcome 
involves the incorporation of the secondary element (the co-former) and the formation of a multi-
component crystalline system – often termed co-crystallisation (further explanation in section 1.7). 
Co-crystallisation attempts to bring two different molecular species together within one crystalline 
lattice without making or breaking covalent bonds.134 Co-crystals are often formed due to hydrogen 
bond interactions between the two separate molecules. Thus, hydrogen bond interaction prediction 
can be utilised to determine the likelihood of a co-crystal forming. The CCDC software Mercury135-
137 offers the ability to run these calculations for interactions between a target molecule and a list 
of potential additives or co-formers identified by the user. The molecular complementarity check 
gives an indication of which molecules have the potential to form sufficiently strong hydrogen bonds 
to create a new co-crystalline phase.  
1.6.3 Molecular complementarity calculations 
Molecular complementarity is a co-crystal design element incorporated into the CCDC Mercury 
software, utilising informatics approaches to identify common features/patterns in previously 
published structures. Co-crystals presented significant research interest due to the potential for 
modifying and tailoring physiochemical properties of the target molecule, including the potential to 
 
35 
influence morphology. The calculations carried out to assess the likelihood of co-crystallisation 
could be useful in developing a list of potential additive candidates for morphology modifications.  
Calculations are based on quantitative structure-activity relationship molecular descriptors.138-141 
Molecules that tend to co-crystallise have similar properties, such as shape and polarity. Molecular 
descriptors have been given defined threshold values based on the majority of co-crystals entered 
into the CSD database.142 This allows co-formers that are unlikely to interact effectively with the 
target molecule to be filtered out before experimental screening. Libraries of potential co-formers 
can be developed for analysis to fit the outcomes required by the investigation. This type of analysis 
has been particularly effective in cases where co-crystal formation is difficult. In the example of 
artemisinin, 75 co-formers were screened experimentally with only two successful outcomes. Using 
the complementarity calculations, 33 of the 75 co-formers would have been eliminated as potential 
candidates.143 This 44% reduction in co-formers to screen not only increases the efficiency of the 
experimental steps taken, by reducing time and costs associated with the screening, but also the 
success rate of the experiments carried out.  
The outcomes of the calculations can be analysed with respect to each molecular descriptor 
individually. Statistical analysis shows molecules with similar shapes and polarities tend to co-
crystallise more effectively.142 This analysis led to five different descriptors being chosen for 
calculations of molecular complementarity. There are two molecular polarity descriptors, dipole 
moment and the fraction of N and O atoms (FNO). Dipole moments of molecules in co-crystals show 
a strong correlation to each other, while the FNO of a molecule is calculated by dividing the total 
number of N and O in the molecule by the number of heavy atoms.142 Size and shape descriptors 
were defined using the box model of crystal packing. The box model defines a crystal as being made 
up of identical boxes with three unequal sides denoted large (L), medium (M) and small (S), L> M>S. 
These boxes are stacked with faces touching and edges aligned, in a close-packed arrangement.144 
These lengths refer specifically to the size of the molecule, whereas ratios of these lengths describe 
the shape of the molecule. In planar molecules, S/L ratios are small. Small M/L ratios describe rod-
shaped molecules. The size descriptors used in molecular complementarity calculations are S axis, 
S/L ratio and M/L ratio. It is believed the shape descriptors are much more important for co-
crystallisation than the individual dimensions of the molecules.142 
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1.7 Types of crystalline solids 
Crystalline solids can exist in many different distinct solid forms, namely polymorphs, co-crystals, 
solvates/hydrates and salts (figure 1.17). 
 
Figure 1.17. Illustration of possible crystalline forms for single and multi-component systems; (a) polymorphs, (b) salts (c) 
co-crystal and (d) solvate/hydrate. The counter-ion in the salt case can be a simple ion or a molecular ion, the latter is 
often generated by proton transfer during the crystallisation process. 
1.7.1 Polymorphism 
Polymorphism is observed when a solid crystalline phase of a compound has the ability to form in 
two or more different crystalline structures.145 By definition polymorphs have the same elemental 
composition but differ in their unit cell and crystal packing, giving rise to differences in the physical 
properties they exhibit. As a result, polymorphism is of great interest in the pharmaceutical industry 
as the differing properties often have implications on processing steps, formulation and drug 
availability.146  
An example of a pharmaceutical polymorph is paracetamol, which can exist in at least three 
polymorphic forms and is an example of packing polymorphism. Form I shows the molecules packing 
in a herringbone arrangement whereas form II shows a layered structure (figure 1.18). The layering 
observed in form II gives the paracetamol more favourable physical properties, allowing for better 




Figure 1.18. Crystal packing of two paracetamol polymorphs: Form I viewed along crystallographic a axis showing 
herringbone structure (left) and form II viewed along the crystallographic b axis showing the layered packing (right) 
Investigating and understanding polymorphism is crucial in the pharmaceutical industry. Intensive 
screening of new drug molecules is essential under a range of crystallisation conditions. Typically, 
the most stable polymorph is required to prevent any unwanted phase transitions during production 
or whilst the final product is being stored. An example highlighting the importance of thorough 
polymorph screening is Ritonavir. Initially only one solid form of the molecule was determined and 
a formulation developed and sold as Norvir for the treatment of AIDS. A few years later several 
batches of the drug failed a dissolution test. Screening of the contents of the capsules showed a new 
polymorph of ritonavir had formed, form II. This new phase dominated production, as the more 
stable polymorph, and immediate reformulation was necessary. This cost the company huge sums 
of money and threatened the lives of those dependent on the drug. Ritonavir differs from 
paracetamol as it exhibits conformational polymorphism with the different conformational isomers 
crystallising as distinct polymorphic forms.147 
The relative stabilities of polymorphs depend on their free energies, with the most stable polymorph 
having the lowest free energy. The lowest energy polymorph is termed the thermodynamic form, 
with the other forms termed metastable. Often metastable forms are desirable due to their 
favourable properties. Metastable forms are more soluble, for example, and can offer improved 
bioavailability. They can also offer other favourable properties, under grinding and compression for 
example, but have the tendency to transform to the thermodynamic polymorph. This 
transformation can be detrimental in terms of efficacy, such as discussed with ritonavir.10  
Thermodynamically there are two types of polymorphism: enantiotropy and monotropy (figure 
1.19). In monotropic polymorphs, one form is stable over the entire temperature range, until the 
melting point is reached: no solid-solid transition exists below the melting point. Enantiotropic 
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polymorphs exhibit a solid-solid transition at a temperature below the melting point of either 
polymorph: each has a defined temperature range over which it is the most thermodynamically 
stable.145  
 
Figure 1.19. Plots showing the free energy relationship with temperature for enantiotropic systems (left) and monotropic 
systems (right). G is the free energy, T is the temperature, A, B and Liq refer to polymorphs A, B and liquid phase and Tm 
and Tt correspond to temperature of melt and transition respectively. 
The solubility of polymorphs is also affected by enantiotropism and monotropism: in an 
enantiotropic system the solubility curves cross whilst in a monotropic system they do not (figure 
1.20). The temperature at which the curves cross is the temperature at which the phase transition 
occurs. In the monotropic case, where the solubility curves do not cross, the polymorph with the 
higher solubility is the metastable form; in this case the metastable polymorph will retain higher 
solubility than the thermodynamic form over the full temperature range. 
 
Figure 1.20. Solubility curves showing the relationship between two polymorphs enantiotropically related (left) and 




Salts are formed due to proton transfer from an acidic component on one molecule to a basic 
component on the other. This is another way in which a co-crystalline system can be produced, 
through the formation of molecular salts. The major interaction in these systems is now an 
electrostatic interaction between a positively charged component and a negatively charged 
component, adding to the hydrogen bonding as seen with neutral co-crystals. Whether or not 
proton transfer is likely to occur will be determined by the pKa difference between the acidic and 
basic group. While not a definitive rule, if ∆pKa (= pKa(base) ‒ pKa(acid)) is greater than 2-3 a salt is 
expected to form, while for ΔpKa < 0 a co-crystal is generally expected. Knowledge of these values 
can be used to guide the choice of an appropriate co-former to obtain the desired results. No 
prediction of what will form is possible using this method when the ∆pKa value sits between 0 and 
3.148 It should be noted that pKa is a solution characteristic, hence less relevant for the resulting solid 
state structure. 
The formation of salts can again be useful in altering the physical properties, most significantly 
improvements to solubility, without affecting the activity of the drug itself. As a result, it is estimated 
over half of all drug molecules produced are administered as salts.149 
1.7.3 Co-crystals 
Co-crystals are defined as solid-state materials with two or more components creating a structurally 
homogeneous crystalline material.150 Both components exist as neutrally charged species and are 
solids at room temperature. Interactions between the components within the crystalline structure 
are intermolecular and non-covalent interactions, primarily hydrogen bonds, rather than 
electrostatic attractions and covalent bonds. As a result, compounds used to form co-crystals do not 
require any ionisable sites.  The driving force for the creation of co-crystals is the formation of 
stronger, more favourable hydrogen bonds between the two components than those existing in the 
original single component crystals.151 Packing is also an important factor, the packing of the two 
components together must be favourable to allow the crystal to form. This change in the molecular 
arrangement with the addition of a second molecule can result in significant changes to the physical 
properties of the material. 
Crystalline forms of pharmaceutical molecules are the most often utilised due to their stability and 
the ease with which they can be characterised. Co-crystals are of particular interest to the 
pharmaceutical industry due to this potential to improve the physical properties of APIs.152 API 
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molecules are good targets for co-crystallisation as, often, they contain an abundance of hydrogen 
bond donor and acceptor groups. Pharmaceutical co-crystals are formed by combining the target 
API with a GRAS additive which will not affect the therapeutic effect of the drug or cause any harmful 
secondary effects. The ability to alter physicochemical properties of a drug molecule without 
compromising its structural integrity, and as a result the bioactivity, has increased the interest in co-
crystallisation research.153  Co-crystallisation is not yet widely used in pharmaceutical production 
due to complications as a result of having extra components present. The introduction of additional 
components can result in difficulties tightly controlling the form produced and mixed phases are 
often created, from which separation is required and often difficult. 
1.7.4 Solvates/hydrates 
Solvates form as a direct result of the incorporation of solvent molecules into the crystal structure, 
forming a new multi-component crystal structure; they are sometimes inaccurately termed 
pseudopolymorphs, and this terminology remains commonplace. Hydrates are specific forms of 
solvates whereby the solvent being incorporated is water. The inclusion of solvent in the crystal 
structure changes the intermolecular interactions and therefore gives the new form unique physical 
properties. Particularly important for the pharmaceutical industry is the effect on solubility and 
bioavailability of the new form: often solvates possess a lower solubility than the unsolvated phases. 
Hydrates are more common than organic solvates.10 It has been suggested that approximately 33% 
of all organic molecule are able to form hydrates, whereas solvates are reported to be much less 
prevalent (10%).154 Water can often be readily incorporated into a structure due to small molecular 
size, adaptable hydrogen bonding and ability to stabilise structures by correcting imbalances 
present between number of donor and acceptor atoms.155, 156 Although there appear to be benefits 
of hydrated crystalline systems, such as improved solubility, little research has been carried out into 
their long term stability, particularly their thermal stability. The variation of temperature can result 
in the loss of water from the crystal lattice, changing the properties and structure of the product. 
Co-crystal hydrates remain largely unexplored as a class of compounds.154 As a result, it is important 
to determine whether new pharmaceutical molecules form solvates or hydrates for practical 
manufacturing decisions to be made. This is likely due to solvates being less desirable in the 
pharmaceutical industry as a very limited number of solvents are regarded as sufficiently safe as to 
be allowed to be present in stoichiometric quantities in pharmaceutical products.157 
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1.8 Aims and objectives 
The aim of the work presented in this thesis is to produce a favourable morphology modification in 
an industrially relevant active pharmaceutical molecule. The method by which modifications were 
investigated involves changing the conditions of crystallisations, including the solvent systems and 
crystallisation methods used. Particular focus of the research involved the influence of intentionally 
added impurities on the resulting crystal morphology; both in additive quantities and for multi-
component investigation. The major API of interest for this research was isoniazid (IZN), chosen due 
to its tendency to crystallise with a needle morphology. The isoniazid investigation was mirrored for 
another related API which also exhibits a preference for needle morphologies, pyridoxine (PYR).  
The scale up of the impurity investigations is an importance consideration for assessing the potential 
for implementation into the pharmaceutical industry. As a result, a focus was placed on scale up of 
successful morphology modifications and, hopefully, transfer into a continuous platform. 
During the course of the research, crystallisation workflows were produced for the investigation 
into additive effects on a crystallisation and the production of new multi-component materials. 
Another focus of the research, therefore, became the benchmarking and implementation of these 
workflows. These workflows have been applied to both IZN and PYR investigations, as well as a 
number of CMAC target molecules. 
1.8.1 Isoniazid (IZN) 
Isoniazid (IZN) is an anti-mycobacterial agent used in the treatment of latent tuberculosis (TB); the 
state whereby a patient is infected with TB bacteria but does not become ill or experience any 
adverse symptoms.158 The clinical use of IZN to treat TB infections has been in circulation for over 
60 years. Commonly patients are prescribed IZN in combination with further anti-TB drugs, including 
rifampicin, pyrazinamide and ethambutol or streptomycin. This is due to the increasing resistance 
of TB bacteria to the administration of IZN alone.159, 160 In 1999, TB was recognised a global health 
problem by the World Health Organisation (WHO) and they dubbed the fixed-dose combination 




Figure 1.21. Labelled IZN molecule (left) and unit cell projection for IZN (INICAC02) (right)  
IZN has been assumed to be monomorphic for the past 60 years. However, in March 2020 (by other 
researchers, but during the course of the investigations presented here) two new polymorphic 
forms of IZN were isolated from melt and nanoconfinement crystallisations. Both new forms of IZN 
are highly metastable; form II transforms to form I at room temperature within hours and form III is 
only stable at room temperature for less than a minute. 162 Due to the highly metastable nature of 
the newly discovered polymorphs, only the properties and structure of the stable form I will be 
discussed in this thesis.  
The thermodynamic form I of IZN crystallises in the orthorhombic P212121 space group (figure 1.21). 
An almost herringbone packing structure can be seen, creating a zig zag pattern of linked chains 
throughout the lattice (figure 1.22). The aromatic ring systems stack neatly on top of each other, 




Figure 1.22. Packing of an IZN (INICAC02) crystal as viewed along the b axis (left) and a axis (right) 
Chains of IZN molecules are connected via N3-H∙∙∙N1 hydrogen bonds (table 1.2). Both hydrogen 
atoms on N3 donate to the pyridine N1 of two separate IZN molecules, creating a bifurcated 
interaction. One of the hydrogen bonds is observed in the same plane as the accepting IZN molecule, 
with the second occurring out of plane with the accepting IZN molecule. These interactions are 
illustrated in figure 1.23 (left). The chains are further connected to each other by a second hydrogen 
bond between the N2-H amide bond and the terminal amine nitrogen, N2-H∙∙∙N3. This interaction is 
illustrated in the image in figure 1.23 (right). 
 






Table 1.2. Hydrogen bond distances and angles for IZN form I crystal structure 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
N3-H1∙∙N1 0.92(2) 2.14(2) 3.046(2) 172(2) 
N3-H2∙∙N1 0.89(2) 2.58(2) 3.157(2) 123(2) 
N2-H∙∙N3 0.90(2) 2.05(2) 2.919(2) 163(2) 
 
IZN most commonly crystallises in a needle morphology. As this tends to be unfavourable in the 
pharmaceutical industry it is a good target molecule for research into morphological modification. 
The BFDH morphology prediction tool in Mercury predicts an elongated crystal shape (figure 1.24), 
partially agreeing with the experimentally determined needles. The BFDH morphology seems to 
suggest a more rod-shaped crystal, despite the elongation being observed. 
 
Figure 1.24. BFDH predicted morphology of IZN (INICAC02) (left) and associated packing (right) 
In this calculated morphology there are four fast growing faces which lie close to perpendicular to 
the a axis ((101), (110), (1-10) and (10-1)). This results in elongation of the slow growing faces 
parallel to the crystallographic a axis. This suggests the more dominant hydrogen bonds are those 
between the amine N3-H bond and the N1 in the pyridine ring as they allow growth to occur parallel 
to the a axis. The elongation could also be rationalised as a result of π-stacking of the pyridine rings, 
these stack along the a axis (perpendicular to the slow growing faces) and are likely the dominant 
growth factor (figure 1.24; right). Carefully choosing an additive or solvent system that can interrupt 
these favourable interactions and slow the growth of the four fast growing faces could result in less 
elongation and a more equant morphology. 
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Crystals of the IZN starting material were also face indexed experimentally. Using the BFDH function 
in Mercury a schematic of the crystal was generated from this face-indexing (figure 1.25). Similarities 
to the predicted morphology are clear and the packing remains the same. 
 
Figure 1.25. BFDH morphology schematic of IZN obtained from Sigma Aldrich, generated from face-indexing. 
 
Figure 1.26.  PXRD patterns of IZN: (a) form I calculated from SCXRD data (INICAC02), (b) form II calculated from SCXRD 
data (INICAC04) and (c) measured IZN starting material 
Comparison of the calculated PXRD pattern with those of the thermodynamic form I of IZN and 
metastable form II, generated from the known SCXRD structure, to a measured pattern of IZN 
purchased from Sigma Aldrich confirms the purchased sample as pure form I; the patterns match 
well (figure 1.26). Form III has not been included as no structure solution has been achieved for this 
polymorph and therefore a PXRD pattern cannot be calculated. In future PXRD analyses discussed 
in this work, only the form I pattern will be used for analysis due to the highly unstable nature of 
the other two polymorphic forms. 
The IZN material was also characterised using DSC. The trace achieved shows a sharp endothermic 
peak at 171 ⁰C, which corresponds well to the literature value for the melting point of IZN; 170-
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174 ⁰C (figure 1.27).163 The absence of other peaks in the trace and sharpness of the IZN melt peak 
also confirm the purity of the material purchased. 
 
Figure 1.27.  DSC trace of IZN material obtained from Sigma Aldrich 
The solubility of IZN was determined in water (H2O), ethanol (EtOH), propan-2-ol (IPA) and ethyl 
acetate (EtOAc) using observation methods (figure 1.28). 
 
Figure 1.28. Solubility curves for IZN: Crystallised from (a) H2O, (b) EtOH, (c) IPA and (d) EtOAc 
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1.8.2 Pyridoxine (PYR) 
Pyridoxine (PYR) is one of six related components that make up vitamin B6. This vitamin functions 
in the body as a co-enzyme for the metabolism of amino acids, glycogen and sphingoid bases.164 PYR 
is often prescribed alongside IZN to counteract some side effects associated with taking IZN. For 
example, it is knowns to prevent peripheral neuropathy associated with prolonged exposure to IZN 
and can also reduce other IZN toxicities. As a result, PYR is recommended to those in high risk groups 
and those being prescribed IZN for extended periods of time. In some cases, it is included in the FDC 
tablet, due to difficulties procuring and distributing the vitamin separately in some countries.165 
 
Figure 1.29. Labelled PYR molecule (left) and unit cell projection for PYR (BITZAF) (right) 
Like IZN, PYR has no reported polymorphs, hydrates or solvates. The only reported structure for PYR 
crystallises in the orthorhombic Pna21 space group (figure 1.29). A zig-zag pattern is seen in the 
packing of the PYR crystal with the aromatic rings of the molecules stacking on top of one another 
creating layers (figure 1.30).   
 
Figure 1.30. Packing in PYR (BITZAF) crystal  
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In this structure there are three intermolecular hydrogen bonds and one intramolecular interaction 
(table 1.3). The intramolecular interaction is between two terminal OH groups, donating from O1-H 
to O2, following the second general rule for hydrogen bonding: ‘six membered intramolecular 
hydrogen bonds form in preference to intermolecular interactions’.126 An intermolecular hydrogen 
bond is seen to the N in the pyridine ring; donation occurs from O2-H to N1 acceptor in a second 
PYR molecule. The final oxygen, O3, acts as both an acceptor and a donor, forming hydrogen bonds 
to two different PYR molecules. O3 accepts a hydrogen bond donation from an O3-H on second PYR 
molecule and simultaneously is involved in the same hydrogen bond donation to a third PYR 
molecule (figure 1.31).  
 
Figure 1.31. Hydrogen bonds present in PYR (BITZAF) crystal structure 
 Table 1.3. Hydrogen bond distances and angles in PYR crystal structure i 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O1-H∙∙O2 0.96 1.73 2.58 147 
O2-H∙∙N1 0.99 1.74 2.73 177 
O3-H∙∙O3 0.99 1.75 2.70 157 
 
Commonly, the resulting PYR crystals appear to have a needle morphology. Due to this morphology 
being unfavourable in the pharmaceutical industry, it is another good target molecule for research 
into morphological modification. The BFDH morphology prediction tool in Mercury predicts an 
elongated crystal shape (figure 1.32). This partially agrees with the experimentally observed 
needles, however, the prediction suggests a fatter rod-shaped crystal than achieved experimentally. 
                                                          
i Hydrogen bonding distances and angles are taken from published data (BITZAF). No errors are associated 




Figure 1.32. BFDH predicted morphology for PYR (BITZAF) (left) and associated packing (right) 
In this calculated morphology there are six fast growing faces which lie almost parallel to the a axis 
((0-1-1), (0-11), (1-1-1), (1-11), (-1-1-1) and (-1-11)). The fast growth observed on these faces results 
in the elongation observed for the slower growing faces surrounding the needle crystal, parallel to 
the crystallographic b axis. The hydrogen bonds contribute to growth in this direction, indirectly, 
due to the angled nature of the interactions. The elongation is most likely to be the direct result of 
the π-π interactions arising from the stacking of the aromatic rings (figure 1.32, right). These stack 
along the crystallographic b axis contributing to the fast growing faces. This is likely the dominant 
growth factor. Choosing an additive or solvent system that can effectively interrupt these favourable 
interactions, slowing the growth of the fast growing faces, could ultimately influence the overall 
morphology and create a more equant shape.  




Figure 1.33. PXRD data for PYR: (a) calculated from SCXRD data (BITZAF) and (b) measured PYR starting material 
The purity of the starting material, obtained from Sigma Aldrich, was determine by comparison of 
the calculated PXRD pattern, generated from the known SCXRD structure, to a measured PYR 
pattern; these match well (figure 1.33).  
DSC characterisation of the starting material was also carried out. A sharp endothermic peak is 
observed at about 154 ⁰C (figure 1.34). This agrees fairly well with the literature melting point for 
PYR, quoted as 159 ⁰C.166 The slight depression in melting point could be an indication of the 
presence of impurities, with these often causing the melting point of a solid to be lowered. The 
sharpness of the peak can indicate a high level of purity, and the absence of any further peaks 
confirms this. There is a small endothermic event shortly after the melting peak. This is likely to 
represent some decomposition of the sample once melting has occurred.  
 
Figure 1.34. DSC trace for PYR starting material obtained from Sigma Aldrich 
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The solubility of PYR was determined in H2O, EtOH and IPA using observation methods (figure 1.35).  
 






Chapter 2 Analytical methods 
 
A range of analytical techniques were used in this research to characterise the structure and 
properties of the solid products produced from crystallisation experiments. These included a range 
of microscopy, thermal and crystallographic techniques.   
2.1 Crystallography 
2.1.1 Crystalline state 
A crystalline solid comprises of constituent atoms, ions or molecules arranged in a precisely regular 
way repeated in all directions.4, 167, 168 The official IUPAC definition of crystallinity is ‘the presence of 
three-dimensional order on the level of atomic dimensions’.131 Perfectly crystalline materials consist 
of large numbers of identical molecules, or collection of a few molecules, arranged in this way, 
representing a form of symmetry known as translation, a fundamental characteristic of crystalline 
solids. Crystals demonstrate this translational symmetry in three dimensions. 
Crystal structures can be described by combining the contents of one repeat unit with the way in 
which the defined unit is repeated by translation. By representing each molecule within the regular 
repeat unit as a single point, a pattern can be generated whereby each point is surrounded by the 
same environment: a regular infinite array of points in three dimensions results. This three 
dimensional array is known as a lattice, and the points as lattice points.167 Whilst the lattice evidently 
shows the repeating nature of the structure, it gives no information about the contents of the repeat 
unit. Defining the repeat unit of a structure requires a parallelepiped to be drawn between eight 
chosen lattice points, giving rise to a unit cell (figure 2.1).169 Many different possibilities are available 
to define the unit cell, however, at least one possible unit cell exists where the cell edges are the 
three shortest non-coplanar vectors of the lattice: generally, the unit cell with the highest internal 
symmetry and, therefore, the smallest repeating unit possible is chosen when defining the unit cell; 
this is known as the reduced cell. In three-dimensions a unit cell has three defined edges (a, b, c) 
and three defined angles (α, β, γ). The arrangement is such that angle α lies between edges b and c, 




Figure 2.1. Unit cell defined by lengths (a, b, c) and angles (α, β, γ). The molecular components that comprise the crystal 
are contained within the unit cell. 
Four lattice types exist for three-dimensional crystal structures; primitive (P), body centred (I), face 
centred (F) and centred (C) (figure 2.2). The type of lattice defined for a crystal system depends on 
the position of the lattice points within the unit cell. The simplest arrangement exists in the P type 
lattice, with only one lattice point; therefore, the only translational symmetry is that of the unit cell 
itself. The other three lattice types contain extra lattice points within the unit cell volume and, as a 
result, have additional translational symmetry within the unit cell.170  
 
Figure 2.2. The four lattice types. P = primitive, I = body-centred, C = centred and F = face-centred 
By introducing further symmetry elements, such as rotation and reflection, restrictions are applied 
to crystal structures giving rise to seven crystal systems.167, 169 By combining the four lattice types 
with the seven crystal systems, fourteen Bravais lattices are formed (table 2.1). For all crystal 
structures, the unit cell determined will belong to one of the fourteen Bravais lattices. 
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Table 2.1. Seven crystal systems, their unit cell restrictions and the distribution of lattice types 
Crystal System Unit cell parameters Bravais Lattice 
Cubic a=b=c, α=β=λ=90ᵒ P, I, F 
Hexagonal a=b≠c, α=β=90ᵒ λ=120ᵒ P 
Trigonal a=b≠c, α=β=90ᵒ λ=120ᵒ P 
Tetragonal a=b≠c, α=β=λ=90ᵒ P, I 
Orthorhombic a≠b≠c, α=β=λ=90ᵒ P, I, C, F 
Monoclinic a≠b≠c, α=λ=90ᵒ β≠90ᵒ P, C 
Triclinic a≠b≠c, α≠β≠λ≠90ᵒ P 
 
2.1.2 Molecular symmetry  
Further symmetry operations can be applied within the unit cell to reduce it further to smaller 
symmetry-equivalent objects;168 the smallest such unit is known as the asymmetric unit. Individual 
asymmetric units are related to one another by a set combination of symmetry operations, the 
outcome of which generates the unit cell contents, which when translated in three directions 
produces the full crystal structure. The asymmetric unit can consist of a fraction of a molecule, a 
whole molecule or more than one molecule depending on the symmetry present within the 
molecule in question.167 There are a total of six different symmetry elements possible within the 
unit cell (figure 2.3), which can be split into two categories; translational and non-translational 
symmetry. There are four different types of non-translational symmetry; rotation (symbol = order 
of rotation), reflection across a mirror plane (symbol = m), inversion at a point (symbol = ◦) and 
rotation-inversion about an axis (symbol = order of rotation with “bar”). A translational symmetry 
element, as the name suggests, also includes a translation of the asymmetric unit. Two types of 
translational symmetry exist; glide planes and screw axes. A glide plane combines a translation and 
a mirror plane parallel to the translation axis. A screw axis combines a translation and a rotation 












Figure 2.3. Pictorial representations of (a) non-translational symmetry elements: (i) rotation, (ii) inversion, (iii) reflection 
and (iv) rotary-inversion. (b) translational symmetry elements: (i) screw-axis and (ii) glide plane. 
All of the crystal systems highlighted in table 2.1, except triclinic which imposes no restrictions, 
require a combination of essential symmetry elements in order to be generated correctly. 
Combining the essential symmetry elements of a crystal and its Bravais lattice type produces a space 
group for the structure.172 The limited number of possible combinations of the six symmetry 
elements and the 14 Bravais lattice types generates a finite number of space groups; only 230 
possible combinations exist. Space group symmetry describes all the symmetry operations 
necessary to generate the crystal from the initial asymmetric unit.171  
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2.1.3 X-ray diffraction 
As stated above, crystalline solids are the result of a regular arrangement of atoms, molecules or 
ions that extends over three dimensions. This regularity enables crystalline structures to diffract X-
rays and produce regular patterns interpretable using mathematical processes. The use of X-rays 
can provide an abundance of structural information; interatomic distances in molecules are 
comparable to the wavelength associated with X-rays. Commonly, copper and molybdenum X-ray 
target materials are used in lab X-ray diffraction experiments with characteristic wavelengths of 
1.5418 Å and 0.71073 Å respectively.167  
2.1.4 Bragg’s Law 
The regular arrangement of atoms in a crystal means the structure contains long range order, giving 
rise to parallel sets of planes present throughout. W. L. Bragg noted that diffraction could be 
interpreted as reflection from these sets of planes; the Bragg equations, or Bragg’s law, describe 
diffraction in this way. These parallel planes within a crystal are known as Miller planes and assigned 
indices, a set of three integers, (h k l) which describe where a particular plane intercepts along the 
lattice vector. The (h k l) planes are separated by distances of dhkl.173  
When a crystal is exposed to a beam of X-rays, the electrons associated with each atom scatter the 
X-rays in all directions. The diffracted beams can undergo constructive and destructive interference; 
the occurrence of constructive interference is the consequence of crystal orientation and geometry. 
X-ray diffraction from adjacent planes must give rise to constructive interference for the reflection 
to be observed.  The derivation of Bragg’s law can be seen in figure 2.4. The view seen in the 
schematic shows the edge of a set of planes, horizontal lines, separated by distance dhkl. The 
incoming X-ray beams are in phase. To achieve constructive interference, the diffracted waves must 
exit the crystal in phase with one another. For this to be possible, the path difference travelled by 
the waves must be equal to a whole number of wavelengths (equations 2.1 & 2.2):  
𝐴𝐵 + 𝐵𝐶 = 𝑛𝜆                                          Equation 2.1  
𝐴𝐵 = 𝐵𝐶 ∴ 2(𝐴𝐵) = 𝑛𝜆                          Equation 2.2 
Using basic trigonometry, it can be seen that: 
𝐴𝐵 =  𝑑ℎ𝑘𝑙𝑠𝑖𝑛𝜃                              Equation 2.3 
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Therefore, the conditions under which constructive interference occurs and a reflection is observed 
is defined by Bragg’s law:  
𝑛𝜆 = 2𝑑ℎ𝑘𝑙𝑠𝑖𝑛Ө              Equation 2.4 
n denotes an integer value, λ refers to the wavelength of the X-ray beam and dhkl corresponds to the 
distance between two planes in the same Miller set.173  
If the incident X-ray wavelength satisfies the equation a diffraction spot will be observed (figure 2.4).  
 
Figure 2.4. Schematic of Bragg’s law. X-ray diffraction shown between parallel Miller planes (hkl) separated by a distance 
dhkl 
2.1.5 Diffraction patterns and reciprocal space 
Due to the regularity of crystal structures, the diffraction patterns produced consist of an array of 
bright spots (Bragg reflections) that occur where Bragg’s law is satisfied and possess a degree of 
symmetry and a definite geometry that reflect the underlying lattice structure. The crystal structure 
and diffraction pattern are related through the mathematical procedure of Fourier transformation. 
The diffraction pattern exists in ‘reciprocal space’, representing the ‘reciprocal lattice’ and has an 
inversely proportional relationship with the ‘direct lattice’ of the crystal in ‘direct space’.173 
Bragg’s law can be rearranged to show that the distance dhkl is inversely proportional to sinӨ:  






                           Equation 2.5 
The dimension of reciprocal space is, therefore, 
1
𝑑ℎ𝑘𝑙
 . The mathematical relationship between 
reciprocal and direct space is well understood and Fourier transform calculations are used to 
reconstruct the crystal electron density from its diffraction pattern.167, 174  
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2.1.6 Scattering factors 
Bragg’s law does not give any information about the intensity of reflections observed in a diffraction 
experiment. A relationship exists between the number of electrons and the scattering observed. 
Therefore, the interaction between X-rays and electron clouds is characteristic of a particular 
element, due to the different numbers of electrons present in their electron clouds. As such, the 
ability of a neutral atom to scatter electrons, known as atomic scattering factor (𝑓𝑗), is dependent 
on the element present. At low Bragg angles, the ability of an atom to scatter electrons is 
proportional to the number of electrons in the electron cloud. However, X-rays scatter from the 
extended electron cloud, thus at higher angles the path length difference between X-rays scattered 
from different parts of that extended scattering object will increase. As these shifts observed 
between different beams are larger at higher angles, a greater chance exists of destructive 
interference. Consequently, the scattering ability of the electrons drops off when reaching higher 
Bragg angles.167 Scattering curves (figure 2.5) can be used to illustrate the change in diffraction 
intensity as a function of diffraction angle. Information on atomic scattering factors is obtained from 
quantum mechanical calculations and is often built into crystallographic software packages for 
commonly used wavelengths.175  
 
Figure 2.5. Representation of X-ray scattering factors 𝑓𝑗  for atoms A and B. 
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2.1.7 Data collection 
The combination of diffraction from a crystalline array of weakly diffracting molecules gives the 
detectable scattered intensity measured in a diffraction experiment. Scattering from different 
atoms in the structure have different individual contributions to the intensity of a particular Bragg 
intensity; the scattering power of a plane can be represented by the structure factor (Fhkl; equation 
2.6). Structure factors contain information on Miller plane sets and the position and types of all 
atoms contained in the unit cell. As each Fhkl represents one set of Miller planes, measurement of a 
full set of reflections (complete diffraction pattern) is needed to achieve the most complete 
description of the structure; every reflection contains some information about the structure being 
probed.175, 176  
𝐹ℎ𝑘𝑙 = ∑ 𝑓𝑗exp [2𝜋𝑖(ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧)]
𝑗=𝑛
𝑗=1                          Equation 2.6 
Structure factors are complex numbers. Two numerical values are associated with each reflection 
in a diffraction pattern; the amplitude (|Fhkl|) and the phase (φhkl) )(equation 2.7).167 
𝐹ℎ𝑘𝑙 = |𝐹ℎ𝑘𝑙|exp (𝑖 φhkl)              Equation 2.7 
During a SCXRD data collection the intensities (Ihkl) of the diffracted beams from each Miller plane 
set are measured. The amplitudes |Fhkl| can be found using experimentally determined intensities 
by the relationship |𝐹ℎ𝑘𝑙|
2  ∝  𝐼ℎ𝑘𝑙.
176 If the structure factors are fully determined, then performing 
an inverse Fourier transform, the electron density map can be constructed (equation 2.8). Electron 
density is expressed in units of electrons per cubic angstrom (e Å-3). Analysis of an electron density 




∑ ∑ ∑ |𝐹ℎ𝑘𝑙| exp[−2𝜋𝑖(ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧)𝑙𝑘ℎ ]                  Equation 2.8 
Equations 2.6 and 2.8 link the atomic positions to the electron density via the structure factor. 
However, phase information for different reflections cannot be recovered directly from the 
experimental data collected. Thus, for an unknown structure, it is not possible to simply calculate 
the electron density once the diffraction pattern has been recorded, due to this loss of phase 
information.167, 175, 176 This is widely known as the phase problem. 
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2.1.8 Structure solution 
The phase problem must be overcome before structure solution can be achieved; it is necessary to 
determine the phases, which can be done in a number of ways. The most common of these are 
Direct methods, Patterson methods and charge flipping.177, 178 
2.1.8.1  Direct methods 
The aim of Direct methods is to determine phases without any prior knowledge of the structure or 
information on crystal composition. This method is most often used for small molecule 
crystallography, including purely organic molecules or those containing only light atoms. 
The method is based on statistical relations between the measured structure factors, whereby 
generation of possible electron density maps – and hence atomic coordinates – is attempted by 
mathematical approaches using a single set of X-ray intensities.179 To solve the phase problem, 
mathematical relations between the experimental structure factor amplitudes and their phases are 
used. These give a set of probabilistic terms expressing relationships between sets of phases. The 
simplest of these relationships is the triplet relationship. A triplet is a set of three structure factors, 
such as E(h), E(k) and E(h-k), whose related phases satisfy the probability relationship: 179, 180  
φ(h) ≈ φ(k) + φ(h-k)                          Equation 2.9 
A higher probability of these conditions being satisfied occur for larger values of |Ehkl|. In automated 
Direct methods programs, a multi-solution permutation approach amongst the stronger reflections 
is adopted. Random sets of initial phases are assigned to a small starting set of reflections then 
triplets and higher order relationships are used to generate a set of possible solutions for the 
estimated phases of a wider set of structure factors. This in turn generates a set of potential electron 
density maps, from which the crystal structure can be solved.179, 181  
2.1.8.2  Patterson methods 
This method is an older technique, relying on the knowledge of a few atom positions. This method 
is utilised, in the majority, to solve structures containing a few heavy metal atoms, for example in 
coordination complexes, or when a substantial portion of a structure is expected to be well-defined 
and rigid.180 Patterson synthesis generates a map of interatomic vectors; the peaks are proportional 
to the square of the atomic number of the atoms giving rise to them. This makes it easy to identify 
peaks due to vectors between heavy atoms.182, 183 By using the known symmetry relations, the 
positions of these heavier atoms can be determined and structure factor phases calculated based 
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on these known heavy atom coordinates, which are generally sufficiently accurate set to allow 
structure solution.181  
2.1.8.3  Dual-space iterative methods 
With the increase in availability of cheap computer power, new methods have been developed that 
are conceptually similar to the classical methods, with a requirement for more computation. Whilst 
these extensions to traditional methods exist, a new class of methods has also been developed, 
known as dual-space iterative methods.184 These techniques are based on iterative modification of 
an image both in direct and reciprocal space. An example of dual-spaced iterative methods is charge-
flipping; the use of alternating modifications in direct and reciprocal space to find a solution to the 
phase problem.185 This dual-space algorithm is used in the computer software ShelXT to solve the 
phase problem observed in single-crystal reflection data.178 Applications of this method can range 
beyond the standard structure solution. For example, it is possible to solve the structure of 
quasicrystals and crystals with incommensurately modulated structures. The combination of charge 
flipping with histogram matching, a density modification technique, can also allow the solution of 
complex structures to be obtained from powder diffraction patterns. Structures can also be solved 
from neutron scattering experiments using a band flipping variant of this method.184 
2.1.9 Structure completion and refinement 
Structural solution processes produce a reconstruction of the average electron density. This 
reconstruction is not the direct result of the diffraction experiment but uses the observed structure 
factor magnitudes with the initial phases calculated in the structure solution step.186 From this, most 
structural solution programs will be able to output an approximate ‘trial structure’, if provided some 
information on the expected crystal composition. With this prior knowledge the atomic positions in 
the first trial structure can be assigned, however, the structure is often incomplete, and a series of 
calculations is carried out. Electron density maps are calculated from the known atoms to generate 
improved sets of phases, and hence improved maps, that will reveal more atoms until all heavier 
atoms (and often many of the hydrogen atoms) are located.  This “Fourier recycling” process is 
carried out automatically in structure solution programs, usually in combination with refinements 
of the known atomic parameters. 
A refinement process is then required to optimise the parameters of the trial model, ultimately 
achieving the best fit between the observed and calculated data.187 
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A number of important ‘refinable parameters’ require adjusting in order to improve the fit of the 
model, including: scale factor; isotropic or anisotropic displacement parameters; atomic site 
occupancies; and, most importantly, the fractional coordinates of individual atoms.187, 188 
2.1.9.1  Least-squares refinement method 
The aim of crystal structure refinement is to find the best model of the crystal structure, determining 
parameter values which give the best fit to the data collected and estimating the uncertainty of 
these parameters.189 In most ‘small-molecule’ structure determinations, the refinement method 
used is called ‘least-squares’ refinement. This procedure involves the minimisation of the function 
𝑀 =  ∑ 𝑤 (𝑌𝑂 − 𝑌𝐶)
2                        Equation 2.10 
Where 𝑌𝑂  = the strength of an observed reflection (in terms of either FO, FO
2 or I), 𝑌𝐶  = the calculated 
value for the reflection based on the current model (either in terms of FC or FC2) and 𝑤 = an assigned 
weight which reflects the confidence in this particular data point.187 The weight term is derived from 
the standard uncertainty of the measurement; frequently 𝑤 = 1/𝜎.186 The minimisation of M 
should result in optimal values for parameters, and their standard deviations σ, for that structural 
model. It is possible to carry out this minimisation by refining the model against either FO, FO2 or I; 
refinement against F2 is most commonly used.186 
In order to improve the fit of the model it is possible to either increase or decrease the number of 
refinable parameters being dealt with. This is achieved by introducing constraints and restraints to 
the refinement model. Constraints are introduced to reduce the number or refinable parameters, 
which can be particularly useful when the quality of the data is poor. Constraints reduce the number 
of parameters by either expressing one parameter in terms of others, or by predetermining and 
fixing its value, removing the need to refine it.187 One example is the position of hydrogen atoms 
within a structure. A constraint can be used to fix the bonding angles and distances of hydrogen 
atoms bonded to non-hydrogen atoms, treating them as a rigid group. This is known as the ‘riding 
model’ and results in hydrogen atoms moving with the atoms they are bonded to during refinement. 
Restraints can also be introduced; these are considered as additional experimental observations, 
helping include further chemical or physical information about a molecule into the refinement 
process. Examples include specifying bond lengths or angles, based on knowledge of similar 
structures, or fixing the planarity of aromatic groups using the knowledge they tend to be flat. Thus, 
using restraints indirectly increases the number of data points to refine against.186, 187 As with 




2.1.9.2  R-Factors 
Least-squares refinement is an iterative process, cycling through recalculations of the model to 
improve the fit between the experimental and calculated diffraction patterns, proceeding towards 
convergence. The quality of a model is judged using calculated residual factors, or ‘R-factors’.186 R-
factors reduce in magnitude as the agreement between measurements and the parameterised 
model improves; a good refinement will have a low R factor.181, 189 The ‘conventional’ R-factor 
(equation 2.11) is calculated during each refinement cycle, providing an assessment of the 
agreement of calculated structure factors with those determined experimentally. 
𝑅 =  
∑ |𝐹𝑜−𝐹𝑐|
∑ |𝐹𝑜|
                   Equation 2.11 
The final calculated R-factor is used to assess the quality of the final model, and is most often quoted 
in publications due to it almost always giving the lowest value.189 A weighted R-factor, which is most 






2 ]                     Equation 2.12 
This residual factor provides better comparisons for testing the significance of adding or removing 
parameters from the refinement; often the value is higher but statistically more valid. It is frequently 
used to monitor the progress of refinements.186, 189 
2.1.9.3  Structure completion 
It is often difficult to determine when a completed structure is a ‘good structure’. A structure is 
considered ‘good’ when the final refinement converges on a model that shows good agreement 
with the experimental data. A number of key values can be used to conclude whether the final 
structure reached is acceptable. As mentioned, the final R-factor is most frequently used with 
acceptable values, for small, molecular species, typically below <0.05. The standard uncertainties 
calculated for refined parameters can also be taken into account; small values indicate a good fit 
between model and experimental data. Any residual positive peaks present in the electron density 
map that have not been modelled must be taken into account. Generally, if these peaks are smaller 
than those calculated for hydrogen atoms the model is assumed to be a good fit. Finally, a good 
completeness of data must be attained. This requires that the diffraction data collected must cover 
at least the unique region of reciprocal space to allow the structure to be properly modelled. 
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2.1.10 Powder X-ray Diffraction (PXRD) 
In comparison to the single-crystal analysis just discussed, powder X-ray diffraction techniques 
(PXRD) utilise a polycrystalline powder sample. Hence, this is considered an important analysis 
technique due to the difficulty obtaining good quality single crystals for some samples and under 
certain conditions. This technique also allows the bulk sample to be characterised, as opposed to 
individual crystals selected for SCXRD. The principles of PXRD are based on the interaction of a 
monochromatic X-ray beam with a sample capable of diffracting them, similarly to SCXRD. Within 
the polycrystalline sample all crystallites are orientated differently, with a random distribution. 
Diffraction peaks are therefore generated for each crystallite when its orientation is able to satisfy 
Bragg’s law; the random distribution of orientations of very many crystallites ensures that the Bragg 
angle will be met for each reflection. Diffraction for a particular 2Ө value will consist of reflected X-
rays occurring in varying directions depending on the crystallite orientations. As a result, cones of 
reflection are observed (figure 2.6); superimposing the diffraction from each crystallite gives a full 
diffraction pattern of the sample.167, 169 The intensity is measured as the detector intersects these 
cones as it moves through all 2Ө angles, resulting in a plot of intensity verses 2Ө. Due to the random 
nature of the orientation of the crystallites, information on relative orientations of scattering 
vectors is lost, resulting in a 1D pattern.124  
 
Figure 2.6. Cones of reflection observed when irradiating a polycrystalline sample during a powder X-ray diffraction 
experiment. 
PXRD is a powerful diagnostic technique as the patterns produced are unique to different crystal 
structures: most importantly for the work presented here, peak positions are determined by the 
unit cell parameters. This unique nature means the technique can be used as a fingerprinting tool. 
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As a result, useful applications of PXRD involve the identification of unknown crystalline phases, 
determination of sample purity and investigating phase changes.170 Structure solution and 
refinement is also possible with well-resolved powder diffraction data, using methods such as 
Rietveld refinement. As the peak positions in a diffraction pattern are determined by unit cell 
parameters, indexing the data can determine these for a structure. However, this indexation is made 
difficult, in less well-resolved data, by peak overlap and a low number of uniquely observed peaks. 
The intensities of peaks reflect the unit cell contents and can be used in structure refinement if very 
good data are available; this is not used in the research presented here. The intensity of peaks can 
be affected by other external factors. Preferred orientation effects can increase the intensity of 
some peaks irrespective of the structure. To mitigate these effects samples are often ground down 
before analysis and rotated for the duration of the PXRD experiment.167, 169   
2.2  Thermal analysis 
Knowing how different materials act under different temperature environments can be very 
important. Temperature can affect the stability and activity of materials, which can greatly affect 
their uses and methods for their production. Thermal analytical methods which measure a physical 
property, such as weight or the flow of heat energy, as a function or temperature or time are 
especially valuable for pharmaceutical applications.190 In most thermal techniques, samples are 
subjected to a defined temperature program, involving linear heating and cooling. The thermal 
events that occur can be recorded and interpreted as physical or chemical changes. Thermal 
analytical techniques detect both exothermic processes, including crystallisation and some phase 
changes, and endothermic processes, such as melting, desolvation and some phase changes. They 
can also determine mass changes in a sample, such as during desolvation processes. 
2.2.1  Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) ‘measures the energy transferred as heat to or from a 
sample at constant pressure during a physical or chemical change’.191 A sample is measured into a 
sealed pan and subjected to a program of temperature changes and thermal events recorded. DSC 
is commonly used to identify the solid form of a sample and recognise the phase transitions that 
may occur as a function of temperature. There are two different forms of DSC, using different 
methods to maintain constant temperature between sample and reference during a temperature 
scan; power compensation and heat flux. During a power compensation DSC experiment, the 
temperature difference between the sample and the reference is maintained at a constant level. 
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The difference in power supplied to each to allow this to happen is measured and is proportional to 
heat flow. In a heat flux DSC, the temperature is allowed to vary slightly and then converted back 
rapidly by an input of power.  
Thermal events are identified by the heat flows required to maintain the reference and sample at 
the same temperature: thermal events exhibit as a change in heat flow with respect to temperature. 
For example, in an endothermic event more heat will be required to keep the temperature of the 
sample increasing at the same rate relative to the empty reference pan. From a DSC plot (figure 2.7) 
the temperature at which a transition occurs can be determined by the position of endothermic and 
exothermic peaks and the enthalpy of the associated thermal event can be determined by 
integration of the area under the peak. Typically, DSC plots are presented as ‘exo up’ whereby 
exothermic events are plotted as positive on the graph with endothermic events being negative.  
 
Figure 2.7. DSC schematic showing some commonly observed thermal events in pharmaceutical solids. (a) glass 
transition, (b) recrystallisation or decomposition, (c) desolvation or phase transition and (d) melting or decomposition.190 
For pharmaceutical solids, the thermal events observed are often endothermic events. Most 
commonly melting points of crystalline solids can be determined. This helps identify the solid form 
achieved and the purity of the sample. Phase transitions, desolvation and dehydration of samples 
can also be hypothesised from endothermic events. Endothermic events can also correspond to 
decomposition and sublimation events. In pharmaceutical crystals, exothermic events often 
correspond to recrystallisation events, for example as the result of the formation of a new 
polymorphic form. Glass transitions are observed when there is amorphous content in the initial 
sample. It is not always clear exactly what is causing each peak observed in a DSC trace. As a result, 
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further thermal analysis techniques should be used alongside DSC analysis to fully characterise each 
thermal event observed. 
2.2.2  Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) is a technique used to measure the change in mass of a sample, 
as determined by a thermobalance, as a function of temperature and/or time.190 TGA is useful in 
determining many physical and chemical properties and is often used to investigate the 
decomposition of a sample with increasing temperature.192 In pharmaceutical applications, TGA can 
be particularly useful in identifying solvate or hydrate samples and determining their stoichiometry. 
This technique can be coupled with mass spectrometry (TG-MS), allowing the identification of any 
products of the degradation process. Nitrogen flow into the sample chamber is often used to 
maintain an inert atmosphere, preventing any chemical reactions occurring during the programmed 
temperature changes. A known mass of sample is placed in a pan, either ceramic or aluminium, and 
suspended inside the sample chamber. As the temperature increases at the rate programmed the 
mass of the sample is recorded. Plots of the percentage mass change verses temperature allow the 
quantification of thermal events occurring within the sample (figure 2.8).  
 
Figure 2.8. Typical TGA graph showing mass loss from a sample 
2.2.3  Hot-stage Microscopy (HSM) 
Hot-stage microscopy (HSM) uses optical microscopy to monitor a sample during a heating and/or 
cooling cycle; adding a hot-stage to a microscope allows thermal events to be recorded and 
visualised. This technique has important advantages to other thermal techniques already discussed: 
differentiation between thermal events that may exhibit similar energy profiles in other thermal 
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techniques, for example distinguishing between melting and other phase transitions, such as the 
desolvation of a crystal structure, is possible through visualisation. Coupling this technique with DSC 
and TGA is particularly useful in aiding the interpretation of thermal events that may be unclear: 
this visualisation can confirm or contradict any conclusions drawn from a DSC or TGA trace. This 
method can assist in understanding the behaviour of hydrates, polymorphs and solvates, making it 
particularly useful in pharmaceutical research.193 HSM can also be a useful tool when investigating 
other properties affected by temperature. One such example would be the identification of 
thermochromic materials which change colour with varying temperature.  
2.3  Optical microscopy 
Optical microscopy is a useful analytical tool in solid state chemistry. As noted above, this forms part 
of the HSM technique that is used as a complement to other analytical thermal methods; however, 
standard optical microscopy is also used. For crystal analysis it is particularly useful to use a 
microscope with a polarising lens. The polariser acts as a filter and allows light oscillating in only one 
orientation to pass through the lens. This phenomenon can be used to determine the crystallinity 
of a sample. Single crystals possess a property known as double refraction, where incoming light is 
split into different directions with differing speeds. Upon recombination of the light under a 
polarising microscope interference occurs, forming a black focal plane for the crystal. As a result, 
single crystals appear to ‘extinguish’ and become dark when the light is rotated. This allows the 
identification of possible samples for single crystal X-ray diffraction experiments.194 Optical 
microscopy can also be useful to examine further properties of crystals, including the morphology, 
size and colour. In this work, optical microscopy was used mainly to examine the shapes of 
crystalline products and identify samples that may require further analysis.  
2.4  Fourier Transform Infra-red spectroscopy (FTIR) 
Infra-red spectroscopy probes molecular vibrations through the absorption of infra-red light by the 
sample. The percentage transmission is measured as a function of frequency; the transmission will 
be reduced (producing the characteristic infra-red bands) when strong absorption occurs at 
particular frequencies. The infra-red light is absorbed by a molecule when the vibrations of the 
bonds present match the frequency of light being used, allowing the energy to be absorbed through 
excitation to a higher vibrational energy state. This method allows for the identification of functional 
groups as specific bonds absorb with characteristic infra-red frequencies.  
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Most modern infra-red spectrometers use Fourier transform techniques. The infra-red beam in split 
into two and reflects off two mirrors within the spectrometer. One mirror is fixed in position whilst 
the second is movable and can be used to alter the path length of the beam, creating a path 
difference. The two beams are recombined giving an interference pattern, due to the constructive 
and destructive interference resulting from the path difference. The interference pattern can then 
be converted to a spectrum using a Fourier transformation. The use of FTIR allows multiple 
frequencies to be collected simultaneously and also increases the sensitivity of the 
measurements.195  
The speed of data collection coupled with the non-destructive nature of the technique makes this a 
useful analysis technique. In pharmaceutical studies, it can be used to identify and monitor 
characteristic functional or hydrogen bonded groups, either during crystallisation processes or in 
product samples, notably allowing polymorphs to be distinguished. 
2.5  Nuclear Magnetic Resonance spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) is an analysis technique that aids in the determination of the 
structure of a molecule. Many types of NMR spectroscopy are available, however, for the purpose 
of the work presented here only proton NMR spectroscopy (1H-NMR spectroscopy) has been used.  
NMR spectroscopy is a radiofrequency technique, with proton resonance occurring at about 400 
MHz. An NMR spectrometer consists of a magnet producing an intense, uniform field and a radio 
frequency source. The magnetic field is often provided using an electromagnet or, in more advanced 
experiments, a superconducting magnet.196 
In NMR spectroscopy the sample is placed within the strong magnetic field within the spectrometer. 
Certain nuclei within the sample which have a non-zero nuclear spin (notably including 1H) can act 
as tiny magnets, aligning with or against the applied magnetic field. The different alignments of the 
nuclei are known as spin states and will be split in energy in the presence of the external magnetic 
field. Electromagnetic radiation is then used to irradiate the sample. The radiation is absorbed if it 
equals the difference in the energy of the spin states of the nuclei present. This absorption promotes 
the nuclei in the lower energy spin state to the higher energy spin state, producing resonance. The 
excited nuclei then relax back down to the lower energy state releasing energy. 1H-NMR 
spectroscopy is a particularly valuable technique as the different protons in molecules will likely 
experience different magnetic fields, as effects caused by electronic environment close to a proton 
will result in the local magnetic field being slightly different from the applied field in the 
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spectrometer, resulting in them absorbing different frequencies of the radio wave radiation. These 
differences (chemical shifts) are detected and give rise to the NMR spectrum; the knowledge gained 
of the proton environments often allows the molecular structure to de deduced.197 
For the purposes of the work presented here, 1H-NMR spectroscopy was used for confirmation of 






Chapter 3 Experimental methods and 
analysis equipment 
 
3.1  Solubility and metastable zone width measurements 
Knowledge of the solubility of a material is essential to be able to control solution mediated 
crystallisation processes. It is also a key physical property that needs to be determined for 
pharmaceutical molecules in order not only to develop a production process, but also to formulate 
the final pharmaceutical product. Two methods have been used to determine solubility throughout 
this research, gravimetric analysis and solubility by observation. It is also important to determine 
the metastable zone in order to have better control over controlled cooling crystallisation methods. 
This was determined for some systems using the same observation method used for solubility 
determination. 
3.1.1  Gravimetric solubility determination 
Gravimetric solubility is based upon the measurement of mass, relating the mass of a solute 
dissolved to the mass of the solvent used. Slurries of excess solute are created in a given solvent 
and placed at different temperature intervals. The slurries are stirred continuously for 48 hours to 
aid dissolution and allow an equilibrium to be reached and the solvent to become saturated with 
the solute. Stirring is ceased and the remaining undissolved solute allowed to settle before an 
amount of solution is removed from the top of the vial, without disturbing the undissolved solute. 
The solution is decanted into a clean vial of known weight and the weight of solution determined. 
The solution is then left to completely evaporate, leaving behind any solute that was dissolved in 
the solvent. By calculating the mass of solution removed from the slurry and the mass of solute 
remaining after evaporation a solubility data point can be determined (with units of g of solute /g 
of solvent). Repeating this method for a range of different temperatures allows a solubility curve to 
be plotted.  
The accuracy of this method can be called into question for a number of different reasons. There is 
the possibility that the solutions, while slurrying, could become supersaturated and as a result 
skewing the data and overestimating the solubility of the solute. The solubility measurement can 
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also be affected when removing the solution from the vial. There is a high possibility of also 
removing some undissolved solute particles, exaggerating the mass of solute that could dissolve in 
the amount of solute. The reverse is also possible with solute dissolved at higher temperatures 
crashing out of solution when removed due to the change in temperature. This solute may remain 
behind in the pipette used and therefore an underestimation of the amount of solute that can be 
dissolved would result. Accuracy can be improved, however, by repeating each temperature 
measurement multiple times.  
Whilst there are some accuracy concerns, this method is a reasonably time efficient way of 
determining the solubility of a compound.  
3.1.2  Solubility and metastable zone width determination via observation 
Solubility by observation is arguably a more accurate determination of solubility. The set up uses 
controlled heating to steadily increase the temperature of the solution. The method relies on 
observational determination of the clear point temperature of a solution, the point at which all 
solute dissolves in the solvent. To determine the MSZW the opposite method is used. Controlled 
cooling is used to steadily decrease the temperature of the solution and find the cloud point 
temperature, the point at which the solute crystallises back out of solution. These two points can 
be determined in tandem using a cycling mechanism. The concentration of the solution is known 
and the temperature is cycled up and down to determine the clear and cloud points of the solution. 
This cycle can happen multiple times to obtain repeated measurements for the same concentration. 
Tight control over the temperature of the solution is important for accurate results. Slow heating 
and cooling rates are required to give the system time to equilibrate and prevent the true 
temperature points being overshot. 
In this research a Polar Bear Plus crystalliser from Cambridge Reactor Design was used to control 
the heating rate of the solvent (figure 3.1). Starting from the minimum temperature required, about 
5 ⁰C, solvent was heated in a 50 mL round bottom flask at a rate of 0.3 ⁰C/minute to a maximum 
temperature, around 60 ⁰C. An initial amount of solute was added and stirred continuously at 
700 rpm using a magnetic bottom stirrer. The temperature at which the solute had fully dissolved 
was recorded and the concentration of the solution calculated. With the flask still heating this 
method was then repeated for set mass intervals until the maximum temperature required was 
reached. Plotting concentration against temperature from the data produces a solubility curve. This 
was repeated three times for each sample investigated, to increase the accuracy of the solubility 




Figure 3.1. Cambridge Reactor Designs Polar Bear Plus crystalliser set up. Left: Polar Bear with overhead stirrer set up. 
Right: Different sized inserts for Polar Bear (top, left to right: 1 mL + 50 mL; bottom, left to right: 10 mL + 250 mL) 
For MSZW measurements a cyclic approach was used. Again a Polar Bear Plus crystalliser was used 
to gain tight control over the temperature profile. Using a 50 mL round bottom flask of solvent, 
stirring at 700 rpm, approximate values of the clear and cloud points of each concentration being 
investigated were determined. A programme was then set up to heat and cool at 0.3 ⁰C/minute in 
a cycle 5 ⁰C above and below the approximate temperatures previously determined for each 
concentration, to achieve more accurate measurements of the clear and cloud points of the 
solution. The concentrations of the solutions were plotted against the clear and cloud point data 
obtained to give a solubility curve with corresponding MSZ. Again each measurement was repeated 
three times to obtain an accurate determination. 
This method used to determine the solubility and MSZW of a solute is similar to that utilised in the 
crystal16 device (manufactured by Technobis crystallisation systems) often used in industry. In the 
crystal16 set up multiple solutions at different concentrations are cycled three times through a pre-
set temperature profile. The clear and cloud points are determined using an FBRM probe to measure 
the turbidity of the solutions. The benefit of this method is the ability to carry out accurate 
experiments on a small amount of solute, ideal for an industry setting where typically there is an 
initially limited supply of the active ingredient being investigated. 
It is important to note that while solubility is a thermodynamic property of the solute the MSZ is a 
kinetic factor. As a result, the MSZW will change depending on the conditions under which the 
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experiment is being performed. This makes application of the results of a MSZW screen to different 
cooling crystallisation set ups very difficult, so it is often used only as an estimation.  
The results of the solubility determination were used to determine the saturation point for future 
crystallisation experiments. The saturation temperature (Tsat) quoted in experimental sections of 
this thesis refers to the concentration of solute in g/g required to saturate the solvent at the 
temperature quoted.  
3.2  Crystallisation methods 
The crystallisation method used can have a significant effect on the resulting crystals, including their 
morphology. As a result, multiple different crystallisation methods were used during this research. 
Solvent-mediated methods were analysed for their ability to influence the morphology of the 
crystals produced. Some mechanochemical methods were also used in the investigation of new 
multi-component materials. 
3.2.1  Evaporative crystallisation 
Evaporative crystallisation was used as an initial screening method for both multi-component and 
additive crystallisations. Initial screening experiments to establish the effect of different solvents on 
crystal morphology were also carried out using this method. A small mass of target molecule, along 
with any co-former or additive required, is dissolved in solvent in a 7 mL glass vial. Usually the 
minimal amount of solvent required is used to prevent unnecessarily prolonged evaporation times. 
To aid dissolution, sonication and application of heat is sometimes used. PTFE lids were used to seal 
the vials and holes made in these to aid slow evaporation. Vials were left to crystallise at different 
temperatures, including room temperature, using feedback controlled hot plates. Using this method 
multiple crystallisations could be set up using various different conditions. Variables changed 
include solvent system, additive present, and ratios of target and additives/co-formers present. 
3.2.2  Cooling crystallisation 
Two different cooling crystallisation techniques were utilised in this research: uncontrolled crash 
cooling and controlled cooling.  
3.2.2.1  Uncontrolled crash cooling 
Uncontrolled crash cooling was sometimes used in the place of evaporative crystallisation to screen 
for multi-component crystals. The advantage of crash cooling over evaporative crystallisation is a 
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faster crystallisation time is usually achieved. However, the resulting crystals are often of poorer 
quality and not ideally suited to analysis by SCXRD. Solubility data is not necessarily required to carry 
out this kind of cooling crystallisation. A mass of solid that exceeds the room temperature saturation 
in a given solvent was dissolved in 7 mL glass vials. Sonication with heating was utilised to aid 
dissolution of the saturated solution. Vials were transferred to the fridge, set at 4 ⁰C, to create the 
fast cooling conditions. If no crystallisation is induced, slow evaporation can be adopted by piercing 
holes in the plastic lids, however this would then no longer be a purely crash cooled experiment. 
3.2.2.2  Controlled cooling 
For controlled cooling crystallisations a Polar Bear Plus crystalliser from Cambridge Reactor Design 
was used. The set up allows batch crystallisations to be carried out on a number of different scales, 
made possible by a number of different sized inserts (figure 3.1). Crystallisation on scales of 1 mL 
and 20 mL (vials) are possible as well as 50 mL, 100 mL and 250 mL (round bottom flasks). Heating 
and cooling profiles can be programmed to tightly control the crystallisation set up. Stirring is 
possible with both magnetic bottom stirring, in all sizes, and overhead stirring with an impellor, only 
in round bottom flasks. Overhead stirring is achieved using an overhead shaft and motor clamped 
above the round bottom flask crystallisations. 
3.2.3  Grinding (mechanochemical) 
Grinding was carried out to screen the formation of multi-component crystal systems and determine 
the more stable polymorphic form of co-crystals. A small amount, on the milligram scale, of the 
relevant materials were ground together by hand using a pestle and mortar. Experiments were 
carried out with the target molecule and corresponding stoichiometric ratio of co-former or a 1:1 
stoichiometric ratio of two polymorphic forms were used. Liquid assisted experiments (LAG) were 
also carried out where a drop of solvent was added to aid formation of new intermolecular 
interactions. Neither method was used for the investigation of crystal morphology as grinding would 
be an additional influence on the crystal shape, resulting in crushed micro-crystallites.  
 
78 
3.2.4  Slurrying 
Slurrying methods were also used in the formation of multi-component crystal systems. Excess 
starting materials were stirred in solvent for a prolonged period of time to allow for the 
transformation of starting materials into co-crystalline products. This method was used to scale up 
successful multi-component crystallisations to produce a bulk amount of a sample. This method was 
particularly beneficial for the scale up of production of PYR co-crystals (chapter 6) due to their low 
solubility. This method was not used to investigate crystal morphology as the continuous stirring 
often results in a microcrystalline powder. 
3.2.5  Continuous crystallisation 
Continuous crystallisations were carried out using a modified set up of the KRAIC, previously 
discussed in chapter 1. The adapted KRAIC set up is shown in figure 3.2. 
 
Figure 3.2. Adapted KRAIC set up. 1. Air pump; 2. Galden pump; 3. Solution pump; 4. Feed/solution vessel; 5. Submerged 
cross piece; 6. Crystallisation coil; 7. Outlet; 8. Crystal collection; 9. Galden recovery. 
The configuration detailed was developed to allow cooling crystallisations to be carried out within 
a fume hood. This enabled the use of solvents not suitable for use on the bench with an overhead 
extractor. The KRAIC can also be set up to achieve other crystallisations, such as anti-solvent, and 
chemical synthesis in flow. The set up utilises a continuous stream of solution split into discrete 
segments using air pumped into the tube. An inert organic carried fluid is also used to preferentially 
wet the walls of the tubing, further separating the solution segments, known as slugs, and 
preventing a solid/solution interface being available to induce nucleation. The solution cools as it 
travels through the tubing allowing nucleation and growth to occur before the solution is separated 
from the carrier fluid and crystals filtered from solution at the outlet. 
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The KRAIC is constructed from 15 m of fluorinated ethylene propylene (FEP) tubing with an internal 
diameter of 3.2 mm. The tubing is assembled into coils with a gentle ascending gradient between 
each coil. In the set up used here the tubing is coiled around one support only to allow it to fit inside 
a fume hood. Solution, carrier fluid and air are pumped into the coils using individual gear pumps. 
The solution is temperature controlled prior to entering the crystalliser to ensure all solute is fully 
dissolved. The inlets of the feed tubes are fitted with solvent filters to prevent small, undissolved 
nuclei or other foreign particles (such as dust) entering the crystallisation vessel. Any small particles 
entering would seed nucleation in the discrete segments, reducing the chance of primary nucleation 
occurring. Segmentation is created using a glass mixer cross piece with three inlets, one for each of 
solution, carrier fluid and air, and one outlet for the segmented flow. 
Supersaturation is achieved via cooling crystallisation. Solution is saturated at an elevated 
temperature to allow a temperature gradient to be generated across the coiled tubing. Temperature 
control of the tubing after the mixer piece was not possible, however, temperature before this point 
is controlled in a number of ways. The feed vessels are temperature controlled using feedback 
controlled hot plates with Drysyn® formers to house the round bottom flasks. All the inlet tubing is 
jacketed using flexible tubing jackets connected to a circulator bath, allowing the temperature to be 
maintained before the mixer piece. The final step using temperature control is the mixing in the 
cross piece. The cross piece, three inlets and segmentation outlet are submerged in a water bath. 
This temperature is again feedback controlled using a hot plate. Temperature control at this point 
is very important to prevent nucleation induced by the mixing of the three phases; crystallisation at 
this point could block the flow. Finally, the set up finishes with an end piece designed to aid 
expulsion of the crystalline material from the KRAIC and recover the carrier fluid used in the 
experiment. The end piece feeds into a Buchner funnel to collect any crystals produced. Sometimes 
crystals remain in the inlet and a neutral solvent is required, to help flush the crystals out of the end 
piece without re-dissolving any of the product. 
A typical KRAIC experiment follows the general process: 
- The KRAIC set up is primed using pure solvent (same as used to make up the solution), air 
and carrier fluid for 1 hour. This is to ensure the system is at equilibrium and the 
temperature gradient is produced. 
- The pump speeds are set to control the relative flow rates and ensure the segmentation is 
regular and well sized and also to fine tune the residence time, the time the solution takes 
to go through the length of the crystalliser. 
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- The primer inlet is switched to the feed solution and the crystallisation experiment starts. 
- The solution cools over the length of the KRAIC, generating supersaturation and inducing 
primary nucleation in the segments. 
- At the end of the crystalliser the carrier fluid is recovered and crystals collected using 
Buchner filtration. 
3.2.6  Temperature cycling 
Temperature cycling is often utilised to improve particle size distribution and crystal aspect ratio. 
Temperature cycling uses a defined temperature profile that both heats and cools at steady rates. 
Repeating the cycle multiple times can improve particle size distribution by re-dissolving small, fine 
particles produced with uncontrolled nucleation and allowing the larger crystals to act as seeds 
when cooling recommences. The dissolved molecules are then more likely to grow on existing 
crystals than nucleate to form new crystals. A similar argument can be made for improving aspect 
ratios, as all faces have different dissolution and growth rates. 
Temperature cycling was carried out using the Polar Bear Plus crystalliser. A temperature profile 
was determined from solubility and MSZW data obtained for the materials. The cycle is designed 
around the determined solubility line. To initially nucleate the solution must be cooled to fall outside 
the MSZ (in the labile region). Following this the dissolution/recrystallisation cycle should remain 
either side of the solubility limit, from undersaturated to within the MSZ, to encourage crystal 
growth and limit further nucleation. The defined temperature cycle giving rise to the dissolution and 
recrystallisation of the solute is continued until the preferred outcome is achieved. Temperature 
profiles can be simple cycles, returning towards the minimum set immediately after reaching the 
maximum, or contain a hold step at set temperatures to allow more time for the system to 
equilibrate.  
Temperature cycling is a more reliable technique when utilising direct feedback control. Using PAT 
probes, such as FBRM, the cycles can be monitored and an end point easily determined. When using 
PAT probes it is also easier to maintain the crystallisation parameters within the MSZ limits of the 
system.  
3.3  Stability measurements 
A range of experiments were used to characterise the stability of the multi-component crystal forms 
produced throughout the work discussed in this thesis. 
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3.3.1  Slurry 
An excess sample of the multi-component product was slurried in water at 40 ⁰C for a week. The 
samples were continuously stirred in solution for the duration of the experiment. Small amounts of 
each sample were removed throughout the process and analysed by PXRD to determine if any 
breakdown or transformations occurred. The conditions used were chosen to mimic the dissolution 
of the sample within the body.  
3.3.2  Competitive slurrying  
Competitive slurry experiments are used to help distinguish the thermodynamic polymorph from 
metastable polymorphic forms. An excess amount of a 1:1 mixture of two polymorphs was slurried 
in solvent for a week. Slurries were carried out at 20 ⁰C and an elevated temperature of 40 ⁰C. 
Samples were continuously stirred and samples were removed at intervals throughout the process. 
Analysis using PXRD was used to determine the transformations that occurred throughout the 
duration. The samples are expected to convert to the more stable polymorphic form over time. 
3.3.3  Elevated temperature 
Elevated temperature studies were also carried out to investigate the stability of the new solid forms 
to storage conditions throughout the supply chain. A temperature of 50 ⁰C was chosen to accelerate 
any changes and degradation that may be observed when stored at higher than ideal temperatures. 
Samples of each form were left in an oven set to 50 ⁰C for 3 weeks and tested periodically 
throughout using PXRD analysis. The results were compared to the starting materials and original 
form PXRD patterns to determine any degradation or form changes observed as the result of the 
increased storage temperature. 
3.3.4  Humidity 
Humidity studies can be used to investigate the potential stability of the multi-component crystals 
produced in storage conditions that may occur throughout the supply chain. A humidity chamber 
was created using a saturated solution of water and NaCl salt. Upon testing with a humidity probe 
the 70% humidity was maintained with an error of 3%. Samples were placed in 1 mL vials which 
were in turn placed in 20 mL vials before being sealed in the humidity chamber (figure 3.3). PXRD 
analysis was carried out on small amounts of each sample extracted at weekly intervals up to a limit 
of 9 weeks. The results were compared to the PXRD patterns of the individual components and 
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original co-crystalline sample to determine if any changes occurred as the direct result of the 
conditions to which the sample was subjected. 
 
Figure 3.3. Humidity chamber set up with unsealed 1 mL vial inside an unsealed 20 mL vial 
3.4  X-ray diffractometers 
3.4.1  Single Crystal X-ray Diffraction (SCXRD) 
The SCXRD data discussed in this thesis were collected on three different laboratory diffractometers; 
Rigaku Oxford Diffraction SuperNova, Rigaku Oxford Diffraction Xcaliber and a Rigaku Oxford 
Diffraction Gemini A Ultra (figure 3.4). Both the SuperNova and Gemini models are equipped with 
dual sources (Mo-Kα and Cu-Kα), with the Xcaliber only capable of analysis using Mo-Kα radiation. 
The SuperNova utilises a dual micro-focus source and the Gemini A Ultra a dual sealed tube source. 
Both are fitted with graphite monochromators. The Xcaliber has a sealed tube Mo-Kα source and a 
graphite monochromator. 
All diffractometers possess the possibility of data collection at low temperatures using a liquid 
nitrogen stream (either an Oxford Instruments CryoJetXL or a Cryostream 700). Full structure 
analysis was carried out at 150 K using the flow of liquid nitrogen to control the temperature of the 
sample. It is also possible to heat the nitrogen stream, allowing the temperature to be controlled at 




Figure 3.4. Rigaku Oxford Diffraction Gemini A Ultra diffractometer. 1. CCD area detector; 2. Goniometer; 3. Cryostream; 
4. Cu and Mo X-ray tubes; 5. Camera. Backstop can be seen between the X-ray tubes and area detector 
All diffractometers are equipped with a charge coupled device (CCD) area detector, the position of 
which can be altered to increase or decrease the distance from the mounted crystal.  The 
goniometer on which the crystal is mounted also has the ability to move. Each diffractometer is 
equipped with a 4-circle kappa goniometer allowing movement through the angles κ, φ, ω and 2θ 
to produce a full data set for each collection. 
CrysAlisPro198 software was used for data collection and processing for all full structure 
determination experiments carried out. All structures were solved by direct methods using ShelXS177 
and refined using ShelXL177 within Olex2199 software. Following full resolution and refinement of the 
crystal structures, Mercury 3.10.2135 was used to visualise the crystal structures. This software was 
also used to calculate the BFDH morphology for crystals where face indexing was carried out.  
Face indexing experiments were carried out on the Rigaku Oxford Diffraction SuperNova, Rigaku 
Oxford Diffraction Xcaliber and Rigaku Oxford Diffraction Gemini A Ultra diffractometers. Face 
indexing can be performed on either full data collections or pre-experimental data. The analysis is 
carried out using CrysAlisPro software, using a movie collected of the mounted crystal on the 
diffractometer. Using the software to outline the edges of the crystal as it rotates, the faces and 
their hkl values can be determined. In order to analyse the resulting morphology further a face table 
is produced, which can be imported into Mercury 3.10.2 software and the BFDH function used for 
visualisation and comparison.  
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3.4.2  Powder X-ray Diffraction (PXRD) 
PXRD data was collected in transmission mode using a Stoe Stadi P model diffractometer. The Stoe 
has a sealed tube equipped with a primary monochromator to produce pure Kα1 radiation using a 
Cu source. The diffractometer was used in transmission mode with samples mounted using a high 
precision, two-circle goniometer and spun throughout the data collection. Spinning the sample 
produces more reliable intensities than would be achieved in flat plate mode, as it reduces the 
possibility of preferential orientation. Grinding of crystalline samples in a pestle and mortar, before 
being loaded into the sample holders, ensures a more homogeneous microcrystalline powder 
preventing a high background in the data. Data were collected between 2θ values of 2° and 75° at 
room temperature using a Dectris Mythen 1K detector. Data presented in this thesis are shown 
between 2θ values of 5° and 40°. 
Variable temperature PXRD experiments were performed for one complex to develop a better 
understanding of a possible phase transition observed in previous DSC traces. Data were collected 
on beamline I11, situated at a synchrotron source (Diamond Light Source).  Using a borosilicate glass 
capillary as the sample holder, the microcrystalline sample was loaded and held in a brass holder 
using glue. The sample is spun, similar to the laboratory PXRD experiments, to achieve more 
accurate peak intensities and prevent preferential orientation of the micro-crystallites having an 
effect. Radiation on the beamline, monochromated from a Si (111) source, has an energy of 15 keV 
(λ=~0.826 λ). The beamline utilises two detector arrays: the position-sensitive detector, used for 
high throughput experiments, and the multi-analyser crystal for high resolution. The position-
sensitive detector was used to collect data for this experiment. The sample temperature was 
controlled using an Oxford Cryosystems Cryostream Plus, able to both heat and cool the samples 
measured. 
3.5  Thermal analysis 
3.5.1  Hot-stage Microscopy (HSM) 
HSM was carried out on crystals to observe thermal phase transitions occurring when heat is 
applied. Using a Mettler Toledo FP82 hot-stage equipped with a Leica DM1000 microscope, crystals 
were subjected to a defined temperature profile from 30 ⁰C to various maximum temperatures, 
dependent on the sample undergoing the test. A FP90 Central Processor was employed to control 
the heating rate, chosen at 10 ⁰C/minute to correlate the results to those seen in DSC experiments. 
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Films of the crystals were captured using a Lumenera Infinity 2 microscopy camera and recorded 
using Studio Capture software version 4.0.1 © 2001-2010 Studio86Designs. 
3.5.2  Differential Scanning Calorimetry (DSC) 
The DSC instrument used was the Thermal Advantage Q20 DSC from TA Instruments. The instrument 
is operated with a dry nitrogen purge gas at a flow rate of 18 cm3/minute to create an air free 
atmosphere. This prevents any water crystallisation occurring within the system when low 
temperatures are reached. 2-4 mg of sample is sealed in a Tzero aluminium pan and heated at a rate 
of 10 ⁰C/minute to a maximum temperature, determined by the composition of the sample being 
investigated. Cooling is also possible using the DSC instrument and was utilised to determine 
whether recrystallisation was occurring. Data were collected using Advantage for Qseries software 
(version 5.4.0 © 2001-2011 TA Instruments-Waters LLC). Analysis of the peaks observed in the 
collected data was carried out using TA Universal Analysis software.  
3.5.3  Thermogravimetric Analysis (TGA) 
TGA experiments were carried out using a Perkin Elmer TGA4000. 2-5 mg of sample was placed in 
the sample holder and the temperature ramped to 250 ⁰C at a rate of 5 ⁰C/minute. The TGA system 
is maintained under a nitrogen atmosphere using a flow rate of 20 mL/minute.  
3.6  Other analysis techniques 
3.6.1  Fourier Transform Infra-red spectroscopy (FTIR) 
The FTIR spectra obtained in this work were recorded using a Perkin Elmer FTIR Spectrometer in the 
range 4000–500 cm−1 with an attenuated total reflectance (ATR) sampling accessory. Samples were 
analysed at room temperature. 
3.6.2  Nuclear Magnetic Resonance spectroscopy analysis (NMR) 
Proton NMR spectra were obtained using an Agilent Technologies 300 MHz 1H-NMR spectrometer. 
The samples were prepared by dissolving a small amount of crystalline material in a deuterated 
solvent. The experiments were conducted at 298 K. Resulting spectra were compared using 








Chapter 4 Morphology changes observed 
in pure isoniazid 
 
4.1  Introduction and aims 
Morphology is an important physical property to consider for pharmaceutical crystals due to the 
significant influence it can have both on surface-dependent particle properties such as dissolution 
rate and on downstream processing steps. In processing, controlling this property can not only make 
many crucial steps, such as filtration, easier, but also prevent extra steps, such as grinding, being 
required. Controlling morphology without changing the crystal structure of the active ingredient 
requires influencing the crystallisation process to result in a change in the growth of the crystal. The 
influences being investigated here come from the solvent system used and impurities present in the 
crystallisation.  
The aim here is to achieve a morphology change of pure IZN through solvent choice or additive 
impurities. This means no changes should be observed to the crystal structure produced. 
4.2  Solvent effects on isoniazid morphology 
Early in the development of a pharmaceutical product there is likely to be significant freedom with 
solvent choice. Generally, in the early stages of development a large number of solvents would be 
screened for API solubility, the form of the crystalline product produced by recrystallisation from 
these (including the potential to form any solvates) and the quality of the crystals produced. Any 
solvents yielding the correct form of the product can also be screened for their morphological 
influence. It is widely accepted that different solvents can yield different growth mechanisms for 
the same molecule and crystal form, often resulting in changes to the overall morphology.  
The aim of this research was to develop a solvent system for the crystallisation of IZN that produces 
a favoured crystal morphology. Avoidance of needle and plate shapes in favour of more block 
shaped crystals is preferred in pharmaceutical development. The transfer of any solvent effects 
between different crystallisation methods is also necessary, with the final goal in this investigation 
of eventual transfer into continuous crystallisation platforms. Crystal habits were characterised by 
indexation of the faces using SCXRD. As a key element of this investigation is to maintain the original 
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form of IZN, without producing solvates, PXRD, DSC and NMR spectroscopy methods were also used 
to characterise the bulk sample.  
4.2.1  Experimental information 
The IZN and all solvents used in the following experiments were acquired from commercial sources 
and used without any further purification steps. 
4.2.1.1  Choice of solvents for isoniazid crystallisations 
When choosing the solvents for this investigation a variety of factors where considered. Lists of 
commonly used solvents in pharmaceutical production were consulted initially.199 Considerations of 
the volatility of the solvent and ability to dissolve the target molecule were used to determine an 
initial list of solvents. The availability and safety of the solvents are also important concerns taken 
into account. The solvents chosen for these experiments came from a variety of different 
classifications for pharmaceutical production. The final solvents chosen were water (H2O), alcohols 
ethanol (EtOH) and isopropanol (IPA), ethyl acetate (EtOAc) and acetonitrile (ACN).  
A secondary list of esters was chosen as additional solvent options due to the successful morphology 
changes achieved with EtOAc. These esters had varying chain lengths and are shown in figure 4.1. 
 
Figure 4.1. Ester solvents used (a) methyl acetate, (b) isopropyl acetate, (c) isobutyl acetate, (d) ethyl propionate, (e) 
ethyl butyrate, (f) ethyl valerate, (g) ethyl hexanoate and (h) ethyl heptanoate 
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4.2.1.2  Evaporative screening of isoniazid in different solvent systems 
Initial evaporative experiments were carried out using pure IZN in the four initial solvents. 
Approximately 0.01 g of IZN was dissolved in a minimal amount of solvent in 7 mL vials. Holes were 
pierced in plastic lids and the vials left to evaporate at room temperature and 40 ⁰C.  
Evaporative experiments from the broader range of ester solvents were carried out due to the 
success observed from initial screens carried out in EtOAc. Again a small amount of IZN, 0.01 g, was 
dissolved in a minimal amount of ester in 7 mL vials. The vials were sealed and sonication was used 
to aid full dissolution. Holes were poked in the top of the plastic lids to allow slow evaporation and 
the vials left at both room temperature and 40 ⁰C.  
Further experiments were carried out with solvent mixtures. The main solvents chosen were EtOAc 
and IPA, due to their reliability when producing the morphological changes observed with initial 
screens. Mixtures of either IPA or EtOAc with the esters in figure 4.1 in v/v ratios of 10%, 20%, 30%, 
40% and 50% were investigated. In addition, solvent mixtures of IPA and EtOAc were prepared in 
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90% v/v ratios. A 7 mL vial was used to dissolve 0.01 g 
of IZN in the minimal amount of solvent mixture. After sonication, to aid dissolution, the vials were 
left at room temperature and 40 ⁰C to fully evaporate.  
4.2.1.3  Cooling crystallisations of isoniazid in different solvent systems 
Controlled cooling experiments were carried out on IZN in the same five solvents; H2O, EtOH, IPA, 
EtOAc and ACN. A Tsat of 30 ⁰C was used for EtOH and H2O, and a Tsat of 50 ⁰C for IPA, EtOAc and 
ACN, due to low solubility of IZN in these solvents. A mass of 8 g of solvent was saturated for all 
solvents except water, where 4 g was saturated due to the very high solubility. Crystallisations were 
carried out in 20 mL vials without any stirring to prevent breaking/grinding of the resulting crystals. 
Cooling experiments were carried out from 55 ⁰C with cooling rates of both 1 ⁰C/minute and 
0.1 ⁰C/minute. Crystals were filtered at the end using a Buchner funnel and allowed to dry before 
analysis. 
Further controlled cooling experiments were carried out with IPA and EtOAc on a 30 g and 150 g 
solvent scale with overhead stirring. The crystallisations were carried out in 50 mL and 250 mL round 
bottom flasks, respectively. Tsat of 50 ⁰C was used. The solutions were heated to 55 ⁰C and held for 
30 minutes to allow for complete dissolution. Cooling was carried out at 1 ⁰C/ minute to 5 ⁰C and 
the solution held at 5 ⁰C for a further hour. The samples were filtered and left to dry for analysis. 
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4.2.1.4  Isoniazid cooling crystallisations in the KRAIC continuous platform  
Cooling experiments were also carried out in the KRAIC continuous platform, discussed in section 
3.2.5. The cooling mechanism in this platform is uncontrolled as the tubing is not temperature 
controllable in the current set up.  
Crystallisations were carried out in the KRAIC in both IPA and EtOAc solvent. A number of different 
crystallisations were carried out with different temperature profiles and starting saturations to 
optimise the process and achieve the best crystallisations. The temperature settings and saturation 
concentrations are shown in table 4.1. 















1 0.006 50 50 50 
2 0.01 50 50 50 
3 0.015 55 55 55 
4 0.02 55 55 55 
 
EtOAc 
1 0.005 55 55 55 
2 0.005 55 55 60 
3 0.003 55 55 55 
For both solvents, the KRAIC was primed for 1 hour using pure solvent, air and Galden (carrier fluid). 
Priming ensures that steady-state is reached before crystallisation experiments are carried out. A 
residence time is measured whilst priming; the time it takes for the solution to travel the length of 
the crystalliser. The residence time is directly influenced by the flow rates; all pumps were set to a 
flow rate of 2.40 mL/minute. After priming, the feed solution was introduced in place of the pure 
solvent. A temperature gradient is set up, with the feed solution introduced at an elevated 
temperature and allowed to cool to room temperature throughout the tubing. Crystals were 
collected from the end piece into a Buchner funnel and left to dry after the experiment for further 
analysis. Galden was recycled back into the crystalliser via separation through the carrier fluid 
recovery holes in the end piece. A further inlet is utilised above the end piece to allow for the 
introduction of a neutral solvent in the event of crystal build-up in the end piece. The neutral solvent 
is miscible with the crystallisation solvent and does not change the solubility; only increases the 




4.2.1.5  Temperature cycling crystallisation of isoniazid from ethyl acetate  
Two temperature cycling experiments were carried out in EtOAc to try to improve the morphology 
change already successfully achieved from that solvent. The experiments were carried out in the 
Polar Bear Plus crystalliser in a 50 mL round bottom flask. Magnetic bottom stirring at 700 rpm was 
used during the heating phases but turned off during the cooling phases. The solutions were made 
by saturating 30 g of EtOAc with IZN at 40 ⁰C. The temperature cycling profiles are shown in figure 
4.2. The ramp rates used in each experiment were 2 ⁰C/minute during heating and 0.05 ⁰C/minute 
during cooling. In both experiments the solution was first heated to 40 ⁰C and held for 30 minutes 
to allow for full dissolution to occur. Following this, cooling was carried out to 5 ⁰C. The cycling then 
occurred by heating to 5 ⁰C below the previous highest temperature and cooling to 5 ⁰C above the 
previous lowest temperature until eventually converging at 20 ⁰C. The solution was then held at this 
final temperature for 30 minutes. In experiment 1, a short 30-minute dwell was added between the 
heating and cooling portions of the profile to allow for extended periods of growth and dissolution 
of the crystals produced.  
 
Figure 4.2. Temperature profiles for temperature cycling experiment 1 (left) and 2 (right) 
4.2.1.6  Supersaturation experiments with isoniazid 
A series of experiments were set up to investigate the effects of employing different starting 
saturations on the morphologies achieved in both IPA and EtOAc crystallisations. These were carried 
out in both evaporative and cooling crystallisation set ups. 
In evaporative crystallisations, 3 g of solvent was saturated with IZN at 20 ⁰C, 30 ⁰C, 40 ⁰C and 50 ⁰C 
in a 7 mL vial. Each different saturation was then evaporated at a different temperature, using 
feedback controlled hot plates set at 20 ⁰C, 30 ⁰C, 40 ⁰C and 50 ⁰C, respectively. The effects of both 
saturation and the evaporation temperature were therefore investigated in parallel.  
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In cooling crystallisations, 8 g of solvent was saturated at 20 ⁰C, 30 ⁰C, 40 ⁰C and 50 ⁰C in a 20 mL 
vial. Solutions were heated to 55 ⁰C and held for 30 minutes with magnetic bottom stirring at 700 
rpm. Cooling was then carried out at rate of both 1 ⁰C/minute and 0.1 ⁰C/minute, without stirring, 
to a temperature of 5 ⁰C and held for 1 hour.  
4.2.1.7  Analytical methods 
Microscope images of final crystal products were taken using a Nikon Coolpix P5100 camera through 
a Brunel Microscopes microscope. For smaller crystals a Leica DM1000 microscope with an Infinity 
2 microscope camera was used as a higher zoom was able to be achieved with enhanced focus. 
Analysis was also carried out via PXRD and DSC techniques, as explained in Chapter 3, to ensure the 
solid form of the crystals produced remained unchanged. 
Face indexing was carried out using a Rigaku Oxford Diffraction Gemini A Ultra diffractometer with 
Mo-Kα radiation. Screening of unit cells were carried out at 298 K and pre-experimental data 
recorded. Face indexing was performed with CrysAlisPro software to determine the faces and 
overall shape of crystals produced. Crystal structure and morphology were visualized using the BFDH 
tool included in the Mercury software.  
4.2.2  Effects of solvent on isoniazid morphology 
Evaporative crystallisation of IZN from a variety of solvents was initially carried out to determine the 
effect of different solvents on the resulting crystal morphology. PXRD analysis confirms no form 
changes have occurred for the IZN (appendix A1). Initial evaporative crystallisations gave unreliable 




Figure 4.3. IZN crystals from evaporative crystallisations at 40 ⁰C from solvents (a) H2O, (b) EtOH, (c) IPA, (d) EtOAc and 
(e) ACN 
Needle morphology was observed in samples from H2O, EtOH and IPA evaporative crystallisations. 
However, more block shaped morphologies were observed from EtOAc and ACN. The morphology 
observed in both the EtOAc and ACN crystallisations are much more favourable in the 
pharmaceutical industry context than those observed in H2O, EtOH and IPA.  
The same experiments were also carried out in cooling crystallisations. Controlled cooling in the 
Polar Bear Plus crystalliser yielded further morphology changes not observed in evaporative 
crystallisation (figure 4.4). 
 




Again, water yields very thin needle shape IZN crystals which clump significantly upon filtration from 
the crystallisation solution. However, a difference is seen in the morphology produced from both 
EtOH and IPA compared with that seen in the evaporative crystallisations. Both these cooling 
crystallisations yield plate-shaped crystals, in contrast to the needles observed in evaporative. 
Although plates are not the most favourable crystal shape, they indicate the significant influence 
solvent can have on the morphology of IZN. More rod/block shaped crystals were again observed 
for EtOAc, however, the change was less significant and less controllable under these particular 
cooling conditions. It was not possible to achieve the evaporative experiment morphology from ACN 
in cooling crystallisation. Cooling experiments yielded long thin needle crystals in ACN cooling 
experiments, in contrast to the block shapes observed in evaporative crystallisations.  
Face indexing experiments were not carried out for the needle-shaped products obtained in the 
crystallisations from H2O. Needles are difficult to face index due to their length and limited 
thickness. Often the length of the needle crystals does not fit within the camera view on the XRD 
instrument and their faces cannot be distinguished due, mainly, to their very close proximity to one 
another. As a result, the growth habit is projected from the BFDH morphology calculations carried 
out. The fastest growing faces in crystals are those with the smallest surface area and so it is clear 
in needle crystals the fastest faces are those capping the tips of the needles. Using the predicted 











Figure 4.5. Top: BFDH predicted morphology for IZN (INICAC02). Bottom: Molecular packing with respect to BFDH 
morphology  
This calculated morphology for IZN (figure 4.5) shows an elongated, rod-shaped crystal. Whilst the 
actual morphology achieved from H2O is observed to be much thinner and more needle-like than 
that predicted, the calculated morphology does tell us the likely major growth mechanism occurring 
in the crystallisations. By visualising the molecular packing in the crystal with respect to this 
morphology, it can be clearly determined that the major growth mechanism in IZN is the interaction 
between the aromatic π-systems. The packing of the crystal structure allows the π-systems to 
overlap with one another, occurring parallel to the capping faces of the morphology. Due to the 
almost herringbone structure of the packing, the hydrogen bonds are also orientated slightly 
towards the capping faces, also contributing to the major growth. Examination of the predicted 
needle crystal morphology and the underlying packing show there are no hydrogen bonding 
interactions protruding from the capping faces. The long sides of the needle, however, are 
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surrounded by different hydrogen bonding interactions. The interaction of H2O with the growing 
crystal is therefore along the length of the needle crystal, through hydrogen bonding interactions. 
The ability of H2O to hydrogen bond to these faces limits the ability of the solute molecules to adsorb 
to them, inhibiting growth in that direction and favouring further growth to extend the needle axis. 
The high polarity of the solvent makes it very successful in forming strong hydrogen bonds with the 
slower growing faces on the crystal surface. This strong solvent-surface interaction is likely 
responsible for directing the growth in the needle direction, increasing the aspect ratio of the 
crystal. 
Face indexing experiments were carried out on the plates produced in EtOH and IPA to allow for a 
comparison of the faces. Examination of the faces can allow conclusions to be drawn about the 
changes in crystal growth achieved in each different solvent. 
 
 
Figure 4.6. Top: Face indexed morphologies for IZN crystallised from EtOH (left) and IPA (right). Bottom: Molecular 
packing with respect to morphology for EtOH (left) and IPA (right). 
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Plates of IZN are observed from both EtOH and IPA (figure 4.6), but the major growth direction 
appears to differ slightly in each solvent system. In EtOH, the smallest face determined was the  
(-100) / (100). These faces grow as a result of the major growth interaction, π-system overlap. This 
is the same major growth as observed in the needle crystals. However, significant growth has also 
occurred in the (00-1) / (001) directions and these are the smallest faces observed in crystals grown 
from IPA (see below). The growth here is the result of hydrogen bond donation from the terminal 
NH2 group and accepted by the N in the pyridine ring (figure 4.7).  
 
Figure 4.7. Hydrogen bonds contributing to elongation of plate crystals in IPA: viewed from (-100) face (top) and (0-10) 
face (bottom) 
These hydrogen bonds connect in a zig-zag pattern, creating the herringbone structure observed in 
IZN crystals, and therefore also contribute to the growth on the needle axis and stacking of the 
aromatic rings in IZN. The growth on the (0-10) / (010) faces is the result of hydrogen bond donation 
from the NH group and accepted by the NH2 nitrogen. This is a much weaker hydrogen bonding 
interaction than those previously discussed, resulting in the limited growth observed.  
In IPA the major growth direction is different to that observed in EtOH, with the smallest faces now 
being (00-1) / (001), resulting from the hydrogen bond donation from the NH2 group to the N in the 
pyrazine ring. There is still significant growth on the (-100) / (100) faces of the crystal, resulting from 
the π-system stacking. Despite the seeming shift of major growth mechanisms in IPA, the 
morphology observed is very similar to that seen in EtOH. Comparing the morphology produced in 
IPA to that produced from water, minimal growth occurs on the (0-10) / (010) faces, similar to the 
needle growth and the EtOH crystallisation. Again, this reflects a weaker hydrogen bonding 
interaction and explains the slower growth observed in this direction.  
The differences observed between the major growth faces in the EtOH and IPA crystals are thus 
likely due to differences in the available interactions. Solvents can compete with solute at growth 
sites altering the growth mechanism occurring during crystallisation. Interactions between solvents 
 
98 
and specific faces of a growing crystal are possible, limiting the growth of those with stronger 
interactions to a greater extent. The increased growth on the c-direction is probably the result of a 
reduction in the hydrogen bonding potential in the solvents used. EtOH is a more polar solvent than 
IPA, resulting in a higher propensity to hydrogen bond to the slower growing faces of the crystal. 
The lower polarity means the hydrogen bonding interactions between the solvent and the surface 
are weaker and there is a higher ability for the solute molecules to hydrogen bond where the solvent 
would otherwise block the growth.  
The correlation between lower polarity and a more equant morphology can be further shown 
through the crystallisation carried out in EtOAc. EtOAc has a much lower polarity and causes a much 
more equant crystal morphology.  
 
 
Figure 4.8. Top: Face indexed morphology for IZN crystallised from EtOAc. Bottom: Molecular packing with respect to 
morphology 
The face indexed morphology achieved from crystallisations in EtOAc (figure 4.8) has a distinct 
similarity to that calculated using the simple BFDH approach (figure 4.5). The growth on the needle 
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capping faces is significantly reduced in this solvent in comparison that observed in water. There is 
also an increase in the growth of the (0-10) / (010) faces when compared to crystallisations carried 
out in EtOH and IPA. The apparent reduction in the growth resulting from π-system stacking could 
be the result of a specific interaction between the face and the solvent. As the solvent does not 
possess an aromatic ring to interrupt this interaction, this is an unlikely method of disruption. It is 
more likely that an acceleration of growth on the slower faces is occurring, allowing this growth to 
‘catch up’, producing more block shaped crystals. The lower polarity of the solvent system supports 
this potential mechanism. The lower polarity of EtOAc reduces its potential to block hydrogen 
bonding sites on the surface of the growing crystal. In addition to the reduced polarity, the structure 
of EtOAc also has an effect on its ability to hydrogen bond. The combination of these two factors 
reduces the ability of the solvent to interact with the growing surfaces and allows the solute 
molecules to bind preferentially instead.  
The evaporative crystallisation carried out in ACN also results in a more favourable block shaped 
crystal morphology (figure 4.9). Again, ACN has a lower polarity than water, allowing the growth of 














Figure 4.9. Top: Face indexed morphology for IZN crystallised from ACN. Bottom: Molecular packing with respect to 
morphology  
The most significant growth is observed on the capping faces, as discussed above with respect to 
the needles produced. The π-stacking interactions have the strongest effect on the growth of the 
crystal in ACN, as in all the previous solvents discussed. This major growth mechanism is difficult to 
interrupt with aliphatic solvent systems. ACN contains functional groups that form weaker hydrogen 
bonds than the more polar solvents investigated. As a result, ACN has a low affinity for the growing 
surfaces of the crystal and does not efficiently block the approach of the solute growth units. Whilst 
the polarity of ACN is much lower than that of water, comparison of the solvent polarities alone 
would suggest the shape produced from ACN should be more similar to that observed for IPA. The 
more block shape obtained from ACN can therefore be attributed not only to the polarity of the 
solvent but must also be influenced by the structure.  
The same results were not achieved in cooling crystallisation. Only needle crystals were achieved 
from cooling crystallisation in ACN, both with and without overhead stirring. As a result, ACN is not 
a reliable solvent for effecting reproducible morphology changes in IZN. 
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4.2.3 Transfer of isoniazid solvent experiments into the KRAIC continuous 
crystallisation platform 
The KRAIC continuous platform was used to crystallise IZN from both IPA and EtOAc in order to 
determine whether the same morphology modifications could be achieved using a continuous 
crystallisation methodology.  
Successful continuous crystallisation experiments were carried out in IPA at a concentration of 
0.02 g/g. Experiments were also carried out at lower concentrations, but no nucleation was 
observed within the coils of the KRAIC for these experiments. At the concentration of 0.02 g/g, the 
crystallisation was run for three residence times (total of 42 minutes) before crystallisation was 
observed in the outlet of the solution pump. It is not possible to control the temperature of the 
solution as it goes through the pump in the current set up. This means there is the potential for 
nucleation in this part of the KRAIC due to the solution being highly saturated. The chosen 
concentration of 0.02 g/g resulted in the ability to achieve the correct level of supersaturation to 
allow for significant nucleation within the KRAIC coil, resulting in growth of the crystals in the coil 
(figure 4.10).  
 
Figure 4.10. Crystallisation in feed pump outlet (left) and crystals in solution slugs in KRAIC tubing (right) for IZN 
crystallisation from IPA 
The crystals extracted from the KRAIC (figure 4.11) showed the usual plate-shaped morphology 
discussed above for crystallisations carried out in IPA. The consistency in the morphology 
demonstrates the ability of the morphology change to be achieved in a continuous platform, a 
promising finding in terms of implementing morphology control as part of a continuous 
crystallisation approach to process development. Successful transfer of morphology control to 
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continuous crystallisation has previously been achieved for an additive-enabled morphology change 
in a model compound (succinic acid).63, 201 
 
Figure 4.11. Crystals produced from continuous cooling crystallisations in IPA in the KRAIC set up 
Face indexing experiments were carried out to allow comparison of the faces of the plates produced 
in the KRAIC (figure 4.12) to those previously produced in bulk cooling methods.  
 
Figure 4.12. Face indexed crystals of IZN crystallised from IPA in the KRAIC continuous cooling (left) and batch cooling 
(right)  
The faces indexed for the crystals produced in the KRAIC exactly mirror those determined for the 
crystals produced in bulk cooling methods from IPA. This validates the use of IPA solvent as a robust 
influence on changing the morphology of IZN. The ability to achieve the same morphology in the 
KRAIC demonstrates the transferability of the effects of IPA on the growth across different 
crystallisation methods and into continuous crystallisation platforms.   
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PXRD confirms the crystals to be pure IZN, with the peaks from the sample analysed matching the 
unique peaks for the pure IZN structure (figure 4.13). The absence of any distinctive peaks differing 
from those of the known IZN pattern confirms no form change has occurred upon the change in 
morphology and no solvate form has been produced.  
 
Figure 4.13. PXRD data for (a) IZN (INICAC02) and (b) IZN crystallised from IPA in the KRAIC continuous platform 
KRAIC experiments were also carried out for IZN in EtOAc. Using a concentration of 0.005 g/g 
crystallisation of IZN was observed in the coils of the KRAIC (figure 4.14 right). However, significant 
crystallisation was also observed in the outlet of the solution pump (figure 4.14 left). This could 
result in blockages of the pump itself and significant increase of pressure in the system. As a result, 
the experiment was aborted after 21 minutes, within the second residence time of the experiment. 
Repeat runs were carried out with higher set temperatures for the jacketed tubing, resulting again 
in crystallisation in the outlet of the pump, and at lower starting saturations of IZN, resulting in no 




Figure 4.14. Crystallisations in the feed pump outlet (left) and crystals in solution slugs in KRACI tubing (right) for 
crystallisations of IZN from EtOAc 
Despite the issues in optimising the crystallisation, the crystals produced within the KRAIC again 
exhibited a successful morphology change consistent with that observed for EtOAc in previous 
methods. Small, rod-shaped crystals were observed (figure 4.15), closely resembling those 
previously discussed in this chapter. 
 
Figure 4.15. Crystals produced from continuous cooling crystallisations from EtOAc in the KRAIC set up 
The transferability of this morphology change again suggests the KRAIC continuous crystallisation 
method could be a viable route to robustly creating IZN crystals on a large scale that display 
enhanced morphological characteristics. Face indexing was carried out for comparison with the 





Figure 4.16. Face indexed crystals produced from EtOAc in KRAIC continuous cooling (left) and batch cooling (right) 
The indexed faces of the crystals produced in the KRAIC are the same as those indexed in samples 
from the bulk crystallisation experiments. The shape achieved replicates the original morphology, 
with the exception of the capping faces on the end. The (-110) face is missing from the end of the 
crystal, which could be the result of a number of factors. The face could have been missed from the 
indexation of the KRAIC sample, due to its small size and lack of clarity in the movie taken of the 
crystal. The difference could also be the result of breakages to the ends of the crystal as it is moved 
from the vial and mounted onto the single crystal diffractometer. The final reason for the difference 
could be slightly different growth mechanisms occurring in the KRAIC and in the bulk crystallisation 
methods. The reproduction of the morphology confirms EtOAc has a significant influence which can 
be transferred between a number of different crystallisation methods and platforms.   
PXRD analysis was used to confirm the absence of a solvate form or polymorphic change in the pure 
IZN crystals. The peak positions in the pattern measured for the IZN crystals produced in EtOAc 




Figure 4.17. PXRD data for (a) IZN (INICAC02) and (b) IZN crystallised from EtOAc in the KRAIC continuous cooling 
platform 
4.2.4  Temperature cycling effects on isoniazid morphology crystallised from 
ethyl acetate 
Temperature cycling can be a useful tool to improve morphology. Heating and cooling cycles can 
allow the dissolution of fines in the solution and result in the growth of larger crystals with improved 
shapes. As different faces possess different growth and dissolution rates, prolonged cycling allows 
morphologies to be accessed that would otherwise be difficult to achieve.64, 202 However, due to this 
extended cycling, it is a time consuming process.  
Two experiments were carried out to see if the morphology changes in IZN crystals observed in 
EtOAc could be further improved using the cycling method. The resulting crystals show little change 
from those seen previously for crystallisations carried out in EtOAc (figure 4.18). PXRD analysis 




Figure 4.18. IZN crystals produced in temperature cycling experiment 1 where a 30 minute hold was included between 
cycles (left) and experiment 2 where no hold was utilised between heating and cooling (right) 
Experiment 1 shows a slight improvement on the uniformity of the morphology achieved in cooling 
crystallisations and closer resembles the outcome of the evaporative crystallisations. The dwell 
periods between the ramping up and down in temperature has allowed the crystals to grow to be 
larger than seen in experiment 2 and less fines are produced. However, this experiment overall took 
31.5 hours, compared to 13.5 hours for a standard cooling experiment using the same ramp rates 
and conditions. Experiment 2 has a slightly shorter experiment time, 28.5 hours, but does not 
produce as good results as seen in experiment 1. More fines can be seen and the crystals produced 
are longer, thinner and smaller.  
Overall the more successful temperature cycling approach would be experiment 1, with the 
inclusion of the dwell periods between the heating and cooling profiles. However, the improvement 
compared to the shorter, linear cooling crystallisations is likely not enough to justify the significant 
increase in crystallisation time required.  
4.2.5  The effect of supersaturation on isoniazid morphology 
As some crystallisations did not produce the same morphologies in evaporative as they did in 
cooling, experiments were carried out to investigate the effects of starting saturation on the 
morphology achieved. In parallel, the effect of changing the temperature at which a sample is 




Figure 4.19. Evaporative experiments to investigate the effects of saturation and evaporation temperature on the 
morphology of IZN crystallised from IPA 
For evaporative crystallisations carried out in IPA, evaporating at a faster rate seems to allow the 
formation of plates as seen in cooling crystallisations (figure 4.19). At all initial saturations, plates 
are produced when evaporated at a temperature of 50 ⁰C. This suggests the fast evaporation rate 
prevents the formation of the needle crystals. Some plates can also be seen in the evaporative 
crystallisations carried out at 40 ⁰C with higher starting saturations.  
In EtOAc, the rod-shaped crystal morphology was obtained from both evaporative and cooling 
crystallisations. The effect of starting saturation and evaporative temperature was also investigated 
for crystallisation from EtOAc to determine the landscape of the conditions allowing for the 




Figure 4.20. Evaporative experiments to investigate the effects of saturation and evaporation temperature on the 
morphology of IZN crystallised from EtOAc 
The rod-shaped morphology is achieved in all crystallisations carried out in EtOAc (figure 4.20). The 
starting saturation and evaporative temperatures used appear to have no significant impact on the 
morphology of the crystals produced. No discernible pattern can be identified for the crystallisations 
carried out in EtOAc.  
Supersaturation investigations were also carried out in cooling crystallisations, to examine the 
effects of cooling speed and starting saturation of the shapes of the crystals produced. No influence 
on the shape was observed. The only difference resulting from changing the starting saturation was 
the amount of crystals produced. As a result, it can be determined that saturation has little effect 
on the morphology produced under controlled cooling conditions.  
4.2.6  Morphology changes of isoniazid in evaporative crystallisations with 
solvent mixtures  
4.2.6.1  Ethyl acetate:propan-2-ol mixtures 
Crystallisation of IZN from mixtures of IPA and EtOAc were investigated to determine whether the 
presence of a smaller percentage of EtOAc can have the same morphological effects as seen in 
experiments carried out in pure EtOAC. EtOAc was added to IPA in 10% intervals from 90:10 to 10:90 
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IPA:EtOAc solvent mixtures and evaporative IZN crystallisation carried out in each mixture, at 20 ⁰C 
and 40 ⁰C (figure 4.21).  
 
 
Figure 4.21. Evaporative experiments carried out at 20 ⁰C (top) and 40 ⁰C (bottom) to investigate effects of solvent 
mixtures of IPA:EtOAC on IZN morphology 
The results show that successful morphology modifications are observed only at the higher 
percentages of EtOAc. Only those with 90% and 80% EtOAc have produced the rod-shaped crystals 
previously seen for crystallisations carried out in pure solvent. The other crystallisations show the 
plate-shaped crystals seen for pure IPA in both evaporative and cooling crystallisations. There is thus 
no evident benefit of using the mixed IPA:EtOAc solvent in achieving IZN morphology modification. 
4.2.6.2  Ethyl acetate and ester mixtures 
Initially, a selection of esters was chosen for use as the primary crystallisation solvent, with the aim 
of determining whether chain length of the ester had an effect on the morphology produced. The 
solubility of IZN in the esters was found to be minimal however, and the experiment was not 
successfully carried out. As a result, a series of solvent mixture experiments were set up as an 
alternative way to assess any effect of the longer chain length esters. The esters were used in 10% 




Figure 4.22. Evaporative experiments to investigate the effects of solvent mixtures of IPA and assorted esters 
(percentages given) on the morphology of IZN 
Crystallisations of IZN from solvent mixtures of the branched esters with IPA show only plate-shaped 
crystals, as previously observed from IPA alone (figure 4.22). This indicates that the esters do not 
affect the crystallisation in the amounts added; however, no detrimental effects are observed.  
 
Figure 4.23. Evaporative experiments to investigate the effects of solvent mixtures of IPA and assorted esters 
(percentages given) on the morphology of IZN 
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The same can be concluded for the extended carbon chain esters used. Plate-shaped crystals, as 
usually observed for IPA crystallisations, can be seen for almost all of the mixed solvent experiments 
in this set (figure 4.23). The only exception is the IZN morphology produced from crystallisations 
carried out in ethyl heptanoate. The crystals produced in all experiments with ethyl heptanoate 
show needle-shaped crystals. This suggests the addition of the extended chain ester in the 
crystallisation solvent mixture produces less favourable conditions for the desired IZN morphology 
improvement, resulting in the return from plates to needles.  
 
Figure 4.24. Evaporative experiments to investigate the effects of solvent mixtures of EtOAc and assorted esters 
(percentages given) on the morphology of IZN 
The crystals produced from mixtures of EtOAc and the branched esters show similar rod-shaped 
morphologies as achieved from pure EtOAc crystallisations (figure 4.24). No change is observed 




Figure 4.25. Evaporative experiments to investigate the effects of solvent mixtures of EtOAc and assorted esters 
(percentages given) on the morphology of IZN 
Similarly, very little change is observed for crystallisations carried out with solvent mixtures of 
extended chain esters and EtOAc (figure 4.25). The exception to this is the return to needle shapes 
seen for solvent mixtures containing a higher percentages of ethyl valerate and ethyl heptanoate. 
These effects are detrimental to the morphology changes achieved in pure EtOAc.  
The solvent mixture experiments suggest there is little benefit from using a solvent mixture to aid 
the changes in morphology of IZN. In IPA, no promising morphology changes were observed upon 
the addition of the esters. In EtOAc, no further morphology changes are observed that improve upon 
the changes originally achieved in pure EtOAc. As a result, it would not be beneficial to use a solvent 
mixture as the same results can be obtained in pure EtOAc. 
4.3  Additive experiments with isoniazid 
Additives are considered intentionally added impurities when being referred to in the context of 
crystallisation. Whilst many additives are used in pharmaceutical product formulation, it is not 
common to see them used in the crystallisation step. Regulations dictate that only very small 
amounts of impurity are allowed at the crystallisation stage to ensure these do not come through 
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into the final drug product and cause potential harm to patients. As a result, research into the use 
of additives must focus on changes made by the presence of very small quantities. A good additive 
choice would be significantly more soluble that the API target in question in order to allow it to 
remain in solution after crystallisation has occurred and be removed in filtration steps. 
The aim of this work is to identify an additive system that is successful in modifying the morphology 
of IZN when present in solution. The robustness of this control would then be verified by testing the 
system under various crystallisation conditions. As previously discussed, IZN often forms thin needle 
or plate-shaped crystals, the avoidance of which can offer significant benefits for pharmaceutical 
processing steps. Therefore, an additive would ideally yield more block shaped crystals with better 
aspect ratios. For this research two different types of materials have been chosen as additives; 
structurally similar/size-matched molecules and polymers. SCXRD was used to index the crystal 
faces of crystals exhibiting a morphology change to understand any changes occurring in the growth 
of the crystals. Unit cell determination and other bulk analysis techniques, including PXRD, NMR 
spectroscopy and DSC, are also used to confirm the same form of the API is being produced.  
4.3.1  Selection of additives for isoniazid 
Additive selection was carried out using molecular complementarity function in the Mercury 
program. All five molecular descriptors were enabled for the calculations. Molecular 
complementarity is a calculation usually designed to predict the compatibility of molecules for co-
crystallisation.  It is used here to guide the choice of additives. The additives used should be able to 
interact with the active ingredient in a way that changes the growth. Therefore, if a chosen molecule 
has propensity to make a co-crystal with the target API, it follows that there is a chance a small 
amount being present will interact to influence the growth of the API crystals. Two different lists of 
molecules were screened for complementarity; a list of GRAS molecules and a list of common 
molecules found to make co-crystals. The use of non-GRAS additives would not be favourable to the 
pharmaceutical industry, however, the knowledge gained from their use could help design a better 
additive process with safe molecules. 
The molecules that passed the molecular complementarity check are further examined for their 
possible interactions with IZN and their structural similarities. As the major growth in IZN is 
influenced by the interaction between the aromatic rings, molecules containing an aromatic ring 
were favoured. The aim of choosing these would be to interrupt the major growth mechanism of 
the crystal, allowing the slower growing faces to catch up. By capping the fast growing faces it is 
hoped the resulting crystals will be shorter and fatter. The final consideration taken was to check if 
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any of the additives that passed were already known to make co-crystals. This was again favoured 
as they are already known to interact well with the IZN molecules. The additive wt% used should be 
low enough to avoid co-crystal formation from these being present in the system. The final additive 
list chosen is shown in figure 4.26. 
 
Figure 4.26. Additives list for screening with IZN (a) benzoic acid, (b) 3-hydroxybenzoic acid, (c) 2,4-dihydroxybenzoic acid, 
(d) 3,4-dihydroxybenzoic acid, (e) 3,5-dihydroxybenzoic acid, (f) 2,6-dihydroxybenzoic acid, (g) 4-cyanobenzoic acid, (h) 3-
cyanobenzoic acid, (j) 2,4-dinitrobenzoic acid, (k) 3,4-dinitrobenzoic acid, (l) 3,5-dinitrobenzoic acid, (m) trimesic acid, (n) 
isonicotinamide, (p) nicotinamide, (q) pyridoxine, (r) vanillin and (s) L-tartaric acid 
A selection of polymeric additives was chosen based on their hydrophilic or hydrophobic properties. 
The needle morphology of IZN has hydrogen bonding groups along the needle axis and no functional 
groups on the capping faces. In H2O, it is observed that the molecules likely interact with the long 
axis faces, inhibiting growth perpendicular to these, resulting in growth units joining on the capping 
faces and extending the needle length. This would suggest that hydrophobic polymers could cap the 
major growth faces and allow the fattening of the needle morphologies to more favourable, equant 
shapes. By using a mixture of hydrophobic and hydrophilic polymers this hypothesis can be tested 




Figure 4.27. Polymeric additive list for screening with IZN (a) polybutadiene, (b) polyvinylpyrrolidone, (c) poly(ethylene 
glycol), (d) poly(propylene glycol), (e) pluronic P123 and (f) poly(ethylene glycol) diglycidyl ether 
The hydrophobic polymers used were polybutadiene (PBD) and polypropylene glycol (PPG). The 
hydrophilic polymers used were polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and 
poly(ethylene glycol) diglycidyl ether (PDE). Pluronic P123 (PP123) is an amphiphilic polymer, with 
both a hydrophilic and hydrophobic section.  
4.3.2  Experimental information 
All materials and solvents used in these experiments were obtained from commercial sources. No 
further purification steps were carried out on the acquired starting materials. 
4.3.2.1  Evaporative screening of isoniazid with different additives 
Evaporative crystallisations were prepared in 7 mL vials by dissolving small quantities (0.01 g) of IZN 
and the corresponding wt% of additive in a minimal amount of solvent. To allow slow evaporation 
holes were pierced in the plastic lids. Evaporation was carried out at room temperature and an 
elevated temperature of 40 ⁰C. The solvent chosen for this study was IPA, due to the repeatability 
of the plate morphology achieved in this solvent. Although this IZN morphology change was 
observed from IPA, the ideal crystal habit has not been achieved. Therefore, the additive 
investigation was carried out in IPA in an attempt to further improve the morphology change already 
observed. The additives were tested at a range of concentrations, at wt% values of 1%, 5% and 10%. 
Polymers as additives were also investigated in evaporative crystallisations. Small quantities of IZN 
(0.01 g) and polymer additive were dissolved in IPA in 7 mL vials. Holes were pierced in the lids of 
the vials to allow for slow evaporation at both room temperature and an elevated temperature of 
40 ⁰C. Polymer additives were used in percentage mass ratios of 0.1% and 1%. A wt% of 1% was 
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chosen due to success achieved with size-matched additives at this level, while the smaller mass 
ratio of 0.1% was used due to successes reported in literature of much smaller additive percentages. 
4.3.2.2  Cooling crystallisation of isoniazid with different additives 
Controlled cooling experiments were carried out for systems in which successful additive effects 
were observed in evaporative experiments. As transfer to cooling proved challenging, a wide variety 
of different experiments were carried out. The variables changed throughout the experiments 
include starting saturation, cooling rate, length of time held at low temperature and percentage of 
additive. Tsat values of 20 ⁰C, 30 ⁰C, 40 ⁰C and 50 ⁰C were used with respect to IZN in IPA. Cooling 
rates of 1 ⁰C/minute and 0.1 ⁰C/minute were used along with holds at low temperature of 1 hour, 
5 hours and 10 hours. Percentages of (size-matched) additive chosen were 1%, 5% and 10%. A mass 
of 5 g of solvent was saturated in 20 mL glass vials. Stirring was implemented using a magnetic 
bottom stirrer during heating but turned off during cooling to avoid breaking/grinding of the 
resulting crystals. All crystallisations were heated to 55 ⁰C and held for 30 minutes to allow for 
complete dissolution. Cooling was then carried out to a temperature of 5 ⁰C at the chosen rate and 
held at this temperature for the chosen period of time.  
Large scale cooling crystallisations were also carried out in a 250 mL round bottom flask using 
overhead stirring. 150 g of IPA was saturated at 40 ⁰C and additive percentages of 1%, 5% and 10% 
were used. The crystallisations were again cooled from 55 ⁰C, after being held for 30 minutes to 
achieve complete dissolution, at rates of 1 ⁰C/minute and 0.1 ⁰C/minute. Crystallisations were 
finished at 5 ⁰C and held for 1 hour. Overhead stirring was used continuously throughout at a rate 
of 350 rpm. 
Polymeric additives were also tested in cooling crystallisation. The same polymer percentages used 
in evaporative were investigated in cooling, 1% and 0.1%. Crystallisations were carried out in 20 mL 
glass vials and 5 g of solvent was saturated with IZN at 40 ⁰C. Samples were heated to 55 ⁰C and 
held for 30 minutes with stirring to ensure full dissolution. Cooling was carried out at 1 ⁰C/minute 
and 0.1 ⁰C/minute to 5 ⁰C without stirring. The samples were held for an hour to allow nucleated 
crystals to grow. 
4.3.2.3  Transfer of isoniazid additive crystallisations into the KRAIC continuous platform 
Uncontrolled cooling crystallisations of IZN were carried out in the KRAIC in IPA with both 3-
hydroxybenzoic acid (3-HBA) and 3,4-dinitrobenzoic acid (3,4-DNBA) additives. A number of 
different crystallisation runs were carried out to optimise the temperature profile and starting 
concentration of the solution. The optimised conditions are shown in table 4.2. 
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0.0175 55 55 55 
The crystallisations were carried out for additive ratios of 1%, 5% and 10%. The KRAIC was primed 
for 1 hour using IPA, air and Galden (carrier fluid) to ensure steady-state was reached. The flow rate 
of all pumps was set to 2.40 mL/minute. After priming, the feed solution was introduced in place of 
the pure IPA. Crystals were collected from the end piece of the crystalliser tubing into a Buchner 
funnel and left to dry after the experiment for further analysis. Galden was recycled back into the 
crystalliser via separation through the carrier fluid recovery holes in the end piece. If a build-up of 
crystals occurred in the end piece a syringe of neutral solvent, pure IPA, was used to flush the 
crystals into the funnel. 
4.3.2.4  Analytical methods 
Microscope images of final crystal products were taken using a Nikon Coolpix P5100 camera through 
a Brunel Microscopes microscope.  
Analysis was also carried out via PXRD and DSC techniques, as explained in Chapter 3, to ensure the 
form of the crystals produced remained the same. NMR spectroscopy analysis techniques were also 
used to help determine whether any additive was incorporated into the crystal structure in small 
amounts.  
Face indexing was carried out using a Rigaku Oxford Diffraction Gemini A Ultra diffractometer with 
Mo-Kα radiation. Screening of unit cells were carried out at 298 K and pre-experimental data 
recorded. Face indexing was performed with CrysAlisPro software to determine the faces and 
overall shape of crystals produced. Crystal structure and morphology were visualized using the BFDH 
tool included in Mercury software.  
 
119 
4.3.3  Effect of size-matched and structurally similar additives on isoniazid 
morphology achieved via evaporative crystallisation 
Plate or needle-shaped crystals resulted from the majority of the additive experiments carried out 
(appendix A3). However, two successful additive candidates were identified that gave more equant 
morphology; 3-HBA and 3,4-DNBA. Both of these additives are capable of producing multi-
component crystalline materials with IZN; the co-crystal structure for 3-HBA is available via the CSD 
and the structure for IZN:3,4-DNBA is reported later in this thesis (chapter 5). The presence of these 
additives in the crystallisation mixture results in formation of more rod-shaped crystals (figure 4.28), 
in contrast to the original plates, without incorporation of the additive molecule into the crystal 
structure.  
 
Figure 4.28. Face indexed crystals of IZN crystallised from IPA in the presence of 1% 3-HBA (left) and in the absence of 
additives (right) 
The morphology achieved in the presence of 3-HBA (from IPA solvent) is similar to that observed for 
crystallisations carried out in EtOAc. Significant growth is observed on the (-10-1) and (-101) faces, 
resulting from the stacking and interaction between the aromatic rings of the IZN molecules. This 
growth is also seen in the morphology achieved in EtOAc. The growth on the (00-1) face is the result 
of the hydrogen bonding interaction between the terminal NH2 group and the N in the pyridine ring. 
These chains of molecules are also responsible for the elongation in the plates obtained from IPA 
cooling crystallisations in the absence of additive. These similarities are observed in most of the 
solvent influenced crystal morphologies. The differences between the IPA crystal morphology and 
the additive influenced morphology are characterised by the fattening of the morphology and 
increased growth on the (0-10) face. The (0-10) face is only lightly influenced by hydrogen bonding 
 
120 
interactions, explaining the slower growth along this crystallographic axis. The weaker interactions 
appear to have been overcome slightly in the presence of the additive. The additive is likely to 
interact with the IZN crystal structure in two ways. Firstly, the 3-HBA is an aromatic, planar molecule, 
allowing it to interrupt the aromatic interactions causing the major growth in the IZN molecule. By 
partially blocking this face the joining IZN molecules are forced to attach to different faces. Secondly, 
the 3-HBA is likely to form some favourable hydrogen bonding interactions with the N in the pyridine 
ring. Interactions between the COOH and pyridine N are seen in the majority of co-crystals published 
for IZN, including for the published IZN:3HBA co-crystal structure. This potential interaction will act 
as a capping interaction for the growth in this direction; whilst other hydrogen bonding interactions 
are possible with the 3-HBA, the chain growth is the most likely to be interrupted. This capping of 
the hydrogen bonds responsible for the growth on the (00-1) face coupled with the aromatic 
stacking interruption is likely responsible for the increased growth on the (0-10) face. This growth 
face is less heavily influenced by the presence of the additive and, therefore, an easier pathway for 
IZN molecules to join the structure. 
The absence of the additive in the final crystal structure was confirmed using SCXRD, PXRD and DSC 
analysis techniques (appendix A4). A detection limit exists in the analysis techniques used to 
determin absence of the additive in the crystals produced in these crystallisations. In the case of 
PXRD and DSC the detection limit is potentially too high to determine the purity of the crystals 
produced to the level required by regulatory bodies. 
Similar morphology is achieved with the additive 3,4-DNBA (figure 4.29). A rod crystal shape is 




Figure 4.29. Face indexed crystals of IZN crystallised from IPA in the presence of 1% 3,4-DNBA (left) and in the absence of 
additives (right) 
Despite the presence of 3,4-DNBA, significant growth is still observed on the (-100) / (100) faces. 
This is the result of π-π stacking between IZN aromatic rings and is also seen in the morphology 
achieved from IPA in the absence of additive. Hydrogen bonding interactions between terminal NH2 
groups and the heterocyclic N in the pyridine ring contribute to the growth on the (00-1) / (001) 
faces. These interactions form chains of molecules and are also responsible for the elongation 
observed in the plates obtained from IPA cooling crystallisations. These two interactions cause 
similar results in the majority of the solvent-influenced morphologies. The difference observed in 
the presence of the 3,4-DNBA additive is again the fattening of the crystal, to form the rod 
morphology observed. This suggests extra growth is occurring on the (0-10) and (010) faces of the 
crystal. There is only a small influence from hydrogen bonds on this axis, resulting in the slower 
growth observed in the solvent-mediated morphology. The presence of the additive is allowing extra 
growth to occur on this face either by increasing the interactions occurring on this face, or by 
weakening the interactions on the faster growing faces, allowing the slower growth to catch up. The 
latter explanation is perhaps more likely in the presence of this additive. The additive has a similar 
structure to 3-HBA and is therefore likely to interact with the IZN crystal structure in a similar way. 
The aromatic portion of the 3,4-DNBA can interact with the aromatic ring in the IZN, capping the  
(-100) and (100) faces. By blocking molecules from joining this face the major growth mechanism 
can be significantly reduced, allowing the slower faces to catch up and a less needle-like morphology 
to result. The carboxylic acid group in the 3,4-DNBA will also be able to hydrogen bond with the N 
in the IZN pyridine ring. This interaction blocks the primary hydrogen bonding interaction for 
incoming IZN molecules, forcing the weaker interactions to play a larger role in the growth 
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mechanism. The 3,4-DNBA does not have any further hydrogen bonding donors or acceptors, 
therefore, the capping of these interactions will not result in any further growth from this site. It is 
probable the combination of these two capping interactions with the growing IZN crystal are causing 
the increased growth on the (0-10) and (010) faces; the incoming IZN molecules will be favoured to 
join these faces as they will not need to overcome the interactions between IZN and additive on the 
other faces.  
PXRD and DSC analysis were carried out to confirm the absence of any additive in the resulting 
crystal structure (appendix A5). Again, the detection limit needs to be considered for both PXRD and 
DSC analysis techniques. The absence cannot be confirmed to the level of purity potentially required 
for regulatory approval. This was also confirmed by SCXRD analysis of the crystal structure.  
4.3.4  Effect of size-matched and structurally similar additives on isoniazid 
morphology achieved via cooling crystallisation  
Transfer of these successful additive crystallisations to cooling proved not to be straightforward. 
Multiple cooling crystallisation experiments were carried out with both 3-HBA and 3,4-DNBA 
additives under various conditions. The cooling profile variables changed throughout the 
investigations were: the cooling rate used; the dwell time at the end of the crystallisation process; 
the scale of the crystallisation; and stirring mechanism. The cooling method used was also changed 
and included controlled cooling in the Polar Bear Plus crystalliser, at two different scales, and 
uncontrolled cooling in the KRAIC continuous crystallisation platform. Different percentages of 
additive used were investigated, despite the evaporative crystallisations suggesting 1% was the 
optimal amount, and, where possible, the starting saturation of IZN was also altered between 
experiments. This extensive set of variables were investigated as there is evidence of these variables 
proving strongly influential in similar examples in the past.63  
4.3.4.1  Cooling crystallisations at 10 g solvent scale 
The crystallisations carried out for each additive at this small scale were unsuccessful. No stirring 
was used during the cooling profile in the 10 g scale experiments; only magnetic bottom stirring is 
possible at this small scale and would result in a powder product due to the grinding of the crystals. 
Due to the lack of stirring used, lower starting saturations produced little to no crystallisation. Those 
where crystallisation did occur gave only plate-shaped crystals, the morphology that usually results 
in IZN cooling crystallisations from IPA. Under the conditions used at this scale the additive appeared 
to have little if any effect on the morphology of the crystals produced.  
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In cooling experiments such as these, carried out without stirring, crystals took much longer to 
nucleate after cooling. Experiments were therefore held for longer periods after reaching the final 
temperature to attempt to allow more nucleation and growth and, hopefully, achieve the desired 
morphology change towards rod-like crystals. However, this increase in hold time after the full 
cooling profile was achieved had no effect on the morphology of the crystals produced. Plate-shaped 
crystals were still observed for all additive and saturation percentages. Some experiments with 
higher additive percentages even moved the morphology outcome back towards more needle-
shaped crystals. (appendix A6 to A17). 
4.3.4.2  Cooling crystallisations at 150 g solvent scale 
Despite the lack of success in small scale, larger scale cooling crystallisations were carried out; these 
have the benefit of allowing overhead stirring to be utilised. Stirring will change the nucleation 
kinetics of the crystallisation being carried out, creating the potential for a successful morphology 
change to be observed that was not accessed in the small scale crystallisations. The two different 
cooling rates used at small scale were also used at this scale, however, the starting saturation of IZN 
was unchanged between crystallisations (Tsat of 40 ⁰C). 
For the 3-HBA additive, successful morphology changes were observed on this larger scale (figure 
4.30).  
 
Figure 4.30. Microscope images comparing the morphology of IZN crystallised from IPA with 3-HBA additive in 150 g 
cooling with overhead stirring (top and middle) and evaporative crystallisations (bottom) 
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At a cooling rate of 1 ⁰C/minute, all additive percentages produced mainly plate-shaped crystals, 
similar to those normally produced in additive-free IPA cooling crystallisations. Some more rod-
shaped crystals were observed in the crystallisation carried out with 5% and 10% additive, however, 
as these were a minority of the crystals produced this was still determined as a failed procedure. 
The major success is seen for a cooling rate of 0.1 ⁰C/minute with an additive percentage of 1%. This 
is the same additive content that achieved the most success in the original evaporative process. The 
crystals produced are of consistently fat, hexagonal rod-shaped morphology. The shape achieved is 
the same as seen in the successful additive-mediated evaporative crystallisation from IPA and 
similar to that seen for additive free crystallisations in EtOAc. Due to the success of the crystallisation 
with 1% 3-HBA additive, the experiment was not repeated with higher additive percentages.  
PXRD analysis was carried out on the samples to confirm pure IZN was formed in the crystallisations 
(figure 4.31). 
 
Figure 4.31. PXRD data for (a) IZN (INICAC02), (b) 3-HBA form I (BIDLOP), (c) 3-HBA form II (BIDLOP01), (d) 3-HBA hydrate 
(BOMCAJ), (e) IZN 1% 3-HBA, (f) IZN 5% 3-HBA and (g) IZN 10% 3-HBA 
No trace of the additive is observed at any of the additive percentages attempted, however, this 
analysis technique is not particularly sensitive. DSC analysis also showed only one peak, 
corresponding to the melting point of IZN. Again, the detection limit of this technique is potentially 
not sensitive enough to detect the additive amounts of impurity present (appendix A18). NMR 
spectroscopy analysis was thus carried out in an attempt to determine whether any additive was 
present within the sample (appendix A19). NMR spectroscopy is a more sensitive technique than 
either DSC or PXRD, with a better detection limit for the additives present. 1H-NMR spectroscopy 
was carried out for both IZN 1% 3-HBA and pure IZN were carried out in D2O (peak observed at 4.8 
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ppm), with 3-HBA carried out in DMSO (observed at 2.5 ppm). Stacking of the three patterns shows 
that the products from IZN 1% 3-HBA and pure IZN have the same NMR spectroscopy patterns; no 
peaks relating to pure 3-HBA are observed in the additive crystallisation NMR spectra. At this 
detection limit, it can be concluded no additive is present in the product from the additive 
crystallisations. 
Face indexing of the IZN crystals produced with 1% 3-HBA at a cooling rate of 0.1 ᵒC/minute at 150 g 
scale was carried out to allow comparison with the morphology produced from additive evaporative 
crystallisations (figure 4.32). 
 
Figure 4.32. Face indexed crystals of IZN from 150 g cooling crystallisation (left) and evaporative crystallisations (right) in 
IPA with 1% 3-HBA additive 
The morphologies are very similar to each other, with only slight differences in the size of the faces. 
The end faces differ but this is a likely region of breakage when removing crystals from the vial or 
upon contact with the impeller. The overall octagonal shape of the crystal is still observed, with the 
same faces surrounding both crystals. The dominant growth direction is still along the 
crystallographic a axis of the crystal, caused by the aromatic stacking of the rings. The area of the 
(0-10) face has decreased under cooling crystallisation conditions, suggesting growth perpendicular 
to this face is faster under these conditions than in evaporative crystallisation. This results in a less 
uniform octagonal morphology when compared to that achieved in evaporative crystallisation. 
However, the face indexing experiments are carried out on a very small subset of the crystals 
produced, and the differences in the sizes of the faces may not be significant and may be less 
pronounced if a larger number of crystals were sampled. The presence to a significant extent of 
particular indexed faces is the more important factor to take into account. Overall, the additive-
mediated morphology change to thick rods has been successfully reproduced in cooling 
crystallisation with a high level of similarity achieved between cooling and evaporative methods. 
 
126 
The crystals produced have been changed significantly from the needles originally observed in H2O 
and the plates observed from crystallisations in IPA, to a much more favourable morphology for 
pharmaceutical manufacturing.  
For the second additive, 3,4-DNBA, successful morphology changes were again observed on this 
larger 150 g solvent scale (figure 4.33).  
 
Figure 4.33. Microscope images comparing the morphology of IZN crystallised from IPA with 3,4-DNBA additive in 150 g 
cooling with overhead stirring (top and middle) and evaporative crystallisation (bottom 
When a cooling rate of 1 ⁰C/min was used, all three additive percentages produced plate-shaped 
crystals, similar to those normally produced in IPA. No rod-shaped crystals seem to be produced in 
the crystallisations carried out at this cooling rate. This is a similar result to that observed in smaller 
scale crystallisations. When cooled at a rate of 0.1 ⁰C/min with an additive percentage of 1%, rod-
shaped crystals were produced. The morphology observed mirrors that seen in the evaporative 
additive crystallisations originally carried out. The morphology modification is uniform throughout 
the sample, with no plate-shaped crystals observed. The shape achieved is also the same as seen 
for additive-free crystallisations in EtOAc. Due to the success of the crystallisation with 1% 3,4-DNBA 
additive, the experiment was not repeated with higher additive percentages.  
The crystals produced in the additive cooling crystallisation had the same yellow tinge as seen in the 
samples from the evaporative crystallisation also shown in figure 4.33. PXRD analysis was carried 
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out to confirm that the morphology-modified samples were of pure IZN without the presence of co-
crystal or residual additive (figure 4.34).  
 
Figure 4.34. PXRD data for (a) IZN (INICAC02), (b) 3,4-DNBA (YADKOF), (c) IZN 1% 3,4-DNBA, (d) IZN 5% 3,4-DNBA and (e) 
IZN 10% 3,4-DNBA 
The resulting PXRD pattern shows no peaks corresponding to the 3,4-DNBA and matches that of 
pure IZN, strongly suggesting no additive has been incorporated into the structure. DSC also 
confirmed the absence of the additive, with only one sharp endotherm corresponding to the melt 
point for IZN (appendix A20). Further experiments were carried out with NMR spectroscopy to 
determine whether any trace additive remained in the sample (appendix A21). Again, the analyses 
of the product from the additive crystallisation and the pure IZN sample were carried out in D2O and 
that of the additive, 3,4-DNBA, was carried out in DMSO. The 1H-NMR spectroscopy pattern for pure 
IZN and the product from IZN 1% 3,4-DNBA are identical, with no peaks observed that correspond 
to the pure 3,4-DNBA NMR spectrum. At the detection limit of the NMR spectroscopy experiment, 
it can be determined that the IZN crystals produced from the additive crystallisation method are 
pure, with no additive content.  
Face indexing of the crystals of IZN produced with 1% 3,4-DNBA at a cooling rate of 0.1 ᵒC/minute 
was carried out (figure 4.35) to allow comparison with the morphology produced from the additive-




Figure 4.35. Face indexed crystals of IZN from 150 g cooling crystallisation (left) and evaporative crystallisations (right) in 
IPA with 1% 3,4-DNBA additive 
The morphologies produced from cooling and evaporative appear very similar in the photos of the 
crystals shown in figure 4.33. The face indexing confirms this similarity. The overall octagonal shape 
of the crystal is still observed, with the same faces surrounding both crystals. Dominant growth is 
still occurring along the crystallographic a axis of the crystal, although there is a slight difference in 
the hkl values determined for the capping faces. The capping faces are often hard to distinguish 
when face indexing the crystals, and sometimes their indexing requires simplifying due to breakages 
which occur during crystallisation and when extracting and mounting the crystals. Thus, despite the 
faces not being indexed the same, the direction of major growth remains the same. This growth is 
still the result of the aromatic interactions between the individual IZN molecules within the 
structure. The area of the (00-1) face has increased under cooling crystallisation conditions, 
suggesting this face is not growing as fast under these conditions as in evaporative crystallisation. 
Similarly, the area of the (0-10) face has decreased indicated faster growth possibly occurring in the 
direction perpendicular to this face. The results of these changes give the crystal morphology 
obtained from cooling crystallisation a more uniform octagonal shape, when compared to that of 
the morphology produced in evaporative crystallisation. As for the samples produced with the 3-
HBA additive, while this difference seems significant from the above face indexed crystals, this 
represents only one crystal from the bulk product sample, therefore, it is likely this difference is not 
necessarily significant and the consistent production of the rod-like morphology is the most 
important finding. Overall, the morphology changes originally seen in evaporative experiments in 
the presence of the additive have been successfully reproduced in cooling crystallisation with a high 
level of similarity between the two. The crystals produced in bulk are significantly changed from 
those observed from pure IPA and exhibit a much more favourable morphology to take forward into 
future processing steps. 
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4.3.4.3  Transfer of successful additive experiments into the KRAIC continuous platform 
The transfer of the additive-assisted crystallisations into the KRAIC showed little success in achieving 
the altered morphology. Experiments were carried out at three different additive percentages, 
despite the previous experiments determining 1% to be the most successful additive concentration. 
This strategy was adopted due to other variables being more difficult to control in the continuous 
set up.  
For 3-HBA additive no successful morphology change was observed in the KRAIC set up. Plate-
shaped IZN crystals, as observed from IPA cooling crystallisations in the absence of additive, were 
produced at all additive percentages (figure 4.36). PXRD analysis was used to confirm the formation 
of pure IZN crystals, with no evidence of the co-crystal form being present in the final product. 
 
Figure 4.36. Microscope images of crystals achieved from IPA KRAIC crystallisations with different additive percentages of 
3-HBA 
For 3,4-DNBA additive, a similar result was achieved. Plate-shaped crystals were obtained for all 
additive percentages (figure 4.37), with the slight yellow tinge usually observed when this additive 
is present. These plates closely resemble the IZN morphology achieved in cooling crystallisations 
from IPA in the absence of additive. PXRD analysis was carried out and confirmed the formation of 




Figure 4.37. Microscope images of crystals achieved in IPA KRAIC crystallisations with different additive percentages of 
3,4-DNBA 
The design of the KRAIC continuous crystallisation platform gives limitations on the number of 
crystallisation conditions available for variation. The starting saturation of IZN could potentially be 
altered in this set up, however, it was found that doing so greatly affected the point of nucleation; 
an IZN starting saturation of 0.0175 g/g was determined necessary to achieve controlled 
crystallisation within the coils of the KRAIC. Reducing the starting saturation resulted in no 
nucleation being observed in the coil, although some crystallisation did occur on contact with the 
filter paper on extraction from the KRAIC. Increasing the starting concentration caused significant 
crystallisation to occur in the outlet of the SF10 solution pump. The inlet, pump head, and outlet of 
the solution pump cannot be temperature controlled, causing this to become a possible nucleation 
site at high saturations. This position is before segmentation occurs and can cause significant 
problems, with the pump head becoming blocked and a pressure increase occurring. As a result, the 
starting saturation of IZN cannot be varied for this particular continuous crystallisation procedure.  
It is also not possible to control the cooling rate of the crystallisation in this platform set up, due to 
the coil not being temperature controlled. This variable seemed to have a significant influence on 
the cooling crystallisations carried out in batch at larger scale, suggesting favourable morphology 
changes may be possible in a temperature controlled continuous crystalliser.  
Although these two variables cannot be controlled, their effects could be mitigated by altering the 
length of time the solution takes to travel through the length of the coil, the residence time. 
Changing the flow rate by adjusting the speed of the pumps allows shorter or longer residence times 
to be achieved for the platform. Increasing the residence time could potentially result in 
crystallisation occurring within the coil at lower starting saturations. It also has the potential to allow 
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more time for growth to occur once the lower temperature is reached, allowing successful 
morphology changes to be achieved. 
4.3.5  Effect of polymer additives on isoniazid morphology achieved via 
evaporative and cooling crystallisation 
The concentration of polymer additives used was 1%, due to the success observed using this 
concentration of size-matched additives, and 0.1%, from evidence in literature of lower polymer 
concentrations being more successful.63  
 
Figure 4.38. Cooling crystallisations of IZN with 1% polymer additives in IPA at a rate of 0.1⁰C/minute. (a) PP123, (b) PEG, 
(c) PPG, (d) PBD, (e) PVP and (f) PDE 
 
Figure 4.39. Cooling crystallisations of IZN with 0.1% polymer additives in IPA at rate of 0.1 ⁰C/minute. (a) PP123, (b) PEG, 
(c) PPG, (d) PBD, (e) PVP and (f) PDE 
Most of the 1% polymer additive cooling crystallisations produced plate-shaped crystals (figure 
4.38), similar to those seen for cooling crystallisations from IPA without the polymer present. The 
crystals produced in the presence of P123 polymer show smaller, almost needle-shaped crystals. 
This suggests the presence of this polymer is working against the effect of the solvent system and 
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reverting back to the least favourable crystal morphology for IZN. Crystals produced in the presence 
of PDE are also much smaller and significantly clumped. The morphology is still small, thin plates 
and this crystallisation clearly demonstrates the problem with this crystal morphology in terms of 
downstream crystal processing steps. The same results were seen for faster cooling rates of 
1 ⁰C/minute: no improvements to the morphology are observed in these crystallisations (appendix 
A22 and A23). 
Crystallisations with 0.1% polymer additive also showed no improvement in the morphology 
achieved (figure 4.39). For all polymers the same plate-shaped crystals were observed as those from 
cooling crystallisations from IPA in the absence of polymers. 
The same polymer additive percentages were used in a set of evaporative crystallisations, which 
were carried out at 20 ⁰C (appendix A24 and A25) and 40 ⁰C.  
 
Figure 4.40. 40 ⁰C evaporative crystallisations of IZN with 1% polymer additives from IPA. (a) PP123, (b) PEG, (c) PPG, (d) 
PBD, (e) PVP and (f) PDE 
 
Figure 4.41. 40 ⁰C evaporative crystallisations of IZN with 0.1% polymer additives from IPA. (a) PP123, (b) PEG, (c) PPG, 
(d) PBD, (e) PVP and (f) PDE 
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The overriding morphology observed in the evaporative crystallisations is needle-shaped crystals 
(figures 4.40, 4.41). This is again the same as that predominantly observed for evaporative 
crystallisation from IPA in the absence of polymers. Some plates are observed in some samples but 
no improvement on the usual morphology achieved from IPA is observed.  
In summary, none of the polymers trialed as additives in this work have a positive effect on the 
morphology produced.  
4.4  Conclusions 
Crystallisation of IZN from different solvent systems has proven to be successful in producing 
favourable morphology modifications from the needle shape normally observed for this API. IZN 
crystals are clearly susceptible to solvent effects on the growth mechanisms present. A minor 
positive morphology change was observed in both EtOH and IPA solvents, with thin plate-shaped 
crystals forming. Whilst this is a significant morphology change from the needles originally observed 
in crystallisations from H2O, it is still not a favoured morphology. Crystallisations in EtOAc, however, 
form thick, rod-shaped crystals. This is close to the block shaped morphology favoured in most 
processing steps in the manufacturing process.  
Achieving these morphology modifications is easily repeatable through a number of different 
cooling crystallisation scales and methods. The modifications can be recreated in the KRAIC 
continuous cooling platform as well as in batch methods of different volumes. This makes the 
observed solvent effects potentially useful for pharmaceutical applications as the versatility across 
crystallisation conditions will allow for easier design of crystallisation and implementation into 
already existing crystallisation processes.  
The effects of saturation concentration on the shape of the crystals produced was significant in the 
evaporative crystallisations carried out, with some concentrations resulting in needles and others 
the modified morphologies. However, these same effects were not observed in cooling 
crystallisations. The starting saturation of the solution had no effect on the morphology achieved in 
cooling, only affecting the yield of the product produced. This lack of influence on the results of a 
cooling crystallisation confirms the robust nature of this method in this case. Implementation into 
existing processes will also be aided by the fact that starting concentration has little effect on the 
final morphology achieved from each solvent when crystallised via cooling. 
In an attempt to determine how much EtOAc must be present to observe the changes, solvent 
mixtures were investigated. The results of these crystallisations showed that a high content of EtOAc 
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was required in these mixtures to reproduce the desired morphology, indicating essentially no 
improvement over the use of pure EtOAc. Different chain length esters were also used as solvents 
and in mixtures and showed no improvement in morphology modification from that achieved with 
EtOAc alone.  
In addition to successful solvent effects, two size-matched additives also offered promising 
morphology changes. Both 3-HBA and 3,4-DNBA additives in a 1% ratio allowed crystals produced 
from IPA to form the same thick, rod-shaped crystals as seen in crystallisations from EtOAc. This 
favourable morphology change was originally observed in evaporative additive crystallisations but 
successful scale up was achieved in cooling.  
Recreating the same effects of the additive in cooling proved tricky with the effects only being 
observed when carried out on a 150 g solvent scale with overhead stirring. Whilst the scale may be 
affecting the morphology observed, it is more likely to be caused by the change in kinetics due to 
the introduction of overhead stirring. These effects could be investigated on smaller volume scales 
if the ability to implement overhead stirring were possible. The attempts to transfer these additive 
effects into the KRAIC continuous platform were also unsuccessful. Given the effect of the overhead 
stirring in batch cooling this could be down to the kinetics and mixing profiles achievable in the 
KRAIC set up. Whilst transfer to continuous was unsuccessful in this platform the possibility still 
remains for successful transfer into other reactors such as the COBC and cSTR. cSTR’s in particular 
have the capacity for overhead stirring to be implemented and so are much more likely to offer the 
same successful morphology modification.  
Analysis of the crystals produced from additive crystallisations with SCXRD, PXRD, NMR 
spectroscopy and DSC show that no trace of the additive remains in the crystalline product. 
However, there could be a small amount present as point defects within the crystal or sitting on the 
surface of the crystals. This is a particular concern for samples produced in the presence of 3,4-
DNBA additive as the final product is yellow as opposed to white. Further analysis would be needed 
in the case of pharmaceutical applications to ensure the products fit the regulatory requirements 
and the inclusion of any additive impurities is below the threshold set by regulatory bodies. A good 
technique to use could be HPLC as this has a much lower detection limit than the analysis techniques 
already used. 
The polymeric additives tested to date have proven unsuccessful in producing morphology 
modification. No improvement on morphologies achieved in pure solvent was observed with any of 
the polymers used. However, there is substantial literature precedent for the general success of 
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polymer additives in changing morphology so further polymer candidates could be tested to find an 
appropriate system.  
Overall, the use of solvent choice and additives to change the morphology of IZN has been very 
successful with good results seen in both cases. Both methods are suitable for manufacturing 
applications, however, the success of solvent choice alone is possibly the best route to choose. This 
method is uncomplicated and shows the same results that have been achieved using additives. The 
use of solvent also reduces the possibility of impurities being incorporated into the crystal structure 







Chapter 5 Morphology changes observed 
in multi-component crystals of isoniazid 
 
5.1  Introduction 
Co-crystallisation can have many positive effects on the physical properties of pharmaceutical 
materials. The benefits of co-crystals can include improved solubility and stability as well as crystal 
habit modification. As noted previously, IZN is known for not only its poor crystal shape but also its 
reduced stability as part of the FDC tablet. This combination tablet formulation was developed to 
combat the increasing resistance of TB to doses of IZN alone.159, 160 IZN is therefore a good candidate 
for research into multi-component crystal systems in an attempt to combat this reduction in 
stability. Co-crystallisation also changes the crystal structure and, often, macroscopic crystal 
parameters; a new morphology is a possible additional effect of the introduction of a secondary 
molecule into the structure and thus co-crystal formation can also be a route to morphology 
modification of IZN-containing crystals. A large number of co-crystal structures are already 
published due to extensive research into co-crystallisation of IZN. An improved morphology is 
predicted using BFDH for some reported co-crystals, however, as this was not the main focus of 
most of the research carried out on IZN co-crystallisation, the morphology is often not reported in 
the literature. The aim of this work was to investigate the formation of new multi-component 
crystalline materials, not previously reported in the literature, with an emphasis on possible 
morphology changes. It is hoped that in any new co-crystal structures the morphology of the crystal 
will be positively altered with an improved aspect ratio.  
5.2  Selection of co-formers for isoniazid 
The co-former selection process is important to narrow down the potential list of molecules to 
screen for the production of multi-component materials. Designing a robust prediction method is 
vital in reducing the extent of the costly and time-consuming screening process. In this work two 
predictive methods have been used in parallel to obtain a short list of potential co-former molecules. 
Initially the molecular structure of the target molecule is considered to identify potential sites for 
hydrogen bonding. IZN is a weak base with two major functional groups, a hydrazide and a pyridine 
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ring, giving rise to two hydrogen bond donor sites, the NH2 and NH group, and four hydrogen bond 
acceptors, three N atoms and a carbonyl group. Further information on the hydrogen bonding 
nature of the target molecule can be obtained by investigating the multi-component materials (co-
crystals) already published in the CSD. A search within the CSD provides 81 hits for IZN, including 56 
co-crystal structures. Of the total reported co-crystals only 12 contain a co-former without a 
carboxylic acid group. Of the 44 co-crystals formed with carboxylic acid containing co-formers, 19 
are formed with dicarboxylic acids. There are only two reported co-crystals with co-formers that 
have neither a carboxylic acid group nor a hydroxyl group. Analysis of the carboxylic acid containing 
co-crystals indicated the predominant hydrogen bonding interaction occurs via donation from the 
co-former carboxylic acid to the N in the pyridine ring. The main hydrogen bonding interactions seen 
in IZN co-crystal structures containing carboxylic acids are shown in figure 5.1.   
The following discussion focusses on the hydrogen bonding interactions illustrated in figure 5.1. The 
carboxylic−pyridine synthon, (vi), is reported in co-crystals with 4-aminosalicylic acid and other co-
formers containing hydroxybenzoic and dicarboxylic acids; a total of 11 structures show this 
interaction, often with proton transfer to the pyridine N. Hydrazide−hydrazide hydrogen bonds, (i) 
– (v), can be seen in 31 co-crystals with dicarboxylic acids and hydroxybenzoic acids.203 A series of 
co-crystals with mono- and dicarboxylic acid co-formers was reported with the conclusion that the 
dominant interaction in all cases was (iv).125 A further study extended this to include co-
crystallisation with an aromatic carboxylic acid, terephthalic acid. The co-crystal produced was 
isostructural to the adipic acid co-crystal previously published and, again, contained the COO-
H∙∙Nheterocyclic hydrogen bond as the major interaction between the molecules. However, the 




Figure 5.1. Supramolecular synthons observed in IZN co-crystals in the CSD 203  
Of the above interactions, the chain link interactions (iii, iv, v, vi and vii) are the most commonly 
observed. For the dimeric interactions, nine co-crystals exhibit (ii) and 12 contain (i). These dimeric 
interactions are not observed in pure IZN; interactions in the structure of IZN are (iv) and a second 
interaction between the NH2 group and the ring N (not illustrated here). The ability of the IZN 
molecules to form dimeric interactions in the presence of secondary molecules in the structure 
could suggest the existence of other polymorphic forms of IZN that require very specific conditions 
to encourage their formation. This hypothesis was confirmed in mid-2020 with the discovery of a 
second IZN polymorph showing these dimeric interactions. The new polymorph can only be 
obtained through confined crystallisations and is only stable for less than an hour at room 
temperature and pressure.162  
Using the information obtained from examination of the published structures in the CSD, an initial 
list was drafted of potential co-formers for IZN co-crystallisation experiments. The molecules chosen 
included at least one carboxylic acid group and some also contained aromatic ring centers. The co-
formers were chosen from either the GRAS list or the list of common co-formers found in published 
structures in the CSD.  
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A computational approach was used to narrow down the lists further, using calculations carried out 
using the molecular complementarity tool in the CCDC Mercury software. This tool calculates the 
likelihood of two molecules interacting to form a multi-component material by taking into account 
the size and shape of the two molecules and their crystal structures. A comparison is made and a 
pass or fail verdict reached, with those that are most similar resulting in a pass. Five different criteria 
can be used to carry out these calculations, which can be used in any combination; in this work all 
five descriptors were used. The calculations produce a full list of potential candidates. The final list 
was decided by elimination of molecules that are already known to form co-crystals published in 
the CSD. The set of co-formers screened in the resulting experiments is shown in figure 5.2. 
 
Figure 5.2. Structure of co-formers determined from initial molecular complementarity calculations with IZN (a) malic 
acid, (b) citric acid, (c) sorbic acid, (d) (L)-tartaric acid, (e) pyridoxine, (f) trimesic acid, (g) glutamic acid, (h) (L)-
pyroglutamic acid, (j) 3,5-dinitrosalicylic acid, (k) 3,5-dinitrobenzoic acid, (l) 3,4-dinitrobenzoic acid, (m) D-mannitol 
5.3  Experimental information 
All solvent and materials used in this research were obtained from commercial sources. No further 
purification was carried out prior to any experimental procedure outlined.  
5.3.1  Evaporative screening for isoniazid co-crystals 
Evaporative crystallisations were carried out from solutions containing 1:1 stoichiometric ratios of 
API and co-former. A small amount of IZN, 0.01 g, and the corresponding mass of co-former were 
dissolved in minimal solvent in 7 mL glass vials. Solvents used were H2O, EtOH, IPA and EtOAc. Vials 
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were sealed with PTFE lids containing pierced holes, to allow slow evaporation, and left to evaporate 
at both room temperature and 40 ⁰C. 
5.3.2  Crash cooling of isoniazid co-crystals 
Crash cooling crystallisations were carried out in the fridge at 4 ⁰C. Crystallisations were set up in all 
four solvents with a saturation temperature arbitrarily chosen as 30 ⁰C (Tsat= 30 ⁰C). For both H2O 
and EtOH, the crystallisations were carried out in only 1 g of solvent. For IPA, 2 g of solvent was used 
due to the saturation concentration being much lower. Similarly, in EtOAc the limited solubility led 
to 3 g of solvent being used. Crystallisations were prepared in 7 mL vials in a 1:1 ratio of IZN and the 
corresponding molar ratio of the additive. Each sample was sonicated at an elevated temperature 
to allow full dissolution of the IZN and additive starting materials. Once full dissolution had been 
observed the solutions were transferred to the fridge until crystallisation occurred. If no 
crystallisation occurred, holes were pierced in the lids to allow for some very slow evaporation.  
5.3.3  Isoniazid single crystal structures 
Crash cooling and evaporative crystallisations from solutions of IZN in a 1:1 ratio with a number of 
co-formers resulted in the formation of new multi-component crystalline materials. Single crystal 
structures were determined for all five new materials. All structures were solved using ShelXS and 
refined using ShelXL within Olex2 software. Crystallographic data for all new complexes are shown 
in table 5.1. 
(1) Isoniazid with (L)-tartaric acid (IZN:LTA)  
A 1:1 molar ratio of IZN (0.160 g) and LTA (0.175 g) were dissolved in H2O in a 7 mL glass vial. Crash 
cooling produced clumped plate-shaped crystals. Single crystal data were collected using a Rigaku 
Oxford Diffraction Xcaliber diffractometer with Mo-Kα radiation (λ=0.70173 Å) at 150 K.  
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(2) Isoniazid with (D)-tartaric acid (IZN:DTA)  
A second complex was produced with IZN (0.160 g) and DTA (0.175 g). Crash cooling in H2O was 
again carried out and clumped plate crystals produced. Single crystal data were collected using a 
Rigaku Oxford Diffraction Xcaliber diffractometer with Mo-Kα radiation (λ=0.70173 Å) at 150 K.  
(3) Isoniazid with (DL)-tartaric acid (IZN:DLTA:H2O)  
A hydrated salt system of IZN (0.160 g) and DLTA (0.175 g) was produced via crash cooling in the 
fridge in H2O. The crystals produced take on a plate like morphology and clump together. Single 
crystal data were collected using a Rigaku Oxford Diffraction Gemini A Ultra diffractometer with Mo-
Kα radiation (λ=0.70173 Å) at 150 K. 
(4) Isoniazid with (DL)-tartaric acid (IZN:DLTA) 
The hydrated salt of (IZN:DLTA:H2O) was heated using a hot stage microscope to 120 ⁰C to drive off 
the H2O included in the crystal lattice and isolate the anhydrous co-crystal. The crystal morphology 
remained plate like. Single crystal data were collected using a Rigaku Oxford Diffraction Gemini A 
Ultra diffractometer with Mo-Kα radiation (λ=0.70173 Å) at 150 K. 
(5) Isoniazid with 3,4-dinitrobenzoic acid (IZN:3,4-DNBA) 
A 1:1 molar ratio of IZN (0.02 g) and 3,4-DNBA (0.031 g) was crystallised from IPA in a 7 mL glass vial. 
Evaporative cooling produced plate-shaped crystals. Single crystal data were collected using a 








Table 5.1. Crystallographic parameters for newly discovered co-crystal structures formed with IPA IZN ii 
 1 2 3 4 5 
Code IZN:LTA IZN:DTA IZN:DLTA:H2O IZN:DLTA IZN:3,4DNBA 
Formula C20H26N6O14 C20H26N6O14 C10H15N3O8 C10H13N3O7 C13H11N5O7 
M / g mol-1 575.47 575.47 305.25 287.24 349.27 
T (K), radiation 149.99(10), Mo Kα 156(9), Mo Kα 150.00(10), Mo Kα 150.00(10), Mo Kα 150.00(10), Mo K 
Space group P212121 P212121 P1̅ P21/c P1̅ 
a (Å) 7.8134(3) 7.82710(10) 7.3170(8) 12.394(4) 6.7471(7) 
b (Å) 15.1461(5) 15.1575(2) 7.3838(6) 7.1835(10) 7.6631(9) 
c (Å) 19.7911(9) 19.7998(2) 12.6567(13) 22.554(8) 14.9606(16) 
α (ᵒ) 90 90 78.380(8) 90 76.604(10) 
β (ᵒ) 90 90 74.540(9) 143.53(8) 86.936(9) 
γ (ᵒ) 90 90 88.874(11) 90 71.072(10) 
Volume (Å3) 2342.13(16) 2349.03(5) 646.27(14) 1193.5(15) 711.58(14) 
Z 4 4 2 4 2 
ρcal/ g cm-3 1.629 1.624 1.571 1.598 1.630 
μ/ mm-1 0.140 0.139 0.137 0.137 0.135 
2Ө range/ᵒ 5.866 – 60.866 5.86 – 60.72 5.78 – 57.314 6.078 – 59.078 6.912 – 60.6 
Completeness 95% 98% 99% 100% 100% 
Refln. Collected 10167 9783 4459 6071 12192 
Independent refln.  5602 5696 2670 2850 3763 
Rint 3.87% 2.86% 5.58% 9.59% 6.99% 
GooF 1.096 1.098 1.053 0.963 1.054 
R1 (obs) 7.58% 6.41% 8.10% 7.93% 7.21% 
R1 (all) 10.02% 7.34% 15.30% 23.29% 16.14% 
wR2 (all) 18.39% 15.79% 19.98% 24.43% 16.99% 
Ρmax,min/e Å-3 1.37/-0.54 1.18/-0.58 0.49/-0.39 0.29/-0.31 0.47/-0.31 
                                                          
ii Molecular formula and molecular mass correspond to the asymmetric unit of the crystal structure 
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5.3.4  Further preparations of isoniazid co-crystals 
To investigate whether the formation of the co-crystals was robust, further crystallisation 
techniques were used in an attempt to repeat their production. 
5.3.4.1  Isoniazid co-crystal production using mechanochemical grinding 
Mechanochemical crystallisation was carried out via grinding of IZN and co-formers in a pestle and 
mortar. A small quantity of IZN (0.01 g) and the corresponding molar ratio of additive were ground 
together in the absence of solvent for 30 minutes. Grinding was carried out in a 1:1 IZN:co-former 
ratio.  
LAG experiments were also carried out for the successful solvent-mediated crystal screens. A small 
quantity of IZN (0.01 g) and the corresponding (1:1) molar ratio of additive were ground in a pestle 
and mortar with a few drops of solvent until it had fully evaporated. The solvent used for these 
crystallisations was H2O for the TA family and IPA for the 3,4-DNBA.  
5.3.4.2 Isoniazid co-crystal production via slurrying  
An excess amount of IZN and co-former, in a 1:1 molar ratio, were weighed into a 7 mL glass vial. 
The amount of solvent added is crucial, it must not be enough to fully dissolve the material added 
to the vial. The solutions were continuously stirred at room temperature, using a magnetic bottom 
stirrer at 250 rpm, for 2 hours. Again, the TA family (0.5 g IZN, 0.55 g TA) were slurried in H2O (3 g) 
and 3,4-DNBA (0.12 g IZN, 0.186 g 3,4-DNBA) in IPA (3 g).  
This production was also scaled up in the Polar Bear Plus crystalliser. For new materials with LTA, 
DTA and DLTA, H2O was used as the solvent on a 60 g scale (in a 100 mL round bottom flask). For 
the 3,4-DNBA co-crystal a slurry was carried out on a 200 g scale (in a 250 mL round bottom flask) 
in IPA. Slurrying was maintained at 20 ⁰C with overhead stirring at 350 rpm.  
5.3.4.3  Scale up of isoniazid co-crystals using controlled cooling 
Scaled up production of the co-crystals was achieved using controlled cooling profiles set up on the 
Polar Bear Plus crystalliser. Scale up was achieved for all new multi-component materials, to 10 g 
and 30 g (for TA co-crystals) and 200 g (for 3,4-DNBA co-crystal).  
For multi-component materials of LTA, DTA and DLTA, H2O was used as the solvent. H2O was 
saturated at a temperature of 30 ⁰C with respect to IZN (Tsat = 30 ⁰C). For the co-crystal formed with 
3,4-DNBA, IPA was used as the solvent system. IPA was saturated at a temperature of 30 ⁰C with 
respect to IZN (Tsat = 30 ⁰C). For each different scale a different insert and vessel were used for the 
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crystallisation; 20 mL glass vial with screw lid (for 10 g), 50 mL round bottom flask (for 30 g) and 
250 mL round bottom flask (for 200 g). The 1:1 molar ratio of IZN and co-former were added to the 
vessel. In the glass vials magnetic bottom stirring at 350 rpm was used, whereas, in the round 
bottom flasks overhead stirring at 350 rpm was used. All solutions were heated to 50 ⁰C and held 
for an hour to allow complete dissolution. Cooling was programmed at a rate of 1 ⁰C/minute to a 
minimum of 5 ⁰C and held there for a further hour.  
5.3.5  Solubility determination of isoniazid co-crystals 
The solubility of the co-crystals was determined using observational heating techniques. Using the 
Polar Bear Plus crystalliser, a heating profile was set up to heat from 5 ⁰C to 60 ⁰C at a rate of 
0.3 ⁰C/minute. In 50 mL round bottom flask, 20 g of solvent was stirred at 700 rpm using a magnetic 
bottom stirrer. An initial mass of co-crystal was added to the stirring solution and observed as it was 
slowly heated. When the co-crystal had fully dissolved the temperature was recorded and a second 
pre-determined mass added to the round bottom flask. This was repeated, recording the 
temperature and adding an additional amount of co-crystal every time full dissolution was observed. 
This method was repeated three times for each co-crystal system. The co-crystal solubility was 
determined in the solvent from which it was originally produced.  
5.3.6  Stability testing of isoniazid co-crystals 
Three different stability tests were carried out for each new multi-component material. Stability at 
high temperatures was determined by placing small amounts of each co-crystal on a watch glass in 
an oven held at 50 ⁰C. Samples were analysed using PXRD after 24 hours, 48 hours, 73 hours, 1 week, 
2 weeks and 3 weeks. Humidity studies were carried out in a 70% humidity chamber formed using 
NaCl salt and H2O. Each co-crystal was placed in a 1 mL vial and then into a 20 mL vial, to prevent 
any H2O/salt mixture from entering the smaller vial (figure 3.3). The vials were sealed in the humidity 
chamber and samples analysed by PXRD every week for 9 weeks. The final stability study saw all the 
co-crystals slurried in H2O at 40 ⁰C for a week. An excess amount of co-crystal was continuously 
stirred in 3 mL of H2O in a 7 mL glass vial. The vials were kept on a heated stirrer plate and a magnetic 
bottom stirrer was used. A sample of the suspended powder was taken at 2 hours, 4 hours, 6 hours, 




5.3.7  Analytical methods 
Images of the crystals were taken using a Nikon Coolpix P5100 camera through a Brunel Microscopes 
microscope. Images of the phase transition occurring from IZN:DLTA:H2O to form anhydrous 
IZN:DLTA were taken using an Infinity 2 microscope camera connected to a Leica DM1000 
microscope with an attached hot-stage mount. 
Crystal structure data were collected using CrysAlisPro software and calculations and refinement 
carried out using Olex2.0. Mercury software was utilised to analyse the structure of the new multi-
component crystals. 
Face indexing was executed with CrysAlisPro software to determine the faces and overall shape of 
crystals produced. Crystal structure and morphology were visualized using the BFDH tool included 
in Mercury software.  
Analysis was also carried out via PXRD, DSC, TGA and IR techniques in the manner outlined in 
Chapter 3. Variable temperature PXRD was used exclusively in the investigation of IZN:DLTA:H2O 
and is outlined below. 
5.3.7.1  Variable temperature Powder X-ray Diffraction (vtPXRD) 
Analysis of samples via vtPXRD was carried out at Diamond Light Source on the I11 high resolution 
powder diffraction beamline. A sample of IZN:DLTA:H2O was ground and loaded into a borosilicate 
capillary. The sample was heated to 75 ⁰C and PXRD patterns recorded at 2 ⁰C intervals from 75 ⁰C 
to 100 ⁰C, by which temperature complete transformation to the anhydrous phase had been 
observed.  
5.4  Crystallisation of isoniazid with tartaric acid enantiomers 
Three new co-crystalline structures were discovered between TA and IZN. Discussion of the 





Figure 5.3. Structure of IZN and TA showing the numbering system used in hydrogen bonding discussions. 
5.4.1  Crystallisation of isoniazid with (L)-tartaric acid and (D)-tartaric acid iii 
Evaporative crystallisations from H2O of (L)-tartaric acid (LTA) and IZN in a 1:1 molar ratio yielded a 
pale yellow suspension that would not dissolve without significant heating. Filtration and initial 
PXRD analysis of the remaining powder suggested a new multi-component form may have been 
produced. As a result, crash cooling crystallisation was utilised to grow single crystals and 
characterise the new form. These crash cooling crystallisations yielded a multi-component salt form 
with a 1:1 ratio of LTA and IZN. The complex crystallises in the P212121 space group with an 
asymmetric unit consisting of two protonated IZN molecules and two deprotonated LTA molecules. 
Proton transfer has occurred from one carboxylic acid group on the LTA molecules, resulting in a 
deprotonated carboxylic acid group and a protonated N in the pyridyl ring. Protonation of the N in 
the ring is commonly observed within IZN multi-component structures.  
After the initial successful co-crystallisation of IZN with LTA, experiments were also carried out with 
equimolar amounts of (D)-tartaric acid (DTA). These were again carried out via crash cooling 
crystallisations from H2O and were also successful in producing a new multi-component salt form. 
The complex again crystallises in the P212121 space group with the same asymmetric unit as the LTA 
salt. As expected the LTA and DTA co-crystals are isostructural with opposing chirality: the two 
structures with the opposite enantiomers are mirror images of each other. Proton transfer is again 
observed with a carboxylic acid group on DTA being deprotonated and the pyridyl N in IZN 
protonated. A search of the CSD highlighted 11 structures with a protonated IZN at the N in the ring, 
six of which contained a deprotonated carboxylic acid. There was only one example of proton 
                                                          
iii The structure for the DTA multi-component crystal has been added to the CSD (WETZAZ) since this research was 
carried out. A paper was published in 2019 describing the structure of the (D)-tartaric acid co-crystal. 
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transfer occurring from a carboxylic acid group that was not directly involved in a hydrogen bond 
with the IZN ring.  
 
Figure 5.4. View along the crystallographic a axis of IZN:LTA (left) and IZN:DTA (right) 
 
Figure 5.5. View along the crystallographic b axis of IZN:LTA (left) and IZN:DTA (right) 
The structure of these two co-crystals consists of chains of TA co-formers and chains of IZN 
alternating throughout (figures 5.4 and 5.5). Due to the enantiomeric nature of the acid co-former 
the orientation of the IZN flips, resulting in the mirror image crystal structures observed. The 
aromatic rings of the IZN molecule are slightly eclipsed, overlapping with each other to form π-
stacking interactions. The stacked IZN molecules result in s-shaped spirals (figure 5.5), illustrating 
the 21 screw axis present, parallel to the crystallographic a axis.  
There are a large number of hydrogen bonds present in this crystal structure (table 5.2 for IZN:LTA 
and table 5.3 for IZN:DTA), holding the TA co-formers and the IZN molecules in chains throughout. 
The IZN molecules form a bifurcated hydrogen bonding interaction to each other, creating the 
chains that form along the crystallographic c axis. Donation occurs from the protonated N in the 
pyridyl ring to the NH2 group and carbonyl on the neighbouring IZN molecule. The involvement of 
the IZN carbonyl is not seen in pure IZN crystals. In IZN-containing structures in the CSD, the carbonyl 
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bond is involved in hydrogen bonding interactions in 21 different co-crystals; 12 of these are due to 
dimeric interactions between the carbonyl on one IZN to the NH2 group on a second molecule. The 
bifurcated hydrogen bond interaction observed in this structure is present in four other co-crystals 
that show a proton transfer to the pyridyl N. None of these co-crystals involve a carboxylic acid 
group. 
The IZN molecules form hydrogen bonds to a total of four different TA molecules (figure 5.6). The 
NH in the IZN donates a hydrogen bond to the carbonyl of the protonated carboxylic acid group. 
Further hydrogen bonds form from the NH2 group to the central hydroxyl groups on two TA 
molecules and the deprotonated carboxylic acid on the final TA molecule. Hydrogen transfer has 
occurred in this structure, but the route of transfer is not clear. The deprotonated carboxylic acid is 
hydrogen bonded the NH2 group, but the transferred proton lies on the pyridyl ring N. The ring N 
forms an intramolecular interaction with the NH2 group indicating further transfer of a proton has 
occurred. This suggests two proton transfers have occurred, one from the TA molecule to the NH2 
group and one from the NH2 group to the pyridyl ring. The lack of direct interaction between the 
deprotonated co-former and protonated site on IZN has only been observed previously in structures 
that do not contain a carboxylic acid group. Four structures show the suspected indirect proton 
transfer whilst six feature the deprotonated carboxylic acid with a direct interaction to the 
protonated N in the ring. 
 
Figure 5.6. Hydrogen bonding interactions formed with IZN molecules in the LTA co-crystal structure (left) and DTA co-
crystal structure (right)  
The chains of TA molecules are linked together between the deprotonated carboxylic acid group on 
one end and the protonated carboxylic acid on the second TA (figure 5.7). The rotation of the central 
hydroxyl groups in the TA molecules shifts slightly down the chain, resulting in alternating molecules 
experiencing different hydrogen bonding interactions. In one TA molecule both central hydroxyl 
groups form a bifurcated hydrogen bond by donating to the oxygen in the deprotonated carboxylic 
acid group. The TA molecule accepting this hydrogen bond donates back to the deprotonated 




Figure 5.7. Hydrogen bonding interactions between TA molecules: LTA co-crystal (left) and DTA co-crystal (right) 
 
Table 5.2. Hydrogen bond distances and angles for IZN:LTAiv  
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
N1a-H∙∙N3a1 0.93(9) 0.71(5) 1.9(1) 160(9) 
N1a-H∙∙Oa1 0.93(9) 2.41(9) 3.013(4) 123(8) 
N1b-H∙∙N3b3 0.87(9) 1.92(9) 2.756(6) 160(8) 
N2b-H∙∙O5a 0.76(6) 2.08(7) 2.783(6) 154(7) 
N3b-H∙∙O1a2 0.85(6) 2.16(6) 2.848(7) 138(5) 
N3a-H∙∙N1a6 0.97(7) 1.92(7) 2.857(11) 162(6) 
O6b-H∙∙O2a5 0.55(7) 2.02(7) 2.562(6) 173(11) 
O3b-H∙∙O1a2 1.00(8) 1.74(9) 2.741(6) 176(8) 
O6a-H∙∙O2b 1.18(8) 1.34(8) 2.498(5) 165(7) 
O4a-H∙∙O1b2 0.94(9) 1.79(9) 2.713(5) 170(8) 
O4b-H∙∙O2a4 0.89(6) 1.81(6) 2.659(5) 159(5) 
 
  
                                                          
iv 12-X,-1/2+Y,1/2-Z 2-1/2+X,3/2-Y,1-Z  31-X,-1/2+Y,1/2-Z  41/2+X,3/2-Y,1-Z  
5+X,1+Y,+Z  62-X,1/2+Y,+Z   
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Table 5.3. Hydrogen bond distances and angles for IZN:DTAv 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
N1a-H∙∙N3a1 0.71(5) 2.11(5) 2.768(5) 154(6) 
N1a-H∙∙Oa1 0.71(5) 2.49(5) 3.022(4) 134(5) 
N1b-H∙∙N3b2 0.78(7) 2.03(7) 2.764(5) 156(7) 
N2b-H∙∙O5a2 0.78(5) 20.4(5) 2.785(5) 159(5) 
N3b-H∙∙O1a3 0.88(5) 2.12(5) 2.854(5) 141(4) 
N3a-H∙∙N1a7 0.88(9) 1.97(9) 2.848(7) 176(8) 
O6b-H∙∙O2a4 0.71(7) 1.87(7) 2.565(4) 168(7) 
O3b-H∙∙O1a5 0.91(5) 1.86(6) 2.749(4) 168(5) 
O6a-H∙∙O2b6 1.06(8) 1.45(8) 2.500(4) 168(7) 
In addition to SCXRD analysis, PXRD analysis was carried out to examine the bulk product and 
determine the phase purity of this multi-component crystallisation.  
 
Figure 5.8. PXRD data for IZN:LTA (left) and IZN:DTA (right): (a) IZN (INICAC02), (b) LTA (TARTAL), (c) IZN:LTA co-crystal 
calculated from SCXRD, (d) IZN:LTA co-crystal from H2O crash cooling, (e) DTA (TARTAC), DTA form II (TARTAC24), (g) 
IZN:DTA co-crystal calculated from SCXRD and (h) IZN:DTA co-crystal from H2O crash cooling experiment 
Some small traces of the starting materials can be seen in the data for both crystallisations (figure 
5.8). Despite this, reasonably good phase purity was achieved for this crystallisation. Both co-crystals 
result in the same PXRD pattern just as they show the same SCXRD structure. It is not possible to 
differentiate between the enantiomers from the location of the peaks alone. 
  
                                                          
v 11-X,-1/2+Y,1/2-Z 2-X,-1/2+Y,1/2-Z  3-1/2-X,-Y,-1/2+Z  41/2+X,-1/2-Y,1-Z  
51+X,+Y,+Z  6-1/2+X,1/2-Y,1-Z  71-X,1/2+Y,1/2-Z 
 
152 
DSC analysis was used to determine the thermal behaviour of the new crystalline form (figure 5.9). 
 
Figure 5.9. DSC data for IZN:LTA co-crystal (left) and IZN:DTA co-crystal (right). IZN melting point = 171-174 ᵒC 163, TA 
melting point = 170-172 ᵒC 205 
An endothermic event is observed at 166 ⁰C for the LTA multi-component crystal and 163 ⁰C for the 
DTA multi-component crystal. These differ from the melting points of the starting materials, 
occurring at lower temperatures than both IZN and the TA enantiomers. This suggests the multi-
component forms are less thermodynamically stable than the initial starting materials. 
Attempts at reproducing the formation of these co-crystals across multiple crystallisation methods 
were also carried out. Successful transformations were achieved for both solvent-mediated 
methods and mechanochemical grinding (appendix A26 – A29). Grinding in the absence of solvent 
was less successful than LAG. Some evidence in PXRD data was seen of partial transformation of the 
starting materials but the phase purity was low. Higher conversion was observed with LAG, 
suggesting the solvent may be required to allow for successful proton transfer and hydrogen bond 
formation. Attempts to form the co-crystal via slurrying in H2O were successful with high conversion 
and phase purity. In addition, controlled cooling crystallisation of both materials was achieved on 
10 g and 30 g scales (appendix A30 and A31). Co-crystallisation was not carried out at a 200 g scale 
due to the high solubility of the pure starting material phases.  
The solubility of the co-crystal was determined using observational analysis. Although not reflecting 
a phase transition, the solubility relationship between the co-crystal and the pure IZN starting 
material can be classed as being analogous to monotropic in nature (figure 5.10); pure IZN is more 
soluble than the co-crystal system in H2O. Co-crystallisation is often carried out to increase the 
solubility, which is not the case in this co-crystal. Co-crystallisation is of interest for IZN as it could 
be used to increase the stability of the FDC tablet: the reduced solubility may be an acceptable 
compromise if increased stability was achieved in the FDC formulation. Other interests associated 
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with co-crystallisation, such as improved flow and compressibility, could also provide benefits that 
outweigh the reduction in solubility observed. 
 
Figure 5.10. Solubility plot for IZN:TA co-crystal (purple circle marker) and pure IZN (black square marker) measured by 
observation in H2O 
The stability of the new solid forms was tested via all three techniques noted above: annealing, 
slurrying and humidity, with outcomes characterised by PXRD (figure 5.11). Samples kept in the oven 
at 50 ⁰C for 3 weeks showed no change in the PXRD patterns. Slurry experiments in H2O showed no 
visible breakdown after 1 week and samples stored at 70% humidity showed no change after 9 
weeks. 
 
Figure 5.11. PXRD data for (a) IZN (INICAC02), (b) LTA (TARTAL), (c) IZN:LTA co-crystal calculated from SCXRD, (D) IZN:LTA 
co-crystal slurry 1 week, (e) IZN:LTA co-crystal 50 ⁰C 3 weeks and (f) IZN:LTA co-crystal 70% humidity 9 weeks 
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The co-crystals exhibit a plate morphology when crystallised from H2O (figure 5.12). This is a contrast 
to the needles usually observed for crystallisations of pure IZN from H2O. The co-crystal formation 
has thus successfully produced a morphology change, one of the main targets of this research. 
 
Figure 5.12.Plate-shaped crystals of  IZN:LTA co-crystal (left) and IZN:DTA co-crystal (right) crystallised from H2O 
The crystals were face indexed using SCXRD and then compared to the predicted morphology for 
this crystal system (figure 5.13).  
 
Figure 5.13. Predicted BFDH morphology for IZN:TA (left); observed morphology for IZN:LTA (middle) and IZN:DTA (right) 
The predicted BFDH morphology for the new crystalline system is the same as that of pure IZN. This 
is due to pure IZN and the new multi-component salts crystallising in the same space group (P212121), 
with similar unit cell parameters. BFDH calculations use the inter-planar spacing of crystals to predict 
morphology and, as the same space group is achieved with very similar unit cell parameters, the 
same result when calculating the morphology using this simple methodology is likely (as described 
in 1.3.1). In contrast, the observed morphology shows very thin plate crystals. The π-stacking 
interactions are responsible for the growth on the (100) and (-100) faces, corresponding to the edge 
where the (-10-1) and (-101) faces meet in the predicted morphology. Significant growth is also 
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observed on the (010) and (0-10) faces. These faces would sit directly across the apex of the (011) 
and (01-1) and the apex of the (0-1-1) and (0-11) faces, observed in the predicted morphology, 
respectively. The interactions contributing to this growth are the hydrogen bonds that increase the 
length of the chains of IZN molecules. The elongation of the crystal structure in this direction is 
similar to that contributed to by the π-π interactions creating the overall plate shape with a relatively 
square cross-section. Very little growth occurs on the (001) and (00-1) faces, equivalent to the (002) 
and (00-2) faces observed in the predicted structure. This direction is dependent on the interaction 
between individual chains of IZN molecules and TA molecules. Whilst there are a number of 
hydrogen bonding interactions linking the chains, they are weaker than those seen making up each 
chain. Between IZN molecules the interactions are bifurcated and between the TA molecules there 
are significant numbers of hydrogen bonds contributing to the overall strength of interaction. 
However, between the two there are only single hydrogen bonds between NH groups and either 
OH or CO groups, significantly weaker than the other hydrogen bonds present. This coupled with 
the fast growth of the strong π-π interactions causes the plate morphology to arise.  The elongation 
of existing layers is more favourable than the building up of adjacent layers. 
Whilst the predicted structure appears to be a more favourable block shape, the calculations do not 
take into account any additional influences on the growth, such as solvent. Comparing the observed 
co-crystal morphology to that observed for pure IZN crystallisations in H2O there is a significant 
change. Production of the plate shape, in contrast to long thin needles, illustrates the potential to 
modify morphology, alongside other significant crystal properties, using multi-component 
crystallisation. Further improvements could be made to the morphology observed in multi-
component crystals using techniques such as temperature cycling, by changing the solvent or using 
additives.  
5.4.2  Crystallisation of isoniazid with (DL)-tartaric acid forming a hydrate  
Following the successful co-crystallisations of IZN with LTA and DTA, further experiments were 
carried out with the racemic mixture (DL)-tartaric acid (DLTA). Crash cooling crystallisation of a 1:1 
molar ratio of IZN and DLTA from H2O yielded a hydrated co-crystalline salt form with the three 
components in a 1:1:1 ratio. The structure is in space group P1̅, an achiral space group confirming 
the presence of the racemic DLTA in this crystal structure. The asymmetric unit consists of one IZN 
molecule, one DLTA molecule and one H2O molecule (figure 5.14). Again, proton transfer has 
occurred resulting in formation of a multi-component salt. The proton transfer differs from that in 
the LTA and DTA structures as it occurs between a carboxylic acid group on the DLTA and the 
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terminal NH2 group of the IZN, forming an NH3+ terminal group. The pyridyl N is hydrogen bonded 
to DLTA, however, the bond is with a central hydroxyl instead of the terminal carboxylic acid, as 
seen in the enantiomeric structures. This hydroxyl group is much less easily polarisable than the 
terminal carboxylic acid and, as a result, limited proton transfer occurs towards the N. The hydrogen 
bond distances are 0.94(6) Å for the O-H and 1.79(6) Å for the H∙∙N interaction (table 5.4). Analysis 
of the co-crystals already published in the CSD show one structure with proton transfer to the NH2 
group. This structure also contains IZN molecules with proton transfer to the pyridyl N. There are 
no reported IZN structures where proton transfer to the NH2 group is the only proton transfer 
observed. 
 
Figure 5.14. Unit cell for IZN:DLTA:H2O co-crystal structure 
The IZN molecules again stack via the interactions between their aromatic rings, however these lie 
in alternate directions (figure 5.15). This alternating sequence is not seen for the single enantiomers 
and is the result of having the racemic mixture present. The DLTA molecules form chains between 
the IZN molecules, again with alternating geometries. This is due to the two enantiomeric 
conformations and their differing interactions with the IZN molecules. The result of these is a loss 





Figure 5.15. Hydrogen bonding interactions present in the IZN:DLTA:H2O co-crystal showing the alternating nature of the 
IZN stacking and the chains of DLTA 
A number of hydrogen bonding interactions are present between the three components present in 
the crystal structure (table 5.4). The H2O molecule in the structure becomes part of the DLTA chain, 
with each H2O molecule forming six hydrogen bonds to two separate DLTA molecules. No direct 
hydrogen bonding interactions exist between the IZN molecules in the structure; instead these are 
linked by aromatic interactions. Chains are formed with DLTA bridging the gaps in between, which 
are stacked in layers of alternating directions. The ring systems in the IZN overlap, enabling the 
interactions between the aromatic rings. IZN molecules form six hydrogen bond interactions with 
five different DLTA molecules. The N in the pyridyl ring accepts a hydrogen bond from a central 
hydroxyl group on the first DLTA molecule. As the donor is a hydroxyl group in this structure and not 
a carboxylic acid the hydrogen bond formed is weaker and proton transfer does not occur. The NH 
group on the IZN donates a hydrogen bond to the carbonyl group of the unprotonated carboxylic 
acid group on a second DLTA molecule. The NH3+ group forms four hydrogen bonding interactions 
with three separate DLTA molecules. A bifurcated hydrogen bond forms, consisting of an interaction 
from the NH3+ group to the deprotonated carboxylic acid group and an interaction to the central 
hydroxyl group on the next carbon along in the same molecule. The final hydrogen bond is donated 
from the NH3+ to the carbonyl in the protonated carboxylic acid group. In addition to hydrogen 
bonding to five different IZN molecules and three H2O molecules, the DLTA forms a final hydrogen 
bond to a second DLTA molecule creating the chain. This interaction is a donation from the 
protonated carboxylic acid group in one molecule to the deprotonated carboxylic acid group in the 
neighbouring molecule.  
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Table 5.4. Hydrogen bond distances and angles for IZN:DLTA:H2O co-crystal vi 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O4-H∙∙N1 0.94(6) 1.79(6) 2.693(5) 162(6) 
N2-H∙∙O12 0.81(5) 2.00(5) 2.797(5) 174(4) 
N3-H∙∙O44 0.96(7) 1.86(7) 2.807(6) 168(5) 
N3-H∙∙O55 0.76(6) 2.06(6) 2.805(6) 170(6) 
N3-H∙∙O23 0.99(8) 1.90(8) 2.782(6) 146(6) 
N3-H∙∙O33 0.99(8) 2.14(8) 2.879(6) 130(7) 
O6-H∙∙O11 1.22(6) 1.37(6) 2.571(5) 166(5) 
O3-H∙∙OH2 1.11(6) 1.57(6) 2.661(5) 167(5) 
HO-H∙∙O21 0.80(6) 2.59(6) 3.157(4) 129(6) 
H2O can be incorporated into crystal structures in a number of diverse ways. The three classes of 
hydrate are isolated site hydrates, channel hydrates and ion-associated hydrates (figure 5.16). In 
isolated site hydrates it is characteristic for the incorporated H2O molecules not to interact with one 
another, instead forming hydrogen bonds to the API molecules (or co-former in the case of co-
crystals). The H2O molecules in channel hydrates form chains, hydrogen bonding to each other along 
a given crystal axis. Upon dehydration, the H2O molecules can be removed without affecting the 
structure of the original hydrate. This results in void spaces remaining within the crystal which can 
be filled again with either H2O or another solvent molecule, whilst still maintaining the original 
crystal structure. Finally the third class of hydrate, ion-associated hydrates, see the H2O molecules 
ion-coordinated with the API molecules.206  
 
 
Figure 5.16. Schematic demonstrating (a) an isolated site hydrate, where H2O molecules do not interact. (b) a channel 
hydrate, where H2O molecules hydrogen bond to each other in a channel (orange dashed line). (c) an ion-associated 
hydrate, where the H2O molecules are ion coordinated with the API (green dashed lines) 
                                                          
vi 11+X,+Y,+Z 2-X,1-Y,1-Z 3+X,-1+Y,1+Z 4-X,-Y,1-Z 51-X,-Y,1-Z 
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From observation of the structural data for the IZN:DLTA:H2O co-crystal, the hydrate is likely to fall 
under the classification of an isolated site hydrate. Analysis of the hydrogen bonding interactions 
present shows no direct interaction between individual H2O molecules, with no chains forming 
throughout the structure, eliminating the possibility of it being a channel hydrate. There also does 
not appear to be an ion-coordinating interaction between the H2O molecules and the API or co-
former molecules in the structure ruling out the ion-assisted hydrate classification. 
The class of a pharmaceutical hydrate can be further confirmed using a variety of analysis 
techniques, namely DSC, TGA and IR spectroscopy. Isolated site hydrates show sharp dehydration 
endotherms (showing sharp peaks in DSC traces), narrow weight loss regions (in TGA) and sharp OH 
bands (in IR spectroscopy). Channel hydrates also show sharp OH bands but, in contrast to isolated 
site hydrates, show wide TGA weight loss ranges and broad endothermic peaks in DSC, often 
observed at lower temperatures. Finally, ion-associated hydrates show high dehydration 
temperatures due to the ionic interactions between the H2O and crystal molecule.206 
Characterisation of the bulk was also carried out using PXRD. 
 
Figure 5.17. PXRD data for (a) IZN (INICAC02), (b) DLTA (ZZZDUI01), (c) DLTA monohydrate (TARTDL), (d) IZN:DLTA:H2O 
co-crystal calculated from SCXRD and (e) IZN:DLTA:H2O co-crystal from H2O crash cooling 
As expected, the PXRD data shows a new crystalline form when compared to the raw starting 
materials (figure 5.17). The calculated pattern from single crystal data matches that of the bulk with 




Figure 5.18. DSC trace for IZN:DLTA:H2O co-crystal. IZN melting point = 171-174 ᵒC 163, DLTA melting point = 210-212 ᵒC 207 
DSC analysis also confirms the formation of a new crystalline form. The DSC trace of the multi-
component structure (figure 5.18) shows two sharp endotherms, one at 92 ⁰C and one at 161 ⁰C. 
The endotherm at 92 ⁰C could be the result of H2O being eliminated from the system. The sharpness 
of this endotherm suggests the hydrated structure can be classified as an isolated site hydrate, in 
agreement with the analysis of the structural data. This interpretation is supported by observation 
of a second endotherm, suggesting a stable anhydrous crystalline form of the multi-component 
crystal has been formed. The second endotherm at 161 ⁰C falls in the same place as that of the single 
enantiomer co-crystals. This could indicate the anhydrous structure formed is the same as that 
previously reported for the single enantiomers.  
The formation of the hydrated co-crystal was attempted in a number of solvent-mediated methods 
as well as using mechanochemical grinding (appendix A32 and A33). Grinding in the absence of 
solvent and LAG showed PXRD patterns that differ from that of the co-crystal, containing many 
peaks not corresponding to the starting materials, but which did not correspond to the known 
hydrated co-crystal. The LAG experiments showed higher conversion to the potential new phase 
than the grinding in the absence of solvent. These results suggest a second form exists of this crystal 
system. The PXRD interpretation is confirmed by the DSC data obtained for both the grinding and 
LAG experiments; both showing a single melt at approximately the same temperature, matching the 
second endotherm observed in the crash cooling analysis. This could take the form of a hemi-
hydrate or, more likely, an anhydrous form. Attempts to form the hydrated co-crystal via slurrying 
in H2O were successful with high conversion and phase purity. In addition, controlled cooling 
crystallisation yielded the hydrated co-crystal on 10 g and 30 g solvent scales (appendix A34). 
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Crystallisation on larger 200 g solvent scales were not carried out due to the high solubility of the 
starting materials in H2O. 
Co-crystal solubility was determined using observation techniques. The IZN:DLTA:H2O co-crystal and 
pure IZN starting material have a relationship that can be regarded as analogous to monotropic 
(figure 5.19): the co-crystal is less soluble over the full temperature range. As a result, this co-crystal 
form is also a potential candidate for improving other physical properties of IZN, notably the stability 
of IZN in the FDC tablet. The presence of more intermolecular interactions could result in an overall 
increase in crystal stability, when formulated into the FDC table, and therefore a reduction in 
solubility would be a worthwhile compromise.  
 
Figure 5.19. Solubility plot for IZN:DLTA:H2O co-crystal (purple circle marker) and pure IZN (black square marker) 
measured by observation in H2O 
The effects of the inclusion of H2O into pharmaceutical crystals is also important to consider. 
Hydrates can possess different dissolution profiles to anhydrous forms, however this is also affected 
by a number of other factors. They can also experience a change in mechanical properties. It is 
possible for these changes to be a positive result for the crystal system in question but does require 
careful investigation. Chemical stability is one property that can be affected that needs to be 
considered very carefully. The inclusion of the H2O in the structure during crystallisation could pose 
the problem of dehydration during storage, depending on the type of hydrate that has been formed. 
Later processing steps often involve the use of heat, giving rise to the possibility for dehydration to 
occur. This could result in a change in an unstable product leading to unfavourable properties due 
to variation in hydrate content or uncontrolled hydrate formation and dehydration processes. 
Therefore, in order to be considered as a viable option, the structural (crystallographic) aspects of 
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hydrates, the mechanism for their formation and the effects on the properties of the API must be 
fully understood.206 
Confirmation of the H2O stoichiometry in the crystal structure was carried out by TGA analysis.  
 
Figure 5.20. TGA trace for IZN:DLTA:H2O co-crystal showing the mass loss with increasing temperature 
The TGA trace of this crystalline form confirmed the loss of H2O hypothesised from the DSC analysis 
(figure 5.20). The first mass loss is 0.7 mg, about 5.1% of the total mass of the crystal added. The 
molecular mass of a 1:1:1 co-crystal would be 305 g/mol, with 18 g/mol corresponding to H2O. This 
would correspond to the crystal being in a 1:1:0.84 ratio, assuming all H2O in the structure has been 
fully eliminated. This is close to the 1:1:1 ratio originally hypothesized for the crystal structure. The 
loss of mass corresponding to H2O occurs between 77 ⁰C and 116 ⁰C, matching the endotherm 
observed in the DSC experiment. The mid-point of the initial mass loss corresponds to 98 ⁰C, close 
to the boiling point of H2O. The small deviation in the temperatures between DSC and TGA are due 
to the DSC pan being sealed and the TGA sample holder being open to the atmosphere. The second 
loss of mass starts at about 160 ⁰C. This is comparable to the second thermal event observed in the 
DSC and shows full decomposition of the remaining crystal structure. The weight loss region 
corresponding to the dehydration is relatively narrow, spanning about 20 ⁰C. This narrow weight 
loss region would, again, suggest the hydrate formed falls into the class of isolated site hydrate. This 
agrees with the DSC and the structural analysis. 
The use of FTIR analysis to confirm the type of hydrate is complicated in this case, due to the 
structure of the co-former present. As well as the H2O molecules the co-former has two COOH 
functional groups and two OH functional groups; the IR bands from these all overlap in the spectrum 




Figure 5.21. FTIR scan of IZN:DLTA:H2O co-crystal 
The broad set of peaks between 3600 cm-1 and 2200 cm-1 is due to the OH functional groups present 
in the DLTA co-former and H2O molecules. Within this region, OH peaks from alcohol groups and the 
H2O molecules are present at the top end of the peak, between 3600 cm-1 and 3400 cm-1, OH peaks 
from COOH functional groups are present between 3300 cm-1 and 2500 cm-1, and peaks caused by 
the N-H bonds within the molecule, between 3500 cm-1 and 3300 cm-1. Isolated site hydrates show 
sharp OH peaks and, whilst it is difficult to determine exactly which part of the peak the H2O is 
responsible for, the initial high wavenumber part of the peak does begin sharply. When combined 
with the DSC and TGA data, this helps confirm the presence of the isolated site hydrate; however, 
in isolation from the other data, the IR spectrum would not allow definitive determination of the 
type of hydrate in this case. 
Whilst the DSC trace (figure 5.18) suggested a dehydrated crystalline structure may exist, 
determination of whether this second structure was fully crystalline was necessary. HSM and 




Figure 5.22. Variable temperature PXRD data obtained from beamline I11 at Diamond light source showing the 
conversion from the hydrated co-crystal to a secondary crystal structure. (a) initial collection at 75 ⁰C, (b) collection at 
79 ⁰C, (c) collection at 81 ⁰C showing the transition, (d) collection at 83 ⁰C and (e) collection at 85 ⁰C 
The variable temperature PXRD data were collected on beamline I11 at Diamond Light Source (figure 
5.22). In pattern (c), the beginning of a transition from the initial crystal structure can be observed. 
At around 81 ⁰C the pattern remains mostly similar to the hydrated co-crystal pattern but with the 
emergence of a small peak at 8° 2θ. This peak signifies the start of the transition to the secondary 
structure with full transformation having occurred by 83 ⁰C (pattern (d)). This temperature 
corresponds well to the onset of the H2O loss observed in both DSC and TGA analysis. The second, 
dehydrated, structure is confirmed as fully crystalline by its sharp PXRD pattern. The substantial 
change in structure is further evidence that the hydrate is not a channel hydrate, as eliminating H2O 
from channels within a structure would tend to result in little or no change in the crystal parameters. 
The co-crystal stability was investigated in slurry techniques for up to 1 week. No conversion was 
observed in PXRD (figure 5.23), with the co-crystal remaining stable without any degradation or 
additional uptake of H2O. However, the co-crystal stability at high temperatures was found to be 
reduced. From the data produced in vtPXRD, DSC, TGA and solubility experiments it has been 
suggested the co-crystal becomes less stable as the temperature is increased, eventually converting 
to a second, assumed anhydrous, form. Conversion of the co-crystal system begins to be observed 
after only 24 hours at an elevated temperature of 50 ⁰C. The second (anhydrous) structure is fully 
achieved after 48 hours at 50 ⁰C. This reduced stability at elevated temperatures is directly related 
to the inclusion of H2O in the crystal structure and provides a good example of the problems with 
using hydrated crystals in the pharmaceutical industry. Samples subjected to increased humidity 




Figure 5.23. PXRD data for (a) IZN (INICAC02), (b) DLTA (ZZZDUI05), (c) DLTA monohydrate (TARTDL), (d) IZN:DLTA:H2O 
co-crystal calculated from SCXRD, (d) IZN:DLTA:H2O slurry 1 week, (e) IZN:DLTA:H2O co-crystal 50 ᵒC 24 hours, (f) 
IZN:DLTA:H2O co-crystal 50 ᵒC 1 week and (g) IZN:DLTA:H2O co-crystal 70% humidity 9 weeks 
The new hydrated salt form has a plate like morphology (figure 5.24). The addition of co-former and 
H2O molecules has influenced the structure and growth of the crystal to significantly change the 
morphology seen in pure IZN crystallisations from H2O.  
 
Figure 5.24.Plate-shaped IZN:DLTA:H2O co-crystals crystallised from H2O 
Plate-shaped crystals are still not favoured by the pharmaceutical industry but, as previous research 
has shown, a change of solvent could in turn result in more favourable block shaped crystals forming 





Figure 5.25. Predicted BFDH morphology for IZN:DLTA:H2O (left); observed morphology for IZN:DLTA:H2O (right) 
The BFDH morphology is different from the observed face-indexed morphology of the crystals 
produced (figure 5.25). Whilst the face indexed crystal is a thin plate, the calculated morphology 
appears thicker and closer to a block. The calculated morphology still suggests the major growth 
mechanism occurs in the (100) and (101) directions with the π-π interactions contributing to the 
major growth. In the experimental morphology, the plate-shaped crystals show the major growth 
occurring on the (011) / (0-1-1) faces. The major growth interaction has shifted from those between 
the aromatic rings to the hydrogen bonds between the IZN, TA and H2O components, illustrated 
mainly in the right image of figure 5.15. Little growth is seen parallel to the crystallographic a axis 
as very few interactions exist between the layers of IZN and TA in this direction. The π-systems 
alternate their orientation between layers. As a result, fewer π-stacking interactions are present 
causing the significant reduction of growth observed in this direction. The incorporation of H2O 
molecules and the two different orientations of TA involved in the structure could explain the 
alternating nature of the IZN π-systems.  
Comparison of the resulting morphology with that observed for pure IZN gives credibility to the 
approach of changing morphology using multi-component crystallisation. Again a plate shape crystal 
is observed as opposed to the thin needle usually crystallised from H2O. This co-crystal not only has 
a different morphology but also a different major growth mechanism. This could be beneficial in 
attempting to alter this crystal habit with further techniques, for example the weakening of the 




5.4.3  Dehydration of isoniazid and (DL)-tartaric acid hydrate to give an 
anhydrous form vii 
Attempts were made to isolate a single crystal for the second crystal structure observed in the 
variable temperature PXRD data for the DLTA hydrated co-crystal. A single crystal was successfully 
isolated using the HSM set up. Single crystals of the hydrated DLTA co-crystal were heated on the 
hot stage to a temperature just above the first thermal event observed in the DSC and TGA data. To 
ensure the H2O had fully left the structure the temperature chosen was 130 ⁰C. The remaining 
crystals were then analysed using the Rigaku Oxford Diffraction Gemini A ultra to determine the 
crystal structure. The new crystal structure has a different space group to the hydrated co-crystal. 
This anhydrous form has space group P21/c and exhibits extra symmetry without the H2O present. 
This is again an achiral space group, confirming the presence of the racemic form DLTA.  The 
asymmetric unit consists of one IZN molecule and one DLTA molecule (figure 5.26). The hydrogen 
bonding distances again show the transferred proton sitting closer to midway between the donor 
and acceptor atoms: N3-H distance is 1.2(2) Å; H∙∙O2 distance is 1.6(1) Å (table 5.5). Again, unlike 
the enantiomeric crystal structures, the pyridyl N is hydrogen bonded to a central hydroxyl group 
on the DLTA. Consequently, no proton transfer occurs towards the N in this structure.  
 
Figure 5.26. Unit cell of IZN:DLTA anhydrous co-crystal 
The packing of this co-crystal is very similar to that of the hydrated co-crystal. The unit cell volume 
has reduced due to the loss of H2O. IZN molecules stack via the interactions between their aromatic 
rings with the molecules alternating directions. Therefore, the direct overlap occurs between every 
other IZN molecule looking down the crystallographic b axis. This alternation is the same as observed 
in the hydrated structure. The DLTA chains observed in the hydrated structure are again seen here 
                                                          
vii The structure for the anhydrous DL-tartaric acid co-crystal has been added to the CSD (BOPHOG) since this 
research was carried out with a paper published in 2019. 
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and lie between the stacked IZN molecules. The loss of H2O in the structure has led to the adoption 
of a higher symmetry in the unit cell (figure 5.27).  
 
Figure 5.27. Hydrogen bonding interactions present in IZN:DLTA co-crystal showing the alternating nature of the IZN 
stacking and chains of the DLTA molecules 
The hydrogen bonds present are listed in table 5.5. Each IZN molecule accepts a hydrogen bond at 
the pyridyl ring N, donated from a central hydroxyl group on a DLTA molecule. Due to the low 
polarizability of the hydroxyl group no proton transfer is observed. Each IZN molecule then hydrogen 
bonds to a further four DLTA molecules. The NH donates to the carbonyl group of the deprotonated 
carboxyl on a second DLTA molecule. The NH3+ donates to three separate DLTA molecules; one to a 
central hydroxyl group, one to the carbonyl of the protonated carboxylic acid group and the final 
bond is between the deprotonated carboxylic acid where proton transfer has occurred. Each DLTA 
molecule is bonded to five separate IZN molecules through the five interactions previously 
discussed. The DLTA molecules are also hydrogen bonded to each other through the terminal 
carboxylic acid groups to form the chains. The deprotonated end of the DLTA molecule accepts a 
hydrogen bond donated from the protonated end of a second DLTA creating a chain through the 





Table 5.5 Hydrogen bond distances and angles for IZN:DLTA co-crystal viii 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O4-H∙∙N1 1.01(7) 1.71(7) 2.706(5) 167(6) 
N2-H∙∙O14 1.01(6) 1.80(6) 2.809(7) 178(7) 
N3-H∙∙O23 1.2(2) 1.6(1) 2.73(1) 157(7) 
N3-H∙∙O32 0.83(6) 2.08(6) 2.811(7) 146(5) 
N3-H∙∙O51 0.95(6) 1.99(6) 2.761(7) 137(5) 
O6-H∙∙O15 1.07(8) 1.47(8) 2.538(5) 171(6) 
Bulk analysis for this co-crystal was carried out on a sample of the preparation of hydrated IZN:DLTA 
co-crystal that had undergone dehydration in the oven at 50 ⁰C. PXRD analysis was carried out to 
compare the calculated pattern with the bulk-produced sample and determine the phase purity and 
conversion (figure 5.28). 
 
Figure 5.28. PXRD data for (a) IZN (INICAC02), (b) DLTA (ZZZDUI05), (c) DLTA monohydrate (TARTDL), (d) IZN:DLTA co-
crystal calculated from SCXRD and (e) IZN:DLTA co-crystal produced by dehydrating the hydrated form at 50 ⁰C 
Full conversion to the dehydrated co-crystal is found to be possible without significant degradation 
back to starting materials. The new dehydrated crystalline form is confirmed with no discernable 
traces of the hydrated co-crystal or further decomposition of the crystalline structure. 
Thermal techniques were also used to characterise the thermal behavior of the new anhydrous co-
crystal structure and confirm the crystal structure to be fully dehydrated. This would allow for the 
                                                          
viii 1-X,-Y,1-Z 2-1+X,+Y,+Z 3-1+X,-1+Y,+Z 41-X,-1/2+Y,3/2-Z  5+X,-1+Y,+Z 
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possibility that a hemi-hydrate could have formed in the bulk from incomplete evaporation of the 
H2O present. 
 
Figure 5.29. DSC trace for IZN:DLTA co-crystal. IZN melting point = 171-174 ᵒC 163, DLTA melting point = 210-212 ᵒC 207 
The DSC trace shows a sharp endothermic peak at 155 ⁰C (figure 5.29), representing the melting 
point of the new co-crystal structure. This is lower than both starting materials suggesting that the 
anhydrous co-crystal is less stable than the pure forms are individually. The melting endotherm and 
the complex endothermic peak directly following match the trace observed for the equivalent 
thermal events in the hydrated IZN:DLTA co-crystal, confirming the hypothesis that the dehydrated 
co-crystal is formed upon heating of the hydrated crystal.  
 
Figure 5.30. TGA trace for IZN:DLTA co-crystal confirming the absence of H2O in the structure 
TGA analysis confirms the anhydrous form of the crystal and discounts the possibility of a second, 
hemi-hydrate being formed (figure 5.29). No mass loss is observed in the TGA data until 160 ⁰C 
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where decomposition of the co-crystal structure begins to occur. There is no mass loss observed 
that would be attributed to H2O as seen in the hydrated crystal, confirming the absence of H2O in 
this form. 
FTIR analysis of the dehydrated form was carried out in an attempt to confirm further the absence 
of H2O (figure 5.31). Again the presence of many OH groups in the co-former makes this 
determination difficult. 
 
Figure 5.31. FTIR scan of IZN:DLTA co-crystal 
A broad OH peak is observed between 3300 cm-1 and 2500 cm-1 caused by the OH group in the 
carboxylic functional groups observed in the co-crystal. Also falling within this region is a peak 
corresponding to the N-H bonds present in IZN and formed due to donation of the H from a 
carboxylic acid group to the N in the pyridine ring, between 3500 cm-1 and 3300 cm-1, and from the 
alcohol groups also present in the co-former. Comparison of this broad peak with that seen in figure 
5.20 shows that the broad peak starts at a slightly lower wavenumber, around 3300 cm-1 compared 
to 3600 cm-1, suggesting the absence of the H2O molecules in this structure. While it is difficult to 
determine with certainty from these data that the H2O has been eliminated within this structure, 
when combined with the DSC, TGA and structural analysis it can be determined that no H2O remains 
within the structure. 
The dehydrated co-crystal solubility was determined using observation techniques. A monotropic 
relationship between pure IZN and the co-crystal is observed (figure 5.32, left). The solubility of the 
co-crystal is lower than pure IZN, indicating the co-crystal has good stability. Thus, the potential 
exists for this form to improve the stability of IZN in the FDC tablet. The solubility of the hydrated 
and dehydrated co-crystal are very similar, almost identical at low temperatures. At higher 
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temperatures, slight deviation is observed with the hydrated co-crystal becoming slightly less 
soluble (figure 5.32, right). Whilst this agrees with the general finding that hydrated co-crystals tend 
to be less soluble than their anhydrous counter parts, due to the changes in intermolecular 
interactions leading to a reduction in Gibbs free energy205, the differences are likely negligible when 
taking into account the error of the experimental procedure. The similarity could be the result of 
the anhydrous form re-hydrating in solution and, therefore, the experiment is just measuring the 
solubility of the hydrated co-crystal once again. 
 
Figure 5.32. Left: Solubility plot for IZN:DLTA co-crystal (purple circle marker) and pure IZN (black square marker) 
measured by observation in H2O. Right: comparison of IZN:DLTA co-crystal solubility (purple circle marker) and 
IZN:DLTA:H2O co-crystal (black square marker) 
Stability testing of the dehydrated crystal structure was again carried out via slurrying, high 
temperature studies and increased humidity, with outcomes monitored by PXRD (figure 5.33). The 
co-crystal was stable for three weeks when stored at 50 ⁰C with no degradation to the starting 
materials observed. However, in slurry experiments a conversion back to the hydrated form of the 
co-crystal was witnessed. This conversion occurred completely after 48 hours of continuous mixing 
in H2O at 40 ⁰C. No changes were observed after 9 weeks in the humidity chamber, indicating the 




Figure 5.33. PXRD data for (a) IZN (INICAC02), (b) DLTA (ZZZDUI05), (c) DLTA monohydrate (TARTDL), (d) IZN:DLTA co-
crystal calculated from SCXRD, (e) IZN:DLTA co-crystal slurry 48 hours, (f) IZN:DLTA co-crystal 50 C 3 weeks and (g) 
IZN:DLTA co-crystal 70% humidity 9 weeks 
Further experiments showed that H2O elimination and re-uptake are not reversible; it is not possible 
to rehydrate the anhydrous structure. This was to be expected due to the classification of the 
hydrate as an isolated site hydrate. If a channel hydrate were formed, the re-uptake of H2O would 
be possible. Cycling experiments on the DSC and HSM instruments were carried out with no 
successful recrystallisation of the hydrated form of the co-crystal (appendix A35). Slurrying on the 
other hand, can induce rehydration, assisting the transition through the continuous dissolution and 
recrystallisation of the co-crystal over time. The significant reduction in unit cell volume observed 
on dehydration further confirms the irreversible nature of the transformation observed on heating 
the hydrated crystal.  
The crystal morphology for this structure remains a plate due to the method of isolation used to 
achieve this crystal form. Obtaining the crystal via heating in HSM causes the morphology to remain 




Figure 5.34. Images isolated from HSM video footage showing the morphology retention when IZN:DLTA:H2O co-crystal 
(left) transforming to IZN:DLTA co-crystal (right) upon heating 
The overall BFDH predicted morphology for this crystal structure is similar to that calculated for the 
hydrated co-crystal, but with significantly different growth faces as expected given the different unit 
cell parameters. The block-like morphology has an overall predicted hexagonal shape in comparison 
to the square shape predicted for the hydrated co-crystal. The predicted morphology still shows an 
overlap of the aromatic rings after the elimination of H2O, however, the growth from hydrogen 
bonding is predicted to be more equal throughout the structure. 
 
Figure 5.35. Predicted BFDH morphology for IZN:DLTA (left); observed morphology for IZN:DLTA (right) 
The observed plate-shaped crystals share the same major growth as the hydrated crystal structure 
(figure 5.35). The fastest growing faces are now the (00-1) and (001) faces, due to hydrogen bonding. 
From this observed morphology, it would appear that the aromatic ring interaction is not 
responsible for the major growth of the crystal, as predicted in the BFDH morphology. In this 
interpretation, the overall contribution from the many hydrogen bonds in this structure could 
potentially outweigh the strength of the aromatic interactions. It is more likely, however, that this 
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morphology is purely the result of the method of isolation used. This is further confirmed by Sarma 
et al., in a paper published in 2019 since this work was carried out. The research successfully 
crystallised the anhydrous co-crystal using solvent-mediated techniques. In both ACN and EtOH 
crystallisations needle-shaped crystals resulted for this form.207 It is likely in this case that the major 
growth mechanism is again the π-π interactions between the aromatic rings in the IZN, resulting in 
the same needle morphology observed in crystallisations of pure IZN. This is a good example of 
different crystallisation methods resulting in different crystal morphologies. By eliminating the H2O 
from the hydrated co-crystal through dehydration, a significantly different morphology can be 
obtained to that produced from solution methods. It may be possible to alter this further using 
additives in the crystallisation process.  
5.5  Crystallisation of isoniazid with 3,4-dinitrobenzoic acid 
A co-crystal of IZN was also obtained from a 1:1 ratio of IZN and 3,4-dinitrobenzoic acid (3,4-DNBA) 
in IPA (figure 5.36).  
 
Figure 5.36. Structure of IZN and 3,4-DNBA showing the numbering system used in hydrogen bonding discussions 
The new form crystallises in the P1̅ space group with an asymmetric unit consisting of one IZN and 
one 3,4-DNBA molecule (figure 5.37). In this structure no proton transfer is observed between the 




Figure 5.37. Unit cell of co-crystal IZN:3,4-DNBA 
The hydrogen bonding interactions occurring in this structure (table 5.6) create discrete 1D chains 
of molecules (figure 5.38). The first creates a link between the pyridyl N on the IZN to the carboxylic 
acid group on the 3,4-DNBA. Unlike the other co-crystal structures discussed in this chapter, this 
hydrogen bond does not appear to show transfer of the H from the carboxylic acid group to the N. 
However, there appears to be significant elongation of the O-H distance and corresponding 
shortening of the N∙∙H distance: the N∙∙H distance is 1.46(4) Å and O-H distance is 1.10(4) Å. This 
could suggest the hydrogen is not strongly held on the carboxylic acid in this structure and the 
hydrogen could migrate or transfer as observed in other structures. The data for this co-crystal 
structure shows significant errors (ESD’s) for the bond lengths measured. As a result the position of 
the hydrogen is essentially undetermined. Examination of the CSD database shows there are 19 
crystals with this hydrogen bond interaction with 13 occurring without a shift in the proton. Further 
hydrogen bonds form between the NH and NH2 groups in the IZN molecules. These interact head on 
with each other and create dimeric ring interactions. This is an unusual interaction for IZN. In the 
CSD, only nine co-crystalline structures form this type of interaction of 56 co-crystalline structures 
published in total. This is a stark contrast to the carboxylic acid/pyridyl N interaction previously 
discussed. These interactions form chains through the molecule in an alternating fashion, 3,4-
DNBA∙∙IZN∙∙IZN∙∙3,4-DNBA. The IZN and 3,4-DNBA singularly bonded heterodimers exist in the same 
plane as each other, with the aromatic rings flat. The ring interactions between the two 
heterodimers result in a slight offset and do not occur in the same plane (figure 5.38). The aromatic 
rings of the second heterodimer still remain flat with respect to the first. The chains do not form 





Figure 5.38. Hydrogen bonding and close interactions of IZN:3,4-DNBA co-crystal 
 
Figure 5.39. Offset of dimeric hydrogen bonding interactions 
The 1D layers produced by the discrete hydrogen bonded chains in turn interact to form the 2D 
crystal. One hydrogen bond exists to link the stacked chains together (figure 5.38 and 5.39). This 
hydrogen bond occurs between the IZN NH2 group and the NO2 group in position four of the 3,4-
DNBA molecule. The link influences the arrangement of the chains in comparison to one another. A 
slight shift occurs between each stacked chain meaning the ring interactions are not directly stacked 
and the molecules alternate when stacked. Due to the rings being planar to each other, the π-
systems present a face-stacked geometry contributing to the intermolecular interactions holding 
the structure together. 
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Table 5.6. Hydrogen bond distances and angles for co-crystal IZN:3,4-DNBA ix 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O-H∙∙N11 1.10(4) 1.46(4) 2.561(3) 178(3) 
N2-H∙∙N34 0.82(3) 2.20(3) 2.966(4) 155(3) 
N3-H∙∙O(Nitro-3)3 0.94(3) 2.27(3) 3.148(3) 155(2) 
When visualising the structure using Mercury software, further interactions are suggested between 
the nitro groups on the 3,4-DNBA. The distances calculated are between 2.8 Å and 3.9 Å, but no 
hydrogens are present between these two functional groups; a different interaction may be 
occurring. In the literature, there is mention of interactions, similar to hydrogen bonds, existing 
between two nitro groups. A study conducted by Daszkiewicz209 observed N∙∙O interactions between 
nitro groups on adjacent molecules. However, these interactions were only detected for nitro 
groups arranged perpendicular to each other.  The nitro groups within the present co-crystal 
structure are parallel, figure 5.38, suggesting this interaction is not present here. Further evidence 
to suggest this interaction is not present comes from the bond distances. In all structures noting the 
NO2-NO2 interaction, the intermolecular N…O distance is below 3 Å; here the N∙∙O intermolecular 
distances between adjacent 3,4-DNBA molecules is much larger (table 5.7). The incorrect 
orientation of nitro groups and this long distance strongly suggests the interactions discussed by 
Daszkiewicz are not present between nitro groups within this crystal structure. 
Table 5.7. Distances and angles for interactions between nitro groups  
N∙∙O Nitro-group position d(N∙∙O) (Å) >(NOO) (ᵒ) 
Intermolecular N∙∙O Nitro 3 to 3 3.842(3) 114.6(2) 
Intermolecular N∙∙O Nitro 3 to 4 3.652(3) 126.5(2) 
PXRD analysis was used to collect data from the bulk and determine the phase purity of the product 
from this crystallisation. A comparison was made to the raw starting materials as well as the pattern 
calculated from the SCXRD data obtained (figure 5.40). 
                                                          




Figure 5.40. PXRD data for (a) IZN (INICAC02) (b) 3,4-DNBA (YADKOF), (c) IZN:3,4-DNBA calculated from SCXRD and (d) 
IZN:3,4-DNBA crystals from evaporative crystallisation in IPA 
The calculated and experimental patterns for the co-crystal system match well; they are slightly 
offset from one another due to the calculated data being generated from structural parameters 
collected at 150 K and the experimental pattern being collected at 298 K. The lower temperature 
will be reflected in a smaller unit cell size and hence the PXRD data shift slightly in 2θ. There are no 
unassigned peaks in the experimental pattern corresponding to any starting material so phase purity 
can be considered quite high. 
The thermal behaviour of the co-crystal was investigated using DSC analysis (figure 5.41). The DSC 
trace for the new co-crystal form has a sharp endothermic peak at 152 ⁰C, a lower temperature than 
the melting points of IZN and 3,4-DNBA, confirming the formation of a new co-crystal. The lower 




Figure 5.41. DSC trace for IZN:3,4-DNBA co-crystal. IZN melting point = 171-174 ᵒC 163, 3,4-DNBA melting point = 165 ᵒC 210 
After the sharp endotherm the trace immediately shows a sharp exothermic peak. The close 
proximity of these two peaks in a crystalline sample suggests a recrystallisation after the initial melt. 
The exothermic peak could be the result of either a new form of the co-crystal recrystallising or, 
perhaps more likely, one of the starting components recrystallising. However, as no further melting 
is observed, the exothermic peak is less likely to correspond to a recrystallisation. HSM was carried 
out on the sample to characterise further the events observed in the DSC trace. Melting of the 
crystals was witnessed at 152 ⁰C, corroborating the assignment of the endotherm in the DSC data. 
However, no recrystallisation was observed following the melt so is not the cause of the sharp 
exothermic peak. Another possible explanation for the exothermic peak is a liquid rearrangement. 
From experiments on the HSM it is known that the sample remains a liquid until its eventual 
decomposition, therefore the peak could be the result of the liquid rearranging to a slightly more 
ordered material without reaching full crystallinity. The broader peak following the sharp exotherm 
is indicative of an exothermic decomposition. This could be due to the hydrazine group decomposing 
within the IZN, reported as exothermic in the literature. This is not observed in the DSC trace of pure 
IZN, but it may be occurring at a lower temperature in this mixture as a result of reduced stability 
due to the presence of 3,4-DNBA. 
The co-crystal system was also subjected to TGA analysis to understand further the potential 




Figure 5.42. TGA trace for IZN:3,4-DNBA co-crystal 
The TGA data (figure 5.42) shows a number of mass loss events, occurring above 152 ⁰C, 
corresponding to the melting point of the co-crystal. Analysis of the masses lost can allow the nature 
of the decomposition to be studied. The first mass loss occurs at 156 ⁰C, at a temperature close to 
the melting endotherm. This mass loss could also potentially be attributed to the initial exothermic 
peak, as the temperature range of the full loss overlaps with this peak. The first mass loss is 8.1% of 
the total mass and one possible explanation is that this could be the result of a loss of remaining 
crystallisation solvent from the bulk system. Although no solvent was incorporated into the crystal 
structure some may have remained in the sample, for example on the surface. However, the boiling 
point of IPA, 82 ⁰C, is much lower than the temperature at which the mass loss occurs. Whilst the 
temperature could be higher if the solvent is being held in the crystal structure there is no evidence 
of this from crystallographic studies so can likely be discounted.  A second mass loss 16% of the total 
mass is observed at 179 ⁰C, the same temperature as the broad exothermic peak. This mass loss 
supports the rapid decomposition theory discussed above, but gives no further information as to 
which groups may be lost to cause the mass loss. 
Further crystallisation methods were attempted to produce this co-crystalline form on different 
scales (appendix A36 and A37). Grinding mechanochemical methods in the absence of solvent did 
not successfully form the new co-crystal to an acceptable level of phase purity. The addition of a 
small amount of solvent, LAG, achieved better conversion with minimal evidence of the initial 
starting materials remaining. Slurry techniques were also attempted with good conversion from 
starting materials to co-crystal after stirring for 24 hours in IPA. Crash cooling also exhibited good 
results with the co-crystal produced at the same purity as achieved in evaporative crystallisation.  
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Scale up of this crystallisation was carried out using the Polar Bear Plus crystalliser. Using inserts for 
20 mL and 250 mL vessels the crystallisation process was successfully scaled to 10 g and 200 g 
(solvent mass). The 30 g scale was not attempted for this co-crystal in light of the success at these 
two scales. Production of the co-crystal was also achieved through slurry crystallisations in IPA 
(appendix A38). 
The solubility of the co-crystal was determined using observation techniques. The data show that 
the co-crystal is more soluble in IPA than pure IZN (figure 5.43). The relationship appears to be 
monotropic, within the temperature range sampled; it cannot be determined with certainty with 
the data provided. This increased solubility suggests the co-crystal is less stable than pure IZN in the 
temperature range examined. This increase in solubility and associated decrease in thermodynamic 
stability differs from that observed in the other multi-component materials discussed in this 
chapter. This co-crystal differs from those with TA derivatives in that there is no hydrogen transfer; 
this structure is a neutral co-crystal not a co-crystalline salt. The combination of intermolecular 
forces within this structure is different and the overall strength of interactions is likely lower, which 
may explain the reduction in stability for this co-crystal system. With respect to the instability of IZN 
in the FDC tablet, this co-crystal would thus not be a favoured candidate to provide an improvement. 
The reduced stability could be an appropriate compromise to achieve increased solubility; however, 
due to the use of a non-GRAS co-former in this structure, its potential in pharmaceutical applications 
are limited. Thus, the IZN:TA co-crystals would be favoured.  
 
Figure 5.43. Solubility plot for IZN:3,4-DNBA co-crystal (purple circle marker) and pure IZN (black square marker) 
measured by observation in IPA 
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The stability of the co-crystal was tested by all three stability methods; exposure to high 
temperatures for prolonged periods, slurrying at a temperature of 40 ⁰C and humidity studies; the 
outcomes were monitored by PXRD (figure 5.44). This co-crystal system remained stable at 50 ⁰C 
for three weeks with no conversion into a second form or decomposition back to the starting 
materials. Slurrying experiments showed no changes in the PXRD data after a week. No significant 
amount of solvent became incorporated into the crystal structure and no significant decomposition 
occurred back to the starting materials. Finally, no significant decomposition or changes were 
observed in the PXRD data for the co-crystal when held in a 70% humidity chamber for 9 weeks.  
 
Figure 5.44. PXRD data for (a) IZN (INICAC02), (b) 3,4-DNBA (YADKOF), (c) IZN:3,4-DNBA calculated from SCXRD, (d) 
IZN:3,4-DNBA co-crystal slurry 1 week, (e) IZN:3,4-DNBA co-crystal 50 ⁰C 3 weeks and (f) IZN:3,4-DNBA co-crystal 70% 
humidity 9 weeks 
Crystallisation of the IZN:3,4-DNBA co-crystal from IPA yields a plate-shaped crystal (figure 5.45). 
The morphology observed for pure IZN in IPA is also plate-shaped crystals. A significant change in 
morphology has thus not been observed for this co-crystal under the given crystallisation conditions. 
     
Figure 5.45. Plate-shaped IZN:3,4-DNBA co-crystals crystallised from IPA 
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The calculated BFDH morphology for the co-crystal structure is a fat, hexagonal plate, verging on a 
block shaped crystal (figure 5.46, left). The major growth occurs on the (100) and (-100) faces, the 
same direction as observed in most of the structures reported here. The major interaction 
contributing to the growth in this direction is, again, the π-π interactions between the aromatic rings 
in the two molecular components in the crystal. The hydrogen bonding interactions are likely 
responsible for the growth in the (00-1) and (001) directions associated with the calculated 
morphology. 
 
Figure 5.46. Predicted morphology for IZN:3,4-DNBA (left); observed morphology for IZN:3,4-DNBA (right) 
The plates produced in the crystallisation are extremely thin and delicate, making face indexing a 
challenge; the result highlights the thin nature of the crystals when compared to the calculated 
morphology (figure 5.46, right). The major growth direction for the calculated morphology appears 
to be perpendicular to the (-100) and (100) faces. This differs from the observed morphology, which 
suggests the major growth is perpendicular to the (0-10) and (010) faces. The major contribution of 
the π-system interactions acts on the (-100) / (100) face set: whilst this is still responsible for some 
growth in the predicted structure it does not show the level of growth that has been seen in other 
IZN co-crystal structures discussed. The hydrogen bonding contribution is greatly diminished in the 
predicted structure, with very little growth seen on the (00-1) face. External factors within the 
crystallisation, such as solvent effects or impurities present, may be influencing the hydrogen 
bonding interactions and preventing their formation. An increase in the favourability of the 
hydrogen bonding interactions would tend to drive the predicted morphology and the calculated 
morphology towards looking more similar.  
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5.6  Conclusions 
The work discussed in this chapter is focussed on the formation of new multi-component solid forms 
(co-crystals) of IZN and characterising their physical properties. The overall aim was to determine 
whether the morphology can be improved through the formation of new co-crystalline structures.  
IZN was found to form three new structures with different enantiomeric combinations of tartaric 
acid. New multi-component crystal structures were found with L-TA, D-TA and DL-TA, with a hydrate 
of the latter also accessed. The solubility of each of the new crystal forms produced was less than 
that observed for pure IZN, a possible negative effect of the formation of the multi-component 
structures. However, IZN has a BCS (biopharmaceutics classification system) class of 1, due to its 
high solubility, suggesting a reduction in solubility would be acceptable for this API.211 In addition, 
the potential improvements in other physical properties, such as solid form stability, compressibility 
and flowability, may outweigh the reduction in solubility. In depth stability analysis showed that 
each new form was stable for up to 9 weeks at 70% humidity. All forms were stable for at least 3 
weeks at 50 ⁰C except the hydrate, which had fully converted to the dehydrated form after 1 week. 
Slurry experiments in H2O also proved the stability of the co-crystals for up to 1 week, with the 
exception of the dehydrated DLTA co-crystal which converted back to the hydrated version through 
dissolution: the dehydration is not a reversible process without this dissolution step.  
IZN:TA co-crystals were all found to crystallise in a plate-shaped morphology. All crystallisations 
were carried out in H2O, which gives needle-shaped crystals for pure IZN. The morphology change 
upon the addition of the co-formers into the crystal structure is significant. The needles are no 
longer formed due to the co-former allowing for more hydrogen bonding interactions to occur, 
diminishing the strength of the π-π-interactions between the aromatic rings. Whilst the morphology 
change is significant, the plate-shaped morphologies achieved are still undesirable for the 
downstream processing steps required for a pharmaceutical ingredient.  
A further multi-component crystal for IZN was produced with 3,4-DNBA. The solubility of the new 
form in this case was found to have increased when compared to pure IZN, which is potentially 
favourable. However, this co-former is non-GRAS, meaning the application of this co-crystal to 
pharmaceutical production is highly unlikely compared to those with TA. Stability tests again show 
the new form is significantly stable under numerous conditions. The co-crystal remained stable for 
9 weeks at 70% humidity, 3 weeks at 50 ⁰C and 1 week when slurried.  
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The IZN:3,4-DNBA co-crystal was crystallised from IPA and gave a thin plate morphology. The crystals 
were extremely thin, verging on flakes. The morphology usually achieved through crystallising pure 
IZN from IPA is a plate-shaped morphology, therefore no improvement was observed upon the 
formation of this co-crystal structure. The very thin flakes would likely cause significant problems 
for downstream processing steps. Given the lack of positive morphology change and the use of the 
non-GRAS co-former this multi-component form would not be favoured as a potential solution to 
the IZN morphology problem.  
Overall, the creation of multi-component materials of IZN has resulted in morphology changes of 
the crystals. This is especially clear when comparing the needles previously achieved from 
crystallisations in H2O to the plates achieved when co-crystallised with the GRAS co-former TA. 
However, the plate-shaped morphology is not necessarily sufficient to have a significant 
improvement on the ease of downstream processing steps. Given the difficulty in obtaining FDA 
approval for the secondary component, this approach would be unlikely to be worthwhile in practice 
as the improvements in the morphology are not substantial enough. In all co-crystals, apart from 
the IZN:3,4-DNBA, the addition of the secondary component has also significantly reduced the 
solubility when compared to pure IZN, often extremely unfavourable in the pharmaceutical industry. 
More significant improvements in IZN morphology were reported in chapter 4, with the use of 
different solvents and additives. As a result, the formation of new multi-component materials would 






Chapter 6 Changing the morphology of 
pyridoxine 
 
6.1  Introduction 
Following the success of changing the morphology of IZN by variation of solvent, use of additives 
and the creation of multi-component materials, an equivalent set of experiments were attempted 
with a structurally similar molecule, pyridoxine (PYR). PYR (figure 6.1) has a similar structure to IZN, 
with the aromatic ring containing an N atom and a range of R groups. PYR also forms a needle crystal 
morphology, with the major growth attributed to the stacking of the aromatic rings within the 
structure.  
 
Figure 6.1. Labelled PYR molecule showing the functional groups present 
The aim of the investigation on PYR was to achieve similar morphology modifications to those 
discussed for IZN in chapters 4 and 5. 
6.2  Selection of co-formers and additives for pyridoxine 
Additive selection was carried out using the molecular complementarity function in the Mercury 
program. Calculations were carried out with all five molecular descriptors enabled. Two different 
lists of molecules were screened for complementarity; a list of GRAS molecules and a list of common 
molecules found to make co-crystals. Using GRAS additives would be more favourable to the 
pharmaceutical industry, however, the knowledge gained from non-GRAS additives can be useful in 
helping to design an additive process with safe molecules. 
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Molecules that passed the molecular complementarity check were further examined for their 
possible interactions with PYR and their structural similarities. In PYR, the major growth is influenced 
by the interaction between the aromatic rings, causing the needle crystals most often observed. The 
rings stack on an angle along the crystallographic b axis and contributing to the growth on the fast 
growing faces (figure 1.32).  Therefore, molecules containing an aromatic ring were favoured as 
potential additives. For such aromatic ring-containing additives it is predicted they will cap the fast 
growing faces, interrupting the major growth mechanism of the crystal, and allowing the slower 
growing faces to catch up, resulting in shorter, fatter, more block shaped crystals. Finally, the 
possibility that any of the additives passing the complementary calculations were already known to 
form co-crystals with PYR was considered. Those that formed co-crystals were favoured as they are 
already known to interact well with the PYR molecules. In the context of morphology control 
targeted here, the additive wt% used should be low enough to avoid co-crystal formation. 
The final additive list chosen is shown in figure 6.2. 
 
Figure 6.2. Additive list for screening with PYR (a) benzoic acid, (b) trimesic acid, (c) imidazole, (d) benzimidazole, (e) 2,4-
dinitrobenzoic acid, (f) isonicotinamide, (g) isonicotinic acid, (h) nicotinic acid, (j) nicotinamide, (k) 3,5-dinitrobenzoic acid, 
(l) 2-aminobenzoic acid, (m) barbituric acid, (n) tartaric acid, (p) 2,2’-bipyridine and (q) 4,4’-bipyridine 
Co-former choices for co-crystal formation followed the same molecular complementarity 
calculations as used to determine additive candidates, which are in fact more generally used in the 
design of new co-crystalline materials. Prior to the complementarity calculations, the molecular 
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structure of PYR was examined to identify possible sites for hydrogen bonding and identify a 
potential list of co-formers to utilise.  
PYR has two major functional groups, three alcohol groups and a pyridine ring. This gives rise to 
three hydrogen bond donor sites, the three OH groups, and four hydrogen bond acceptors, the N in 
the ring and the three O atoms. The OH group directly bonded to the aromatic ring donates a 
hydrogen bond to the neighbouring OH group. Investigating the multi-component materials already 
published in the CSD can give further information on the hydrogen bonding nature of the target 
molecule. Less research has been published on PYR than was the case for IZN; a search within the 
CSD provides only 18 hits. This consists of 15 different materials, which includes 12 different co-
crystal structures and two halogenated salts. Of the reported co-crystals, all result from hydrogen 
transfer to the N in the aromatic ring forming co-crystalline salts.  Of the 12 co-crystalline salts 
formed, seven form with carboxylic acid containing co-formers and two are formed with alcohol 
containing co-formers. There are only three reported co-crystals with co-formers that have neither 
a carboxylic acid group nor a hydroxyl group. Analysis of the carboxylic acid containing co-crystals 
indicated that the predominant hydrogen bonding interaction occurs between the co-former 
carboxylic acid and the N in the pyridine ring. The main hydrogen bonding interactions seen in PYR 
co-crystal structures containing carboxylic acids are shown in figure 6.3. All interactions observed 
are chain link hydrogen bonding, with only one published co-crystal showing the bifurcated 
hydrogen bonding interaction (ii).  
 
Figure 6.3. Supramolecular synthons observed in PYR co-crystals in CSD 
From this analysis of published PYR co-crystal structures, an initial list of co-formers can be created. 
The common functional groups in published structures include alcohol, carboxylic acid and nitro 
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groups; all of these were incorporated into the initial co-former list, shown in figure 6.4. Due to the 
similarities in the hydrogen bonding between PYR and IZN, the majority of the co-formers used were 
the same in both cases. 
 
Figure 6.4. Co-formers used in multi-component crystallisation screening (a) isonicotinamide, (b) nicotinamide, (c) 
nicotinic acid, (d) imidazole, (e) benzimidazole, (f) 2,4-dinitrobenzoic acid, (g) 3,4-dinitrobenzoic acid, (h) 3,5-
dinitrobenzoic acid, (j) phthalic acid, (k) trimesic acid and (l) barbituric acid 
Polymer additives chosen for experiments with PYR are the same as those used for experiments 
with IZN (discussed in chapter 5; shown here in figure 6.5). The needle morphology of PYR 
predominantly resulting from aromatic interactions shows the potential for hydrophilic interaction 
along the long axis of the needle, with the potential for hydrophobic interactions on the capping 
faces. This suggests hydrophobic polymers could be utilised to cap the fast growing faces, preventing 
the major growth mechanism from occurring, allowing the crystals to become fatter and more 
equant in shape. A selection of hydrophobic and hydrophilic polymers was utilised to examine the 
effects of both on the morphology achieved. 
 
Figure 6.5. Polymer additives used (a) Polybutadiene, (b) polyvinylpyrrolidone, (c) poly(ethylene glycol), (d) 
poly(propylene glycol), (e) pluronic P123 and (f) poly(ethylene glycol) diglycidyl ether 
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The hydrophobic polymers employed are polybutadiene (PBD) and polypropylene glycol (PPG). The 
hydrophilic polymers are polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and poly(ethylene 
glycol) diglycidyl ether (PDE). The block co-polymer pluronic P123 (PP123) is amphiphilic and has 
both a hydrophilic and hydrophobic section. 
6.3  Experimental information 
All solvents and materials utilised in this research were obtained from commercial sources and used 
without any further purification being carried out.  
6.3.1  Additive and solvent experiments with pyridoxine 
6.3.1.1  Evaporative screening of pyridoxine with different solvents and additives 
Initial evaporative experiments were carried out using pure PYR in H2O, IPA and EtOH. 0.01 g of PYR 
was dissolved in a minimal amount of solvent in 7 mL vials. Holes were pierced in plastic lids and the 
vials left to evaporate at room temperature and 40 ⁰C.  
Evaporative crystallisations were also carried out with additives present. Small quantities of PYR 
(0.01 g) were dissolved in minimal solvent with the corresponding wt% of additive using a minimal 
amount of solvent. Holes were pierced in the plastic lids to allow slow evaporation. Evaporation was 
carried out at room temperature and an elevated temperature of 40 ⁰C. These experiments were 
carried out in IPA only. IPA was chosen arbitrarily as no influence of solvent was identified on the 
morphology of PYR. The additives were tested in wt% of 1%, 5% and 10%. 
Polymer additives were also investigated in evaporative crystallisation. 0.01 g of PYR with the 
corresponding wt% of additive were dissolved in 7 mL vials. The crystallisations were carried out in 
3 g of IPA. Holes were pierced in the lids of the vials to allow for slow evaporation at both room 
temperature and an elevated temperature of 40 ⁰C. Polymer additives were used in percentage 
mass ratios of 0.1% and 1%. 
6.3.1.2  Cooling crystallisation of pyridoxine with different solvents and additives 
Controlled cooling experiments were carried out for PYR in three different solvents: H2O, EtOH and 
IPA. A mass of 8 g for each solvent was saturated at 40 ⁰C with PYR. Crystallisations were carried out 
in 20 mL vials without magnetic bottom stirring to prevent breaking/grinding of the resulting 
crystals. Cooling rates of 1 ⁰C/minute and 0.1 ⁰C/minute were used with each solvent, with cooling 
occurring between 55 ⁰C and 5 ⁰C. Crystals were filtered at the end using a Buchner funnel and 
allowed to dry before analysis. 
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Cooling crystallisations were carried out with 1% wt ratio of additives. This percentage was chosen 
due to the success of this percentage in IZN crystallisations. Cooling experiments were carried out 
using cooling rates of 1 ⁰C/minute and 0.1 ⁰C/minute. 20 mL vials were used without any magnetic 
bottom stirring to prevent breaking/grinding of the resulting crystals. Crystals were filtered at the 
end using a Buchner funnel and allowed to dry before analysis. 
6.4  Multi-component experiments with pyridoxine 
6.4.1  Evaporative screening for pyridoxine co-crystals 
All evaporative crystallisations were initially carried out in 1:1 stoichiometric ratios of API and co-
former. 0.01 g of PYR and the corresponding mass of co-former were dissolved in minimal solvent 
in 7 mL glass vials. Solvents used were H2O, EtOH and IPA. Vials were sealed with PTFE lids with holes 
pierced in, to allow slow evaporation, and left to evaporate at both room temperature and 40 ⁰C. 
Experiments with trimesic acid (TRI) co-former were also repeated at 2:1 stoichiometry, in IPA, due 
to the formation of a new co-crystalline system of the same stoichiometric ratio. 
6.4.2  Pyridoxine single crystal structures 
Evaporative crystallisations of PYR in a 1:1 ratio with a number of co-formers resulted in the 
formation of new multi-component crystalline materials. Single crystal structures were determined 
for these new co-crystal materials. All structures were solved using ShelXS and refined using ShelXL 
within Olex2 software. Crystallographic data for all complexes are shown in table 6.1. 
(1) Pyridoxine with 2,4-dinitrobenzoic acid (PYR:2,4-DNBA)  
A 1:1 molar ratio of PYR (0.010 g) and 2,4-DNBA (0.012 g) were dissolved in IPA in a 7 mL glass vial. 
Evaporative crystallisation produced thick plate-shaped crystals. Single crystal data were collected 
using a Rigaku Oxford Diffraction Xcaliber diffractometer with Mo-Kα radiation (λ=0.70173 Å) at 
150 K.  
(2) Pyridoxine with 2,4-dinitrobenzoic acid (PYR:2,4-DNBA II)  
A second polymorph of PYR:2,4-DNBA was formed via slurrying form I in H2O. Single crystal data 
were collected using a Rigaku Oxford Diffraction Supernova diffractometer with Cu-Kα radiation 
(λ=1.5406 Å) at 150 K.  
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(3) Pyridoxine with 3,5-dinitrobenzoic acid (PYR:3,4-DNBA)  
A second complex was produced with PYR (0.010 g) and 3,5-DNBA (0.012 g). Evaporative 
crystallisation in H2O was carried out and produced block shaped co-crystals. Single crystal data 
were collected using a Rigaku Oxford Diffraction Xcaliber diffractometer with Mo-Kα radiation 
(λ=0.70173 Å) at 150 K.  
(4) Pyridoxine with trimesic acid (2PYR:TRI) 
The third novel co-crystal complex was formed from a 1:1 molar ratio of PYR (0.010 g) and TRI 
(0.012 g). However, the resulting crystal structure is a 2:1 co-crystalline salt. The crystal was 
produced via evaporative crystallisation from IPA and produced plate-shaped crystals. Single crystal 
data were collected using a Rigaku Oxford Diffraction Supernova diffractometer with Mo-Kα 
radiation (λ=0.70173 Å) at 150 K.  
(5) Pyridoxine with phthalic acid (PYR:PtA) 
The fourth novel co-crystal complex was formed from a 1:1 molar ratio of PYR (0.010 g) and TRI 
(0.0081 g). The structure shows a 1:1 stoichiometry and the plate-shaped single crystals were 
produced via evaporative crystallisation in EtOH. Single crystal data were collected using a Rigaku 







Table 6.1. Crystallographic parameters of newly discovered co-crystal structures formed with API PYR x 
 1 2 3 4 5 
Code PYR:2,4-DNBA I PYR:2,4-DNBA II PYR:3,5-DNBA PYR:TRI PYR:PtA 
Formula C15H15N3O9 C15H15N3O9 C15H15N3O9 C50H56N4O24 C16H17NO7 
M / g mol-1 381.30 381.30 381.30 1096.98 335.30 
T (K), radiation 150.00(10), Mo Kα 150.00(10), Cu Kα 150.01(10), Mo Kα 150.00(10), Mo Kα 150.00(10), Cu Kα 
Space group C2/c P1̅ P21/c P1̅ P21/n 
a (Å) 28.7601(13) 6.9759(3) 9.1930(19) 7.3526(4) 8.1175(2) 
b (Å) 12.6869(6) 9.6261(4) 14.1287(7) 17.3839(10) 12.1753(3) 
c (Å) 9.7150(4) 12.1988(4) 17.299(4) 20.0646(12) 15.0049(3) 
α (ᵒ) 90 82.507(3) 90 107.653(5) 90 
β (ᵒ) 111.029(5) 83.219(3) 135.54(4) 98.762(5) 90.353(2) 
γ (ᵒ) 90 86.892(3) 90 97.736(5) 90 
Volume (Å3) 3308.7(3) 805.85(6) 1573.7(9) 2370.4(2) 1473.87(6) 
Z 8 2 4 2 4 
ρcal/ g cm-3 1.531 1.571 1.609 1.537 1.511 
μ/ mm-1 0.129 1.145 0.136 0.124 1.018 
2Ө range/ᵒ 7.104-56.556 7.356-142.724 6.954-56.636 5.444-60.69 9.378-142.39 
Completeness 100% 100% 100% 100% 100% 
Refln. Collected 7185 4962 6347 22015 5216 
Independent refln.  3407 3051 3225 11992 2803 
Rint 1.76% 1.24% 2.86% 3.02% 2.49% 
GooF 1.029 0.968 1.044 1.031 1.041 
R1 (obs) 3.64% 3.41% 5.13% 5.93% 4.78% 
R1 (all) 5.07% 3.65% 8.28% 11.19% 5.36% 
%wR2 (all) 9.04% 9.70% 12.82% 15.94% 13.9% 
Ρmax,min/e Å-3 0.19/-0.23 0.23/-0.23 0.24/-0.27 0.44/-0.29 0.29/-0.37 
                                                          
x Molecular formula and molecular mass correspond to the asymmetric unit of the crystal structure 
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6.4.3  Further pyridoxine co-crystal preparation 
6.4.3.1  Mechanochemical grinding of pyridoxine co-crystals 
Grinding of PYR with successful co-crystallisation co-formers was carried out in a pestle and 
mortar. A small quantity of PYR (0.01 g) and the corresponding molar ratio of additive were 
ground together in both the absence of solvent and via liquid assisted grinding (LAG) for 30 
minutes. Grinding was carried out on a 1:1 ratio for 2,4-DNBA, 3,5-DNBA and PtA, and a 2:1 ratio 
was used for TRI. Solvents used for each LAG experiment corresponded to those used in the 
successful evaporative crystallisations. 
6.4.3.2  Pyridoxine co-crystal production via slurrying 
PYR and co-former in chosen stoichiometric ratios (1:1 molar ratio for 2,4-DNBA, 3,5-DNBA and 
PtA; 2:1 molar ratio of TRI) were weighed into a 7 mL glass vial. The amount of solvent added is 
crucial, it must allow the amount of solid used to be in excess in the solution, but not be enough 
to fully dissolve the material added to the vial. The solutions were continuously stirred at room 
temperature, using a magnetic bottom stirrer at 250 rpm, for 2 hours.  
6.4.3.3  Scale up of pyridoxine co-crystals using controlled cooling 
A Polar Bear Plus crystalliser was used to scale up production of the co-crystals. Scale up to 10 g 
and 30 g of solvent was carried out for all new multi-component materials.  
Each multi-component material was crystallised from a different solvent system: PYR:2,4-DNBA 
form I was crystallised from IPA; PYR:2,4-DNBA form II was crystallised in H2O; PYR:3,5-DNBA 
was crystallised in H2O; PYR:PtA was crystallised in EtOH; and PYR:TRI was crystallised in IPA. All 
solvents were saturated at Tsat = 40 ⁰C. For each different scale a different insert and vessel were 
used for the crystallisation: 20 mL glass vial with screw lid and 50 mL round bottom flask. The 
correct molar ratio of PYR and co-former were added to the vessel. In the glass vials magnetic 
bottom stirring at 700 rpm was used, whereas in the round bottom flasks overhead stirring at 
350 rpm was used. All solutions were heated to 55 ⁰C and held for 30 minutes to allow complete 
dissolution. Cooling was programmed at a rate of 1 ⁰C/minute to a minimum of 5 ⁰C and the 
system held for a further hour at that final temperature. 
6.4.4  Solubility determination of pyridoxine co-crystals 
Observational solubility techniques were used to determine the solubility of the co-crystals, 
using the Polar Bear Plus crystalliser. The heating profile used was set to heat from 5 ⁰C to 60 ⁰C 
at a rate of 0.3 ⁰C/minute. Using a 20 mL glass vial, 3 g of solvent was stirred at 700 rpm using a 
magnetic bottom stirrer. An initial mass of co-crystal was added to the stirring solution and 
observed as it was slowly heated. When the co-crystal had fully dissolved the temperature was 
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recorded and a second pre-determined mass added to the round bottom flask. This was 
repeated, recording the temperature and adding an additional amount of co-crystal every time 
full dissolution was observed. This method was repeated three times for each co-crystal system. 
The co-crystal solubility was determined in the solvent from which it was produced. 
6.4.5  Analytical methods 
Crystal images were taken using a Nikon Coolpix P5100 camera through a Brunel Microscopes 
microscope.  
Crystal structure data were collected using CrysAlisPro software and calculations and 
refinements were carried out using Olex2.0. Mercury software was utilized to analyse the 
structures of the new multi-component crystals. 
Face indexing was executed with CrysAlisPro software to determine the faces and overall shape 
of crystals produced. Crystal structure and morphology were visualized using the BFDH tool 
included in Mercury software.  
Analysis was also carried out via PXRD and DSC techniques in the manner outlined in Chapter 3.  
6.5  Solvent effects on pyridoxine morphology 
Crystallisations were carried out in three main solvents; H2O, EtOH and IPA. No form changes 
occurred in the solvents chosen (appendix A39) and no morphology changes were observed in 
either cooling crystallisation or evaporative crystallisation (figure 6.6 and 6.7, respectively). 
 
Figure 6.6. PYR morphology achieved in cooling crystallisations carried out in (a) H2O, (b) EtOH and (c) IPA 
 
Figure 6.7. PYR morphology achieved in evaporative crystallisations carried out in (a) H2O, (b) EtOH and (c) IPA 
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All crystallisations yielded very thin needle crystals with significant clumping observed. PYR thus 
shows significantly less susceptibility than IZN to influence from different solvents.  
6.6  Effect of additives on pyridoxine morphology 
6.6.1  Effect of size-matched and structurally similar additives in 
evaporative and cooling crystallisation 
A number of different additives were investigated in an attempt to change the morphology of 
PYR. The crystallisations were carried out in IPA. As no significant changes were observed in any 
particular solvent, IPA was chosen to remain in line with the experiments carried out with IZN. 
Optical microscopy analysis of the final crystals produced showed that all crystallisations 
resulted in needle crystals, as seen in the absence of additives (appendix A40). No morphology 
modifications have been achieved with any of the additives attempted. As no modifications can 
be seen for neither solvent nor size-matched additives, it stands that this form of morphology 
modification is not a viable route for influencing the growth morphology of PYR crystals.  
6.6.2  Effect of polymeric additives in evaporative and cooling 
crystallisation  
The polymeric additive experiments were carried out in both evaporative and cooling 
crystallisations, with the additives in both a 1% and 0.1% ratio. 
In cooling, neither percentage of additive resulted in a morphology change. Experiments carried 
out at 1 ⁰C/minute resulted in no crystallisation. The faster cooling rate does not give the system 
enough time to grow to an appropriate size before the end of the experiment. As the result, 
there are no images for these crystallisations. However, cooling at the slower rate of 
0.1 ⁰C/minute allows the crystals to grow sufficiently to allow the morphology to be observed 
(figure 6.8 and appendix A41). Again, no morphology modification is observed and only needle-




Figure 6.8. Cooling crystallisations of PYR with 0.1% polymer additives in IPA at rate of 0.1 ⁰C/minute. (a) PP123, (b) 
PEG, (c) PPG, (d) PBD, (e) PVP and (f) PDE 
Evaporative experiments also showed no changes in the morphology in the presence of the 
polymeric additives, neither at a 1% ratio nor a 0.1% ratio (figure 6.9 and 6.10 respectively). Only 
needle-shaped crystals were observed when evaporated at both 20 ⁰C (appendix A42 and A43) 
and 40 ⁰C.  
 
Figure 6.9. 40 ⁰C evaporative crystallisations of PYR with 1% polymer additives in IPA. (a) PP123, (b) PEG, (c) PPG, (d) 
PBD, (e) PVP and (f) PDE 
 
Figure 6.10. 40 ⁰C evaporative crystallisations of PYR with 0.1% polymer additives in IPA. (a) PP123, (b) PEG, (c) PPG, 
(d) PBD, (e) PVP and (f) PDE 
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None of the polymers attempted so far appear to have any effect on the morphology of the PYR 
crystals produced. This suggests their use for morphology modification is not worth pursuing for 
PYR crystallisations. However, further investigations could be carried out with other polymers 
to rule the approach out entirely. In addition, other methods of crystallisation could be 
attempted, including temperature cycling, if this route of modification were to be investigated 
further.  
6.7  Multi-component crystallisations with pyridoxine 
6.7.1  Crystallisation of pyridoxine with 2,4-dinitrobenzoic acid 
A successful co-crystallisation was achieved from a 1:1 ratio of PYR and 2,4-DNBA (figure 6.11) 
in IPA.  
 
Figure 6.11. Structure of PYR and 2,4-DNBA showing the numbering system used in hydrogen bonding discussions 
The new form crystallises in the monoclinic C2/c space group (figure 6.12). The asymmetric unit 
contains one PYR and one 2,4-DNBA molecule. Proton transfer occurs between the two 
molecules, resulting in a deprotonated carboxylic acid group on the 2,4-DNBA and a protonated 




Figure 6.12. Unit cell of co-crystal PYR:2,4-DNBA 
The PYR molecules stack on a diagonal with a slight overlap of the aromatic rings in their 
structure (figure 6.13, left). The 2,4-DNBA molecules also stack on a diagonal with again an 
overlap of their aromatic rings, forming the layers within the structure. Two asymmetric units, 
each consisting of one PYR and one 2,4-DNBA molecule, on two different layers are hydrogen 
bonded together to form a ring structure (figure 6.13, right). Each ring is then hydrogen bonded 
to the next via a chain link to the next asymmetric unit on the same level.  
 
Figure 6.13. Hydrogen bonding interactions present in PYR:2,4-DNBA co-crystal showing the nature of the stacking  
The hydrogen bonding network within the structure is reasonably simple, with only four 
different interactions occurring (table 6.2). Bifurcated hydrogen bonds allow the ring structure 
to form within the structure. Each 2,4-DNBA carboxylic acid group accepts a hydrogen bond from 
two different PYR molecules, O3-H∙∙O4 from one PYR molecule and O2-H∙∙O4 from a second 
molecule. These hydrogen bonds are then repeated with a second 2,4-DNBA molecule, 
ultimately creating a four membered ring (shown in figure 6.13). The ring exists on two different 
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layers, with the PYR molecules in one and the 2,4-DNBA molecules being above and below. Chain 
link hydrogen bonds connect the rings together between the N in the PYR ring and the 2,4-DNBA 
carboxylic hydroxyl. Proton transfer occurs in this interaction, resulting in a protonated PYR 
molecule and a 2,4-DNBA molecule with a deprotonated carboxylic acid group. This proton 
transfer can be confirmed by analysis of the hydrogen bonding distances: N+∙∙H has a distance 
of 0.97(2) Å and the O∙∙H has a distance of 1.74(2) Å, confirming salt formation. These chain link 
hydrogen bonds are in the same plane as the PYR molecules, in comparison to the ring hydrogen 
bonds which are perpendicular to the plane of the PYR molecules. This is possible due to the 
geometry of the carboxylic acid groups in the 2,4-DNBA with respect to the hydroxyl groups in 
the PYR molecule. The O2 hydroxyl group in the PYR molecule has a fixed geometry due to an 
intramolecular hydrogen bonding interaction. This interaction exists between O1-H∙∙O2, 
ensuring the geometry of the PYR molecule remains planar. 
Table 6.2. Hydrogen bond distances and angles for PYR:2,4-DNBA co-crystal xi 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O2-H∙∙O42 0.89(2) 1.76(2) 2.646(2) 170(2) 
O3-H∙∙O4 0.85(2) 1.87(2) 2.714(2) 175(2) 
O1-H∙∙O2 0.89(2) 1.69(2) 2.520(2) 155(2) 
N1-H∙∙O51 0.97(2) 1.74(2) 2.715(1) 175(2) 
Characterisation of the bulk product was carried out using PXRD and DSC techniques. 
 
Figure 6.14. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) PYR:2,4-DNBA co-crystal calculated from 
SCXRD data and (d) PYR:2,4-DNBA co-crystal from evaporative crystallisation in IPA 
                                                          
xi 1+X,1-Y,1/2+Z 2-X,1-Y,1-Z 
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The new co-crystal system is confirmed by the PXRD pattern for the sample (figure 6.14). The 
experimental PXRD pattern (d) is significantly different to that of the two starting materials. The 
experimental pattern also matches the calculated pattern for the co-crystal structure. Some 
subtle differences can be seen between the two patterns as a result of the temperatures the 
experiments were carried out at. PXRD experiments were carried out a room temperature, 
whilst SCXRD was carried out at 150 K. The crystal structure is slightly contracted at the lower 
temperatures resulting in a slight expansion of the 2Ө values in the calculated pattern. There 
are no obvious unassigned peaks in the experimental pattern corresponding to any starting 
material. Phase purity can be considered relatively high in this crystallisation. 
Thermal analysis by DSC, also confirms the formation of a new co-crystalline structure (figure 
6.15). 
 
Figure 6.15. DSC trace of co-crystal PYR:2,4-DNBA. PYR melting point = 159-162 ᵒC 166, 2,4-DNBA melting point = 
182 ᵒC 210 
DSC analysis produces an endothermic peak at about 140 ⁰C, yielding the melting point of the 
new co-crystal structure. This is at a different temperature to the melting points of the two 
starting materials, confirming the formation of the new structure. The high phase purity is also 
confirmed due to the absence of any peaks relating to the starting materials, suggesting 
conversion to the co-crystal was complete, and the sharpness of the melting peak. A small, broad 
exothermic peak occurs after the initial melt. This broad exotherm is similar to that observed in 
the DSC of the IZN:3,4-DNBA complex reported in chapter 5. It was hypothesized the endotherm 
was as a result of a decomposition of the nitro groups in the co-former. The similarity here could 
help confirm this hypothesis. Due to the broad nature of the peak it is unlikely this peak is the 
result of a recrystallisation. The nature of the exothermic peak could be confirmed using HSM. 
Mechanochemical grinding experiments carried out appear to show some successful formation 
of the co-crystal in DSC and PXRD analysis (appendix A44 and A45). The grinding experiment in 
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the absence of solvent shows peaks corresponding to both the starting materials and the new 
co-crystal form. The LAG experiments using IPA show better conversion of starting materials to 
the co-crystal. The peaks corresponding to the starting materials reduce in intensity and the co-
crystal peaks have increased in intensity. Full conversion has not been achieved in either case, 
although the presence of some conversion could suggest grinding for increased periods of time 
could result in full conversion. Attempts to make the co-crystal via slurry experiments in IPA 
were successful, with full conversion of starting materials to new co-crystal form. In addition, 
controlled cooling crystallisation was achieved on 10 g and 30 g solvent scales (appendix A46).  
The solubility of the co-crystal was determined via observation methods (figure 6.16). The co-
crystal and the pure PYR have a monotropic relationship in IPA with the co-crystal solubility 
being significantly lower than that of pure PYR in IPA, suggesting the co-crystal is highly stable. 
This stability is further confirmed by the difficulties arising when attempting to form the co-
crystal via cooling crystallisation. Initial attempts were unsuccessful as the starting materials 
converted to the co-crystal too quickly to allow for complete dissolution. The increased 
hydrogen bonding interactions are likely responsible for the increased stability. The ease of 
formation of the co-crystal suggests the hydrogen bonds within the co-crystal are highly 
favoured in comparison to those found in the pure PYR crystal structure; the strength of the 
hydrogen bonding interactions is expected to have increased from the pure PYR structure to the 
co-crystalline structure. A decrease in solubility is not often favoured in the pharmaceutical 
industry, due to the probable reduction this causes in the bioavailability of the drug. However, 
reduction in solubility is potentially advantageous in pharmaceuticals that require slow release, 
if it is linked to dissolution rate. Fast dissolution can result in dosages needing to be taken in 
quick succession, meaning lower solubility could be a benefit to highly water-soluble 




Figure 6.16. Solubility plot for PYR:2,4-DNBA co-crystal (purple, circle marker) and pure PYR (black, square marker) 
from observation in IPA 
In order to determine the stability of the new co-crystalline form, three different experiments 
were carried out (figure 6.17). Samples were stored at an elevated temperature of 50 ⁰C and in 
a 70% humidity chamber for extended periods of time and also slurried continuously in H2O at 
40 ⁰C. 
 
Figure 6.17. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) PYR:2,4-DNBA form I calculated from 
SCXRD, (d) PYR:2,4-DNBA form I slurry 1 week, (e) PYR:2,4-DNBA form I 50dc 3 weeks and (f) PYR:2,4-DNBA form I 
humidity 9 weeks 
No changes in the PXRD pattern were observed for the samples subjected to elevated 
temperature or humidity. This form of the co-crystal is stable up to three weeks under both 
these conditions. However, a change in the sample taken from the slurry in H2O after 6 hours 
shows a change in the PXRD pattern to a potential new form. This pattern was maintained up to 
the week limit of the slurry. The new PXRD pattern does not match the peaks seen in the starting 
material patterns shown below, ruling out a break-down of the co-crystal form to its single 
 
205 
molecule counterparts. The product is therefore likely to be a new form of the PYR:2,4-DNBA 
co-crystal. This new crystal could be a number of potential forms: a hydrate, formed from the 
continuous slurrying in H2O, a new polymorph of the original co-crystal or a co-crystal consisting 
of a different stoichiometry. To determine the nature of the new co-crystalline form DSC analysis 
and SCXRD experiments were carried out (discussed in section 6.7.2.) 
The PYR-2,4-DNBA co-crystal from IPA shows a significant change in morphology from the 
needles previously seen in PYR crystallisations (figure 6.18). These are fattened, with a much 
improved aspect ratio when compared to a needle. However, it is difficult to describe the shape 
of the crystals as they all have significant irregularities. 
 
Figure 6.18. Thickened crystals of PYR:2,4-DNBA form I co-crystal crystallised from IPA 
Face indexing the crystals also posed significant difficulties due to the size of the crystals 
produced. Most crystals were too big to be able to face index properly. This resulted in smaller, 
likely broken crystals having to be face indexed to determine which faces are present in the new 
co-crystal system.  
 




The BFDH predicted morphology is similar in shape to that of a number of crystals observed in 
figure 6.17. The predicted shape is also very similar to that achieved from face indexing crystals 
from the sample (figure 6.19). The experimental morphology has an extra plane of faces, (-105) 
and (10-5), which could be the result of breakages in the crystals. The hydrogen bonding 
interactions contribute to the growth on both the (-105) / (10-5) set and the (-100) / (100) set. 
The (-100) and (100) faces are parallel to the crystallographic c axis and this direction is where 
the most significant growth occurs. As well as the hydrogen bonding interactions present on the 
surface of this face there is some influence from the interactions between aromatic rings within 
the structure. The overlap between the π systems is limited, due to the offset of the positions 
of the aromatic rings, but, there is likely still to be some influence from these interactions 
allowing the faster growth on the (-100) and (100) faces.  
The morphology of the co-crystals produced here is a substantial improvement on the needle 
crystals previously produced for pure IZN, suggesting that co-crystallisation could be a viable 
solution for improving the morphology of PYR. 
6.7.2  Determining the structure of the second polymorph of the PYR:2,4-
DNBA co-crystal 
Due to the change in the PXRD pattern after slurrying the PYR:2,4-DNBA co-crystal in H2O for 24 
hours, a SCXRD experiment was carried out to determine the nature of the possible new form 
produced.  
 
Figure 6.20. Unit cell of PYR:2,4-DNBA form II co-crystal 
The second form crystallises in the triclinic P1̅ space group, with an asymmetric unit containing 
one PYR and one 2,4-DNBA molecule (figure 6.20).  
The PYR molecules are all in plane with each other, with the 2,4-DNBA molecules at an, 
approximately, 45ᵒ angle to those (figure 6.21). This differs from the original polymorph 
observed, in which the PYR and 2,4-DNBA molecules remain in the same plane. The aromatic 
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ring centers of the PYR molecules overlap in an alternating step pattern due to the inversion 
center present in the structure. The two asymmetric units are hydrogen bonded together to 
form a 4 membered ring system, with the center of inversion in the middle. The same ring type 
hydrogen bonding structure is seen in the original polymorph, with slightly different bonding 
distances and angles between the molecules.  These ring systems are then hydrogen bonded to 
each other via donation from a PYR molecule in one ring system to a 2,4-DNBA molecule in the 
neighbouring system. 
 
Figure 6.21. Hydrogen bonding interactions present in PYR:2,4-DNBA form II co-crystal showing the ring interactions 
formed between the API and co-former and the chain links between the rings. 
The hydrogen bonding network within this new polymorphic structure remains simple, with only 
four different interactions occurring within the structure (figure 6.21; table 6.3). The hydrogen 
bonding closely mimics that observed in polymorph I, with some subtle differences as the result 
of the change in the orientation of the PYR molecules (numbering system used is the same as 
shown in figure 6.11). A bifurcated hydrogen interaction is present with O5 at the center, 
allowing the ring system to form. The 2,4-DNBA carboxylic acid group donates a hydrogen to the 
N in the PYR ring, O5∙∙H-N, and simultaneously accepts a hydrogen bond donated from O3 in a 
second PYR molecule, O3-H∙∙O5. This differs from that observed in form I, where the carbonyl 
group (O4) accepts a hydrogen bond donation from an OH group on two different PYR 
molecules. In form I the N within the PYR ring is not involved in the bifurcated hydrogen bond 
or the formation of the 4-membered hydrogen bonded ring system. The molecules present in 
the ring systems formed in form II do not lie within the same plane, as is seen in form I; the 2,4-
DNBA molecules are twisted by approximately 45ᵒ. The hydrogen bond connecting the rings 
together forms between the remaining alcohol group on the PYR molecules and the carbonyl 
group on a 2,4-DNBA molecule in the neighbouring ring formation, O2-H∙∙O4. This interaction in 
form I involves the donation of the H from the carboxylic acid group within the 2,4-DNBA 
 
208 
molecule to the N in the PYR ring. The final hydrogen bonding interaction observed within the 
structure is the intramolecular hydrogen bond within the PYR molecule, O1-H∙∙O2.  
Table 6.3. Table of distances and angles for PYR:2,4-DNBA form II co-crystal xii 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
N1-H∙∙O51 0.93(2) 1.84(2) 2.753(1) 163(2) 
O3-H∙∙O52 0.88(2) 1.83(2) 2.706(1) 163(2) 
O1-H∙∙O2 0.91(2) 1.74(2) 2.549(1) 148(2) 
O2-H∙∙O4 0.91(2) 1.72(2) 2.630(1) 179(2) 
The structure of form II sees the same hydrogen transfer as observed in form I, with differing 
hydrogen bonding distances. In form II the N∙∙H distance is 0.93(2) Å and the O∙∙H distance is 
1.86(2) Å, confirming the formation of the salt and transfer of the hydrogen. In form I, the 
distances are N∙∙H, 0.97(2) Å and O∙∙H, 1.74(2) Å. The slightly decreased N∙∙H distance and slightly 
increases O∙∙H distance in form II suggests the H is held more strongly by the N in this structure. 
This could potentially be the result of the H transfer taking part in the bifurcated hydrogen 
bonding interaction within the ring in form II but not in form I. 
A comparison of the calculated PXRD pattern for the above crystal structure and that of the bulk 
formed in the stability slurry test was made to ensure the single crystal picked out of the sample 
was representative of the bulk product (figure 6.22). 
 
Figure 6.22. PXRD data for (a) PYR:2,4-DNBA form I calculated from SCXRD, (b) PYR:2,4-DNBA form II calculated from 
SCXRD and (c) PYR:2,4-DNBA form II co-crystal from slurry of PYR:2,4-DNBA form I in H2O 
Comparison of the PXRD patterns confirms the bulk product from slurrying matches that 
predicted from the SCXRD data for the crystal selected. This confirms that slurrying PYR:2,4-
                                                          
xii 11-X,2-Y,-Z 2+X,1+Y,+Z 
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DNBA form I in H2O at 40 ᵒC for 6 hours facilitates the conversion to PYR:2,4-DNBA form II. This 
suggests the second form found is the more thermodynamically stable form. 
DSC analysis was carried out in an attempt to confirm the more thermodynamically stable of the 
two polymorphs and determine the melting point of the newly discovered form II (figure 6.23).  
 
Figure 6.23. DSC trace of co-crystal PYR:2,4-DNBA form II (solid black line) compared to form I (dotted purple line). 
PYR melting point = 159-162 ᵒC 166, 2,4-DNBA melting point = 182 ᵒC 210 
The trace shows a sharp endothermic peak at 140 ⁰C, corresponding to the melt of the new 
polymorphic form. No peaks corresponding to the melt temperatures of the starting materials 
are observed in the trace. The melt peak falls at the same temperature as that of form I of the 
co-crystal, making determination of the thermodynamically stable polymorphs difficult via this 
method. When closely inspecting the two traces, a slight decrease in the onset of the melt from 
form I to form II has been observed. Although the melting points are very close to each other, 
this could possibly suggest that form I may be slightly more thermodynamically stable than form 
II. However, this is in contrast to the prediction made based on the conversion to form II during 
slurry experiments. A similar situation to this was recently discussed in polymorphic co-crystals 
of the material urea-barbituric acid, where form I and form III show very similar thermal 
events.212  
Formation of form II was attempted in evaporative, in order to determine the morphology, and 
cooling crystallisations. The products from initial evaporative crystallisations set up in H2O were 
not tested using PXRD and DSC due to an amorphous oil like substance being formed. As a result, 
cooling crystallisations were used to determine the morphology of the new crystal form.  
Cooling crystallisation from H2O yielded form II of the co-crystal with a high level of purity (figure 
6.24). Cooling was carried out in an identical manner to the scale up crystallisations in IPA, which 




Figure 6.24. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) PYR:2,4-DNBA form II co-crystal calculated 
from SCXRD data and (d) PYR:2,4-DNBA co-crystal form II from cooling crystallisation in H2O 
Mechanochemical grinding experiments carried out appear to show some successful formation 
of the form I co-crystal in DSC and PXRD analysis. The experiments were repeated for form II 
(appendix A47). The PXRD analysis shows that grinding the starting materials in the absence of 
solvent does not form either of the two forms, producing only a mixture of the starting materials. 
The LAG experiments were carried out in H2O and again in IPA. Both LAG experiments show the 
formation of form I as the major component. Attempts to make the co-crystal via solvent-
mediated methods were more successful. Slurrying the starting materials in H2O produced form 
II of the co-crystal purely and controlled cooling on both 10 g and 30 g scales in H2O also yielded 
form II of the co-crystal (appendix A48).   
The solubility of the new polymorphic form was determined via observation methods, in H2O 
(figure 6.25). Form II also shows a monotropic relationship with pure PYR in H2O, with the co-
crystal solubility being significantly lower. This suggests the co-crystalline form is very stable. 
The hydrogen bonding interactions are very similar between form I and form II and are likely 
responsible for the elevated stability. This polymorph forms with ease in H2O crystallisations, 
indicating the hydrogen bonds within the co-crystal are highly favoured: the strength of the 
hydrogen bonding interactions is expected to have increased from the pure PYR structure to the 
co-crystalline structure. As previously discussed, a decrease in solubility is not often favoured in 
the pharmaceutical industry, however, reduction in solubility is potentially advantageous in 




Figure 6.25. Solubility plot for PYR:2,4-DNBA form II co-crystal (purple, circle marker) and pure PYR (black, square 
marker) from observation in H2O 
The stability of the new polymorph was also analysed using the three different methods (figure 
6.26). No change was observed in the PXRD data in any of the humidity studies carried out. After 
3 weeks, samples taken from the humidity chamber and those from elevated temperature 
studies remain as form II of the co-crystal. After slurrying the form II co-crystal in H2O for 1 week 
no changes in the form was observed and no breakdown of the co-crystal has occurred. This is 
in contrast to the transformation observed when form I is slurried in H2O; after 6 hours of slurry 
in H2O form I transforms to form II. This suggests that form II is more stable than the originally 
discovered form I. Under the stability experiments carried out no breakdown of the co-crystal 
can be detected, suggesting the form is stable for a prolonged period of time.  
 
Figure 6.26. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) PYR:2,4-DNBA form II calculated from 
SCXRD, (d) PYR:2,4-DNBA form II slurry 1 week, (e) PYR:2,4-DNBA form II 50dc 3 weeks and (f) PYR:2,4-DNBA form II 
humidity 9 weeks 
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The new polymorphic form of the co-crystal could not be made via evaporative crystallisation in 
H2O; form I was instead achieved. As a result, cooling crystallisation had to be used to determine 
the morphology of this polymorphic form. The morphology achieved (figure 6.27) is significantly 
different to the needles usually seen for pure PYR and closely resembles that of the form I co-
crystals produced in IPA. The shape is fatter than a needle, with a much improved aspect ratio, 
but is hard to describe due to the irregular nature of the crystalline product.   
 
Figure 6.27. Irregular shaped crystals of PYR:2,4-DNBA form II from cooling in H2O 
As a result, face indexing the crystals posed similar difficulties to those seen in the form I co-
crystals. Most crystals were too large or broken to be successfully indexed. An attempt was 
made, but it is unlikely to be representative of all the crystals in the bulk sample. However, the 
results give an idea of which faces are important in the new co-crystalline form (figure 6.28). 
 
Figure 6.28. Predicted BFDH morphology for PYR:2,4-DNBA form II (left); observed morphology for PYR:2,4-DNBA 
form II (right) 
The predicted morphology shows a block shaped crystal. The molecules in the structure are 
orientated in the same plane as the (011) and (0-1-1) faces, albeit on a slight angle. As a result, 
the hydrogen bonding groups extend from the molecules towards the (-100) and (100) faces, 
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the fastest growing faces in the crystal structure. However, most of the hydrogen bonds are not 
in the same plane as the molecules. The hydrogen bonds contribute also to the growth of the 
surrounding faces. This is likely the reason for the more block shaped crystal predicted by BFDH 
calculations. If any aromatic interactions are present in this crystal structure, their contribution 
would be to the growth of the (011) and (0-1-1) faces. However, due to the angles of the 
molecules, no complete overlap is likely to be present. The experimental morphology is similar 
to the calculated morphology. The slower growing, surrounding faces are the same as observed 
in predicted morphology. The major difference in the two shapes is the (-100) and (100) faces, 
these are not observed in the experimental morphology. The likelihood of that the capping faces 
have broken in the process of removing the crystals from the vial and mounting them on the 
goniometer is high, potentially distorting the shape of the experimental crystal. The high 
similarity in general suggests the prediction is good for this co-crystalline form. The suggestion 
from face indexing is the final morphology achieved would be favourable for pharmaceutical 
applications due to the increased block like nature of the crystals produced.   
6.7.3  Identifying the thermodynamically stable polymorphic form of the 
PYR:2,4-DNBA co-crystal 
In an attempt to determine the thermodynamically stable polymorph, two experiments were 
carried out. First, additional solubility measurements were made for both forms in the solvent 
system from which it was not initially crystallised, form I in H2O and form II in IPA, for comparison 
(figure 6.29). 
 
Figure 6.29. Solubility of PYR:2,4-DNBA form I (black) and form II (purple) in H2O (left) and IPA (right) from 
observation methods 
In both solvents, the polymorph with the lower solubility is form II. This suggests form II is the 
more thermodynamically stable of the two polymorphs. In H2O, the solubility of the two 
different forms is almost indistinguishable and likely falls within the error of the measurements. 
In IPA, the differences are more noticeable, with the solubility difference seeming to increase 
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with increasing temperature. The solubility measurements for the forms do not cross over 
throughout the temperature range sampled, suggesting the polymorphs have a monotropic 
relationship with each other. The solubility data does not give any indication as to why form I 
can be formed selectively from crystallisations in IPA and form II can be formed selectively from 
crystallisations in H2O; understanding these further would involve more detailed kinetic 
considerations in the nucleation and crystallisation process. 
The second experiment carried out was competitive slurrying of the two polymorphic forms in 
both IPA and H2O. The experiments were carried out at 20 ⁰C. Over time, it is expected that the 
metastable polymorph would convert to the thermodynamically stable form. Competitive slurry 
experiments allow this process to be expedited due to the solvent medium, the use of a 
continuous stirring environment.  
After slurrying the two forms together for 2 hours, complete transformation from the initial 
mixture to form II was achieved (figure 6.30). Form II is therefore determined to be the 
thermodynamically stable form.  
 
Figure 6.30. PXRD data for (a) PYR:2,4-DNBA form I calculated from SCXRD, (b) PYR:2,4-DNBA form II calculated from 
SCXRD, (c) competitive slurry of 1:1 form I:form II mixture in IPA and (d) competitive slurry of 1:1 form I:form II 
mixture in H2O 
Due to the very rapid conversion in competitive slurry methods further experiments were 
carried out that, hopefully, have a slower conversion time. To achieve this, the two forms were 
mixed together in the absence of any solvent medium and sampled every 24 hours. In addition, 
the two forms were ground together to determine whether phase transformations can occur 
using this method. Co-grinding the two forms together also results in conversion to form II of 




Figure 6.31. PXRD data for (a) PYR:2,4-DNBA form I calculated from SCXRD, (b) PYR:2,4-DNBA form II calculated from 
SCXRD, (c) mixture of form I and form II after 3 months and (d) co-grinding experiment of 1:1 form I:form II PYR:2,4-
DNBA co-crystal 
The forms remain stable for a long period of time when isolated from one another, as well as 
when kept as a physical mixture; further suggesting the thermodynamic stability of both forms 
is very similar.  The conversion to form II appears to be favourable when the system is ground 
together, the addition of energy allowing complete conversion. Fast conversion is also observed 
in solvent-mediated slurry experiments, when both forms are present and when form I is slurried 
in H2O. This suggests that form II is the thermodynamically stable form. It is unknown for how 
long form I can remain stable in the dry physical mixture, however, experiments suggest it would 
remain stable for an extended period of time unless given some form of energy to allow for the 
conversion.  
6.7.4  Crystallisation of pyridoxine with 3,5-dinitrobenzoic acid 
A second successful co-crystallisation was achieved with a 1:1 ratio of PYR:3,5-DNBA (figure 
6.32). 
 
Figure 6.32. Structure of PYR and 3,5-DNBA showing the numbering system used in hydrogen bonding discussions 
 
216 
This new co-crystalline form crystallises in the monoclinic P21/c space group, with an asymmetric 
unit consisting of one PYR and one 3,5-DNBA molecule.  
 
Figure 6.33. Unit cell of co-crystal PYR:3,5-DNBA 
The packing of the co-crystal is made up of discrete sheets of molecules in the crystallographic 
bc plane (figure 6.33). These sheets of molecules stack on top of each other in the direction of 
the a axis as a result of the overlap of the aromatic rings present in the two molecules. The ring 
overlap alternates between the two molecular species throughout the structure, ∙∙PYR∙∙3,5-
DNBA∙∙PYR∙∙. No hydrogen bonds exist between the discrete sheets, with π-ring overlap and 
other intermolecular interactions being responsible for holding the layers together. All the 
molecules within the structure are in the same plane, with all the hydrogen bonding interactions 
existing within this plane (figure 6.34). Each PYR molecule is surrounded by, and hydrogen 
bonded to, three different 3,5-DNBA molecules. In return, each 3,5-DNBA molecule is hydrogen 
bonded to three different PYR molecules. 
 
Figure 6.34. Hydrogen bonding interactions present in PYR:3,5-DNBA co-crystal showing the discrete layers of 




The hydrogen bonding network within this structure is relatively straightforward to describe, as 
all the interactions exist within the same plane (figure 6.34). An internal hydrogen bond is 
present within the PYR molecule between two hydroxyl groups, O1-H∙∙O2. This intramolecular 
interaction helps fix the geometry of the PYR molecules and maintains their planar 
conformation. A bifurcated hydrogen bond interaction exists between the N in the PYR ring and 
the carboxylic acid group in the 3,5-DNBA. Hydrogen transfer is again observed in this structure, 
with the bond distances (table 6.4) confirming the proton presence on the PYR ring: The N1-H 
distance is 1.03(3) Å and the H∙∙O distance is 1.60(3) Å. The transfer appears less distinct in this 
structure, with a slightly elongated N-H distance in comparison to the other structures 
previously discussed.  The data has quite significant ESDs associated with these bond lengths, 
resulting in a large possible distance range for the hydrogen to sit in. Ultimately, it is not possible 
to state exactly where the hydrogen is residing. Further hydrogen bonds are donated from each 
of the PYR hydroxyl groups to two separate co-former molecules. The second hydroxyl group 
donates a hydrogen bond to the deprotonated carboxylic acid group, O2-H∙∙O4, and the third 
hydroxyl group donates a hydrogen bond to the nitro-group of another co-former molecule, O3-
H∙∙O(Nitro3). Similar hydrogen bond interactions between a nitro group and the PYR molecule 
are observed in other co-crystal structures consisting of co-formers containing nitro-groups. All 
three of the reported PYR structures in the CSD containing co-formers including nitro-groups 
show a similar interaction to that observed here, but this interaction is not seen in the PYR-2,4-
DNBA structure. The presence of this interaction is likely the result of the differing geometry of 
the nitro-groups in the co-former molecule. There are five different hydrogen bonding 
interactions within this structure, however, none exist between the same molecular entity. 
Table 6.4. Hydrogen bond distances and angles for PYR:3,5-DNBA co-crystal xiii 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O1-H∙∙O2 0.91(3) 1.74(3) 2.569(2) 149(3) 
O2-H∙∙O42 0.83(3) 1.80(3) 2.600(2) 162(3) 
N1-H∙∙O41 1.03(2) 1.60(3) 2.626(3) 172(3) 
 
  
                                                          
xiii 11-X,1-Y,2-Z 21-X,1/2+Y,3/2-Z 
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Analysis via PXRD and DSC, confirms the bulk of material produced in the crystallisation has 
formed the new co-crystal structure. 
 
Figure 6.35. PXRD data for (a) PYR (BITZAF), (b) 3,5-DNBA form I (CUKCAM01), (c) pure 3,5-DNBA form II 
(CUKCAM02), (d) 3,5-DNBA hydrate (OKEMAT), (e) PYR:3,5-DNBA co-crystal calculated from SCXRD data and (f) 
PYR:3,5-DNBA co-crystal from evaporative crystallisation 
The calculated and experimental PXRD patterns show the same peaks across the 2Ө value range 
(figure 6.35). At higher 2Ө values there is a slight disagreement between the peaks due to the 
differences in temperature at which the samples were analysed; the low 150 K analysis 
temperature for SCXRD results in a shift along the 2Ө axis. The agreement between the two 
patterns suggests there are no unassigned peaks in the experimental PXRD corresponding to any 
unconverted starting material. The phase purity of the sample can, therefore, be considered 
relatively high.  
 
Figure 6.36. DSC trace of PYR:3,5-DNBA co-crystal. PYR melting point = 159-162 ᵒC 166,  3,5-DNBA melting point = 
204-206 ᵒC 213 
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DSC analysis shows one endothermic peak at 152 ⁰C, giving the melting point of the new co-
crystalline form (figure 6.36). The melting point is very similar to that of pure PYR, causing the 
DSC analysis alone to be insufficient to confirm the conversion to a new crystalline form. The 
peak is sharp, suggesting purity, but due to the closeness of the melting temperatures it is a less 
clear indicator. No endothermic peak is observed at around 205-207 ⁰C, strongly indicating the 
full incorporation of the co-former into the co-crystalline structure. A small, broad exotherm is 
again observed after the initial melt of the co-crystal. As previously discussed, this could be due 
to decomposition of the nitro-groups in the co-former. This exothermic peak has been observed 
in all three co-crystals containing the dinitro-groups; the continued appearance in co-crystals 
containing dinitro groups increases the probability the hypothesis is correct. 
Again, the mechanochemical grinding of the starting materials showed some success in forming 
the co-crystal (appendix A49 and A50). Grinding in the absence of solvent shows three 
endothermic peaks corresponding to the melting points of both the starting materials and the 
new co-crystal form. The LAG experiment still shows three peaks, however, those relating to the 
starting materials are significantly reduced in their intensity. Better conversion of starting 
materials to co-crystal was thus achieved using LAG methods, the presence of solvent clearly 
aiding the conversion. Full conversion was not achieved in the time frame of the grinding carried 
out, but with an increased grinding time full conversion may be possible. Slurry experiments 
were also successful in forming the co-crystal system, with good conversion and high phase 
purity achieved. In addition, controlled cooling crystallisation was achieved on 10 g and 30 g 
solvent scales (appendix A51).  
Determination of the co-crystal solubility, again by observation methods, shows a substantial 
reduction in comparison to the pure PYR crystals (figure 6.37). Solubility determination for the 
PYR:3,5-DNBA co-crystal was carried out in H2O. The lower solubility is indicative of a stable 
structure forming. The favourable nature of this co-crystal was also confirmed by the rapid 
precipitation of the new multi-component crystal structure from solution at higher 
temperatures, before the intended cooling could commence in initial cooling experiments. As a 
result of this precipitation, slurries were initially used to create bulk products of the co-crystal; 
achieving full dissolution without solubility data proved difficult. The reduction in solubility, in 
addition to the ease of formation, suggests the hydrogen bonding interactions in the co-crystal 
are stronger and more favoured than those in the pure PYR co-crystal, resulting in their 
formation in preference to the pure PYR crystal. Despite crystal engineering usually being 
utilised to increase the aqueous solubility of poorly soluble APIs, the reduction in solubility for 




Figure 6.37. Solubility plot for PYR:3,5-DNBA co-crystal (purple, circle marker) and pure PYR (black, square marker) 
from observation in H2O 
The stability of the 3,5-DNBA co-crystal was determined using slurry, elevated temperature and 
humidity studies (figure 6.38). 
 
Figure 6.38. PXRD data for (a) PYR (BITZAF), (b) 3,5-DNBA form I (CUKCAM01), (c) 3,5-DNBA form II (CUKCAM02), (d) 
3,5-DNBA hydrate (OKEMAT), (e) PYR:3,5-DNBA co-crystal calculated from SCXRD, (f) PYR:3,5-DNBA co-crystal slurry 
1 week, (g) PYR:3,5-DNBA 50 ⁰C 3 weeks and (h) PYR:3,5-DNBA 70 % humidity 9 weeks. 
The PXRD patterns for samples taken from the slurry solution after 1 week, the humidity study 
after 3 weeks and the elevated temperature after 3 weeks all matched the initial pattern taken 
for the co-crystalline sample. The patterns do not show any degradation of the samples after 
the allocated periods of time, indicating the new co-crystalline product is stable under these 
conditions. This is a good indication in the case of elevated temperature and humidity studies 
that the co-crystal would not degrade when stored for prolonged periods of time, as is often the 
case in the pharmaceutical supply chain. The lack of conversion in slurrying suggests a hydrated 
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form of the co-crystal is not likely to be formed. As the co-crystal does not break down this also 
tells us it is likely more stable under these conditions than the individual starting materials.  
Upon co-crystallisation, a morphology change is observed from that often observed for PYR. The 
shape of the crystals produced closer resembles a block shaped crystal (figure 6.39). 
 
Figure 6.39. Fat, plate-shaped crystals of PYR:3,5-DNBA co-crystal crystallised from H2O 
Face indexing experiments carried out determine that the crystals produced are plates (figure 
6.40). The plates produced are fattened, rather than very thin and breakable. This change is 
favourable in comparison to the needles usually observed. Although plates are not always a 
favourable crystal morphology, the fattening of these crystals moves them closer to blocks than 
plates. 
 
Figure 6.40. Predicted BFDH morphology for PYR:3,5-DNBA form II (left); observed morphology for PYR:3,5-DNBA 
form II (right) 
The observed morphology does not resemble the predicted morphology in this case. The 
predicted morphology shows a block shaped crystal whose development is governed by the 
aromatic rings of the molecules stacking parallel to the (-100) and (100) faces. These faces are 
the smallest, suggesting they are the fastest growing faces. The hydrogen bonding interactions 
are, therefore, observed on the surrounding faces of the crystal structure. Whilst the prediction 
would indicate the π-π interactions are responsible for the major growth, the predicted 
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morphology shows fairly even growth throughout the whole structure. The major differences 
observed in the predicted and observed crystal structure are likely the result of external 
influences not being taken into account in the BFDH calculations. The fattened plate shape 
crystal shows the major growth direction to be on the (0-10) and (010) faces. This growth 
direction is influenced by hydrogen bonding interactions occurring along the crystallographic b 
axis, which is perpendicular to the face. Hydrogen bonding interactions are also responsible for 
the growth on the (00-1) and (001) faces. These faces are perpendicular to the crystallographic 
c axis, where the further extending on the hydrogen bonded network occurs. The stacking of the 
layers of hydrogen bonded molecules occurs parallel to the apex between the (00-1) and (-101) 
faces. The limited growth on the (-10-1) face could be the result of reduced π-π interactions 
within the growing structure. The solvent could potentially be reducing the strength of these 
interactions in favour of the hydrogen bonding, explaining the plate shape observed instead of 
the block shape predicted.  
6.7.5  Crystallisation of pyridoxine with trimesic acid  
The third new co-crystal system was initially achieved from a 1:1 molar ratio of PYR and TRI 
(figure 6.41). 
 
Figure 6.41. Structure of PYR and TRI molecules and positions in the co-crystal showing the numbering system used 
in hydrogen bonding discussions 
The new crystalline form has a 2:1 stoichiometry of PYR:TRI, despite being crystallised from a 
1:1 molar ratio. The crystal structure belongs to the triclinic P1̅ space group, with an asymmetric 




Figure 6.42. Unit cell of 2:1 PYR:TRI co-crystal 
The packing of the co-crystal is similar to that observed for the PYR:3,5-DNBA co-crystal, with 
sheets of molecules aligned in the bc crystallographic plane (figure 6.43). The sheets are not 
perfectly planar due to the angles required for hydrogen bonding interactions between the two 
aromatic molecules, however, the layers can be clearly seen. The sheets of molecules stack on 
top of each other in the direction of the crystallographic a axis due to the overlap of the aromatic 
rings present in the two molecules. The ring overlap is slightly offset, giving the structure an off-
set parallel stacking arrangement. In contrast to the PYR:3,5-DNBA co-crystal, the layers of 
molecules are not discrete, with hydrogen bonds existing between molecules of different layers. 
This hydrogen bond, with π-ring overlap and other intermolecular interactions, is responsible 
for holding the layers together.  
 
Figure 6.43. Hydrogen bonding interactions present in PYR:TRI co-crystal: All hydrogen bonds for PYR molecule 
(right) and all hydrogen bonds to a central TRI molecule (left) 
The hydrogen bonding network within this structure is extensive, with multiple links between 
PYR and TRI molecules (figure 6.43). Due to the 2:1 stoichiometry and the nature of the 
structure, with four different PYR and two different TRI molecules in the asymmetric unit, there 
are a significant number of unique bonding interactions within the structure. There are no direct 
intermolecular hydrogen bonds between PYR molecules within the structure, however, the 
intramolecular hydrogen bond donated from O1-H to O2 is still present in all four PYR molecules. 
In general, each PYR molecule partakes in three different intermolecular hydrogen bonds, 
donating from the O2, O3 and accepting a H transfer at N. The exception is PYR molecule b, 
which donates an extra hydrogen bond from O1. The N in the pyridine ring, in all PYR molecules, 
accepts a hydrogen donation from one of the deprotonated acid groups; PYRa is protonated by 
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O4e, PYRb is protonated by O6e, PYRc is protonated by O6f and PYRd is protonated by O4f. The 
donation of the hydrogen bonds is confirmed by the bond lengths in table 6.5, with the N-H 
bond length being significantly shorter than the O-H bond length. The TRI molecules donate one 
hydrogen bond from O9e to O5f and O9f to O5e, creating a chain of PYR molecules. This is the 
only H bond forming between two TRI molecules. All the other H bonds involving the TRI 
molecules are donated by the surrounding PYR molecules; due to the already donated H atoms 
from two acid groups the only functional groups remaining are acceptors. The TRI molecules 
both accept a total of seven hydrogen bonds from surrounding PYR molecules and donate one 
to the neighbouring TRI molecule. The donation from TRI to TRI is within the same plane. Four 
bifurcated hydrogen bonds are observed within the structure; all involve the H transfer from a 
deprotonated acid group and two separate PYR molecules. These are unconventional bifurcated 
hydrogen bonds as they result from the hydrogen transfer from the acid groups, with the N to 
which the H has been transferred acting as the donor.  
Table 6.5. Hydrogen bond distances and angles for PYR:TRI co-crystal xiv 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
O1a-H∙∙O2a 0.94(3) 1.90(3) 2.752(3) 149(3) 
O2a-H∙∙O8e1 0.85(3) 1.93(3) 2.752(2) 164(3) 
O3a-H∙∙O4f2 1.02(4) 1.72(4) 2.717(3) 166(3) 
Na-H∙∙O4e 0.98(3) 1.71(3) 2.676(2) 166(3) 
O1b-H∙∙O2b 0.92(4) 1.73(4) 2.576(3) 152(3) 
O2b-H∙∙O6e4 0.84(3) 1.82(3) 2.647(2) 172(3) 
O3b-H∙∙O7f2 0.84(3) 1.87(3) 2.685(2) 162(3) 
Nb-H∙∙O6e 1.01(3) 1.64(3) 2.628(3) 168(3) 
O1c-H∙∙O2c 0.91(4) 1.74(4) 2.575(3) 150(3) 
O2c-H∙∙O6f5 0.91(3) 1.75(3) 2.649(2) 176(3) 
O3c-H∙∙O7e 0.82(3) 1.89(3) 2.681(2) 162(3) 
Nc-H∙∙O6f 0.94(3) 1.71(3) 2.637(3) 170(3) 
O1d-H∙∙O2d 0.90(3) 1.89(3) 2.687(3) 146(3) 
O2d-H∙∙O8f3 0.88(3) 1.88(3) 2.747(2) 166(3) 
O3d-H∙∙O4e 1.03(4) 1.74(4) 2.771(3) 176(3) 
Nd-H∙∙O4f 1.03(3) 1.70(3) 2.721(3) 170(3) 
O9e-H∙∙O5f 0.80(4) 1.81(4) 2.569(3) 157(3) 
O9f-H∙∙O5e6 0.88(3) 1.73(4) 2.568(3) 158(3) 
                                                          
xiv 11-X,1-Y,1-Z 2+X,1+Y,+Z 31-X,-Y,1-Z 4-X,1-Y,-Z 5-X,-Y,-Z  6+X,-1+Y,+Z 
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Analysis via PXRD and DSC confirms the bulk of material produced in the crystallisation has 
formed the new co-crystal structure. 
 
Figure 6.44. PXRD data for (a) PYR (BITZAF), (b) TRI (BTCOAC), (c) PYR:TRI co-crystal calculated from SCXRD and (d) 
PYR:TRI co-crystal from IPA evaporative crystallisation 
Whilst the experimental and calculated patterns for the co-crystal match, there are possibly 
some residual peaks from the excess PYR starting material in the sample (figure 6.44). As the 
crystallisation was set up in a 1:1 stoichiometry and the resulting co-crystal formed has a 2:1 
stoichiometry, there will be some PYR left over in the bulk product from the crystallisation, 
which is likely to show up in the pattern observed. However, it is less likely there will be any 
unconverted TRI, due to it being the limiting mass in the crystallisation. The significant peaks 
observed for TRI at 6-7° 2Ө are correspondingly completely absent from the experimental data, 
suggesting it is no longer present in the final bulk sample and has been fully utilised in co-crystal 
formation.  
 
Figure 6.45. DSC trace of PYR:TRI co-crystal. PYR melting point = 159-162 ᵒC 166, TRI melting point = >300 ᵒC 214 
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The DSC data for the co-crystal shows a sharp endothermic peak at about 180 ⁰C, indicating the 
melting point of the new co-crystal system (figure 6.45). There is no endothermic peak seen at 
around 160 ⁰C, indicating there is no PYR remaining in the bulk product of the crystallisation, in 
contrast to the indications of possible residual PYR from the PXRD. There is also little indication 
of any residual TRI in the bulk, though only the lower limit of the melting point range of TRI has 
been reached in this scan. Taken together, the DSC confirms the formation of a co-crystal 
structure, but not necessarily the complete conversion of all starting materials.  
Grinding experiments for the PYR:TRI co-crystal were carried out in 2:1 molar ratios, due to the 
stoichiometric nature of the co-crystal (appendix A52 and A53). The DSC data for grinding in the 
absence of solvent shows a peak for the PYR starting material and a second melting point at 
170 ⁰C. This is slightly lower than the melting of the co-crystal. Comparing this to the LAG 
grinding experiment, a peak for unconverted PYR starting material and a peak at 170 ⁰C are 
observed, but in addition there is a small peak seen at 180 ⁰C, corresponding to the co-crystal 
2:1 form. The peaks observed at 170 ⁰C could potentially be due to a second multi-component 
form of a different stoichiometry. The LAG experiment is the only grinding experiment to show 
evidence of the formation of the 2:1 co-crystal form, however, full conversion is not achieved. 
Both experiments show an unknown peak and suggest a different stoichiometric form is possible 
using this co-crystal preparation method. Full conversion has not been achieved in either case. 
Slurry experiments were also carried out at a 2:1 molar ratio, achieving full conversion to the 
2:1 co-crystal form characterised above. In addition, production of this co-crystal was achieved 
by controlled cooling crystallisation on 10 g solvent scale (appendix A54). Crystallisation at 30 g 
solvent scale was not achieved due to precipitation of the co-crystalline form before cooling 
could occur. Experiments at lower saturations resulted in no crystallisation being observed.  
Observational solubility experiments for the 2:1 PYR:TRI co-crystal in IPA were carried out in the 
Polar Bear Plus crystalliser (figure 6.46). The multi-component crystal was determined to be 
more stable than the pure PYR crystal structure with a significantly reduced solubility profile. 
The solubility for this co-crystal is very similar to that seen for the PYR:2,4-DNBA co-crystal in 
IPA. The increased stability is due to the substantial increase in hydrogen bonding interactions 
within the structure. There could also be some significance in the 2:1 stoichiometry of the 
structure, although it is likely the effects of this will be increased strength of intermolecular 
interactions. As with the other two co-crystalline structures, initial formation of the multi-
component structure was achieved through slurry techniques. The ease at which this co-crystal 
forms in solution is further testament to the favoured interactions within the structure and the 
increased stability this affords. The creation of a less soluble form of PYR could be of use in some 
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pharmaceutical applications as the pure PYR has a very high solubility. However, this is often not 
the goal of co-crystal formation. 
 
Figure 6.46. Solubility plot for PYR:TRI co-crystal (purple, circle marker) and pure PYR (black, square marker) from 
observation in IPA 
The same three stability tests as for previous co-crystals were carried out on samples of the 
PYR:TRI co-crystal.  
 
Figure 6.47. PXRD data for (a) PYR (BITZAF), (b) TRI (BTCOAC), (c) PYR:TRI co-crystal calculated from SCXRD, (d) 
PYR:TRI slurry 1 week, (e) PYR:TRI 50 ⁰C 3 weeks and (f) PYR:TRI 70% humidity 9 weeks. 
The PXRD patterns for all three stability studies match that of the original co-crystal (figure 6.47). 
No degradation is seen over the duration of the studies. The stability at increased humidity and 
elevated temperature suggests that storage of the co-crystal in the pharmaceutical supply chain 
would not be a problem, with no conversion to a different form or degradation back to the 
individual components. The lack of hydrate formation in the slurry suggests this is not likely to 
form over time, which is beneficial for storage. The absence of any breakdown of the co-crystal 
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suggests the co-crystal structure is more stable than the individual components under these 
conditions. 
The morphology of the co-crystals produced has changed significantly from the needles normally 
observed for PYR crystallisations. 
 
Figure 6.48. Plate-shaped crystals of PYR:TRI co-crystal crystallised from IPA 
The crystals produced from the crystallisation show a plate-shaped morphology (figure 6.48). 
This is an improvement on the usual morphology observed, although not as significant as 
observed with the other two co-crystals discovered. 
 
Figure 6.49. Predicted BFDH morphology for PYR:TRII (left); observed morphology for PYR:TRII (right) 
The predicted morphology is similar to that observed for pure PYR (figure 6.49). It suggests the 
morphology should be a slightly fattened needle. The major growth direction is highly influenced 
by the π-interactions between the aromatic rings within the structure. However, as with pure 
PYR, it is likely the expected morphology would be closer to a needle. The observed morphology 
shows a plate-shaped crystal that has different interactions contributing to the major growth. 
The major growth face is the (0-10) face, making the major growth interactions the hydrogen 
bonds between molecules. This is in contrast to the predicted morphology and is most likely the 
result of the solvent interactions not being taken into account in the prediction calculations. The 
second major growth face, (-101), is contributed to by the aromatic rings stacking within the 
structure. The two major growth directions are likely to be very equally matched, with the 
 
229 
differences being difficult to distinguish between when many different crystals are face indexed. 
Very slow growth occurs on the (00-1) faces. Analysis of the interactions show the 
intramolecular hydrogen bond within the PYR molecules lies directly along this face, limiting the 
number of possible interactions that allow growth in this direction. The creation of a co-crystal 
has achieved a new morphology, plate-shaped crystals as opposed to the commonly seen 
needles formed in EtOH. Whilst plate crystals are not the favoured morphology in the 
pharmaceutical industry, they are deemed an improvement from needle crystals. Further 
investigation could be carried out into the crystallisation conditions under which the co-crystal 
is formed in an attempt to alter the morphology even further and obtain a more block shaped 
morphology.  
6.7.6  Crystallisation of pyridoxine with phthalic acid  
A fourth co-crystal was discovered from an initial crystallisation of a 1:1 molar ratio of PYR and 
PtA (figure 6.50). 
 
Figure 6.50. Structure of PYR and PtA showing the numbering system used in hydrogen bonding discussions 
This co-crystalline material crystallises in the monoclinic P21/n space group, with an asymmetric 
unit consisting of one PYR and one PtA molecule.  
 
Figure 6.51. Unit cell of 1:1 PYR:PtA co-crystal  
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The packing of the co-crystal shows an overall zig-zag pattern, when viewed along the 
crystallographic c axis (figure 6.51). The molecules within the structure are not co-planar, with 
pairs of molecules alternating their orientation. The aromatic rings in each molecule stack 
parallel to the crystallographic a axis. This stacking occurs in an alternating pattern of PYR-PtA-
PYR-PtA etc.; within each stack the aromatic rings remain at the same angle.  
 
Figure 6.52. Hydrogen bonding interactions present in PYR:PtA co-crystal 
The hydrogen bonding in the structure looks more complicated due to the zig-zag orientation of 
the molecules (figure 6.52). The PYR molecules donate a hydrogen bond from each alcohol group 
in the structure, with O2 also accepting a hydrogen bond from a neighbouring PYR molecule. 
The hydrogen bonding distances (table 6.6) suggest proton transfer has again occurred in this 
co-crystalline form: transfer has occurred from one of the carboxylic acid groups on PtA to the 
N in the pyridine ring of the PYR molecule. The N-H bonding distance is 0.92(2) Å and the H∙∙O5 
bonding distance is 1.85(2) Å. Each PtA molecule forms hydrogen bonds to three different PYR 
molecules and one PtA molecule. One carboxylic acid forms two bifurcated hydrogen bonding 
interactions; O5 accepts a hydrogen bonding interaction donated by O2-H on a PYR molecule 
and is also involved in the proton transfer with the N in a second PYR molecule; O4 accepts 
donation from both O1 in a third PYR molecule and O7 from another PtA molecule. This 
carboxylic acid group is out of plane with the aromatic ring system of the PtA and is responsible 
for the hydrogen bonds linking the stacking of alternating ∙∙PYR∙∙PtA∙∙PYR∙∙ molecules together. 
The second carboxylic acid group is in plane with the PtA aromatic ring and is only involved in 
one hydrogen bonding interaction: O7 donates to another PtA molecule. This structure differs 
from all the other PYR co-crystals discovered as there is no intramolecular hydrogen bond 
between O1-H∙∙O2; this intramolecular hydrogen bond is also observed in the pure PYR crystal 
structure. Its absence in the PYR:PtA co-crystal contradicts the second general rule for hydrogen 
bonding, as described by Etter: ‘six membered intramolecular hydrogen bonds form in 
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preference to intermolecular interactions’.126 The creation of the co-crystal has required a 
change in the angles of the O1-H and O2-H groups and therefore moved the structure away from 
a favoured 6-membered ring geometry, eliminating the intramolecular interaction. Inspection 
of the published structures in the CSD shows only one example where this intramolecular 
hydrogen bond does not form, PYR:p-aminobenzoic acid co-crystal (VUKPIC).215 
Table 6.6. Hydrogen bond distances and angles for PYR:PtA co-crystal xv 
D-H∙∙A d(D-H) (Å) d(H∙∙A) (Å) d(D∙∙A) (Å) >(DHA) (ᵒ) 
N-H∙∙O54 0.92(2) 1.85(2) 2.768(2) 171(2) 
O1-H∙∙O41 0.87(3) 1.83(3) 2.695(2) 172(2) 
O2-H∙∙O5 0.86(2) 1.88(2) 2.680(2) 154(2) 
O3-H∙∙O22 0.89(3) 1.96(3) 2.814(2) 159(3) 
O7-H∙∙O43 0.93(3) 1.70(3) 2.616(2) 170(2) 
Analysis via PXRD and DSC was used to determine that the bulk of material produced in the 
crystallisation has formed the new co-crystal structure. 
 
Figure 6.53. PXRD data for (a) PYR (BITZAF), (b) PtA (PHTHAC), (c) PtA hydrate (WODVAN), (d) PYR:PtA co-crystal 
calculated from SCXRD data and (e) PYR:PtA co-crystal from EtOH evaporative crystallisation 
The calculated and experimental PXRD patterns show good agreement, with no extra peaks 
observed in the experimental pattern (figure 6.53). The agreement between the two patterns 
suggests no unconverted starting material remains and no other forms are present in the 
crystallisation. The phase purity of the sample is therefore relatively high.  
                                                          




Figure 6.54. DSC trace of PYR:PtA co-crystal. PYR melting point = 159-162 ᵒC 166, PtA melting point = 210-211 ᵒC 216 
The DSC trace shows one endothermic peak at 140 ᵒC, determining the melting point of the new 
co-crystalline form (figure 6.54). The peak is sharp, confirming the high conversion of the 
crystalllisation to the new form at high purity. A further, small endothermic event is observed at 
169 o C. This could be caused by residual PYR in the sample with a slightly increased melting point 
due to the presence of the co-crystal. It could also be a second form of the co-crystalline 
structure, however, this is not supported by the PXRD data shown in figure 6.53. 
Further crystallisation methods were carried out to determine how the co-crystalline form can 
be made (appendix A55 – A57). Mechanochemical grinding of the starting materials showed 
little success in forming the co-crystal, with the PXRD pattern resembling a mixture of PYR and 
PtA starting materials. In DSC no sharp peaks are observed. The LAG experiment with EtOH is 
more promising, showing a PXRD pattern that resembles the calculated pattern for the co-crystal 
structure. Some small impurity peaks remain suggesting full conversion was not obtained in this 
technique. Again, the DSC shows no sharp peaks in the trace resulting in no conclusions being 
able to be drawn from this data. Further solvent-mediated methods, namely slurry cooling 
experiments, showed good conversion to the new co-crystal system with high phase purity. 
Scale up was achieved to 10 g and 30 g solvent scales in cooling crystallisation.   
Observation methods were used to determine the solubility of the new PYR:PtA co-crystal 
(figure 6.55). The solubility of the co-crystal is lower than that of PYR in EtOH, but the difference 
is less significant than with some of the other co-crystals and the co-crystal has a lower melting 
point. The data shown here is an average, therefore reducing the potential significance in the 
difference between the two further. However, the co-crystal forms favourably, indicating the 
stability of the co-crystal structure in general.  The observed reduction is solubility is often 
unfavoured in the pharmaceutical industry, with the formation of co-crystals usually employed 




Figure 6.55. Solubility plot for PYR:PtA co-crystal (purple, circle marker) and pure PYR (black, square marker) from 
observation in EtOH 
Three stability tests were carried out on samples of the PYR:PtA co-crystal; humidity, slurry and 
high temperature studies.  
 
Figure 6.56. PXRD data for (a) PYR (BITZAF), (b) PtA (PHTHAC), (c) PtA hydrate (WODVAN), (d) PYR:PtA co-crystal 
calculated from SCXRD, (d) PYR:PtA slurry 1 week, (e) PYR:PtA 50 ⁰C 3 weeks and (f) PYR:PtA 70% humidity 9 weeks. 
The PXRD patterns for samples resulting from all three stability studies match that calculated for 
the co-crystalline form (figure 6.56). The confirmation of stability of the co-crystal at increased 
humidity and elevated temperature suggest that storage of the co-crystal would be possible for 
long periods of time without conversion to a different form or degradation back to the individual 
components. In the slurry, a hydrated form is not formed and the original structure is 
maintained, which is also beneficial for long term storage. The absence of any breakdown of the 
co-crystal suggests the hydrogen bonding in the co-crystal structure is sufficiently favourable 
under these conditions. 
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Again, the morphology change on formation of this co-crystal is significant: the co-crystal forms 
plate-shaped crystals in EtOH, a significant improvement on the needles usually observed for 
PYR (figure 6.57).  
 
Figure 6.57. Plate-shaped crystals of PYR:PtA co-crystal produced from IPA 
The plates produced here are much more substantial than those observed for PYR:TRI co-
crystals. Although the change is more favourable, the optimal morphology for pharmaceutical 
processing has still not been achieved. Optimisation of this co-crystal form may be possible with 
further investigation. Face indexing experiments could not be carried out in this co-crystalline 
form to determine the major growth mechanisms due to equipment unavailability at the end of 
the project.  
6.7.7  Crystallisation of further multi-component materials of pyridoxine 
An investigation into the formation of PYR co-crystals with a set of aliphatic di-carboxylic acids 
was carried out under the author’s supervision by Dave Collins (MChem student) towards the 
end of this research project. A number of new, co-crystalline forms are indicated to have been 
found; confirmed through PXRD and DSC analysis. Full single crystal XRD structure determination 
was carried out on some of these new co-crystals, confirming the formation of PYR:succinic acid 
2:1, PYR:succinic acid:H2O 2:1:2 and PYR:fumaric acid 1:1. Structure elucidation was not possible 
for the other promising forms due to breakdown of equipment. The full analysis of these co-
crystals was not included in this thesis as they do not appear to show favourable morphology 
changes and further research would be required to achieve full structure determination of all 
forms in the series. 
6.8  Conclusion 
The modification of the morphology of PYR using different solvents was not achieved with the 
selection of solvents utilised in this research. Little influence can be seen on the growth 
morphology in different solvents, indicating that the potential to access a better morphology 
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through changing the solvent is limited. It may be that an appropriate solvent is yet to be 
discovered. There are many computational modelling projects being carried out to attempt to 
predict the morphology achievable from a particular solvent, without the need to carry out 
excess screening experiments. In the case of PYR, this would be a good place to start if the 
influence of solvent were to be further investigated.  
In terms of additive effects, both polymeric and size-matched additives were unsuccessful in 
changing PYR morphology under the conditions used in these experiments. In both cases, the 
additives and conditions utilised have not been exhaustive and further investigation could be 
carried out. Further size-matched and polymeric additives could be screened for their influence 
on the growth of PYR crystals in numerous different wt% ratios. The additives used in the 
screening discussed here could also be investigated in different wt% ratios than those already 
attempted. In addition, the option to screen the additives in different solvent systems also exists 
and could be investigated if a solvent system allowed the PYR to be more susceptible to 
morphological modification. The scope of additive screening could be large, covering a wide 
range of different variables. However, as no change has been observed in PYR to date, further 
screening could also prove fruitless for morphology modification. As a result, further screening 
would not be advised as the best method to improve the morphology of this particular API. 
Some success was observed in changing the morphology of PYR upon the creation of multi-
component materials. Four new co-crystalline structures of PYR were discovered (one of these 
in two polymorphic forms), all with morphology changes compared with pure PYR crystals. New 
multi-component crystal structures were found with 2,4-DNBA (two forms), 3,5-DNBA, TRI and 
PtA. The physical properties of each new co-crystalline structure were determined, along with 
the resulting crystal structures. In addition, the morphology was analysed and the faces 
determined using SCXRD and face indexing methods.  
The solubility of each of the new crystal forms produced was less than that of pure PYR, a 
possible negative effect of the formation of the multi-component structures. Usually higher 
solubility is more favourable in pharmaceutical applications, however, the lower solubility could 
be a compromise worth making if the morphology improvement has significant effects on the 
processing steps. In depth stability analysis carried out determined each new form was stable 
for up to 9 weeks at 70% humidity. All forms were also stable for at least 3 weeks at 50 ⁰C. Slurry 
experiments in H2O also proved the stability of the co-crystals for up to 1 week, with the 
exception of the 2,4-DNBA form I co-crystal which converted to a second form (form II) of the 
co-crystalline structure under slurrying.  
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Determining the thermodynamic polymorphic form of the PYR:2,4-DNBA co-crystal was not 
possible using melting points or solubility data; the difference in stability between the two 
polymorphs appears to be small and likely within the error of the experiments carried out. Form 
II showed a slightly reduced solubility so was hypothesised to be the more stable form, 
supported by the fact that competitive slurry experiments showed full conversion of the sample 
to form II within 2 hours. In addition, co-grinding the two forms together also yields complete 
conversion to form II. Whilst both forms have very similar stabilities, the experiments carried 
out confirm form II of the co-crystal to be slightly more thermodynamically stable than form I 
and conversion to form II is possible through grinding and slurrying methods.    
PYR:2,4-DNBA co-crystals show an irregular block shaped crystal, a significant improvement on 
the shape seen for PYR under most crystallisation conditions. The needles no longer form as the 
co-former allows different hydrogen bonding interactions to occur, reducing the strength of the 
π-π-interactions between the aromatic rings. The morphology change observed in the 
production of this co-crystal is much more favourable for downstream processing.   
The PYR:3,5-DNBA co-crystal forms a fattened-plate-shaped crystal morphology. Again, this is a 
significant improvement on the usual needle morphology observed for pure PYR crystals. Whilst 
plate-shaped crystals are often unfavourable in processing, the fattened nature of those 
produced here suggests they could significantly improve the downstream processing steps 
required for production. The PYR:TRI co-crystal also forms plate-shaped crystals. The plates 
produced here are much thinner than observed for the PYR:3,5-DNBA co-crystal and are a much 
less favourable change. The change is still a major difference from the needles usually observed, 
however, the thin nature of the plates would makes them also difficult to process into a final 
pharmaceutical product. The PYR:PtA co-crystal also shows a plate morphology. The plates are 
more substantial than those produced with TRI co-former, but still thinner than those produced 
with 3,5-DNBA. Although plates are more favoured than needles, they still cause difficulties in 
processing steps, therefore, these three co-crystals would be less desirable to the 
pharmaceutical industry: the inclusion of a secondary molecule is likely not giving a large enough 
morphology improvement to justify exploring these co-crystal systems as a pharmaceutical 
crystal system for PYR.  
Overall, the creation of PYR co-crystals has resulted in positive morphology changes not 
previously observed in additive or solvent experiments. The improvement is particularly 
beneficial in the case of the PYR:2,4-DNBA co-crystal, where an almost block shape is achieved. 
Although there would be difficulty obtaining FDA approval for crystals involving a secondary 
component, this would be the most promising method to utilise to change the morphology of 
the PYR crystals. No improvement was seen for either of the methods attempted which do not 
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change the crystal structure of the API; neither additives nor solvent were shown to influence 
the growth shapes of pure PYR.  In contrast to the conclusions reached about IZN, the formation 
of multi-component crystal structures is more successful in morphology modification for PYR 
and would be a promising route for further investigation, despite the difficulties potentially 







Chapter 7 Benchmarking CMAC 
workflows 
 
7.1  Introduction 
This strand of the project is carried out in the broader context of the CMAC Future 
Manufacturing Hub. The CMAC consortium as a whole focuses on tackling the optimisation of 
pharmaceutical manufacturing through adopting continuous crystallisation methods.217 This 
provides the opportunity to improve product quality and improve cost effectiveness, 
sustainability, energy usage and other environmental benefits. Moving towards continuous 
manufacturing processes presents new technical and economic challenges that need to be 
overcome to enable their implementation.111, 218 To address this, CMAC has developed a 
microfactory approach. This involves the implementation of modular lab scale process steps, the 
choice and optimisation of which for a particular target process-product combination are based 
on an underpinning set of workflows developed within CMAC. The workflows rely on a 
combination of experimental and digital approaches which can be implemented and linked to 
allow for rapid evaluation of the feasibility of potential methods for the production of a given 
target molecule.219 
The work presented in this chapter was published in part as Hatcher, Burgess, Payne and Wilson, 
“From structure to crystallisation and pharmaceutical manufacturing: the CSD in CMAC 
workflows”, 2020, CrystEngComm, 22, 7475; doi: https://doi.org/10.1039/D0CE00898B. 
 
7.2  Importance of workflows 
Standardised workflows are important within collaborative environments such as CMAC, and in 
cross-industry approaches, to ensure research is being carried out in a reproducible way. 
Workflows can also be useful for researchers carrying out research and development in areas in 
which they are not expert. When interlinked, they also offer advantages in developing integrated 
process approaches such as the CMAC microfactories, giving a standardised approach in which 
the compatibility and effectiveness of overall end-to-end process can be developed with respect 
to optimised individual unit processes; workflows also offer key decision points to aid such 
process development. The workflows developed at the University of Bath, by Dr. Lauren 
Hatcher, relate to two different primary crystallisation screening techniques used to modify the 
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primary crystalline particle properties to control/change a chosen physical property – multi-
component crystal screening and additive crystallisation screening. 
Both workflows were designed to drive the decision-making process surrounding the screening 
of potential new multi-component materials (MCM) and additive crystallisations in order to 
achieve a change in the physical properties of the primary API crystals. Included in the workflows 
are a number of check points to help navigate the decision points where challenges are often 
presented in crystallisation screening. 
7.3  Outline of workflows 
7.3.1  Multi-component (MC) workflow 
MCM screening is often considered in the early stages of primary processing as a way to improve 
physical properties both of the particle, for example size and shape, and the API itself (as a co-
crystal or salt), including solubility/dissolution and bioavailability. MC crystal screening should 
only be considered in situations where the composition of the crystal of the delivered API can 
be varied (i.e. co-crystals or salts are acceptable). This method of investigation is often already 
well established in laboratories, but usually without a formalised workflow/decision point 








Figure 7.1 CMAC MCM screening workflow driven by the decision points capturing key elements to indicate successes. Decision 1: is crystallinity retained following evaporation?; Decision 2: is there 
evidence for a new product from the PXRD and DSC analysis?; Decision 3: are there single crystals formed from the evaporation?; Decision 4: is there good diffraction from the single crystal and can a 
structure be solved?; Decision 5: is the product material stable to slurrying in solution?; Decision 1a: is crystallinity retained after grinding?; Decision 2a: is there evidence for a new product from the 
PXRD and DSC analysis?; Decision 3a: is the new product pure, or is there a mixture of product and starting materials present? 
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Before commencing any experiments, the key API property to be targeted should be 
outlined, along with the criteria to decide the success of the screening. Additionally, 
molecules for potential co-formers need to be determined. This can be done in a number of 
ways, including computational calculations and analysis of potential intermolecular 
interactions possible with the API, for example using the CCDC Mercury molecular 
complementarity tool. Finally, any solubility data relating to the target API or potential co-
formers should be available for workflow evaluation; this is often found in literature or from 
previous experimental studies. These decisions are included in the pre-requisite section of 
the workflow. 
The first three stages focus on discovery experiments at a small scale. The workflow suggests 
a parallel approach using both mechanochemical and evaporative screening methods to 
enable a wider range of possibilities to be investigated in a shorter period of time. Decisions 
made at this point are used to decide if a new co-crystalline product has been accessed and 
can be characterised. The following stages move towards developing the new MCM on a 
larger scale and determine whether any improvement has been achieved to the initial 
physical property outlined in the pre-requisites. These stages also include further 
investigation into determining other important physical property information, such as 
solubility and stability. The goal of the workflow is to produce a new MC crystalline form that 
is well characterised and deliverable at a meso-scale in either a microcrystalline powder or 
single crystal form. 
7.3.2  Additive workflow 
In contrast to the MCM discovery, it is less common for additive intervention to be 
implemented into crystallisation processes, in spite of the potential benefits of this 
approach.219 Additive screening may be considered early in the primary processing stages as 
a way to improve physical particle attributes, including particle size, crystal 
habit/morphology and polymorphic form.  Additive interventions are particularly worthy of 
consideration in situations where the API is only acceptably delivered in its pure form (i.e. 
salts or co-crystals are not acceptable). Much of the additive workflow (figure 7.2) follows 
the same process as the MC workflow, with an emphasis on the concentrations of the 
secondary component being much lower than the stoichiometric amounts used in the 
discovery of MC materials, and of course with a different outcome targeted.
 





Figure 7.2. CMAC additive screening workflow driven by the decision points capturing key elements to indicate successes. Decision 1: are the chosen additives soluble in the solvents used for optimised 
non-additive API crystallisation process? (i.e. can a co-solvent be found easily?); Decision 2: does the API solubility/MSZW remain the same in the presence of each additive candidate?; Decision 3: does 
the analysis indicate a change in targeted property (e.g. solid-form/morphology/PSD etc.) in the presence of each additive candidate?; Decision 4: does the crystallisation process chosen for the 
product proceed unchanged following a change in additive ratio?
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The workflow again begins with a similar pre-requisite section to that of the MC workflow. 
The API property being targeted must be outlined, along with the key criteria that must be 
met to be deemed successful. As the additive intervention does not intend to change the 
composition of the API material, the physical properties being targeted tend to be crystal 
particle attributes, such as particle size distribution (PSD), shape/morphology etc. 
Stage 1 of the workflow is concerned with ensuring the crystallisation of the target API is 
optimised, including solvent choice and solubility. This is particularly important for 
investigating the effects of additives due to the choice of target properties often being 
primary particle attributes. It is important to know the outcome of the crystallisation process 
in the absence of additives to ensure any changes observed are the result of the additives 
present and not due to changes in the experimental set up. The next two stages (2 and 3) are 
concerned with choosing suitable additive candidates and understanding their solubility. This 
can again be done via computational approaches, similar to those utilised in the MC 
workflow, or other empirical methods. One important additional element in the additive 
workflow is use of SCXRD data to enable face indexing methods to determine the surrounding 
faces of the crystal. By visualising this information using the BFDH morphology function in 
the CSD Mercury software, the interactions responsible for the major growth of a crystal and 
functional groups present on each of the faces can be determined. 
Stages 4 and 5 begin the screening process of the additives in small scale crystallisations. All 
decisions included in these stages focus on whether an enhancement of the target property 
has been observed or whether no significant changes have been observed. It is also important 
to confirm at this stage that no additive has become incorporated into the structure and no 
form changes have been induced by the presence of the additive. Once an additive has been 
deemed successful, the final stages focus on optimising the crystallisation conditions with 
the additive present to achieve the best and most reproducible enhancement possible. This 
includes identifying the best additive concentration (stage 6) and maintaining other 
important crystallisation parameters at an optimal level, for example the solvent choice, API 
concentration, etc. 
The overall goal of the workflow is to determine an additive candidate that has the potential 
to deliver an API crystallisation process with enhanced particle properties, without any 
unwanted inclusion of additive into the final product crystal or solid form changes of the 
target API. Any information obtained in this screening process would be used in the design 
of a scaled-up version of the additive crystallisation route. 
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7.4  Multi-component workflow benchmarking 
The benchmarking of the multi-component workflow was carried out largely by Dr. Lauren 
Hatcher and Bath MChem student Ayrton Burgess, using the CMAC target molecule of 
mefenamic acid (MFA) and other members of the fenamic acid (FA) family. A new co-crystal 
form of flufenamic acid and 2,2’-bipyridine was discovered using the workflow discussed.219 
The discovery and further analysis of PYR co-crystals, discussed in chapter 6, was also carried 
out using the MC workflow, by the present author. The MC work carried out with IZN, 
presented in chapter 5, was undertaken before the workflow was formalised; however, it 
followed essentially the same methodology. 
7.5  Additive workflow benchmarking 
The additive workflow was used to determine whether additive crystallisations were a 
suitable consideration for morphology modification in a number of target molecules. 
Experiments were carried out on FA and its derivative MFA. Both form plate-shaped crystals 
which can cause problems with downstream processing steps in the manufacturing process. 
By introducing additives into the crystallisations in small quantities the potential exists to 
modify the growth and resulting morphology of the crystals without incorporating the 
perceived impurity into the crystal structure. 
7.5.1  Fenamic acid (FA) and mefenamic acid (MFA)  
FA is a monomorphic material which crystallises in the triclinic space group 𝑃1. The hydrogen 
bonding interactions show an intermolecular dimeric ring interaction between the carboxylic 
acid groups on the molecule (figure 7.3). There is also an intramolecular hydrogen bonding 
interaction between the N-H group in the centre of the FA and the C=O group within the 
carboxylic acid group. This intramolecular hydrogen bond plays a role in fixing the geometry 





Figure 7.3. Dimeric hydrogen bonding interaction between FA molecules 
The solvent utilised in the benchmarking process was IPA; crystallisation from this solvent 
resulted in a plate morphology with a parallelogram shaped end face (figure 7.4). 
 
Figure 7.4. Face indexed morphology for FA crystallised from IPA and molecular packing with respect to 
morphology  
The major growth faces are (01-1) / (0-11). Stacking of one of the aromatic rings in the FA 
structure contributes to this growth direction, while the dimeric hydrogen bonding is present 
along these faces. The second aromatic ring is at 90ᵒ to the other and contributes to growth 
in the (-1-1-1) / (111) direction; from the observed morphology growth in this direction is less 
pronounced. 
MFA has three polymorphic forms, which show distinct PXRD patterns (figure 7.5). Form I is 
the most stable at room temperature with form II and form III the metastable forms. Form II 




Figure 7.5. PXRD data for (a) MFA form I, (b) MFA form II, (c) MFA form III and (d) MFA crystallised from IPA 
Form 1 also crystallises in the 𝑃1 space group with a similar hydrogen bonding structure to 
that of FA, showing an inter-molecular dimeric ring interaction between the carboxylic acid 
groups on the molecule (figure 7.6). The intra-molecular hydrogen bond is also observed 
between the N-H group and the C=O group, as seen in the FA structure, fixing the geometry 
of the molecule. The MFA molecule features two methyl groups not observed in FA. 
 
Figure 7.6. Dimeric hydrogen bonding interaction between MFA molecules 
The use of IPA as a solvent allows the stable form I of MFA to form, without the presence of 
the metastable forms, as evidenced from the PXRD (figure 7.5). Using additives in the system 
has the potential to allow a metastable polymorph to form more favourably due to the 
influence it may have on the packing and growth of the crystals. As additives can also affect 
growth, the morphology of resulting crystals was also analysed. 
The morphology observed for MFA in IPA shows a very thin plate with the faces forming a 




Figure 7.7. Face indexed morphology for MFA crystallised from IPA and molecular packing with respect to 
morphology  
The major growth direction appears to benefit from major contributions from π-π 
interactions between the aromatic rings in neighbouring MFA molecules. 
7.5.2  Workflow benchmarking for fenamic acid and mefenamic acid 
Workflow inputs/pre-requisites 
Initial CSD data mining with ConQuest 
The possible solid forms already reported and their structures must first be identified for 
each API. This can be effectively achieved via a structure search in ConQuest. The structures 
of the target molecules are shown in figure 7.8. Similar to the searches carried out for the 
MC workflow, the following filters were used for the CSD search: 
- 3D coordinates must be determined 
- No polymeric structures 
- Only organic structures. 
Adding explicit hydrogen assignment on COOH groups prevents the return of salt structures 




Figure 7.8. Structure of target molecules used in ConQuest structure search with all the hydrogens explicitly 
assigned: FA (left), MFA (right) 
The search for FA returned five hits, of which two were structure determinations of the single 
polymorphic form isolated so far (QQQBTY). The remaining three consist of two MC materials 
with co-formers acridine and 4,4’-bipyridine. The CSD search carried out for MFA returned 
26 hits in the data base. Seven of these were determinations (and re-determinations) of the 
three polymorphic forms that exist for the structure (form I = XYANAC). The remaining 19 
structures consist of 14 different MC materials with various co-former molecules. 
Stage 1: Optimisation of non-additive crystallisation parameters 
Small scale evaporative crystallisation experiments were used to determine the parameters 
to be used for each target API. This stage can also be carried out in cooling crystallisation if 
the equipment is available. The solvent chosen for this set of experiments was IPA due to the 
ease of dissolution of each target in the solvent system. 10 mg of API was dissolved in a 
minimum amount of solvent (based on solubility data available) and allowed to evaporate 
slowly at a constant temperature of 40 ⁰C. 
The resulting product materials were analysed by optical microscopy and in each case the 
morphology determined. Face indexing experiments were also carried out on the crystals 
using SCXRD platforms to determine the faces contributing to the external morphology. 
Stage 2: Selection of suitable additive candidates 
Selection of additives was carried out using the molecular complementarity screening tool 
(previously discussed in chapter 4). This calculation is primarily used to design MC materials, 
however, it also has the potential to be useful in the determination of possible additive 
molecules. This relies on the fact that if a material was likely to form a MC material with the 
target molecule it may also, in smaller quantities, have a sufficiently significant interaction 
with the growing crystal to influence the morphological outcome. 
For this benchmarking study both the GRAS list and the list of non-GRAS co-formers, 
discussed previously in chapter 4, were used. Incorporation of the additives into the final 
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crystal structure is not the aim of this screening process, therefore the use of non-GRAS 
materials should be less problematic in these experiments than when focusing on the 
creation of MC materials. Screening searches were performed for both target molecules with 
all five molecular descriptors enabled. In addition to these screening experiments, the CSD 
searches previously carried out were further analysed to identify any potential additives that 
already form MC materials with the target molecules. The formation of a MC material 
confirms there is a strong interaction between the target API and the chosen co-former, 
suggesting this may be successful as an additive when present in smaller quantities in the 
crystallisation. As a result of these investigations, a total of eight additives were short listed 
for both FA and MFA: isonicotinamide (EHOWIH), nicotinamide (NICOAM), flufenamic acid 
(FPAMCA), tolfenamic acid (KAXXAI), adipic acid (ADIPAC), 4,4’-bipyridine (HIQWEJ), 2,2’-
bipyridine (BIPYRL) and sorbic acid (ZZNWQ). All the chosen additive candidates either pass 
the screening tests carried out or are known to form a MC material with one/both of the 
target molecules. MFA has reported MC material crystals with nicotinamide, flufenamic acid, 
tolfenamic acid and 4,4’-bipyridine. By contrast, FA only shows a MC material with 4,4’-
bipyridine. 
At this stage in the workflow we have reached decision 1: Are the chosen additives soluble in 
the solvents used for the optimised non-additive API crystallisation?’. This is an important 
consideration when choosing the additives. All eight candidates shortlisted for each target 
were chosen in part due to their solubility in IPA, the chosen solvent for this experiment set. 
Stage 3: Determine API solubility with additives 
During the benchmarking process, the position of this stage of the workflow was called into 
question. The initial draft of the workflow suggests solubility testing needs to be carried out 
at this point, to determine any changes to the solubility of the API with an additive present. 
The presence of the additive could significantly affect the solubility profile of the API in the 
solvent system chosen, therefore, identifying this at an early stage could save time in later 
steps of the workflow. However, determining the solubility for every additive at this stage is 
a time-consuming process, especially if there are a large number of potential additives 
chosen for screening. In reality, most additives investigated are likely to be unsuccessful in 
improving the chosen target property, with this stage resulting in the generation of a lot of 
surplus data that will not be required. In addition, at this stage of the workflow the 
concentration of the additive required for optimal enhancement of target properties has yet 
to be identified, making it difficult to know for what percentage of additive it would be 
relevant to carry out the solubility determination. As additives are often used in small 
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quantities, frequently ≤ 1% of the API weight, the influence on the solubility may be 
negligible. As a result, spending time investigating the solubility at this point is likely to be 
time consuming without necessarily adding significantly to the investigation. 
Decision 2 would be considered at this point: Does the API solubility/MSZW remain the same 
in the presence of each additive candidate? Due to the nature of the workflow, decision 2 is 
made redundant if stage 3 is removed. As a result of the benchmarking studies presented 
here, it is suggested that stage 3 and decision 2 would be moved to later in the workflow 
when optimisation of successful additives is being considered. It is likely this stage would be 
more appropriate after stage 7, where decision 4 already indicated the potential for a change 
in solubility due to optimisation of the additive concentration. 
Stage 4:  Screening of additive candidates 
Small scale evaporative crystallisations were set up for each target molecule to mimic those 
carried out in stage 1. 10 mg of target molecule with 1% wt/wt of the additive molecule 
added to each crystallisation. Each crystallisation was then allowed to evaporate at a 
constant temperature of 40 ⁰C. 
This stage should be carried out using identical conditions to those determined in stage 1 of 
the workflow and optimised for each target molecule. By using identical conditions, the 
results from stage 1 can be used as a control experiment during comparison to the 
crystallisations carried out at this stage. In this benchmarking study, the morphology is being 
probed and as a result the morphology of the crystals achieved in the presence of additive 
will be compared to those observed in stage 1, in the absence of additive. 
Stage 5: Initial analysis of results 
The analysis methods chosen will depend on the desired particle property for control. In this 
benchmarking exercise the property being controlled is particle morphology, thus the first 





Figure 7.9. The morphology of FA crystals from IPA observed in the presence of additives. (a) absence of additive, 
(b) nicotinamide, (c) isonicotinamide, (d) flufenamic acid, (e) tolfenamic acid, (f) adipic acid, (g) 4,4’-bipyridine, 
(h) 2,2’-bipyridine and (j) sorbic acid 
Analysis of the FA crystals produced show minimal additive effects on the morphology 
achieved (figure 7.9). Despite this, large differences can be seen between the pictures. Some 
show larger crystals with many fine crystallites, whilst others show more uniformity with 
some smaller fines present. This is likely due to changes in the nucleation of the samples. 
Evaporative crystallisation is uncontrolled and therefore not the best method to get 
reproducible crystallisation conditions. The crystallisations show mainly elongated plate-like 
crystals similar to the shape observed from IPA alone. 
 
Figure 7.10. The morphology of MFA crystals from IPA observed in the presence of additives. (a) absence of 
additive, (b) isonicotinamide, (c) nicotinamide, (d) flufenamic acid, (e) tolfenamic acid, (f) adipic acid, (g) 4,4’-
bipyridine, (h) 2,2’-bipyridine and (j) sorbic acid 
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The microscopy analysis of the MFA crystals also shows no influence of the additives on the 
morphology achieved (figure 7.10). Most crystallisations show elongated, plate-shaped 
crystals similar to the shape observed from IPA alone. Again some crystallisations show an 
increased number of smaller crystallites due to the uncontrolled nature of evaporative 
crystallisation. 
As MFA has more than one known polymorphic form, further analysis is necessary to confirm 
the experiments all yield the same polymorph. Using PXRD analysis, the products of each 
crystallisation were analysed and compared to calculated patterns from published structures 
in the CSD database. All crystallisations were confirmed to produce MFA form I (figure 7.11). 
 
Figure 7.11. PXRD data for (a) MFA form I calculated for SCXRD, (b) MFA crystallised from IPA in absence of 
additive, (c) with isonicotinamide, (d) with nicotinamide, (e) with flufenamic acid, (f) with tolfenamic acid, (g) 
with adipic acid, (h) with 4,4’-bipyridine, (k) with 2,2’-bipyridine and (l) with sorbic acid 
Further analysis that can be carried out at this point includes face indexing experiments to 
determine the nature of the morphology changes observed. 
At this point in the workflow we arrive at another decision point: Does analysis indicate a 
change in the targeted property (e.g. solid form/morphology/PSD etc) in the presence of each 
additive candidate? In the case of FA and MFA, the answer at this decision point would be 
no. The influences of the additive in the crystallisations carried out is minimal and does not 
achieve a significant morphology change. As a result, these additives would be discarded. At 
this point, further investigations could be carried out using a different set of additives 
identified in stage 2 or the conclusion can be drawn that additive intervention is not a viable 
method to achieve a morphology change in these target molecules. 
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An example of a successful morphology change due to additive interventions can be seen in 
chapter 4 for IZN. If the workflow had been established when the IZN investigation was 
undertaken, stages 6 and 7 could be carried out as follows. 
Stage 6: Select best additive to control target property. 
As discussed in chapter 4, IZN shows a favourable morphology change with two additives: 3-
HBA and 3,4-DNBA. Repetition of any successful additive crystallisations in cooling could 
potentially aid the decision as to which additive to choose. Another consideration to make at 
this point would be the safety of the potential candidates for the use in pharmaceutical 
products. As there are only two potential additives it would be possible to continue the 
research on both until one could be ruled out. 
Stage 7: Optimise API to additive ratio 
Experiments carried out on IZN showed that a ratio of 1% additive is sufficient to change the 
morphology. More experiments could be carried out in an industrial setting to determine 
further the optimal ratio between these two concentrations. This would be particularly 
important in the case where the lowest concentration of additive possible is favourable in 
the crystallisation process. 
7.6  Conclusions 
The benchmarking experiments showed that both workflows provide structured and logical 
approaches to the challenges they have been developed to solve. The decision points work 
well within the experimental process, allowing for the research to move on in a smooth and 
effective way. The workflows offer a reproducible approach to process design, harnessing 
the strength of experimental data alongside the computational modelling elements included 
in the steps. The use of early intervention, at the primary particle stage of development in 
pharmaceutical manufacturing, can result in a reduction of process steps, including 
downstream processing requirements, and allow for the design of optimised particle 
properties. Evaluation of the potential of any additional steps at the primary particle stage is 
necessary as they may not be considered the ‘first choice fix’ in process development but 
may offer significant benefits over other downstream interventions. The approach from the 
workflows discussed places an increased importance on the early stage design of a 
crystallisation processes. In addition, the workflows allow a more targeted screening 
approach, reducing the experimental screening required before an appropriate decision can 
be made, saving both time and money for the researchers and manufacturers. 
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Benchmarking with both MFA and FA have demonstrated the versatility of the workflows 
created and confirmed the decision points are appropriately placed within the workflow. 
Whilst the research on additive intervention in changing morphology was unsuccessful with 
both target molecules investigated here, the workflow allowed for this decision to be made 
and the research to cease in a timely manner. It was also evident that the successful additive-
induced morphology modification produced for IZN in chapter 4 followed and exemplified 
the first five stages of the workflow methodology. The benchmarking research highlighted a 
possible change that would need to be made in step 3 of the additive workflow; ‘Determine 
API solubility with additives’. This step would be better placed towards the end of the 
workflow, after step 7, due to the unnecessary time this step would take and the excess data 
it would have the potential to generate. Moving step 3 would also require decision 2 to be 
moved and result in a potential re-wording of decision 4. This change was discussed with 
other researchers and industry members, confirming the step was not completely necessary 
in the early stages of the workflow and could be moved as suggested. As the workflow is a 
guide document, this step could be included at the discretion of the researchers carrying out 
the screening, depending on their specific requirements. 
Further benchmarking tests could be useful to gain a more detailed understanding of the 
workflows. These could include research into controlling other physical properties, such as 
polymorphic form or PSD. In addition, initial screening steps should be carried out using 
different crystallisation methods, such as small scale controlled cooling crystallisation. 
Evaporative crystallisation is quick to set up and allows many screening experiments to be 
carried out in parallel, however, is not a controllable method of crystallisation and often gives 
a large variation of results in the same experiment. Whilst this is often enough to suggest 
where a success may occur, it can cause useful results to be missed. Carrying out 
benchmarking tests using small scale controlled cooling crystallisations may allow for more 
repeatable experiments/results and allow for easier scale-up procedures in the later steps of 
the workflow.  Finally, the development of some standard operating procedures for the key 
steps in the workflow may be beneficial in allowing researchers to carry out easily repeatable 







Chapter 8 Conclusions and future work 
 
8.1  Conclusions 
The work presented in this thesis shows the results of investigations into optimising the 
particle morphology of pharmaceutically active ingredients IZN and PYR, with the particular 
aim of achieving a more block shaped crystal as opposed to the needles usually produced for 
IZN and PYR. Various methods were utilised to influence the morphology of the crystals 
produced, including additives and solvent effects. Both size-matched and polymeric additives 
were used in small quantities as intentionally added impurities in the crystallisations. In 
addition, an investigation into the creation of new multi-component materials was also 
carried out in an attempt to form more block shaped morphologies.  
The solvent effects on IZN are significant, with a number of morphological changes achieved. 
Initial evaporative crystallisations in EtOAc and ACN produced thickened rod block shaped 
crystals, a significant change from the thin needles previously observed in H2O. In cooling 
crystallisations, EtOH and IPA showed thin plate-shaped crystals; a significant morphology 
change but not as favourable. The rod-shaped crystals achieved in EtOAc could also be 
accessed in cooling crystallisations, however, the ACN effects were not observed in cooling, 
with needle-shaped crystals resulting. Further research was carried out on EtOAc, which 
showed the most favourable change, and IPA solvent effects. It was proven that the 
morphology changes observed were repeatable via a number of different cooling 
crystallisation methods, including in the KRAIC continuous platform. The ease of transfer 
from evaporative to small scale cooling to large scale continuous methods shows the 
versatility of the changes achieved using different solvents. This is particularly useful for 
pharmaceutical applications as it allows for easier implementation into already existing 
crystallisation processes.  
The effect of supersaturation on the morphology was investigated using the above solvents. 
It was determined to be possible to achieve the same morphology observed in cooling in 
evaporative crystallisations, depending on the starting saturation used. Plate-shaped crystals 
were observed for IPA in evaporative crystallisations at higher starting concentrations of IZN. 
The same effects were not observed in cooling crystallisation. The increase in starting 
supersaturation in cooling only serves to increase the amount of crystallisation occurring, not 
the morphology achieved. The lack of influence on cooling morphologies also points to the 
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robust nature of this method and the ease of the potential implementation into already 
existing pharmaceutical manufacturing processes.  
The most favourable solvent effect can be attributed to EtOAc crystallisations. Upon indexing 
the faces, the morphology closely resembles that predicted using BFDH calculations. The 
major growth mechanism seems to still be as a result of the aromatic interactions between 
the rings in the IZN molecules. The solvent prevents this happening as fast as observed in 
H2O, meaning the needle does not grow as long and can fatten up; the slow growing faces 
have been allowed to catch up. This is likely due to the reduction in polarity of the solvent. 
In contrast, H2O is a strongly polar solvent and is therefore likely to interact with the polar, 
hydrogen bonding groups that exist on the slow growing faces. This blocks the approach of 
growth units, meaning they are more likely to join the growing crystal on the fast growing 
face. In a less polar solvent such as EtOAc, there is less interruption to growth on the slower 
growing faces from the solvent molecules, allowing these faces to catch up a bit with the fast 
growing needle axis faces. 
Studies carried out in solvents with PYR show very little influence of the solvent used on the 
morphology achieved. All solvents used give needle crystals. Due to low solubility in other 
solvents, the number of solvents used in this screen was limited. A wider screen is necessary 
to rule this out definitively as a possible route. This could initially be done computationally 
using methods currently employed with CMAC. 
Investigations into size-matched additives effects on IZN yielded two potential candidates for 
further experimentation: 3-HBA and 3,4-DNBA. Initial evaporative investigations carried out 
will small additive percentages of 1%, 5% and 10% showed positive morphology changes with 
1% of the additive. The addition of these additives allowed thickened, rod-shaped crystals to 
result, where previously thin plate-shaped crystals were observed. The morphology achieved 
in IPA in the presence of these additives closely resembles the morphology observed from 
crystallisations in EtOAc. Transfer of these effects from evaporative crystallisation to cooling 
crystallisation proved difficult, with a number of different conditions and platforms 
attempted. The scale up was eventually achieved at a 200 mL scale in the Polar Bear Plus 
crystalliser, with the 250 mL round-bottomed flask insert. The success of the crystallisation 
can be attributed to the use of overhead stirring. Cooling crystallisations at the same scale 
without overhead stirring still yielded plate-shaped crystals observed in IPA alone. The 
stirring with influence the kinetics of the crystallisation, potentially responsible for the more 
favourable morphology change achieved. More research into the kinetics is required to fully 
understand the influence of the stirring on the growth morphologies achieved in the 
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presence of additives in cooling crystallsations. Transfer of the size-matched additive effects 
into continuous cooling platform the KRAIC, was also unsuccessful. Conventional stirring is 
also not possible in this continuous platform, considered the likely reason for the limited 
success given the outcomes of the batch cooling investigation. As a result, further 
experiments into other continuous methods should be carried out.  
A condition the pharmaceutical industry must consider when investigating the use of 
additives to influence morphology, is the possible inclusion of the additive into the crystal 
structure. As the additives used here are size-matched the possibility exists that the additive 
could be included into the crystal structure, forming a new multi-component material. This 
would be an unfavourable outcome as the new crystal form would need to go through 
rigorous testing and approval before being marketed to the public. As such, additives are 
treated as impurities and must be below the threshold set up by the regulatory bodies. Upon 
using SCXRD, PXRD, DSC and NMR spectroscopy to analyse the final crystal products, no trace 
of the additive was determined in the crystal structure or left behind in the bulk sample. 
These results suggest the additive was in sufficiently low concentrations to remain in solution 
and be filtered out when the crystals were isolated from the mother liquor. However, these 
analysis techniques are not the most sensitive ones that could be carried out. As a result, to 
take this forward a pharmaceutical company would need to use other techniques to quantify 
exactly how much, if any, of the additive remained in the crystalline samples produced.  
No influence of polymeric additives on the morphology of IZN has been determined within 
the scope of the screens carried out in this thesis. For the selection of additives investigated 
here, no successful morphology change was observed. The polymers showed no sign of 
influencing the morphology in either cooling or evaporative platforms. The correct polymer 
may not yet have been found and so further investigation into this could be considered.  
Crystallisations carried out in the presence of both size-matched and polymeric additives 
were deemed unsuccessful with PYR, showing no evidence of any morphology changes being 
achieved in their presence. This closely mimics what was observed in the different solvent 
screens attempted for PYR. This further suggests PYR is less prone to changes to the growth 
mechanisms present. Further additives could be investigated for PYR, however, care should 
be taken not to spend too much time as the screens already carried out point to this being 
an unsuccessful venture.  
Research into the creation of new multi-component materials of IZN found three new 
structures with different enantiomeric combinations of tartaric acid and a new co-crystalline 
structure with 3,4-DNBA. All the new multi-component forms with IZN were determined to 
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have thin plate morphologies. The change seen in the TA co-crystals was significant as the 
crystallisations were carried out in water, which previously only yielded very thin needle 
crystals. The 3,4-DNBA co-crystal was crystallised from IPA, which also yields a plate-shaped 
crystal without the co-former molecule. Upon analysing other physical properties of the new 
co-crystals, their solubility was determined to be lower than that observed for pure IZN. This 
could be considered a possible negative effect of the formation of the multi-component 
structures. All new co-crystals showed a solubility relationship mimicking that of monotropic 
polymorphs. Stability analysis experiments, humidity studies, slurry studies and temperature 
studies, confirmed all forms were stable with respect to the conditions subjected to for 
extended periods of time. The exception being the DLTA hydrated crystal. When subjected 
to high temperatutes the crystal structure fully converted to a dehydrated crystalline form 
after approximately 1 week. This dehydrated crystal was shown to rehydrate when slurried 
in water. However, this transition is believed not to be fully reversible due to the shrinking in 
the crystal unit cell parameters on dehydration. The rehydration is likely the result of the 
dehydrated co-crystal dissolving and reincorporating the water molecules upon 
recrystallisation.  
The co-crystalline products produced with IZN were all easily scaled up in batch cooling 
crystallisations and large scale slurry experiments. In addition, the crystallisation products of 
the scaled up experiments maintained a good conversion of starting materials, with no trace 
remaining in the DSC or PXRD data obtained.  
Whilst limited success was observed in attempts to change the morphology of PYR using 
additives and solvent, some success was observed upon the creation of multi-component 
materials. Throughout the research presented here three new co-crystalline structures of 
PYR were discovered, all exhibiting favourable morphology changes. New multi-component 
crystal structures were found with 2,4-DNBA, 3,5-DNBA, TRI and PtA. 
Similar to the co-crystals produced with IZN, the solubility of each of the new PYR crystal 
forms produced was much lower than pure PYR. Whilst a reduction in solubility is generally 
considered detrimental to pharmaceutical applications, if it remains over a certain threshold 
it may be a compromise worth considering to achieve a beneficial morphology change that 
will improve manufacturing processes. The co-crystals were all determined to be stable with 
respect to the studies carried out, high temperature, high humidity and slurry experiments, 
with the exception of the PYR:2,4-DNBA co-crystal. During slurry experiments in water a new 
polymorphic form of the co-crystal (form II) was discovered. It was not possible to determine 
the thermodynamic form using traditional physical properties, such as melting points or 
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solubility, as the difference between the two polymorphs was negligible. As a result, 
competitive slurry and co-grinding experiments were carried out. These both showed full 
conversion from form I to form II (within 2 hours for the slurry experiment). Consequently, 
form II was determined to be thermodynamically more stable. Although it should be noted 
their stabilities are very similar and another, more stable, form could be possible.  
The morphology change observed for the PYR:2,4-DNBA co-crystals was significant, with an 
irregular block shaped crystal as opposed to the needles previously observed in IPA. The co-
former causes a different hydrogen bonding network to be present in the structure reducing 
the strength of the π-π-interactions between the aromatic rings. A fattened, plate-shaped 
crystal is observed for PYR:3,5-DNBA co-crystals. This is much closer to a block shape and is 
a significant improvement on the usual needle morphology observed for pure PYR crystals. 
Whilst plate-shaped crystals are often unfavourable in processing, the fattened nature of 
those produced here suggests they could significantly improve the downstream processing 
steps required for production. The least beneficial morphology change was observed for the 
PYR:TRI co-crystal. Plate-shaped crystals are also seen here, although much thinner than for 
3,5-DNBA. Whilst the change is still a major difference from the needles usually observed, 
the thin nature of the plates makes them difficult to process into the final pharmaceutical 
product. Finally, the PYR:PtA co-crystal also showed a plate shape morphology. It was not 
possible to face index these within the time constraints of this work due to equipment failure 
in the last 3 months of research. 
Overall, the creation of PYR co-crystals has resulted in positive morphology changes not 
previously observed in additive or solvent experiments. The improvement is particularly 
beneficial in the case of the PYR:2,4-DNBA co-crystal, where an almost block shape is 
achieved. Although there would be difficulty obtaining FDA approval for crystals involving a 
secondary component, this would be the most promising method to utilise to change the 
morphology of the PYR crystals. No improvement was seen for either of the methods 
attempted which do not change the crystal structure of the API; both additives and solvent 
showed no influence on the growth shapes.  In contrast to the conclusions made about IZN, 
the formation of multi-component crystal structures is more successful in morphology 
modification and would be a good route for further investigation, despite the difficulties 
potentially faced when seeking approval. 
Overall, the creation of multi-component materials of IZN and PYR has resulted in 
morphology changes of the crystals. This is especially clear when comparing the needles 
previously achieved from crystallisations in. In terms of PYR the changes seen upon co-
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crystallisation are a major improvement, particularly in the case of PYR:2,4-DNBA. No 
changes were observed for additive crystallisations with PYR so the creation of multi-
component materials would be the best method to pursue for this API. An attempt should 
be made to find some successful GRAS co-formers in order to allow their approval by the 
FDA. For IZN, the plate-shaped morphologies achieved as not as beneficial in easing the 
downstream processing steps as the morphology changes achieved via solvent and additive 
interventions. The difficulty obtaining FDA approval for the secondary component would not 
be a worthwhile venture for IZN, as the improvements in the morphology are not substantial 
enough. The addition of the secondary component has also significantly reduced the 
solubility when compared to pure IZN, this is often extremely unfavourable in the 
pharmaceutical industry. More significant improvements for IZN were seen with the 
additives 3-HBA and 3,4-DNBA and in the solvent EtOAc. One of these routes would be best 
to take forward into pharmaceutical processes. When considering regulatory approval, the 
solvent effects may be favoured as there are no impurities to quantify in the final product. 
However, once the amount of additive remaining is quantified, and if this falls below the 
threshold, this may be the more favoured route due to better reproducibility of the 
morphologies achieved.  
8.2  Future work 
In the research carried out here, it was shown significant morphological changes in IZN 
crystals could be achieved in the presence of small wt% of both 3-HBA and 3,4-DNBA 
additives, when crystallised from IPA. In the process of scaling up these crystallisations the 
influence of overhead stirring was determined to have a significant impact on the success of 
the crystallisations carried out. Further, in depth research into the reasons behind this could 
help achieve similar outcomes in other similar molecules, for example PYR. Experiments 
which probe the kinetics of the crystallisation could help determine why the stirring has such 
an influence on the morphology achieved in cooling.  
Determining the influence of the stirring may also aid in the transfer of the additive effects 
into continuous platforms. The research carried in the KRAIC continuous crystallisation 
platform was unsuccessful in achieving the desired morphology change in the presence of 
additives. Due to the apparent importance of stirring, the potential for success exists in a 
platform such as a cSTR. As this set up involves a series of stirred tanks it could allow for the 
correct kinetic conditions to be achieved which allow the crystal growth to achieve the 
desired morphology change.  
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It is also important to quantify whether any additive remains within the crystal structure or 
on the surface of the crystals, particularly in the case where pharmaceutical applications are 
being considered. DSC, PXRD and NMR spectroscopy studies were carried out and showed 
no presence of the additives, however, there are other methods with better detection limits 
which could prove otherwise. A series of HPLC experiments should be carried out to help 
determine the percentages of additive, if any, that remain within the crystalline sample after 
filtration and drying. If a successful polymeric additive was determined, SEM could be used 
to investigate whether any additive remains on the surface. This would not be necessary in 
the case of IZN as the successful additives were all size-matched and, therefore, more prone 
to inclusion in the crystal structure.  
Further research could also be carried out on PYR. None of the additives, size-matched or 
polymer, used so far have succeeded in causing a morphology change to occur. Other 
polymers and additives could be investigated in an attempt to achieve this. However, care 
should be taken as extensive screening has already been carried out with little success 
suggesting further screening would also be unsuccessful.  
Finally, if one of the co-crystalline products developed during the course of this research was 
deemed to have beneficial morphological and other physical properties for a pharmaceutical 
application, further research into the production via continuous methods should be 
attempted. The different conditions in the continuous platforms could cause properties such 
as morphology to change and would need to be quantified before moving forward with the 
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A 1. PXRD data for (a) IZN (INICAC02), (b) IZN crystallised from H2O, (c) IZN crystallised from EtOH, (d) IZN 
crystallised from IPA, (e) IZN crystallied from EtOAc and (f) IZN crystallised from ACN 
 
A 2. PXRD data for (a) IZN (INICAC02), (b) IZN crystallised from EtOAc, (c) IZN temperature cycling experiment 1 




A 3. Evaporative crystallisations at 40 ⁰C with 1% additives (a) benzoic acid, (b) 3-hydroxybenzoic acid, (c) 2,4-
dihydroxybenzoic acid, (d) 3,4-dihydroxybenzoic acid, (e) 3,5-dihydroxybenzoic acid, (f) 2,6-dihydroxybenzoic 
acid, (g) 4-cyanobenzoic acid, (h) 3-cyanobenzoic acid, (j) 2,4-dinitrobenzoic acid, (k) 3,4-dinitrobenzoic acid, (l) 
3,5-dinitrobenzoic acid, (m) trimesic acid, (n) isonicotinamide, (p) nicotinamide, (q) pyridoxine, (r) vanillin and (s) 
L-tartaric acid 
 
A 4. PXRD data for (a) IZN (INICAC02), (b) 3-HBA form I (BIDLOP), (c) 3-HBA form II (BIDLOP01), (c) 3-HBA hydrate 




A 5. PXRD data for (a) IZN (INICAC02), (b) 3,4-DNBA (YADKOF) and (c) IZN evaporative with 1% 3,4-DNBA from 
IPA 
 




A 7. Cooling crystallisations of IZN with 3-HBA additive. Scale: 10 g, cool rate: 1 ⁰C/minute, final dwell: 5 hour 
 




A 9. Cooling crystallisations of IZN with 3-HBA additive. Scale: 10 g, cool rate: 0.1 ⁰C/minute, final dwell: 1 hour 
 




A 11. Cooling crystallisations of IZN with 3-HBA additive. Scale: 10 g, cool rate: 0.1 ⁰C/minute, final dwell: 10 
hour 
 





A 13. Cooling crystallisations of IZN with 3,4-DNBA additive. Scale: 10 g, cool rate: 1 ⁰C/minute, final dwell: 5 
hour 
 





A 15. Cooling crystallisations of IZN with 3,4-DNBA additive. Scale: 10 g, cool rate: 0.1 ⁰C/minute, final dwell: 1 
hour 
 





A 17. Cooling crystallisations of IZN with 3,4-DNBA additive. Scale: 10 g, cool rate: 0.1 ⁰C/minute, final dwell: 10 
hour 
 
A 18. DSC trace for IZN crystallised via 200 mL cooling crystallisation in IPA with 1% 3-HBA additive. IZN melting 




A 19. NMR spectroscopy experimental data for IZN crystallised via 200 mL cooling crystallisation in IPA with 1% 
3-HBA additive (red) compared to pure IZN (green) and pure 3-HBA (blue). 
 
A 20. DSC trace for IZN crystallised via 200 mL cooling crystallisation in IPA with 1% 3,4-DNBA additive. IZN 




A 21. NMR spectroscopy experimental data for IZN crystallised via 200 mL cooling crystallisation in IPA with 1% 
3,4-DNBA additive (red) compared to pure IZN (green) and pure 3,4-DNBA (blue). 
 
A 22. Cooling crystallisations of IZN with 1% polymer additives from IPA at a rate of 1⁰C/minute. (a) PP123, (b) 




A 23. Cooling crystallisations of IZN with 0.1% polymer additives from IPA at a rate of 1⁰C/minute. (a) PP123, (b) 
PEG, (c) PPG, (d) PBD, (e) PVP and (f) PDE 
 
A 24. 20 ⁰C evaporative crystallisations of IZN with 1% polymer additives in IPA. (a) PP123, (b) PEG, (c) PPG, (d) 
PBD, (e) PVP and (f) PDE 
 
A 25. 20 ⁰C evaporative crystallisations of IZN with 0.1% polymer additives from IPA. (a) PP123, (b) PEG, (c) PPG, 








A 26. PXRD data for (a) IZN (INICAC02), (b) LTA (TARTAL), (c) 1:1 IZN:LTA grinding, (d) 1:1 IZN:LTA LAG with H2O 
and (e) IZN:LTA co-crystal produced via crash cooling from H2O 
 
A 27. DSC trace for (a) 1:1 IZN:LTA grinding, (b) 1:1 IZN:LTA LAG with IPA and (c) IZN:LTA co-crystal produced via 




A 28. PXRD data for (a) IZN (INICAC02), (b) DTA (TARTAC), (c) DTA (TARTAC24), (d) 1:1 IZN:DTA grinding, (e) 1:1 
IZN:DTA LAG with H2O and (f) IZN:DTA co-crystal produced via crash cooling from H2O 
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A 30. PXRD data for (a) IZN (INICAC02), (b) LTA (TARTAL), (c) IZN:LTA co-crystal calculated from SCXRD, (d) 10 g 
cooling in H2O, (e) 30 g cooling in H2O and (f) 60 mL slurry in H2O 
 
A 31. PXRD data for (a) IZN (INICAC02), (b) DTA (TARTAC), (c) DTA (TARTAC24), (d) IZN:DTA co-crystal calculated, 





A 32. PXRD data for (a) IZN (INICAC02), (b) DLTA (ZZZDUI01), (c) DLTA monohydrate (TARTDL), (d) 1:1 IZN:DLTA 
grinding, (e) 1:1 IZN:DLTA LAG with H2O and (f) IZN:DLTA co-crystal produced via crash cooling from H2O 
 
A 33. DSC trace for (a) 1:1 IZN:DLTA grinding, (b) 1:1 IZN:DLTA LAG with H2O and (c) IZN:DLTA co-crystal 




A 34. PXRD data for (a) IZN (INICAC02), (b) DLTA (ZZZDUI01), (c) DLTA monohydrate (TARTDL), (d) IZN:DLTA co-
crystal calculated, (e) 10 g cooling in H2O, (f) 30 g cooling in H2O and (g) 60 mL slurry in H2O 
 
A 35 DSC trace for IZN:DLTA:H2O cycled experiment 
 
A 36. PXRD data for (a) IZN (INICAC02), (b) 3,4-DNBA (YADKOF), (c) 1:1 IZN:3,4-DNBA grinding, (d) 1:1 IZN:3,4-




A 37. DSC trace for (a) 1:1 IZN:3,4-DNBA grinding, (b) 1:1 IZN:3,4-DNBA LAG with IPA and (c) IZN:3,4-DNBA co-
crystal produced via crash cooling from IPA 
 
A 38. PXRD data for IZN:3,4-DNBA co-crystal scale up. (a) IZN (INICAC02), (b) 3,4-DNBA (YADKOF), (c) IZN:3,4-
















A 39 PXRD data for (a) PYR (BITZAF), (b) PYR crystallised from H2O, (c) PYR crystallised from EtOH and (d) PYR 
crystallised from IPA 
 
A 40. Evaporative crystallisations for PYR in IPA at 40 ⁰C with 1 % additive (a) benzoic acid, (b) trimesic acid, (c) 
imidazole, (d) benzimidazole, (e) 2,4-dinitrobenzoic acid, (f) isonicotinamide, (g) isonicotinic acid, (h) nicotinic 
acid, (j) nicotinamide, (k) 3,5-dinitrobenzoic acid, (l) 2-aminobenzoic acid, (m) barbituric acid, (n) tartaric acid, (p) 
2,2’-bipyridine and (q) 4,4’-bipyridine. 
 
A 41. Cooling crystallisations of PYR with 1% polymer additives from IPA at rate of 0.1 ⁰C/minute. (a) PP123, (b) 




A 42. 20 ⁰C evaporative crystallisations of PYR with 1% additives from IPA. (a) PP123, (b) PEG, (c) PPG, (d) PBD, 
(e) PVP and (f) PDE 
 
A 43. 20 ⁰C evaporative crystallisations of PYR with 0.1% additives from IPA. (a) PP123, (b) PEG, (c) PPG, (d) PBD, 
(e) PVP and (f) PDE 
 
A 44. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) 1:1 PYR:2,4-DNBA grinding, (d) 1:1 PYR:2,4-




A 45. DSC trace for (a) 1:1 PYR:2,4-DNBA grinding, (b) 1:1 PYR:2,4-DNBA LAG with IPA, (c) 1:1 PYR:2,4-DNBA LAG 
with H2O and (d) PYR:2,4-DNBA co-crystal produced via evaporative from IPA 
 
A 46. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) PYR:2,4-DNBA form I co-crystal calculated from 




A 47. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) 1:1 PYR:2,4-DNBA grinding, (d) 1:1 PYR:2,4-
DNBA LAG with H2O and (e) PYR:2,4-DNBA form II co-crystal produced from cooling in H2O 
 
A 48. PXRD data for (a) PYR (BITZAF), (b) 2,4-DNBA (BAQLUD), (c) PYR:2,4-DNBA form II co-crystal calculated 




A 49. PXRD data for (a) PYR (BITZAF), (b) 3,5-DNBA form I (CUKCAM01), (c) 3,5-DNBA form II (CUKCAM02), (d) 
3,5-DNBA hydrate (OKEMAT), (e) 1:1 PYR:3,5-DNBA grinding, (f) 1:1 PYR:3,5-DNBA LAG with H2O and (g) 
PYR:3,5-DNBA co-crystal produced via evaporative from H2O 
 
A 50. DSC trace for (a) 1:1 PYR:3,5-DNBA grinding, (b) 1:1 PYR:3,5-DNBA LAG with H2O and (c) PYR:3,5-DNBA co-




A 51. PXRD data for (a) PYR (BITZAF), (b) 3,5-DNBA form I (CUKCAM01), (c) 3,5-DNBA form II (CUKCAM02), (d) 
3,5-DNBA hydrate (OKEMAT), (e) PYR:3,5-DNBA co-crystal calculated from SCXRD, (f) 10 g cooling in H2O, (g) 30 
g cooling in H2O, and (h) 10 g slurry in H2O 
 
A 52. PXRD data for (a) PYR (BITZAF), (b) TRI (BTCOAC), (c) 2:1 PYR:TRI grinding, (d) 2:1 PYR:TRI LAG with IPA and 
(e) PYR:TRI co-crystal produced via evaporative from IPA 
 
A 53. DSC trace for (a) 2:1 PYR:TRI grinding, (b) 2:1 PYR:TRI LAG with IPA and (c) PYR:TRI co-crystal produced via 




A 54. PXRD data for (a) PYR (BITZAF), (b) TRI (BTCOAC), (c) PYR:TRI co-crystal calculated from SCXRD, (d) PYR:TRI 
co-crystal calculated from SCXRD, (e) 10 g cooling in IPA and (f) 10 g slurry in IPA 
 
A 55. PXRD data for (a) PYR (BITZAF), (b) PtA (PHTHAC), (c) PtA hydrate (WODVAN), (d) 1:1  PYR:PtA grinding, (e) 
1:1 PYR:PtA LAG with EtOH and (f) PYR:PtA co-crystal produced via evaporative from EtOH 
 
A 56. DSC trace for (a) 1:1 PYR:PtA grinding, (b) 1:1 PYR:PtA LAG with EtOH and (c) PYR:PtA co-crystal produced 




A 57. PXRD data for (a) PYR (BITZAF), (b) PtA (PHTHAC), (c) PtA hydrate (WODVAN), (d) PYR:PtA co-crystal 
calculated from SCXRD, (e) PYR:PtA 10 g cooling in IPA, (f) PYR:PtA 30 g cooling in IPA and (g) PYR:PtA 10 g slurry 
in IPA 
 
 
